Detailed Schedule - Monday, April 7

Transcription

12_14AM_Mon_Layout 1 3/11/14 12:38 PM Page 285
MONDAY, APRIL 7
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
7:00 a.m.-8:00 a.m.
NCI/NIH-Sponsored Session
287
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
288-291
8:00 a.m.-12:00 p.m.
Poster Sessions
292-326
8:00 a.m.-12:00 p.m.
Late-Breaking Poster Sessions
327
8:15 a.m.-10:15 a.m.
Plenary Session
328
8:15 a.m.-10:15 a.m.
WICR Professional Advancement Session
329
9:30 a.m.-11:30 a.m.
Forum
330
10:00 a.m.-11:00 a.m.
Career Conversations
331
10:30 a.m.-12:00 p.m.
332
10:30 a.m.-12:30 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
333
10:30 a.m.-12:30 p.m.
Current Concepts in Epidemiology
and Prevention Research
334
10:30 a.m.-12:30 p.m.
Current Concepts in Organ Site Research
335
10:30 a.m.-12:30 p.m.
Clinical Trials Symposium
336
10:30 a.m.-12:30 p.m.
Major Symposia
337-340
10:30 a.m.-12:30 p.m.
AMC Professional Advancement Session
341
10:30 a.m.-12:30 p.m.
Regulatory Science and Policy Session
342
10:30 a.m.-12:30 p.m.
Science Policy Session
343
12:00 p.m.-1:30 p.m.
CICR Town Meeting
344
12:30 p.m.-1:00 p.m.
Gertrude B. Elion Lecture
345
12:45 p.m.-2:00 p.m.
AACR Special Session
346
12:45 p.m.-2:15 p.m.
SU2C Special Session
347
1:00 p.m.-1:30 p.m.
Meet the Research Icon
348
1:00 p.m.-2:30 p.m.
Science Policy Session
349
1:00 p.m.-3:00 p.m.
Clinical Trials Symposium
350
1:00 p.m.-3:00 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
351
1:00 p.m.-3:00 p.m.
Current Concepts in Epidemiology
and Prevention Research
352
April 5-9, 2014 • San Diego, CA
285
MONDAY, APRIL 7
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
1:00 p.m.-3:00 p.m.
Current Concepts in Organ Site Research
353
1:00 p.m.-3:00 p.m.
Major Symposia
354-357
1:00 p.m.-3:00 p.m.
358
1:00 p.m.-3:00 p.m.
359-360
1:00 p.m.-5:00 p.m.
Poster Sessions
361-396
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
397
2:30 p.m.-3:30 p.m.
398
2:30 p.m.-3:30 p.m.
Meet the AACR President
399
2:30 p.m.-4:00 p.m.
400-401
3:00 p.m.-4:00 p.m.
Meet the Jane Cook Wright Lecturer
402
3:00 p.m.-5:00 p.m.
Minisymposia
403-407
3:00 p.m.-5:00 p.m.
Clinical Trials Minisymposium
408
3:00 p.m.-5:00 p.m.
409
3:00 p.m.-5:00 p.m.
Special Symposium
410
3:15 p.m.-5:15 p.m.
SU2C Special Session
411
3:30 p.m.-4:30 p.m.
AACR-Princess Takamatsu Lecture
412
4:00 p.m.-5:00 p.m.
413
4:00 p.m.-5:30 p.m.
414
4:30 p.m.-5:30 p.m.
AACR OACR Award Lecture
415
5:00 p.m.-6:30 p.m.
Forums
416-418
5:00 p.m.-6:30 p.m.
Major Symposium
419
5:00 p.m.-6:30 p.m.
Special Session
420
5:00 p.m.-6:30 p.m.
MICR Town Meeting
421
5:30 p.m.-6:30 p.m.
AACR-Clowes Award Lecture
422
6:00 p.m.-8:00 p.m.
Professional Advancement Session
423
6:00 p.m.-8:00 p.m.
Special Session
424
6:30 p.m.-8:45 p.m.
MICR Professional Advancement Session
425-426
286
AACR ANNUAL MEETING 2014
NCI/NIH-SPONSORED SESSION
Monday, 7:00 a.m.-8:00 a.m.
(not eligible for CME credit)
Room 28D-E, San Diego Convention Center
NCI Rare Tumors Initiative: Leveraging Expertise in Basic and
Clinical Studies of Rare Tumors to More Effectively Translate
Potential New Therapies
Moderator: Abby Sandler, National Cancer Institute, Bethesda, MD
Rare cancers and genetic tumor predisposition syndromes (GTPS) in children and adults are not
well understood and are understudied. There is an urgent need for an understanding of these
diseases and for the development of effective treatments.
NCI investigators have clinical expertise in rare cancers and GTPS, and the NIH Clinical Center
infrastructure allows for the conduct of complex clinical trials for children and adults with rare
diseases using a multidisciplinary approach. In addition, CCR investigators have expertise in basic
studies of rare diseases including genomic and molecular studies. However, better integration
between these two disciplines is needed in order to more effectively translate potential new
therapies both from bench to bedside and from bedside to bench.
The goal of the newly formed NCI Rare Tumors Initiative is to foster closer collaborations between
basic and clinical scientists and patient advocacy groups in the field of rare diseases to provide
better characterization of rare tumors, and facilitate the development of therapeutic approaches.
Knowledge gained from this initiative can also be applied to common cancers that have similar
molecular alterations. The overarching strategy is to combine and leverage the talents of
intramural investigators with expertise in genetics, genomics, molecular biology, imaging, tumor
models, pharmacokinetics, pharmacodynamics, biomarkers, and clinical trial development and
execution.
The initial focus of this initiative is to conduct small pilot studies focused on Ras-related tumors, in
particular neurofibromatosis type 1 (NF1)-related plexiform neurofibromas, and on non-Ras-related
sarcomas, in particular desmoid tumors. Upon successful completion of the pilot phase, the
scope of the Rare Tumors Initiative will broaden to include the study of additional rare tumors and
will expand collaborations with intramural and extramural researchers and patient advocacy
groups, with the goal to most effectively study rare diseases and develop effective therapies.
This session will provide an overview of the NCI Rare Tumors Initiative, describe the ongoing pilot
studies, current advances in performing mouse preclinical trials in tandem with human clinical
trials, and regulatory aspects of the development of therapies for rare diseases.
Introduction/Overview
Abby Sandler, National Cancer Institute, Bethesda, MD
Developing novel therapies for rare tumors
Shivaani Kummar, National Cancer Institute, Bethesda, MD
Development of effective therapies for neurofibromatosis type 1-related tumors
Brigitte Widemann, National Cancer Institute, Bethesda, MD
Integrating model systems into rare tumor research
Karlyne Reilly, National Cancer Institute, Frederick, MD
Panel Discussion:
Shivaani Kummar. National Cancer Institute, Bethesda, MD
Brigitte Widemann, National Cancer Institute, Bethesda, MD
Karlyne Reilly, National Cancer Institute, Frederick, MD
S. Percy Ivy, National Cancer Institute-DCTD, Rockville, MD
Annette Bakker, Children’s Tumor Foundation, New York, NY
Additional panelists to be announced
287
MEET-THE-EXPERT SESSIONS
Room 6B, San Diego Convention Center
Big Data and Technology: Transforming
Cancer Care and Research
Lynda Chin, The University of Texas MD Anderson
Cancer Center, Houston, TX
It is opportune time now to consider leverages of big
data science and analytic as well as mobile technologies
to improve the effectiveness of cancer care and
research. Our n-of-all™ initiative is built on the premise
that patient outcome can be improved in the short term if
the best evidence-based care of today is delivered to all
patients, irrespective of their access to a state-of-the-art
cancer center. The vision of the n-of-all™ program is to
enhance the effectiveness of cancer care and research
through innovative solutions enabled by the big data
revolution, advances in genomic and health IT
technologies, and by a new culture of collaboration and
cooperation between the research and clinical care
enterprises in academia, as well as with industry
collaborators. To establish initial proof-of-principles of
this approach, we launched an n-of-all™ pilot project in
leukemia to create the APOLLO (Adaptive PatientOriented Longitudinal Learning and Optimization)
platform and to develop the first Oncology Expert
Advisor™ powered by IBM-Watson.
developmental, genes with promoter region, “bivalent”
chromatin. This chromatin, encompassing both
transcriptionally active and repressive marks, modulates
genes key to the maintenance of the stem cell state and
which are vulnerable for evolving epigenetic
abnormalities during tumor progression. Cancer risk
states, such as chronic inflammation, can induce shifts
in transcriptionally repressive protein complexes to
promoters of these genes. One exciting research area
involves recognition of many frequent mutations in genes
encoding regulators of the epigenome and working to
understand the precise downstream consequences of
these. All of this above biology is important to
understand as a background to consider the building
interest in employing “epigenetic and/or differentiation
therapy” for cancer and for designing biomarker
signatures to personalize these therapies for prediction
of, and monitoring of, efficacies. Examples of promise
for these approaches are emerging and will be discussed
with particular excitement for using the approaches to
block key oncogenic drives to cancer, such as for the
C-MYC pathway, and for sensitizing patients to the latest
strategies for immunotherapy.
Room 7, San Diego Convention Center
Computational Approaches to
Functional Cancer Genomics
Ballroom 20D, San Diego Convention Center
The Cancer Epigenome:
Translational Potential
Stephen B. Baylin, Johns Hopkins University School of
Medicine, Baltimore, MD
Ever expanding genome-wide mapping studies are
constantly enriching our knowledge base of normal and
cancer “epigenomes.” More and more we appreciate
that epigenetic abnormalities in cancer encompass DNA
methylation and chromatin alterations throughout the
genome, affecting not only canonical coding region gene
promoters and gene bodies, but also enhancers,
intergenic and many noncoding RNA regions. We also
are learning that there are differential sensitivities for
these regions to become abnormal throughout all steps
in tumorigenesis. A key example is both losses and
gains of DNA methylation which can be simultaneously
biased to distinct genomic regions such as nuclear lamin
enriched, late replicating DNA, and to low transcription,
288
Jill Mesirov, Broad Institute of MIT and Harvard,
Cambridge, MA
Advances in sequencing technologies and the
development of new methods for acquiring biological
data have changed the face of cancer genomics
research. The use of computational approaches takes
advantage of the availability of these data to develop
new methods with the promise of improved
understanding and treatment of disease. It is important
to deliver practical, accessible software tools to bring
these methods to the general cancer research
community. I will describe some of these approaches
that leverage functional data including our work
integrating high-level clinical and genomic features to
stratify pediatric brain tumor patients into groups with
high and low risk of relapse after treatment. The
approach provides a more accurate and biologically
interpretable model than previous models, and
represents one of the few such predictors that
Monday, 7:00 a.m.-8:00 a.m.
generalized to a completely independent patient cohort.
I’ll also describe some more recent work on a method
that may shed light on the relationships between
genomic features and biological function. Finally, I will
review the software that makes our methods available to
the research community.
DNA Damage Response and ARF-p53
Anticancer Barriers: Mechanisms,
Defects, and Relevance for
Chromosomal (In)stability,
Tumorigenesis, and Treatment
Jiri Bartek, Danish Cancer Society - Institute of Cancer
Biology, Copenhagen, Denmark
This presentation will first provide an overview of the
current understanding about the cell-intrinsic barriers to
activated oncogenes and tumor progression, with
emphasis on the roles of the DNA damage response
(DDR) machinery and the ARF-p53 tumor suppressor
pathway. Topics to be covered will include: i) The nature
of the “oncogenic/replication stress” insults that are
sensed by DDR versus ARF; ii) Relative contributions of
DDR vs. ARF and their mutual functional links in cancer
development; iii) Cancer-associated defects in the DDR
and ARF barriers and their impact on chromosomal
instability and cancer biology; iv) Emerging impact of the
DDR and ARF-p53 mechanisms on tumor heterogeneity
and cell-fate plasticity; v) Implications of the status of the
DDR machinery including DNA damage checkpoints and
repair pathways, and the ARF-p53 pathway, for
responses to standard-of-care and targeted therapies,
and prospects for innovative treatment strategies in this
area of cancer research.
Room 29A-D, San Diego Convention Center
From Molecules to Mice: The Role of
Mutationally Activated BRAF in Tumor
Initiation, Cancer Progression, and
Pathway-Targeted Therapy
In the past 12 years, BRAF has vaulted from the status
of a relatively understudied regulator of cell signaling to a
poster child for pathway-targeted cancer therapy.
Furthermore, the invention of novel inhibitors of
BRAF(V600E), the most commonly mutated form of
BRAF, has revealed further unexpected features of how
RAF kinases signal both in normal and cancer cells.
Moreover, our growing understanding of the mechanisms
of sensitivity or resistance to BRAF(V600E) inhibitors
such as vemurafenib or dabrafenib in the clinic has
sharpened focus on how BRAF(V600E) signals within the
cell and what additional events influence the response of
tumors to pathway-targeted blockade of the ERK1/2
MAP kinase pathway. This session will focus on the role
of mouse models of BRAF(V600E)-driven cancer (both
GEMMs and PDXs) in forging a more complete
understanding of the role of mutationally activated BRAF
in tumor initiation, cancer progression, and pathwaytargeted therapy.
Room 28A-C, San Diego Convention Center
Germline Genetic Testing and Risk
Modeling in Patients and Populations
Stephen B. Gruber, USC/Norris Comprehensive Cancer
Center, Los Angeles, CA
Germline genetic testing for cancer susceptibility is
rapidly expanding to include large panels of highpenetrance genes with relatively low levels of
experimental and clinical data to guide the interpretation
of results. In addition, hundreds of low-penetrance
susceptibility variants have been discovered in breast,
prostate, colon, and other cancers that have the
potential to augment genetic testing and risk
stratification. In this session, advances in clinical genetic
testing will be discussed to understand the current state
of the art, the challenges of interpreting data from genes
that have only recently been introduced into practice,
and the opportunities to integrate supplemental genetic
information from high density genotyping of very large
(n=100,000) studies. Risk models that facilitate risk
stratification for individual patients as well as large
populations will be considered to optimize clinical and
public health benefits.
Martin McMahon, UCSF Helen Diller Family
Comprehensive Cancer Center, San Francisco, CA
289
MEET-THE-EXPERT SESSIONS
Hereditary Gastrointestinal Cancer in
Minority Populations
Recombinant Immunotoxins: From
Conception to Clinical Reality in
Mesothelioma and Leukemia
Organized by the Minorities in Cancer Research
(MICR) Council
Marcia R. Cruz-Correa, University of Puerto Rico
Comprehensive Cancer Center, San Juan, PR
During this session we will discuss diagnosis and
management of hereditary gastrointestinal cancer and
the role of germline genetic testing and
chemoprevention. In addition, we will discuss how
familial registries provide a clinical and research
infrastructure.
Room 6CF, San Diego Convention Center
PARP Inhibition: What Have
We Learned?
Ira Pastan, National Cancer Institute, Bethesda, MD
Recombinant immunotoxins are hybrid proteins
consisting of an antibody fragment that binds to a
cancer cell and a protein toxin that inhibits protein
synthesis and kill cells resistant to cytotoxic drugs. In
phase 1 trials with immunotoxin Moxetumomab
pasudotox that targets CD22, we observed 48%
complete responses in drug-resistant hairy cell leukemia
and 24% in pediatric ALL. In a trial combining
immunotoxin SS1P, that targets mesothelin, with
immune-modulatory doses of pentostatin and Cytoxan,
we observed profound and durable remissions in
chemo-refractory mesothelioma patients with advanced
bulky disease. Mechanisms responsible for these striking
tumor responses will be discussed.
Johann S. de Bono, Institute of Cancer Research,
Sutton, United Kingdom
Several drugs targeting poly(ADP-ribose) polymerase
(PARP) enzymes are under development including
olaparib, rucaparib, niraparib, and BMN-673. Responses
have been observed in patients with germline mutations
in BRCA1 and BRCA2, with further data supporting
antitumor activity of PARP inhibitors in some sporadic
cancers including high-grade serous ovarian cancers.
Strategies to identify somatic cell predictive biomarkers
remain under investigation. Iniparib was also purported
to be a PARP inhibitor that showed promising results in
randomized phase II trials in patients with triple-negative
breast cancer. Negative results from a phase III study in
this disease setting, however, tempered enthusiasm for
this agent and recently data from in vitro experiments
suggest that iniparib is not only structurally distinct from
other described PARP inhibitors, but is also a poor
inhibitor of PARP activity. In this presentation we will
scrutinize the development of PARP inhibitors from
preclinical studies to current ongoing trials, and identify
and discuss the pitfalls in the development of anticancer
drugs to prevent future late-stage trial failures.
The Role of PI3-Kinaseδ,γ Inhibition in
Hematological Malignancies
Julian Adams, Infinity Pharmaceuticals, Inc.,
Cambridge, MA
The delta and gamma isoforms of phosphointositide-3kinase are highly expressed in both B and T cell
malignancies. The discovery and development of
IPI-145, a potent inhibitor of both δ and γ inhibit signaling
to Akt which abrogates many proliferation and survival
signals. IPI-145 is an experimental drug and currently in
clinical trials to treat lymphoma and leukemia, and
clinical data will be presented in the context of a
mechanistic interpretation of action.
Targeting Genetic Drivers in
Premalignancy
Scott M. Lippman, UCSD Moores Cancer Center,
La Jolla, CA
Genetic drivers are alterations (e.g., mutations) in genes
that drive the metastatic potential of cancer cells. Recent
work has identified genetic drivers in premalignant
290
Monday, 7:00 a.m.-8:00 a.m.
lesions (Burgess DJ, Nature Reviews Cancer 2012).
Specifically, molecular profiles involving loss of
heterozygosity (LOH) at loci on 3p, 9p, 4q, and 17p in
patients with low-grade oral dysplasia were
prospectively validated to predict progression to oral
cancer. Building on these molecular risk studies in oral
premalignant disease, more recent work (in mouse
models and human specimens) has identified EGFR and
MET gene amplification as potential genetic drivers in
this setting and, along with LOH profiling, are being
studied in the recently completed phase III multicenter
Erlotinib Prevention of Oral Cancer (EPOC) trial. These
studies represent a new paradigm for the development
of personalized cancer treatment and prevention based
on molecular markers.
Room 6A, San Diego Convention Center
Targeting the Genetic and Metabolic
Basis of Cancer
W. Marston Linehan, National Cancer Institute,
Bethesda, MD
Kidney cancer is a novel form of cancer that has a
fundamentally metabolic basis. Each of the known
kidney cancer genes, including VHL, MET, FLCN, TFE3,
fumarate hydratase (FH), and succinate dehydrogenase
(SDH), have been found to alter the cell’s ability to sense
changes in oxygen, iron, nutrients and, most notably in
FH- and SDH-deficient kidney cancer, energy. FH- and
SDH-deficient kidney cancers, which are characterized
by glutamine-dependent reductive carboxylation,
undergo a metabolic shift to aerobic glycolysis and an
inhibition of HIF-prolyl hydroxylase. FH-deficient kidney
cancer is additionally characterized by fumaratemediated activation of the KEAP1-Nrf2 antioxidant
response, which is critical for the maintenance of growth
of this aggressive form of type 2 papillary kidney cancer
as well as other malignancies. Novel therapeutic
approaches are being developed targeting the metabolic
basis of VHL -/-, MET mutant, TFE3 as well as FH- and
SDH-deficient kidney cancer which are currently being
evaluated in clinical trials.
Understanding Tumor Heterogeneity
Using 40 Markers at Single Cell
Resolution
Dana Pe’er, Columbia University, New York, NY
Heterogeneity within tumors is of critical importance,
especially in terms of drug-resistant subpopulations.
Current advances in single-cell measurement technology
have the potential to revolutionize our understanding of
heterogeneity in disease. For example, mass cytometry
can measure the expression and phosphorylation states
of more than forty proteins simultaneously in thousands
of single cells, including surface proteins and signaling
molecules. Single-cell RNA-seq data sets are becoming
available. Our lab has developed a suite of tools geared
toward single-cell data analysis to unlock the potential of
this new data deluge. We will present different
computational algorithms using examples from healthy
hematopoiesis, AML, ALL, melanoma, and ovarian
cancers. Our presentation will focus on the identification
of small cell subsets, particularly in the context of drug
resistance. Moreover, we will show how to construct
maps of intratumor heterogeneity that shed light on how
development is dysregulated and identify novel “stem
cell like” populations in cancers.
Why Do Two of Three People Never
Get Cancer? Evolutionary Aspects of
Cancer Resistance
George Klein, Karolinska Institute, Stockholm, Sweden
Humans are relatively cancer resistant, as judged by the
absence of cancer in two-thirds of the population. The
susceptibility/resistance of other mammalians varies but
shows no relationship to body size. Selection for
longevity and cancer resistance may occur in parallel, as
indicated by the extremely long-lived and cancer-free
mole rat species. Microenvironmental control may play a
major role in the defense against potential neoplastic
cells. Our work confirms that normal fibroblasts inhibit
the growth of tumor cells in vitro, largely by a contactdependent mechanism. The inhibitory capacity of the
fibroblast differs depending on the site of origin, and is
also different between normal and cancer-derived
stroma cells. Preliminary gene analysis points to major
differences in gene expression between inhibitory and
noninhibitory fibroblasts.
291
POSTER SESSION
Hall A-E, Poster Section 2 • Monday, 8:00 a.m.-12:00 p.m.
Tumor Biology 11
Poster
Section
2
2
Angiogenesis 2: Novel Targets and Agents
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
292
1002
Norrin controls colon cancer angiogenesis.
Kestutis Planutis, Marina Planoutene, Randall F. Holcombe.
1003
A novel anti-angiogenic compound F16 that
inhibits xenograft tumor growth. Appu Rathinavelu,
Sivanesan Dhandayuthapani.
1004
LHT7, a heparin-taurocholate conjugate, inhibits
multiple stages of angiogenesis by targeting VEGF, FGF2
and PDGF-B. Seung Woo Chung, Jeong Uk Choi, Sang Yoon
Kim, Youngro Byun.
1005
Leptin increases VEGF expression and enhances
angiogenesis in human chondrosarcoma cells. KaiHsiang Hsu, Chih-Hsin Tang, Tzu-Wei Tan.
1006
Structural peculiarities of flavonoids influence
anti-angiogenic, cytotoxic and antioxidant effects:
experimental and insilico analysis. Raju N. Gacche,
Harshala D. Shegokar, Dhananjay S. Gond, Rohan J.
Meshram.
1007
Nanoformulation enhances anti-angiogenic
efficacy of Tunicamycin. Aditi Banerjee, Dipak K. Banerjee.
1008
Resveratrol causes biphasic apoptotic and
proliferative effects and at higher/proapoptotic/antiangiogenesis concentrations causes suppression of
nitric oxide/cGMP/protein kinase G signaling and
decreased expression of prosurvival proteins c-IAP1,
c-IAP2, livin and XIAP in human umbilical vein
endothelial cells. Janica C. Wong, Renee Coffman, Harry
Rosenberg, Ronald R. Fiscus.
1009
Tumor-specific expression of fatty acid
synthase promotes angiogenesis in colorectal cancer.
Yekaterina Y. Zaytseva, Victoria Elliott, Piotr Rychahou,
William Mustain, Ji Tae Kim, Joseph Valentino, Tianyan Gao,
Kathleen O’Connor, Janna Neltner, Heidi Weiss, B. M. Evers.
1010
Paradoxic effects of metformin on endothelial
cells and angiogenesis. Antonino Bruno, Katiuscia
Dallaglio, Anna Rita Cantelmo, Alessia I. Esposito, Luca
Ruggiero, Stefania Orecchioni, Angelica Callieri, Francesco
Bertolini, Ulrich Pfeffer, Douglas M. Noonan, Adriana Albini.
1011
Metformin inhibits angiogenesis, local and
metastatic growth of triple-negative breast cancer by
targeting two classes of adipose tissue progenitors.
Stefania Orecchioni, Giuliana Gregato, Francesca Reggiani,
Patrizia Mancuso, Angelica Calleri, Giovanna Talarico,
Valentina Labanca, Francesco Bertolini.
1012
Procyanidin B2 3,3ⴖ-di-O-gallate (B2G2), a
biologically active constituent of grape seed extract,
inhibits angiogenesis targeting multiple molecular
pathways. Rahul Kumar, Gagan Deep, Michael Wempe,
Rajesh Agarwal, Chapla Agarwal.
1013
Angiopoietin 1/2 inhibition impairs tumor
growth in an orthotopic model of renal cell carcinoma.
Ashley Orillion, Kiersten Marie Miles, Li Shen, Remi
Adelaiye, Eric Ciamporcero, Swathi Ramakrishnan, Sheng Yu
Ku, May Elbanna, Sreenivasulu Chintala, Roberto Pili.
1014
Novel selective HIF1 alpha inhibitor: Well
tolerated with excellent efficacy in renal cell cancer
xenograft studies. Ramin Dubey, Ivan Grishagin, Usha
Nagavarapu, Chenera Balan, Shalabh Gupta, Bogdan Z.
Olenyuk.
1015
Tea Polyphenols suppress non-small cell lung
cancer angiogenesis and growth by regulating VEGF,
NF-␬B and MMPs expression. Jing Wang, Li Hou,
Elizabeth Gullen, Cheng-jie Ma, Hong-li Wu, Li Xu, Yung-chi
Cheng, Xinyi Chen.
1016
Brain-derived neurotrophic factor increases
vascular endothelial growth factor expression and
subsequently enhances angiogenesis in human
chondrosarcoma cells. Chih-Yang Lin, Chih-Hsin Tang.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1017
Id-1 gene and protein as therapeutic target for
head and neck squamous cell carcinoma. Ryuichi
Murase, Sean McAllister, Yohei Fujita, Tomoki Sumida,
Koichi Nakashiro, Pierre Desprez, Hiroyuki Hamakawa.
1018
The diarylpentanoid curcumin analog GO-Y078
can effectively inhibit tumor angiogenesis through actin
disorganization. shunsuke sugiyama, Chikashi Ishioka,
Hiroyuki Shibata.
1019
Salmonella break tumor immune tolerance by
downregulation tumor indoleamine 2, 3-dioxygenase 1
expression. YU-DIAO KUAN, Che-Hsin Lee.
1020
Trefoil factor 3 promotes angiogenesis in
mammary carcinoma. Wai-Hoe Lau, Vijay Pandey, Xiangjun
Kong, Arindam Banerjee, Tao Zhu, Peter E. Lobie.
1021
JFD, a novel small molecule for inhibiting
vascular endothelial growth factor receptor-mediated
angiogenesis. Sivanesan Dhandayuthapani, Appu
Rathinavelu.
1022
Development and preclinical testing of AMG
780, a fully human antibody targeting angiopoietin 1
(Ang1) and angiopoietin 2 (Ang2). James V. Bready,
Kyung Lee, Rick Jacobsen, Kevin Graham, Juan Estrada,
Stephen A. Kaufman, Dongyin Yu, Angela Coxon, Jon Oliner.
1023
NOV C-ter: A novel preclinical anti-angiogenic
agent. Junfeng Luo, Yong Teng, Minghui Li, Theodore S.
Johnson, Franck Cuttitta, Zhengtao Chu, Xiaoyang Qi, John
K. Cowell, Olivier Rixe.
1024
T11TS impedes glioma angiogenesis by
attenuating brain endothelial Angiopoietin-1/Tie2
signaling and inducing apoptosis of glioma associated
brain endothelial cells. Debanjan Bhattacharya, Suhnrita
Chaudhuri, Swapna Chaudhuri.
1025
Antitumor activity of nintedanib (BIBF 1120), a
triple angiokinase inhibitor, in combination with
gemcitabine in experimental pancreatic cancer. Niranjan
Awasthi, Stefan Hinz, Rolf A. Brekken, Margaret A. Schwarz,
Roderich E. Schwarz.
1026
Novel Tie2 inhibitor with in vivo efficacy in
disseminated hematological tumor models in mice.
Sylvia Gruenewald, Julia Schueler, Michael Haerter, Frank
Suessmeier, Kerstin Klingner, Ulf Boemer, Stefan Kaulfuss,
Alexander Walter, Mario Lobell, Ingo V. Hartung, Bernd
Buchmann, Dieter Heldmann, Holger Hess-Stumpp, Karl
Ziegelbauer.
1027
Nef-M1, a peptide antagonist of CXCR4, inhibits
tumor angiogenesis by attenuating AKT and mitogenactivated protein kinase signaling in colon cancer.
Venkat R. Katkoori, Marc D. Basson, Upender Manne,
Harvey L. Bumpers.
1028
Anti-angiogenic activity of MLN4924 suppresses
the growth of urothelial carcinoma via enhancing
vascular normalization. Kuo-How Huang, Yeong-Shiau Pu,
Yu-Chieh Tsai, Kuan-Lin Kuo, I-Lin Ho, Ju-Ton Hsieh,
Tsung-Hsien Shih.
1029
CAF-derived MFAP5 promotes ovarian tumor
angiogenesis through calcium dependent LPP signaling
pathway. Cecilia S. Leung, Tsz-Lun Yeung, Kay-Pong Yip,
Kwong-Kwok Wong, Anil K. Sood, Michael J. Birrer, Samuel
C. Mok.
1030
Are endothelial cells essential for the
development of leukemia. Indhu Subramanian, Emily S.
Fuller, Katie Powell, Rolfe Howlett, Anthony W. Ashton, Viive
M. Howell.
1031
Blockade of radiation-induced neuropilin-1 in
glioblastoma cells impairs migration of endothelial cells.
Dilip Rajasekhar Maddirela, Divya Kesanakurti,
Venkateswara R. Gogineni, Chandramu Chetty.
POSTER SESSION
Tumor Biology 12
Cell Plasticity in Tumor Metastasis
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1032
Ormeloxifene attenuates metastatic and
glycolytic pathways in breast cancer cells. Aditya Ganju,
Vasudha Sundram, Keith Miskimins, Rishi Gara, Sheema
Khan, Man Mohan Singh, Subhash C. Chauhan, Meena
Jaggi.
1033
Inhibiting bladder cancer metastasis with a
dietary supplement. Kelly T. Hoye, Travis Yates, David
Alonzo, Vinata B. Lokeshwar.
1034
ZEB2 promotes cell motility and metastasis in
ERⴙ breast cancer cells. Hope E. Burks, Lyndsay Rhodes,
Elizabeth Martin, Theresa Phamduy, Steven Elliot, Van
Hoang, Henry Segar, Aaron Buechlein, Douglas Rusch, Dave
Miller, Melody Baddoo, Erik Flemington, Kenneth Nephew,
Douglas Chrisey, Bridgette Collins-Burow, Matthew Burow.
1035
hMENA splicing program and TGF-␤1-mediated
EMT in pancreatic cancer. Roberta Melchionna, Pierluigi
Iapicca, Francesca Di Modugno, Paola Trono, Novella
Gualtieri, Maria Grazia Diodoro, Sheila Spada, Giuliana
Falasca, Gian Luca Grazi, Mina J Bissell, Paola Nisticò.
1036
Expression of PRMT5 in lung adenocarcinoma
and its significance in epithelial-mesenchymal
transition. Daisuke Matsubara, Reem Ibrahim, Wael Osman,
Akteru Goto, Teppei Morikawa, Shigeki Morita, Shumpei
Ishikawa, Hiroyuki Aburatani, Masashi Fukayama, Toshiro
Niki, Yoshinori Murakami.
1037
WISP3/CCN6 regulates epithelial-mesenchymal
transition and tumor initiating cell properties in triple
negative breast cancer cells through Slug. Wei Huang,
Kathy A. Toy, Celina G. Kleer.
1038
ZEB1 plays a pivotal role in hypoxia-mediated
increase of in vitro invasion of glioblastoma-derived cell
cultures and represents a novel neural stem cell marker
in early development. Ulf D. Kahlert, Eric E. Raabe, Florian
A. Siebzehnrubl, Eli E. Bar, Jaroslaw Maciaczyk, Charles G.
Eberhart.
1039
Downregulation of beta1 integrins in E-cadherin
positive triple negative breast cancer cells elicits prometastatic shift in migration strategy through TGFbeta/
miR200/ZEB signaling network. Erik H. Danen.
1040
An integrated analysis of EMT across diverse
cancer types identifies new potential therapeutic
targets. Pan Tong, Milena P. Mak, Lixia Diao, Jing Wang,
Patrick Kwok-Shing Ng, You-hong Fan, William N. William,
John V. Heymach, Kevin R. Coombes, Lauren Averett Byers.
1041
TGF-␤1-induced EMT is suppressed by
berberine in triple negative breast cancers. Jeongmin
Lee.
1042
Activation of AKT negates the pro-apoptotic
function of Par-4 in castration resistant prostate cancer
cells. Trinath P. Das, Suman Suman, Chendil Damodaran.
1043
Distinctive roles of Smad3 C-tail and linker
phosphorylation between cancer progression and
suppression in TGF-beta1/Smad3 signal. Eunjin Bae,
Akira Ooshima, Seong-Jin Kim.
1044
Pyruvate kinase M2 stimulates the epithelialmesenchymal transition by genetically controlling Ecadherin expression in colon cancer. Masamitsu Konno,
Atsushi Hamabe, Yuichiro Doki, Masaki Mori, Hideshi Ishii.
1045
Differentiated tumor cells secrete stem cell
factor (SCF) to promote maintenance of cancer stem
cells and induce EMT in colorectal tumors. Szabolcs
Fatrai, Susanne J. van Schelven, Inne H. Borel Rinkes, Onno
Kranenburg.
1046
Molecular link between HER2 and epithelial-tomesenchymal transition in breast cancer. Parul Gupta,
Sanjay K. Srivastava.
April 5–9, 2014 • San Diego, CA
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1047
The multikinase inhibitor K252a suppresses
hepatocellular carcinoma tumor growth in a mouse
xenograft model. Mitsuhiko Abe, Hironori Koga, Takafumi
Yoshida, Hiroshi Masuda, Masahiro Sakata, Yu Ikezono, Toru
Nakamura, Eitaro Taniguchi, Takumi Kawaguchi, Hirohisa
Yano, Takuji Torimura, Michio Sata.
1048
Dichotomy effects of Akt signaling in breast
cancer. Huey-Jen L. Lin, Zhengang Peng.
1049
Quantitative immunofluorescence assessment of
MET and epithelial to mesenchymal transition (EMT)
biomarker modulation by antiangiogenic inhibitors in
xenograft tumor tissues. Tony Navas, Scott L. Lawrence,
Donna Butcher, Lindsay M. Dutko, Melinda G. Hollingshead,
Robert J. Kinders, Ralph E. Parchment, Donald P. Bottaro,
W. Marston Linehan, Joseph E. Tomaszewski, Apurva K.
Srivastava, James H. Doroshow.
1050
Alvespimycin (17-DMAG) blocks TGF␤-induced
EMT and migration in A549 lung cancer cells. Edna
Gordian, Eric Welsh, Teresita Muñoz-Antonia.
1051
Metastasis suppressor CD82 functions as a
negative regulator in the adhesion-dependent epithelialto-mesenchymal transition in prostate cancer cells. HeeJung Byun, Yong-Sun Lee, Young-June Jin, Jae-Sub Lee,
Young-Myeong Kim, Hansoo Lee.
1052
Dual role of MEK1/2 and MEK5 in the reversal
of epithelial-to-mesenchymal transition. Van T. Hoang,
Steven Elliott, Elizabeth C. Martin, Lyndsay V. Rhodes, Henry
C. Segar, Hope Burks, Suravi Chakrabarty, Darlene Monlish,
Theresa B. Phamduy, Doug Chrisey, Jane E. Cavanaugh,
Patrick Flaherty, Bridgette M. Collins-Burow, Matthew E.
Burow.
1053
Interplay of YB-1 and IL-6 in the acquisition of
EMT-like characteristics. Barbara Castellana, Trond Aasen,
Santiago Ramón y Cajal.
1054
Role of exosomes in tumor growth and
metastasis of lung cancer. Radha Munagala, Cameron
Campbell, Ramesh Gupta.
1055
Syntenin positively regulates TGF-␤1- and
oncogenic Ras-mediated EMT-like phenotypic changes
in cancer cells. Okhwa Kim, Cheol Hwangbo, Nara Tae,
Suhyun Lee, Jeong-Hyung Lee.
1056
COX-2/PGE2-driven lung cancer
invasion/metastasis is dependent on MIG-7 and
phosphorylated prohibitin. Chi-Ming Liang, Ming-Yi Ho,
Shu-Mei Liang.
1057
LPA stimulates EMT of ovarian cancer cells via
gip2 and gep oncogenes. Ji Hee Ha, Jeremy Ward, Danny
N. Dhanasekaran.
1058
Grainyhead-like 2 regulates molecular subtype
switching in epithelial ovarian cancer. Vin Yee Chung,
Meng Kang Wong, Kuee Theng Kuay, Tuan Zea Tan, Ernesto
Guccione, Jean Paul Thiery, Ruby Yun-Ju Huang.
1059
EGF induces epithelial-mesenchymal transition
and cancer stem cell properties in human oral
squamous cell carcinoma. Qilin Xu, Qunzhou Zhang, Anh
Le.
1060
Integrated target discovery in the EMPathy
Breast Cancer Network - Multidimensional analysis of
epithelial mesenchymal plasticity (EMP) in experimental
systems. Tony Blick, Gayle Phillip, Eva Tomaskovic-Crook,
Annet Hammacher, Nicholas Wong, Izhak Haviv, The
EMPathy Breast Cancer Network, Greg Goodall, Melissa
Davis, Erik W. Thompson.
1061
High resolution DNA recognition by the Snail
zinc finger protein: Testing of a molecular dynamics
based model defines the atomic level interactions
required for high affinity binding, E-box specificity and
reveals potential strategies for small molecule control of
EMT transcriptional programs. Yuanjie Liu, Jeremy W.
Prokop, Hongzhuang Peng, Frank J. Rauscher.
3
3
293
POSTER SESSION
Tumor Biology 13
Poster
Section
4
4
Cells and Their Factors in the Tumor Microenvironment
Poster Abstract
Board Number
1.
2.
3.
5.
6.
7.
8.
10.
11.
12.
13.
14.
15.
16.
294
1062 Sustained adrenergic signaling promotes
intratumoral innervation through BDNF induction. Guillermo
N. Armaiz-Pena, Archana S. Nagaraja, Julie K. Allen, Nouara C.
Sadaoui, Rajesha Rupaimoole, sherry Y. wu, Sunila Pradeep,
Hee D. Han, Behrouz Zand, Heather Dalton, Rebecca Previs,
Morgan Taylor, Justin Bottsford-Miller, Lingegowda S. Mangala,
Cristian Rodriguez-Aguayo, Mariela De Biasi, Gabriel LopezBerestein, Steve Cole, Susan K. Lutgendorf, Anil K. Sood.
1063 Inverse hormesis of cancer growth mediated by
narrow ranges of tumor-directed antibodies. Oliver M.
Pearce, Heinz Läubli, Andrea Verhagen, Patrick Secrest, Jiquan
Zhang, Paul R. Crocker, Nissi Varki, Jack Bui, Ajit Varki.
1064 IL-6 secreted by tumor-associated macrophages
promotes DLBCL chemoresistance via expansion of the
CSCs population. Nan Bai.
1066 MicroRNA-125b mediated par2 activation-induced
cell migration. LAN YANG.
1067 Somatic genomic mutations, RNA-Seq, and
proteomic signal transduction network analysis of tumor
and stroma in metastatic triple negative breast cancer.
Virginia A. Espina, Joyce A. O’Shaughnessy, Maren K. Levin,
David W. Craig, John D. Carpten, Daniel Von Hoff, Lance A.
Liotta.
1068 Socs3 deficiency in myeloid cells promotes
prostate tumor development. Hao Yu, Hongwei Qin.
1069 M1 macrophages suppress tumorigenesis via
accumulated p53 and upregulated STAT1 in lung cancer.
Yi-Jing Hsiao, Kang-Yi Su, Jian-Wei Chen, Sung-Liang Yu.
1071 Adoptive transfer of T cells overcomes barriers of
homing to the tumor microenvironment in ovarian cancer.
Emese Zsiros, Priyanka Duttagupta, Thomas Garrabrant, Janos
L. Tanyi, Lana E. Kandalaft, George Coukos.
1072 TAM and CD44 in medullary thyroid carcinoma.
MARTA MIYAZAWA, MARIA JOSE C. SANTOS, LARISSA V. BIM,
ERIKA S. ORTI-RADUAN, FLÁVIA O. VALENTE, ADAUTO F. NUNES,
ROSANA DELCELO, RUI M. MACIEL, JANETE M. CERUTTI.
1073 Significant association of neutrophils in regional
lymph nodes with lymphangiogenesis and micrometastasis
by gastric cancer. Mao Tokumoto, Hiroaki Tanaka, Masaichi
Ohira, Yukie Go, Yoshihiro Okita, Katunobu Sakurai, Takahiro
Toyokawa, Naoshi Kubo, Kazuya Muguruma, Kiyoshi Maeda,
Tetsuji Sawada, Kosei Hirakawa.
1074 Tumor-associated microglia secrete paracrine
factors that promote Nf1-deficient optic glial cell growth.
Anne C. Solga, Winnie W. Pong, Patrick J. Cimino, Keun Y. Kim,
Jason Walker, Todd Wylie, Vincent Magrini, Joshua B. Rubin,
David Piwnica-Worms, Mark H. Ellisman, Elaine R. Mardis, David
H. Gutmann.
1075 Molecular determinants of colon and renal
cancers’ immune contextures. Etienne Becht, Nicolas A.
Giraldo, Romain Remark, Aurelien de Reynies, Laetitia Lacroix,
Diane Damotte, Catherine Sautès-Fridman, Wolf-Herman
Fridman.
1076 Antagonists of the chemokine receptor CCR4
reverse the tumor-promoting microenvironment of renal
cancer. Chiara Berlato, Moddasar N. Kahn, Tiziana Schioppa,
Richard Thompson, Eleni Maniati, Monica Canosa, Hagen Kulbe,
Chris Sheldon, Keith Wreggett, Urs Hagemann, Alexander
Duncan, Laura Fletcher, Robert W. Wilkinson, Thomas Powles,
Sergio Quezada, Frances Balkwill.
1077 Loss of HER2 via trogocytosis by CD14ⴙ cells in
HER2-overexpressing breast cancer cells is associated with
diminishing of trastuzumab-mediated antibody-dependent
cellular cytotoxicity. Eiji Suzuki, Mariko Nishie, Kosuke
Kawaguchi, Sunao Tanaka, Masakazu Toi.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1078 Cancer-associated fibroblasts promote endometrial
cancer cell proliferation in vitro and in vivo. Ivy Chung,
Kavita S. Subramaniam, Seng Tian Tham, Zahurin Mohamed,
Noor Azmi Mat Adenan, Yin Ling Woo.
1079 COX-2 blockade immunologically suppresses brain
metastasis of lung cancer. Mitsugu Fujita, Susumu Nakata,
Takeshi Okuda, Amami Kato, Osamu Yoshie.
1080 The adaptive immune system promotes
spontaneous prostate carcinogenesis in a transgenic mouse
model. Monique H. Melis, J. van Burgsteden, H J. van Zeeburg,
J Zevenhoven, J-Y Song, K E. de Visser, A M. Bergman.
1081 Extent of intranodal macrophage correlates with
lymph node metastasis of gastric cancer. Yukie Go, Hiroaki
Tanaka, Mao Tokumoto, Yoshihiro Okita, Masatsune Shibutani,
Sadaaki Yamazoe, Katsunobu Sakurai, Hisashi Nagahara, Kenjiro
Kimura, Takahiro Toyokawa, Ryosuke Amano, Naoshi Kubo,
Kazuya Muguruma, Hiroshi Otani, Masakazu Yashiro, Kiyoshi
Maeda, Masaichi Ohira, Kosei Hirakawa.
1082 IL27 promotes papilloma formation via inducing a
pro-inflammatory milieu in the skin. Denada Dibra, Xueqing
Xia, Melissa Newman, Camille Keenan, Shulin Li.
1083 Host-tumor immune response for early breast
cancer patients treated with radiofrequency ablation
therapy. Shigeru Imoto, Noriko Nakatsugawa, Takayuki Ueno,
Hiroki Ito, Kentaro Imi, Kaisuke Miyamoto, Manami Kitamura,
Hirotsugu Isaka, Tetsuya Nakatsura.
1084 Triple-negative breast cancer displays a unique
subset of macrophages dependent on CCL5 signaling. Daniel
C. Rabe, Casey Frankenberger, Russell Bainer, Yoav Gilad,
Marsha R. Rosner.
1085 Glioma-infiltrating myeloid derived suppressor cells
inhibit anti-tumor T cell responses. Neha Kamran, Hikmat
Assi, Marianela Candolfi, Mariela Moreno, Youping Li, Pedro R.
Lowenstein, Maria G. Castro.
1086 Paracrine interactions between macrophages,
adipocytes and tumor cells in the breast cancer
microenvironment of the obese female mouse contribute to
tumor progression. Ana M. Santander, Tulay Koru-Sengul,
Olivia Casas, Lidia Sanchez, Osvaldo Perez, Marta TorroellaKouri.
1087 Accumulation of CD11bⴙ Gr1 myeloid cells in liver
metastases stimulates tumor growth and angiogenesis. Su
Yin Lim, Alex Gordon-Weeks, Lei Zhao, Veerle Kersemans,
Danny Allen, Sean Smart, Ruth J. Muschel.
1088 Differences in metastatic patterns in relation to
time between primary surgery and first relapse from breast
cancer suggest synchronized growth of dormant
micrometastases. Hanna Dillekås, Monica Transeth, Martin
Pilskog, Jörg Assmus, Oddbjorn Straume.
1089 Matrix stiffening and ␤1 integrin promote
fibroblast accumulation in lung squamous cell carcinomas
but not in adenocarcinomas. Jordi Alcaraz, Marta Puig,
Roberto Lugo, Alícia Giménez, Adriana Velásquez, Roland
Galgoczy, Josep Ramírez, Abel Gómez-Caro, Pere Gascón,
Noemi Reguart.
1090 Type 2 endometrial cancer is associated with an
M1 subtype, tumor associated macrophage polarization in
the stromal compartment. Michael G. Kelly, Antonio M.
Francisco, Adela Cimic, Anne Wofford, Nora Fitzgerald, Jie Yu,
Robert N. Taylor.
1091 CCR4ⴙ regulatory T cells progressively accumulate
in the presence of leukocyte-derived CCL22/CCL17 in an
experimental model of glioblastoma multiforme. Alan L.
Chang, Derek A. Wainwright, Mahua Dey, Yu Han, Maciej S.
Lesniak.
POSTER SESSION
Tumor Biology 14
Dynamic Interactions in the Tumor Microenvironment
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
1092
Trogocytosis of HER2 overexpressing human
breast cancer cell lines may induce its dormancy
without depending on HER family signal. Junichi Aratake,
Eiji Suzuki, Natsue Uehiro, Mariko Nishie, Kosuke
Kawaguchi, Fumiaki Sato, Masakazu Toi.
1093
Legumain in colorectal cancer: Unorthodox
localization and trafficking. Mads H. Haugen, Kjersti
Flatmark, Ingrid Damgaard, Tripti Tamhane, Birgit
Engesæter, Siri Tveito, Eivind V. Egeland, Rigmor Solberg,
Harald T. Johansen, Solveig J. Pettersen, Kjetil Boye,
Klaudia Brix, Gunhild M. Mælandsmo.
1094
Dynamics of Gemcitabine induced interleukin-8
(IL-8) expression in pancreatic tumor microenvironment.
Sobeyda Gomez, Takahiko Fujii, Haojie Huang, Rosa Hwang,
Viji Ramachandran, Craig Logsdon, Thiru Arumugam.
1095
microRNA-26a expression may suppress tumor
growth by modulating macrophage infiltration in tumor
through down-regulation of M-CSF in hepatocellular
carcinoma. Zong-Tao Chai, Xiao-Dong Zhu, Jian-Yang Ao,
Ling-Qun Kong, Yuan-Yuan Zhang, Hui-Chuan Sun.
1096
Investigating the role of the adipocytemacrophage interaction in breast cancer metastasis.
Nalini V. Yadav, Aaron T. Jacobs, Linda Connelly.
1097
Potentiating antitumor CD4ⴙ T cell responses
with chemotherapeutic agents. Gang Zhou, Xiaoyun Lu.
1098
TIMP-1: A potential biomarker of
neuroendocrine differentiation in metastatic castrationresistant prostate cancer (mCRPC). Yixuan Gong, Uma
Chippada-Venkata, Xudong Dai, Matthew D. Galsky, Jiaoti
Huang.
1099
Sorafenib increases numbers and functions of
tumor-infiltrated T cells and enhances therapeutic
outcomes of adoptive T cell therapy by modifying tumor
microenvironment. Jeng-Jong Hwang, Hui-Yen Chuang,
Ya-Fang Chang.
1100
Macrophage infiltration is associated with
release from dormancy in a novel model of dormant
prostate cancer. Thomas Long, Cynthia C. Sprenger, Ilsa
Coleman, Peter Nelson, Buddy Ratner, Stephen Plymate.
1101
Acidosis-induced NF-␬B promotes cell invasion
in breast cancer. Subash C. Gupta, Yin-Yuan Mo.
1102
Neutrophils impact on growth and mobility of
human colorectal cancer cells. Valeria Governa, Luca
Quagliata, Valentina Mele, Christian Hirt, Luigi Terracciano,
Giulio C. Spagnoli, Elisabetta Padovan.
1103
MDSC targeting therapy for uterine cervical
cancer displaying TRL. Yuri Matsumoto, Mahiru Kawano,
Tomoyuki Sasano, Seiji Mabuchi.
1104
The role of DLL4 in cancer immune-surveillance
and its pathogenicity in p53-dysregulated environment.
Zhixing Yao, Zaki A. Sherif.
1105
A prospective study of lymphocytes infiltrating
the breast cancer microenvironment. Laurence Buisseret,
Soizic Garaud, Hugues Duvillier, Celine Naveaux, Sebastien
Duquenne, Alexandre de Wind, Christos Sotiriou, Karen
Willard-Gallo.
1106
The tumor immune microenvironment
modulates response to chemotherapy in high-grade
serous epithelial ovarian cancer. Madhuri Koti, Andrew
Edwards, Jeremy A. Squire.
1107
Tumor microenvironment based modulation of
thyroid cancer phenotype. Neha Y. Tuli, Jonathan Cabin,
Robert Suriano, Robert Bednarczyk, Elyse Hanly, Jan
Geliebter, Edward Shin, Raj K. Tiwari.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1108
B-cell lymphoma-derived exosomes are
reservoirs of inhibitors of apoptosis. Heather R. Ferguson
Bennit, Malyn M. Asuncion Valenzuela, Jessica S. Jutzy,
Nathan R. Wall.
1109
The antimicrobial peptide LL37 activates
plasmacytoid dendritic cells in breast cancer. Nelly Vey,
Elena Blanc, Vanja Sisirak, Sandra Thys, Céline Le Beux,
Nadège Goutagny, Isabelle Treilleux, Aurélien Marabelle,
Jean-Yves Blay, Christophe Caux, Nathalie BendrissVermare.
1110
Colorectal liver metastases induce a systemic
phase shift of the biological clock. Sander A. Huisman, F.
Tamanini, A. Ahmadi, J.N.M. IJzermans, G.T.J. van der
Horst, R.W.F. de Bruin.
1111
Hypoxia inducible factor regulation of galectin3
expression in neuroblastoma cells:Implications in
controlling malignant phenotype of neuroblastoma cells.
Umadevi V. Wesley, Esat Resad, Robert J. Dempsey.
1112
Role of osteoprotegerin in inflammatory and
invasive breast cancer. Sudeshna Goswami, NEELAM
SHARMA-WALIA.
1113
Targeting the JAK2/STAT3 pathway in ovarian
cancer. Galina Gritsina, Fang Xiao, Shane W. O’Brien,
Marisa A. Maglaty, Ren-Huan Xu, Luis J. Sigal, Samuel
Litwin, Denise C. Connolly.
1114
Combination of a novel CXCR4 antagonist with
chemotherapy reduces breast cancer bone metastatic
tumor burden. Jingyu Xiang, Michelle A. Hurchla, Kathryn
Luker, Garry Douglas, Barbara Romagnoli, Eric Chevalier,
Michael Bauer, Johann Zimmermann, Klaus Dembowsky,
Gary Luker, Katherine N. Weilbaecher.
1115
A discrete tuning of ␣5␤1 integrin activity
sustains the tumor-ECM induced fibroblastic activation
in pancreatic cancer stroma. Janusz Franco-Barraza,
Tiffany Luong, Neelima Shah, Raj Madhani, Katherine
Alpaugh, John Hoffman, Edna Cukierman.
1116
Response to cyclooxygenase-2 inhibition is
regulated by collagen dense stroma. Karla Esbona, David
Inman, Sandeep Saha, Kevin Eliceiri, Lee G. Wilke, Patricia
J. Keely.
1117
Platelet interaction induces Tissue Factor and a
pro-metastatic phenotype in ovarian cancer cells. Renan
F. Orellana, Barbara Oliva, Sumie Kato, Loreto Bravo,
Pamela Gonzalez, Olga Panes, Diego Mezzano, Mauricio
Cuello, Gareth Owen.
1118
Stress-induced differential Survivin release in
prostate cancer health disparities. Salma Khan, David
Turay, Jessica M. Jutzy, Jonathan R. Aspe, Tino W.
Sanchez, Saeid Mirshahidi, Carlos A. Casiano, Nathan R.
Wall.
1119
Utilization of the TGF␤ signaling pathway and
cell substrate interaction in a novel anti-cancer drug
screen. Wontak Kim, Jacob P. Hoj, Nicholas E. Saguibo,
Kendra E. Fullmer.
1120
Bioenergetics of T cells in the context of
adoptive immunotherapy. Ekaterina Moroz, Maxim Moroz,
Inna Serganova, Juan Zurita, Jason Lee, Nisargbhai Shah,
Vladimir Ponomarev, Ronald Blasberg.
1121
Extracellular matrix-integrin 〉1 signaling is a
major mediator of epithelial-to-mesenchymal transition
and contributes to prostate cancer invasion and
metastasis. Steven R. Bugiel, Elisabeth McKittrick, Huijun
Zhao, Grant A. Howe, Christina L. Addison.
Poster
Section
5
5
295
POSTER SESSION
Tumor Biology 15
Poster
Section
6
6
Epithelial-Mesenchymal Transitions in Tumor Metastasis
Poster Abstract
Board Number
1.
2.
3.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
296
1122
Tetrandrine induces expression of
growth/differentiation factor-15 and promoted terminal
differentiation of PCa cells. Sweaty Koul, Hari K. Koul.
1123
Fucosylated TGF-ß receptors transduce a signal
for epithelial-mesenchymal transition in colorectal
cancer cells. Rishu Takimoto, Masahiro Hirakawa, Fumito
Tamura, Makoto Yoshida, Michihiro Ono, Yasushi Sato,
Takahiro Osuga, Junji Kato.
1124
ETS1 regulates epithelial-to-mesenchymal
transition (EMT) in prostate cancer cells. Jamie J.
Rodgers, Michael Epis, Ronald Cohen, Peter Leedman,
Jennet Harvey, Marc Thomas, Jacqueline Bentel.
1126
Tristetraprolin inhibits Twist1-induced cancer
cell migration. Wha Ja Cho, Nal Ae Yoon, Mai-Tram Vo,
Young Joo Min, Jeong Woo Park.
1127
Snail inhibits lung colonization and metastasis
in luminal type A breast cancer cells. Shih-Pei Lin, ShihChieh Hung.
1128
Thrombomodulin mediates the migration of
cervical cancer cells through the regulation of
epithelial-mesenchymal transition biomarkers. Yu-Jia
Chang, Po-Li Wei, Ming-Te Huang.
1129
Adenylate kinase 4 promotes metabolic
reprogramming and induces EMT in lung cancer
through ROS-dependent stabilization of HIF1-␣. Yi-Hua
Jan, Michael Hsiao.
1130
AKT-mediated phosphorylation is responsible
for TWIST1-mediated tumor growth and metastasis.
Osman N. Ozes, Suray Pehivanoglu, Gokhan Ertosun,
Gokhan Gorgisen, Nuray Erin, Duygu Unal, Gamze Tanriover.
1131
Snail- and ERK2-dependent signaling enhances
breast cancer cell resistance to hydroxytamoxifen.
Bethany N. Smith, Peri Nagappan, Latonia Taliaferro-Smith,
Roman Mezencev, Clayton Yates, Cimona Hinton, Valerie
Odero-Marah.
1132
Irradiation promotes a mesenchymal switch in
small cell lung cancer. Suzanne L. Meredith, Jennifer L.
Bryant, Muhammad Babur, Philip Riddell, Kaye J. Williams,
Anne White.
1133
Partial EMT, hybrid epithelial-mesenchymal
phenotype and epithelial plasticity: role of (miR-200/
ZEB) loop. Mohit Kumar Jolly, Mingyang Lu, Herbert Levine,
Jose N. Onuchic, Eshel Ben-Jacob.
1134
Slug promotes survival during metastasis
through suppression of Puma-mediated apoptosis.
Rachel Hazan.
1135
C-myc-SOD2/Bmi1 pathway mediates cancer
stem-like cell migration and invasion in tongue
squamous cell carcinoma. Qianting He, Zhonghua Liu,
Leitao Zhang, Tingting Zhao, Luodan Zhao, Dan Chen, Yu
Chen, Xueqiang Ding, Xiaofeng Zhou, Anxun Wang.
1136
p53-induced miR-15a/16 –1 and AP4 form a
double-negative feedback loop to regulate epithelialmesenchymal transition and metastasis in colorectal
cancer. Lei Shi, Rene Jackstadt, Helge Siemens, Huihui Li,
Thomas Kirchner, Heiko Hermeking.
1137
Bub1 is a key regulator of TGF-␤ signaling.
Shyam Nyati, Katrina Schinske-Sebolt, Sethuramasundaram
Pitchiaya, Katerina Chekhovskiy, Areeb Chator, Nauman
Chaudhry, Joseph Dosch, Marcian E. Van Dort, Varambally,
Kumar-Sinha, Nyati, Ray, Walter, Sooryanarayana
Varambally, Chandan Kumar-Sinha, Mukesh K. Nyati,
Dipankar Ray, Nils G. Walter, Hongtao Yu, Brian D. Ross,
Alnawaz Rehemtulla.
1138
Aberrant expression of Plastin3 (PLS3) induces
liver metastasis via enhancing the epithelialmesenchymal transition and stemness in colorectal
cancer (CRC). Masami Ueda, Keishi Sugimachi, Junji
Kurashige, Shotarou Sakimura, Hidenari Hirata, Ryutarou
Uchi, Yuki Takano, Hiroki Ueo, Tae Matsumura, Yoshiaki
Shinden, Hidetoshi Eguchi, Tomoya Sudo, Masaki Mori,
Koshi Mimori.
Poster Abstract
Board Number
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1139
Extracellular matrix components direct
chromatin texture and nuclear morphological changes in
epithelial-mesenchymal transition. James E. Verdone,
Robert W. Veltri, Steven M. Mooney, James R. Hernandez,
Calvin A. Harberg, Donald S. Coffey, Kenneth J. Pienta.
1140
Par-4 mediates EMT in response to TGF-␤
stimulation. François Fabi, Parvesh Chaudhry, Mohan
Singh, Eric Asselin.
1141
p53-dependent regulation of epithelial-tomescenchymal transition by nf-␬b in head and neck
squamous cell carcinoma. Yuan Lin, Jie Luo, Elliot
Abemayor, Sherven Sharma, Steven Dubinett, Maie St John.
1142
Tropomyosin-related receptor kinase B at the
invasive front of gastric cancer and tumor cell
dedifferentiation. Koji Tanaka, Tadanobu Shimura, Takahito
Kitajima, Satoru Kondo, Shozo Ide, Hiroki Imaoka, Yoshinaga
Okugawa, Susumu Saigusa, Yuji Toiyama, Yasuhiro Inoue,
Tshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri, Masato
Kusunoki.
1143
Induction of epithelial-mesenchymal transition
(EMT) in human gastric cancer cell lines induced by
Tip␣ of H. pylori mediated through surface nucleolin.
Hirota Fujiki, Tatsuro Watanabe, Atsushi Takahashi, Kaori
Suzuki, Miki Kurusu-Kanno, Kensei Yamaguchi, Masami
Suganuma.
1144
Cell plasticity mediated by EMT-inducing
transcription factors contributes to melanoma
development. Julie Caramel, Geoffrey Richard, Michelle
Houang, Arnaud de la Fouchardiere, Lionel Larue, Richard
Marais, Stephane Dalle, Eugene Tulchinsky, Stephane
Ansieau, Alain Puisieux.
1145
Oncogenic p27 promotes tumor progression and
metastasis by regulating epithelial to mesenchymal
transition. Alexandra H. Besser, Dekuang Zhao, Seth A.
Wander, Wen Zhou, Jun Sun, Bin Wang, Joyce M.
Slingerland.
1146
Up-regulation of integrin ␤4 promotes
epithelial-mesenchymal transition and is a novel
prognostic marker in pancreatic cancer. Yohei Masugi,
Ken Yamazaki, Katsura Emoto, Kathryn Effendi, Minoru
Kitago, Osamu Itano, Yuko Kitagawa, Michiie Sakamoto.
1147
CD44s is required for EMT and stemness
properties via ZEB1 activation. Bogdan-Tiberius Preca,
Karolina Bajdak, Jessica Pfannstiel, Thomas Brabletz.
1148
Epithelial to mesenchymal transition might be
induced via CD44 isoform switch in colorectal cancer.
Naoki Mashita, Suguru Yamada, Naoki Iwata, Mitsuro
Kanda, Daisuke Kobayashi, Chie Tanaka, Tsutomu Fujii,
Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Shuji
Nomoto, Michitaka Fujiwara, Yashuhiro Kodera.
1149
The role of the novel Notch1-Sox9 signaling
axis in NSCLC progression and EMT. Kathleen M.
Capaccione, Xuehui Hong, Katherine M. Morgan, Thaddeus
D. Allen, Gregory D. Miles, Elke K. Markert, J. M. Bishop,
Sharon R. Pine.
1150
The role of the tumor suppressor gene THY1 in
suppression of epithelial-mesenchymal transition (EMT)
in nasopharyngeal carcinoma. Hong Lok Lung, Maria Li
Lung.
1151
SIRT6 induces EMT and promotes cancer cell
invasion and migration in prostate cancer. Qian Xie, Alice
ST Wong, Weiliang Xia.
POSTER SESSION
Tumor Biology 16
Factors Influencing the Tumor Microenvironment
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1152
Gene profiling of multiple myeloma: MAPK
pathway deregulation, which is regulated by PIM-1 and
MOS, is associated with relapse within 6 months after
autoSCT in MM patients. Woo June Jung, Kwang-Sung
Ahn, Chansu Lee, Youngil Koh, Hyun Jung Lee, Hyo Jung
Kim, Hwi-Joong Yoon, Sung-Soo Yoon.
1153
Stromal FoxM1 and p53 in lung cancer as
mediators of tumor progression, metastatic spread and
chemo-resistance. Iris Kamer, Inbal Daniel, Gili Perry, Amir
Onn, Jair Bar.
1154
Age of type I collagen is critical for regulation
of HT-1080 cell proliferation in 3D matrices. Charles
Saby, Hassan El Btaouri, Julie Routhier, Céline Charpentier,
Laurence Van-Gulick, Marie P. Courageot, Pierre
Jeannesson, Hamid Morjani.
1155
Chemoresistance acquisition by ovarian
adenocarcinoma cells due to microenvironment. Benoit
Thibault, Magali Castells, Delphine Mihas, Ludivine Genre,
Cecile Gandy, Eliane Mery, Jean Pierre Delord, Bettina C.
Couderc.
1156
Shed syndecan-1 downregulates histone
acetyltransferase activity and shuttles HGF to the
nucleus of tumor and host cells. Mark Stewart, Vishnu
Ramani, Ralph Sanderson.
1157
Differential effects of aluminum exposure on
epithelial and mesenchymal cells. Manar A.
AbdelMageed, Parthena Foltopoulou, Monica BetancurBoissel, Elizabeth A. McNiel.
1158
Microtubule perturbation regulates remodeling
of tumor microenvironment by modulating the
composition of tumor cell secretome. Katsuhiro Kita,
Andy Tran, Lewis M. Brown, Duane C. Hassane, Shawn
Carey, Alexandre Matov, Cynthia A. Reinhart-King, Paraskevi
Giannakakou.
1159
A novel HGF-MET paracrine signaling pathway
promotes growth and resistance to chemotherapy in
lung cancer. Hyejin Choi, Ding Cheng Gao, Sharrell B. Lee,
Anna Durrans, Seongho Ryu, Olivier Elemento, Stephen
Wong, Nasser K. Altorki, Vivek Mittal.
1160
Novel CSF-1 receptor ligand IL-34 modulates
macrophage-breast cancer cell crosstalk. Sandun
Gunawardhana, Karin Zins, Trevor Lucas, Dietmar Abraham.
1161
COX-2 blockade improves efficacy of VEGFtargeting drugs. Isabel Ben Batalla, Miguel Cubas-Cordova,
Florian Udonta, Mark Wroblewski, Stefanie Sawall, Victoria
Gensch, Klaus Pantel, Carsten Bokemeyer, Sonja Loges.
1162
Fibroblast RHAMM promotes breast cancer
aggression by promoting expression of a subset of
ERK1,2 target genes. Cornelia Toelg, Patrick Telmer, Sara
Hamilton, James McCarthy, Eva Turley.
1163
Microenvironment targets in KRAS-mutated
metastatic colorectal cancer. Serena Marchio, Alice
Bartolini, Sabrina Cardaci, Marco Soster, Giorgio Corti,
Simona Lamba, Federico Bussolino, Davide Cora’, Federica
Di Nicolantonio.
1164
sHER3 inhibits the proliferation and migration
of melanoma-derived cells in a tenascin-dependent
manner. Chunlin Cai, Nita J. Maihle.
1165
Focal adhesion kinase (FAK) mediates
fibroblast-induced HER2ⴙ breast cancer cell migration
and invasion through a mechanism involving Stat3.
Glorianne Lazaro, Chris Smith, Stephen Hiscox.
1166
CXCR7-mediated signaling axis regulates breast
cancer growth and metastasis by modulating tumor
microenvironment. Nissar A. Wani.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1167
Osteolysis, splenic and hepatic extramedullary
hematopoiesis, MDSCs, tumor growth, and metastases
by orthotopic mammary tumors are increased by
alcohol consumption and fatty diets. Anand Dusad,
Saraswoti Khadge, Geoffrey M. Thiele, Michael J. Duryee,
Holly C. Britton, Lynell W. Klassen, Alicia J. Dafferner, Tracy
Farrell, Timothy R. McGuire, Carlos D. Hunter, Karen C.
Easterling, Karen J. O’Kane, John G. Sharp, James E.
Talmadge.
1168
Cathelicidin is a novel mediator of cancer
immune surveillance. Emilie T. Gross, Carlos D. Peinado,
Isis G. Perez, Samaneh Keshavarz, Jack D. Bui.
1169
TPL2 kinase regulates the inflammatory milieu
of the myeloma niche. Chelsea Hope, Samuel J. Ollar,
Erika Heninger, Jeffrey L. Jensen, Ellen Hebron, Jaehyup
Kim, Ioanna Maroulakou, Shigeki Miyamoto, Natalie
Callander, Peiman Hematti, Marta Chesi, P. Leif Bergsagel,
Fotis Asimakopoulos.
1170
Maresin 1: a potent endogenous antiinflammatory and pro-resolving inhibitor of primary
tumor growth and metastasis. Dayna Mudge, Mark W.
Kieran, Diane Bielenberg, Ofra Benny, Jesmond Dalli, Sui
Huang, Charles N. Serhan, Dipak Panigrahy.
1171
Proinflammatory chemokine interleukin-8 in the
tumor microenvironment modulates breast cancer
phenotype. Robert Bednarczyk, Neha Tuli, Ghada
Benrahoma, Rui Kitadai, Robert Suriano, Abraham
Mittelman, Raj K. Tiwari.
1172
Targeting c-Met and VEGFR2 in the stromal
compartment of prostate cancer bone metastasis.
Changki Lee, Preston Campbell, Young Mi Whang, Jamey D.
Young, Florent Elefteriou, Serk In Park.
1173
HIF-1 promotes the infiltration of regulatory T
cells into the tumor via TGF-␤. Koji Teramoto, Yasuhiko
Ohshio, Jun Hanaoka, Atsushi Takano, Yataro Daigo.
1174
VCAM-1 enhances immune evasion in a murine
model of metastatic cervical cancer. Francesca Scrimieri,
Iuliana D. Bobanga, Saada Eid, David J. Corn, Deborah
Barkauskas, Jay Jay Myers, Alex Y. Huang.
1175
Interleukin-15 activates NK and CD8 T cells
within the Prostate cancer microenvironment by
expanding activatory NK cell receptors and attenuating
inhibitory HLA ligands on tumour cells. Christina A.
Sakellariou, Oussama Elhage, Osamu Ukimura, Inderbir Gill,
Richard A. Smith, Prokar Dasgupta, Christine Galustian.
1176
Tumor derived peptide from a2 isoform of
Vacuolar ATPase immunomodulates tumor associated
neutrophils. Safaa A. Ibrahim, Magdy Amin, kenneth D.
Beaman.
1177
Pharmacological stimulation of DLL1-Notch
signaling as an effective cancer immunotherapy. Asel K.
Biktasova, Fred D. Dudimah, Roman Uzhachenko, Rajeswara
R. Arasada, Elena E. Tchekneva, David P. Carbone, Anil
Shanker, Mikhail M. Dikov.
1178
Gene and protein expression profiling identifies
molecular signature of resistance to anti-VEGF therapy
in ovarian cancer. Bharat Kumar Devapatla, Pharavee
Jaiprasart, Sukyung Woo.
1179
Macrophage conditioned media increases the
expression of a metastasis-associated oncogene, RhoC,
and the migration of inflammatory breast cancer cells.
Chelsea L. Fournier, Steven G. Allen, Yu-Chih Chen, Euisik
Yoon, Sofia D. Merajver.
1180
CCL-4 affects prostate cancer cell migration
and tumorigenesis. Krizia Rohena-Rivera, María M.
Sánchez-Vázquez, Némesis Merly-Torres, Joseph A.
Casillas-González, Yarimar Padín-López, Ingrid ForestierRomán, Magaly Martínez-Ferrer.
1181
The Apoptosis repressor with a CARD domain
(ARC) is a direct HIF1 target gene and promotes survival
and proliferation of VHL deficient renal cancer cells.
Olga V. Razorenova, Laura Castellini, Renata Colavitti, Laura
E. Edgington, Monica Nicolau, Xin Huang, Barbara Bedogni,
Edward M. Mills, Matthew Bogyo, Amato J. Giaccia.
Poster
Section
7
7
297
POSTER SESSION
Tumor Biology 17
Poster
Section
8
8
Human to Mouse 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
298
1182
Patient derived xenograft (PDX) of human
melanoma to predict clinical responses. Clemens Krepler,
Katrin Sproesser, Patricia Brafford, Min Xiao, Marilda Beqiri,
Wei Xu, Katherine Nathanson, Jennifer Wargo, Keith
Flaherty, Donald L. Morton, Dave S. Hoon, Randall Ryan,
Michael Guarino, Nicholas J. Petrelli, David Elder, Xiawei Xu,
Giorgos Karakousis, Lynn Schuchter, Meenhard Herlyn.
1183
Establishment,characterization and utilization of
models of central nervous system metastasis. Kyle N.
Johnson, Paul M. Gonzalez, Mario Sepulveda, Loren Gorgol,
Jennifer Glen, Danielle M. DiPerna, Mark Bernstein, Steven
A. Toms, Bodour Salhia.
1184
Modeling mechanisms of resistance of
epidermal growth factor receptor (EGFR) mutations to
targeted drugs through patient-derived xenografts (PDX)
of non-small cell lung cancer (NSCLC). Erin L. Stewart,
Celine Mascaux, Shingo Shakashita, Devang Panchal,
Dennis Wang, Ming Li, Nhu-An Pham, Natasha Leighl,
Geoffrey Liu, Frances A. Shepherd, Ming-Sound Tsao.
1185
Altered choline metabolism in pancreatic
cancer cells and tumor xenografts. Marie-France Penet*,
Tariq Shah*, Santosh Bharti, Yelena Mironchik, Flonné
Wildes, Anirban Maitra, Zaver M. Bhujwalla.
1186
Patient-derived breast cancer xenografts
demonstrate molecular evolution in the
phosphatidylinositol 3-kinase pathway upon
engraftment. Priscilla F. McAuliffe, Argun Akcakanat, Kurt
Evans, Agda K. Eterovic, Hao Zhao, Ken Chen, Takafumi
Sangai, Huiqin Chen, Kim-Anh Do, Ashley M. Holder,
Chandeshwar Sharma, William F. Symmans, Mihai Gagea,
Katherine A. Naff, Aysegul Sahin, Asha S. Multani, Gordon
B. Mills, Ana M. Gonzalez-Angulo, Funda Meric-Bernstam.
1187
The Champions TumorGraft Bank: A
demographically-rich repository of preclinical
TumorGraft models. Tin Khor, David Vasquez, Amanda
Katz, Gilson Baia, Daniel Ciznadija, David Sidransky, Keren
Paz.
1188
Primary human breast tumor explant platform
for integrated profiling and target validation. Liina
Nevalaita, Hanna Ala-Hongisto, Maria Lehtivaara, Päivi
Heikkilä, Marjut Leidenius, Panu Kovanen, Outi Monni, Juha
Klefström.
1189
Establishment of patient-derived xenograft
(PDX) models for small cell lung cancer (SCLC) as a
preclinical platform for drug development. Patrick
Carlson, Jill Ricono, Chelsea Mullins, Thomas Broudy, Cyrus
Mirsaidi, Praveen Nair.
1190
Multifactorial biological processes govern
engraftment of patient-derived tumor tissue in
immunodeficient mice. David M. Vasquez-Dunddel, Gilson
Baia, Amanda Katz, Daniel Ciznadija, David Sidransky, Keren
Paz.
1191
Translational Proof-of-Concept (TransPoC), a
not-for-profit research organization enabling access to
large-scale translational oncology platforms: The
Patient-Derived Xenograft network. Peter G. Smith, David
Sutton, Andrea Bertotti, Livio Trusolino, Susan Airhart, Ming
S. Tsao, Bradly G. Wouters, S. Gail Eckhardt, Lai Wang, Tim
Heffernan, David Verbel, Andrea Gerken, Peter Fekkes, Lihua
Yu, Lihua Yu, Markus Warmuth.
1192
Establishment and characterization of a new
patient-derived renal cell carcinoma xenograft panel.
Susanne Flechsig, Annika Wulf-Goldenberg, Christian
Schmees, Burkhard Jandrig, Jörg Hennenlotter, Jens Bedke,
Martin Schostak, Andrew Crockford, Marco Gerlinger, James
Larkin, Charles Swanton, Zoltan Szallasi, Iduna Fichtner,
Jens Hoffmann.
Poster Abstract
Board Number
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
1193
Establishment of patient tumor-derived
orthotopic xenograft models of metastatic pediatric
germinoma. Holly B. Lindsay, Mari Kogiso, Lin Qi, Teo Wan
Yee, Yulun Huang, Hua Mao, Frank Lin, Patricia Baxter, Jack
M. Su, Keita Terashima, Laszlo Perlaky, Ching C. Lau,
Donald W. Parsons, Murali Chintagumpala, Xiao-Nan Li.
1194
IDH1 mutant inhibitor induces cellular
differentiation and offers a combination benefit with
Ara-C in a primary human Idh1 mutant AML xenograft
model. Kate Ellwood-Yen, Yue Chen, Fang Wang, Rene
Lemieux, Janeta Popovici-Muller, Hua Yang, Kimberly
Straley, Sung Choe, Marion Dorsch, Sam Agresta, David
Schenkein, Scott Biller, Michael Su.
1195
Feasibility of using percutaneous tumor
biopsies from a prospective neoadjuvant breast cancer
study to develop patient derived xenografts and assess
in vivo chemotherapy sensitivity. Jia Yu, Ping Yin, Bowen
Gao, Jason P. Sinnwell, Ann M. Moyer, Daniel W. Visscher,
Amy L. Conners, Travis J. Dockter, Krishna R. Kalari, Xiaojia
Tang, Kevin J. Thompson, Hugues Sicotte, Douglas W.
Mahoney, Steven N. Hart, Peter T. Vedell, Poulami Barman,
Katie N. Jones, Sarah A. McLaughlin, John A. Copland,
Alvaro Moreno Aspitia, Donald W. Northfelt, Richard J. Gray,
Vera J. Suman, Jeanette E. Eckel Passow, Eric D. Wieben,
James N. Ingle, Zhenkun Lou, Gianrico Farrugia, Richard
Weinshilboum, Matthew P. Goetz, Judy C. Boughey, Liewei
Wang.
1196
Overexpression of IGF-2 in primary patient
ovarian cancer tumorgrafts increases bowel and
thoracic metastasis. Xiaonan Hou, Marc A Becker, Saravut
J Weroha, Kristina A Butler, Suzanne M Greiner, Paul
Haluksa.
1197
Differential gene expression analysis by RNAseq of primary tumors, circulating tumor cells, and
metastases from a mouse xenograft model of cancer
dissemination. Holly M. Rochefort, Tong Xu, Yucheng Xu,
Meng Li, Yibu Chen, Brian Hu, Amir Goldkorn.
1198
Co-existence of epithelioid and fibroblastoid
subsets in a sarcomatoid renal cell carcinoma:
Comparative studies between clonal sublines and
cytofluorometrically sorted cells. Chin-Hsuan Hsieh, MingLing Kuo, Cheng-Keng Chuang, Shuen-Kuei Liao.
1199
Isolation and characterization of human breast
epithelial cells. Steven Hoynowski.
1200
Characterization of a novel radiation-induced
sarcoma cell line. Julie E. Lang, Brandon Nokes, Grishma
Sheth, Petr Novak, Laura Fuchs, George S. Watts, Bernard
W. Futscher, Neal Mineyev, Weizhu Zhu, Lauren LeBeau,
Ray Nagle, Lee Cranmer.
1201
Establishment and characterization of cell lines
derived from a murine model of PTEN-deficient prostate
cancer. Kazuhiro Yoshikawa, Marco A. De Velasco, Yurie
Kura, Naomi Ando, Emiko Fukushima, Yuji Hatanaka, Yutaka
Yamamoto, Nobutaka Shimizu, Kazuhiro Yoshimura,
Masahiro Nozawa, Kazuto Nishio, Hirotsugu Uemura.
1202
Patient derived xenograft model platform of
high grade serous ovarian cancer supporting discovery
of targeted therapies and biomarkers. Sangeetha S.
Palakurthi, Joyce F. Liu, Qing Zeng, Shan Zhou, Elena
Ivanova, Cloud Paweletz, John Murgo, Justin Evangelista,
Jennifer Curtis, Huiying Piao, Prafulla Gokhale, Jessie M.
English, Paul Kirschmeier, Kwok-Kin Wong, Ursula A.
Matulonis, Ronny Drapkin.
1203
Whole-exome sequencing analysis across 23
histotypes of patient-derived tumor xenografts reveals
their similarities with TCGA patient tumors. Frederic
Foucault, Florian Kiefer, Bruno Zeitouni, Jagatheswari
Virayah, Thomas Metcalfe, Vincent Vuaroqueaux, HeinzHerbert Fiebig.
POSTER SESSION
Tumor Biology 18
Human to Mouse 2
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1204 Establishment of a patient-derived orthotopic
xenograft (PDOX) model of patient cervical cancer. Yukihiko
Hiroshima, Yong Zhang, Ali Maawy, Sho Sato, Takashi Murakami,
Mako Yamamoto, Fuminari Uehara, Shinji Miwa, Shuya Yano,
Masashi Momiyama, Takashi Chishima, Kuniya Tanaka, Ali Maawy,
Itaru Endo, Robert M. Hoffman.
1205 In vivo animal models with patient-derived tumor
xenografts for better clinical prediction. Jun Li, Jessica Kalra,
Dominic Dinh, Wan-ru Chao, Xiaohe Liu, Lidia Sambucetti, Lucia
Beviglia.
1206 Parameters influencing the design of mouse clinical
trial (HuTrialTM). Sheng Guo, Zhun Wang, Dawei Chen, Jie Yang,
Mengmeng Yang, Xuesong Huang, Jean-Pierre Wery, Henry Li.
1207 Pharmacodynamic evaluation of ADCC mediated
effects in humanized IL2 or IL15 NOG mice models. Caroline
Mignard, Jean-Francois Mirjolet, Olivier Duchamp, Yasuyuki Ohnishi,
Ikumi Katano, Mamoru Ito.
1208 Androgen receptor expressing metaplastic carcinoma
cell line established from non-caucasian female patient. Nazia
Riaz, Zulfiqar Naqvi, Anwar A. Siddiqui, Shaista M. Khan, ElNasir
Lalani.
1209 Comparison of lung adenocarcinoma development in
genetically engineered mouse and in humans - similarities and
differences. Helmut H. Popper, Beatrice Grabner, Emilio Casanova,
Robert Eferl, Rao Shuan, Josef Penninger.
1210 A patient derived xenograft tumor model platform for
“mouse trials”. Ying Yan, Tengfei Yu, Wei Du, Guosheng Tong,
Yuefei Yang, Tingting Tan, Xuqin Yang, Zhenhua Liu, Jiali Gu, Liang
Hua, Wei Zhang, Xin K. Ye, Zhenyu Gu.
1211 Application of PDX models in mimic clinical trials for
anticancer drug development. Taiping Chen, Yan Hu, Hui Zhang,
Xiaoqin Sun.
1212 Studying cancer drug resistance in patient derived
xenograft tumor models. Tengfei Yu, Ying Yan, Wei Du, Yuefei
Yang, Tingting Tan, Xuqin Yang, Jiali Gu, Liang Hua, Xin K. Ye,
Zhenyu Gu.
1213 Comparing protein pathway activation mapping
portraits between gliobastoma patient-matched primary tumor,
xenografts and neurospheres: implications for precision
medicine. Claudius Mueller, Ana C. deCarvalho, Tom Mikkelsen,
Laila Poisson, Valerie Calvert, Andrew Borgman, David M. Cherba,
Mary E. Winn, Emanuel F. Petricoin.
1214 Preclinical models of prostate cancer: New patientderived xenografts for preclinical studies and evaluation of
prostate cancer biology. Holly M. Nguyen, Colm Morrissey, Peter S.
Nelson, Xiaotun Zhang, Paul H. Lange, Robert L. Vessella, Eva Corey.
1215 Identifying new treatment options for metastatic
melanoma using patient derived xenografts: Defining the role of
Pim kinases. Berglind O. Einarsdottir, Roger Olofsson, Joydeep
Bhadury, Henrik Jespersen, Jan Mattsson, Lisa Nilsson, Ulrika
Stierner, Lars Ny, Jonas Nilsson.
1216 Effects of phenformin in LKB1/KRAS mutated nonsmall cell lung cancer patient derived xenograft. Massimo Moro,
Luca Roz, Roberto Caserini, Ugo Pastorino, Gabriella Sozzi.
1217 Development of a spontaneous in vivo cachexia model
using the Champions TumorGraft™ platform. Nathan Anderson,
Tin Khor, Andrew Feldhaus, Andreya Gatling, Katie Olson, John
Latham, David Sidransky, Elizabeth M. Bruckheimer.
1218 Telomerase-specific GFP-expressing adenovirus
enables fluorescence-guided surgery (FGS) for patient-derived
orthotopic xenograft (PDOX) in nude mice. Shuya Yano, Yukihiko
Hiroshima, Ali Maawy, Matthew H. Katz, Jason B. Fleming, Hiroyuki
Kishimoto, Atsushi Suetsugu, Fuminari Uehara, Shinji Miwa, Hiroshi
Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
1219 Patient-derived tumor models of resistant metastatic
melanoma. Bruno Gomes, Céline ROBICHON, Arnaud Pillon, JeanPhilippe Annereau, Sandrine Pourtau, Jean-Christophe Blanchet,
Aline Stennevin, Karim Bedjeguelal, Philippe Rochaix, Ignacio
Garrido-Stowhas, Laurence Lamant, Nicolas Meyer, Nicolas Guilbaud,
Christian Bailly, Anna Kruczynski.
1220 Investigation of the biological properties of human
breast cancer in a nude rat model. Reza Bayat Mokhtari, Joris
Tchouala Nofiele, Syed S. Islam, Herman Yeger, Hai-Ling Margaret
Cheng.
1221 Establishment and characterization of a
chemoresistant glioblastoma cell line from an Iraqi patient.
Ahmed M. Al-Shammari, Ahmed A. Al-Juboory, Asmaa A. AlMukhtar, Amal M. Ali, Zaid A. Al-Hili, Nahi Y. Yaseen.
1222 Establishment of a reliable metastasizing syngeneic
breast cancer mouse model using orthotopically implanted 4T1
cells after several rounds of isolating and reimplanting lung
metastases. Andreas Lingnau, Steffen Hoffmann, Sandra Moor,
Cynthia Schaefer-Obodozie, Christoph Schaechtele.
1223 Establishment, characterization and evaluation of a
panel of head and neck patient-derived xenograft (PDX) models.
Michael J. Wick, Teresa Vaught, Lizette Gamez, Armando Diaz,
Justin Meade, Monica Farley, Alyssa Moriarty, Jennifer Carlile,
Anthony Tolcher, Drew Rasco, Amita Patnaik, Richard Newman,
Kyriakos Papadopoulos.
1224 A patient derived xenograft (PDX) platform for
development of next generation KIT kinase inhibitors in
imatinib-resistant gastrointestinal stromal tumors (GIST).
Chelsea Mullins, Jill Ricono, Patrick Carson, Gaston Habets, Rafe
Shellooe, Hoa Nguyen, Thomas Broudy, Cyrus Mirsaidi, Praveen Nair.
1225 Generation and characterization of a sorafenibresistant hepatocellular carcinoma model from patient-derived
tumor xenografts. Gang Hu, Houshan Fang, Xuzhen Tang, Kedong
Ouyang, Xueyan Yang, Fubo Xie, Ke Wang, Yixin Zhang, Zhenzhou
Jiang, Luyong Zhang, He Zhou, Weikang Tao.
1226 Breast and ovarian cancer PDXs show excellent
conservation of original features but are genetically plastic.
Charles G. Theillet, Stanislas du Manoir, Beatrice Orsetti.
1227 Preserved histological and molecular phenotypes
following serial in vivo propagation of patient-derived
xenografts of small cell lung cancer. Taofeek K. Owonikoko,
Guojing Zhang, Gabriel L. Sica, Hyun S. Kim, Onyinye C. OgeeNwankwo, Suresh S. Ramalingam, Michael R. Rossi, Fadlo R. Khuri.
1228 Clinical relevance of FGFR2 amplification in diffuse
gastric cancer. Wen Min Lau, Zhijiang Zang, Eileen Teng, Kakoli
Das, Wei Peng Yong, Ming Teh, Tania Chia, Jin Wei Tan, Amy Tay,
Asim Shabbir, Koji Kono, Jimmy So, Patrick Tan, Shing Leng Chan.
1229 The advantages of patient-derived orthotopic xenograft
(PDOX) of metastatic cervical cancer for individualized therapy
compared to the PDX model. Yukihiko Hiroshima, Yong Zhang, Ali
Maawy, Sho Sato, Takashi Murakami, Mako Yamamoto, Fuminari
Uehara, Shinji Miwa, Shuya Yano, Masashi Momiyama, Takashi
Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo, Robert M.
Hoffman.
1230 Efficacy of Salmonella typhimurium A1-R and antiVEGF therapy on a patient-derived orthotopic xenograft (PDOX)
pancreatic cancer model. Yukihiko Hiroshima, Ming Zhao, Matthew
H. Katz, Jason B. Fleming, Sho Sato, Takashi Murakami, Mako
Yamamoto, Fuminari Uehara, Shinji Miwa, Shuya Yano, Masashi
Momiyama, Yong Zhang, Ali Maawy, Takashi Chishima, Kuniya
Tanaka, Michael Bouvet, Itaru Endo, Robert M. Hoffman.
1231 In vitro anticancer activity of imidazo-acridinone
(HKH40A) in panels of human patient-derived tumor xenografts
(PDXs) and human leukemia and lymphoma cell lines. Heinz H.
Fiebig, Armin Maier, Gerhard Kelter, Vincent Vuaroqueaux, Humcha
K. Hariprakasha, Christopher Michejda.
9
9
299
POSTER SESSION
Prevention Research 2
Poster
Section
10
10
Molecular Targets in Chemoprevention
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
300
1232
Antiproliferative, antioxidant and antiapoptotic
effect of rhamnetin in human prostate cancer cells.
Christine Oak, Natarajan Bhaskaran, Sanjay Gupta, Sanjeev
Shukla.
1233
Inhibition of STAT-3 by piperlongumine induces
anoikis, prevents tumor formation in pancreatic cancer
in vitro and in vivo. Neel M. Fofaria, Sanjay K. Srivastava.
1234
Tamoxifen synergizes cytotoxic activity of 4(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol}
(HPIMBD), a novel resveratrol analogue against breast
cancer cells. Amruta M. Ronghe, Anwesha Chatterjee,
Fatma Abdalla, Hari K. Bhat.
1235
Targeting the DNA binding domain of the
androgen receptor as a potential therapy for prostate
cancer. Kush Dalal, Huifang Li, Mani R. Moniri, Fuqiang
Ban, Aishwariya Sharma, Artem Cherkasov, Paul S. Rennie.
1236
A gemini vitamin D analogue, BXL0124,
represses mammosphere formation and decreases
expression of stem cell markers in MCF10DCIS breast
cancer cells. Joseph Wahler, Hubert Maehr, Milan
Uskokovic, Nanjoo Suh.
1237
Mechanisms of Vernonia amygdalina-induced
apoptosis of human breast adenocarcinoma (MCF-7)
cells. Clement G. Yedjou, Paul Tchounwou.
1238
Apigenin suppresses inhibitor of apoptosis
family protein expression and disrupts Ku70-bax
interaction in prostate cancer cells in culture and in
vivo. Sanjeev Shukla, Pingfu Fu, Sanjay Gupta.
1239
Dietary grape seed proanthocyanidins inhibit
UV-induced immune suppression by targeting the
development of regulatory T cells in mice. Santosh K.
Katiyar, Tripti Singh, Mudit Vaid.
1240
Bioactive proanthocyanidins from grape seeds
inhibit cigarette smoke condensate-enhanced invasion
of human non-small cell lung cancer cells by targeting
NADPH oxidase and epithelial-mesenchymal transition.
Mudit Vaid, Santosh K. Katiyar.
1241
Kaempferol suppresses solar ultraviolet
radiation-induced skin cancers by targeting RSK2 and
MSK1. Ke Yao, Hanyong Chen, Mee-Hyun Lee, Alyssa
Langfald, Myoung Ok Kim, Dong Hoon Yu, Kangdong Liu,
Wei-Ya Ma, Ann M. Bode, Ziming Dong, Zigang Dong.
1242
Green tea polyphenols inhibit the growth and
induce death of melanoma cells by initiating DNA
damage and inhibition of class I histone deacetylases.
Ram Prasad, Santosh K. Katiyar.
1243
A novel series of celecoxib derivatives lacking
COX-2 inhibitory activity more potently inhibits cancer
cell growth by inhibiting PDE5. Sara C. Sigler, Veronica
Ramirez, Ashraf Abadi, Gary Piazza.
1244
Licofelone, a dual COX-LOX inhibitor prevents
transitional cell carcinoma of urinary bladder in UPIISV40T transgenic mice. Venkateshwar Madka, Altaf
Mohammed, Qian Li, Yuting Zhang, Laura Biddick, Stanley
Lightfoot, Xue-Re Wu, Levy Kopelovich, Vernon Steele,
Chinthallapally V. Rao.
1245
Reactivation of growth/differentiation factor 1
contributes to the chemopreventive effect of 5-aza2’deoxycytidine in gastric cancer. Wei Q. Yang, May S. Li,
Wei Kang, Li H. Zeng, Tian H. Wang, Anthony W. Chan,
Enders K. Ng, Ka F. To, Francis K. Chan, Jun Yu, Michael
W. Chan, Joseph J. Sung, Alfred S. Cheng.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1246
Development and validation of a global
proteomics approach for identifying novel binding
partners of resveratrol. Christina J. Kovoor, Robert G.
Britton, Emma Horner-Glister, Catherine Andreadi, Raj Singh,
Rebekah Jukes-Jones, Kelvin Cain, William P. Steward,
Andreas Gescher, Karen Brown.
1247
Assessment of the roles of prostaglandin E2
receptors in a rodent model of chemically induced
esophageal carcinogenesis. Ni Shi, Tong Chen.
1248
The Gemini vitamin D analogue BXL0124
inhibits Notch signaling via HES1, resulting in the
reduction of CD44ⴙ/CD24-/low subpopulation and
proliferation of MCF10DCIS cells. Jae Young So, David M.
Salerno, Hubert Maehr, Milan Uskokovic, Nanjoo Suh.
1249
ERK1/2 targeting with magnolin as a
chemopreventive agent. Cheol-Jung Lee, Mee-Hyun Lee,
Ji-Young Lee, Ji Hong Song, Yong-Yeon Cho.
1250
Inhibition of pancreatic carcinogenesis by tCUPM, a dual inhibitor of c-Raf and soluble epoxide
hydrolase. Jie Liao, Wanying Zhang, Sung Hee Hwng,
Haonan Li, Aaron T. Wecksler, Ke Ma, Bruce D. Hammock,
Guang-Yu Yang.
1251
Repurposing antipsychotic drug Penfluridol for
cancer treatment. Alok Ranjan, Sanjay K. Srivastava.
1252
6-c-(e-phenylethenyl)-naringenin suppresses
colorectal cancer growth by inhibiting cyclooxygenase1. Haitao Li, Feng Zhu, Hanyong Chen, Ka Wing Cheng,
Tatyana Zykova, Naomi Oi, Ronald A. Lubet, Ann M. Bode,
Mingfu Wang, Zigang Dong.
1253
Dual PI3K/mTOR inhibitor NVP-BEZ235 in
combination with AKT inhibitor MK2206 in esophageal
carcinoma cells. Hao Yu, Ni Shi, Zui Pan, Tong Chen.
1254
Novel acetal and halogen oridonin analogues
potently induce apoptosis in prostate cancer cell lines
via induction of p53/p73 and PUMA expression. Yu Ke,
Zhongbo Liu, Hong-Min Liu, Xiaolin Zi.
1255
The Mediterranean herb rosemary modulates ER
stress proteins to promote androgen receptor
degradation in prostate cancer cells. Sakina M. Petiwala,
Saba Berhe, Gongbo Li, Angela G. Puthenveetil, Larisa Nonn,
Jeremy J. Johnson.
1256
The chemopreventive effects of carvedilol on
skin carcinogenesis. Andy Chang, Mandy Liu, Steven
Yeung, Jijun Hao, Cyrus Parsa, Robert Orlando, Bradley
Andresen, Ying Huang.
1257
From chemoprevention strategy to identification
of potential therapeutic targets and biomarkers for
breast cancer. Allal Ouhtit, Somya Shanmuganathan, Ishita
Gupta, Hamad Al-Riyami, Madhwa Raj.
1258
Knockdown or inhibition of Aldo-keto reductase
1B10 inhibits pancreatic carcinogenesis via modulating
Kras-E-cadherin pathway. Wanying Zhang, Haonan Li, Ke
Ma, Jie Liao, Guang-Yu Yang.
1259
Gut microbiota and mucosal inflammation and
colorectal neoplasia. Temitope O. Keku, Romin Bonakdar,
Felix Araujo Perez, Amber N. McCoy, Patrick Edmundson,
Kevin Smith.
1260
CP-31398 prevents the progression of oral
squamous cell carcinomas from carcinogen-induced
premalignant lesions. Lynn A. Vitale-Cross, Daniel Martin,
Chinthalapally V. Rao, Levy Kopelovich, J. Silvio Gutkind.
1261
Targeting IL-11R␣ inhibits osteosarcoma
pulmonary metastasis in an orthotopic xenograft mouse
model. Valerae O. Lewis, Eswaran Devarajan, Dennis P.
Hughes.
POSTER SESSION
Epidemiology 4
Diet and Cancer Risk/Mortality
Poster
Section
Poster Abstract
Board Number
1.
1262
Established genetic variants and dietary
patterns jointly impact risk of renal cell carcinoma in
non-Hispanic whites. Melkonian Stephanie, Carrie R.
Daniel, Michelle Hildebrandt, Nizar Tannir, Yuanqing Ye,
Wong-Ho Chow, Christopher Wood, Xifeng Wu.
2.
1263
Dietary patterns after prostate cancer diagnosis
in relation to disease-specific and total mortality. Meng
Yang, Stacey A. Kenfield, Erin L. Van Blarigan, Julie L.
Kasperzyk, Howard D. Sesso, Jing Ma, Meir Stampfer, Jorge
E. Chavarro.
3.
1264
Dietary n-6 fatty acids and risk of
hepatocellular carcinoma among Chinese in Singapore:
The Singapore Chinese Health Study. Woon-Puay Koh,
Yock Young Dan, An Pan, Jian-Min Yuan.
4.
1265
Carbohydrate intake, glycemic index and
prostate cancer risk. Adriana C Vidal, Christina C Williams,
Emma H Allott, Lauren E Howard, Delores J Grant, Megan
McPhail, Katharine N Sourbeer, Paolo Boffetta, Cathrine
Hoyo, Stephen J Freedland.
5.
1266
Racial differences in the association of
cruciferous vegetable intake with breast cancer
hormone receptor status and tumor subtype. Li Tang,
Marilyn L. Kwan, Song Yao, Janise M. Roh, Cecile A.
Laurent, Dawn L. Hershman, Schicha Kumar, Gregory E.
Wilding, Christine B. Ambrosone, Lawrence H. Kushi.
6.
1267
Coffee consumption and the risk of colorectal
cancer. Stephanie Stenzel, Hedy S. Rennert, Gad Rennert,
Stephen B. Gruber.
7.
1268
High coffee consumption and different brewing
methods in relation to postmenopausal endometrial
cancer risk in the norwegian women and cancer study:
A population-based prospective study. Oxana Gavrilyuk,
Tonje Braaten, Guri Skeie, Elisabete Weiderpass, Vanessa
Dumeaux, Eiliv Lund.
Poster Abstract
Board Number
12.
1273
Association between smoking, alcohol, and
salty food intake and risk of stomach cancer by
topographic location and histological type in Seoul Male
Cohort. Myung-Hee Shin, Seon-Mi Hwang, Min-Gew Choi,
Duk-Hwan Kim, Jong-Myon Bae, Moo-Song Lee, Dong-Hyun
Kim, Zhong-Min Li, Yoon-Ok Ahn.
13.
1274
Alcohol and lung cancer risk: a pooled analysis
using International Lung Cancer Consortium studies.
Gordon Fehringer, Darren Brenner, Zuo-Feng Zhang, YuanChin Amy Lee, Keitaro Matsuo, Isabelle Stucker, Paolo
Vineis, Paolo Boffetta, Paul Brennan, Maria T. Landi, Hal
Morgenstern, Curtis C. Harris, Qing Lan, Yun-Chul Hong,
Jack Siemiatycki, John R. McLaughlin, Philip Lazarus,
Joshua Muscat, Ann G. Schwartz, Juan M. Barros Dios,
Alberto R. Raviña, Gad Rennert, David C. Christiani, Adonina
Tardon, Loic Le Marchand, Irene Orlow, Eric J. Duell,
Angeline S. Andrew, Hermann Brenner, Dario Consonni, Ann
Olsson, Kurt Straif, Rayjean J. Hung.
14.
1275
Intake of meat mutagens and risk prostate
cancer in a cohort of U.S. health professionals. Sabine
Rohrmann, Katharina Nimptsch, Rashmi Sinha, Walter C.
Willett, Edward Giovannucci, Elizabeth Platz, Kana Wu.
15.
1276
Red meat, poultry, and fish intake, genetic risk
variants, and breast cancer risk among Hispanic and
non-Hispanic white women: Results from the Breast
Cancer Health Disparities Study. Andre E. Kim, Mariana C.
Stern, Abbie Lundgreen, Juan Pablo Lewinger, Roger K.
Wolff, Laura Fejerman, Esther M. John, Gabriela TorresMejia, Sue A. Ingles, Avonne E. Connor, Lisa M. Hines,
Kathy B. Baumgartner, Anna R. Giuliano, Martha L. Slattery.
16.
1277
The association between seasonality, vitamin D
and calcium intake and mammographic density in
Norwegian postmenopausal women. Merete EllingjordDale, Isabel dos Santos Silva, Tom Grotmol, Amrit Kaur
Sakhi, Samera Qureshi, Solveig Hofvind, Marianne Skov
Markussen, Elisabeth Couto, Lene Frost Andersen, Giske
Ursin, Giske Ursin.
8.
1269
Alcohol intake in relation to lethal breast
cancer. Caroline E. Boeke, A. H. Eliassen, Wendy Y. Chen,
Michelle D. Holmes, Bernard Rosner, Walter C. Willett, Rulla
M. Tamimi.
9.
1270
Lifetime alcohol consumption and risk of breast
cancer, by tumor androgen receptor expression. Jun
Wang, Xuehong Zhang, Andrew H. Beck, Laura C. Collins,
Wendy Chen, Rulla M. Tamimi, Aditi Hazra, Bernard Rosner,
Susan E. Hankinson.
17.
1278
Vitamin D receptor Fok1 gene polymorphisms
may be associated with CRC among African American
and Hispanic participants. Marianna Sarkissyan, Yanyuan
Wu, Zuijan Chen, Dhruva Mishra, Suren Sarkissyan, Ioannis
Giannikopoulos, Jaydutt V. Vadgama.
10.
1271
Alcohol intake and breast cancer in the
European Prospective investigation into Cancer and
Nutrition (EPIC) study. Isabelle Romieu, Chiara Scoccianti,
Veronique Chajes, Jordi De Batlle, Sabina Rinaldi.
18.
1279
Association between vitamin D levels and
colorectal cancer in African Americans. Sariya Siddiqi,
Fabio Pibiri, Rosa Munoz Xicola, Rick A. Kittles, Xavier Llor,
Sonia S. Kupfer, Nathan A. Ellis.
11.
1272
Alcohol and dietary folate intake and gene
promoter methylation in clear-cell renal cell cancer. Leo
J. Schouten, Ivette A. Deckers, Piet A. van den Brandt,
Patricia M. Soetekouw, Marcella M. Baldewijns, Manon van
Engeland.
12
12
301
POSTER SESSION
Epidemiology 5
Poster
Section
13
13
Genetic Epidemiology of Familial Cancers
Poster Abstract
Board Number
1.
1280
Germline PALB2 genetic variations of familial
esophageal squamous cell carcinoma (ESCC) in Henan,
a high risk ESCC region. Josephine Mun Yee Ko, Li Dong
Wang, Maria Lung.
2.
1281
Identification of novel susceptibility genes in
familial gastric cancer using next generation
sequencing and identity-by-descent mapping. Ruta M.
Sahasrabudhe, Paul Lott, Clara Ruiz-Ponte, Manuel Teixeira,
Luis G. Carvajal-Carmona.
3.
4.
1283
Prevalence of synchronous oligopolyposis in
Hispanics with incident colorectal cancer: A populationbased analysis. Carlos E. Bertran, Juan M. Marques,
Vanessa Mendez, Katerina Freyre, Yaritza Diaz-Algorri, Luis
R. Pericchi, Marievelisse Soto, Marcia R. Cruz-Correa.
5.
1284
A p53 noncoding germline variant is a cancer
susceptibility allele associated with Lynch syndrome
rather than Li-Fraumeni syndrome. Yong Li, Qipan Deng.
6.
1285
Identification of MMR gene exonic
rearrangements in suspected Lynch syndrome tumors
without loss of MMR expression. Murali D. Bashyam,
Viswakalyan Kotapalli, Ratheesh Raman, Brijesh K. Yadav,
Ajay K. Chaudhary, Swarnalata Gowrishankar, Shantveer G.
Uppin, Ravikanth Kongara, Regulagadda A. Sastry, Mohana
Vamsy, Sujit Patnaik, Shoba Dsouza, Devendra C. Desai,
Tester Ashavaid.
7.
8.
1286
Linkage analysis on Swedish colon and rectal
familial non-lynch syndrome families and exome
sequencing analysis of candidate regions. Susanna E.
von Holst.
1287
Mutations in the CBL gene among breast
cancer patients in an Asian clinic-based population.
Edward Wong, Yoon Sim Yap, Ying Ying Cheng, Delia Chua,
Lewis Zuocheng Hong, William F. Burkholder, Gay Hui Ho,
Min Han Tan, Peter Ang, Ann S. Lee.
9.
1288
Impact of germline TP53 mutations and
polymorphisms in women with pre-menopausal breast
cancer. Nardin Samuel, Ana Novokmet, Thomas J. Hudson,
David Malkin.
10.
1289
Breast cancer predisposition in multiple
endocrine neoplasia type 1. Koen Dreijerink, Elfi
Conemans, Chantal Cornelissen, Marja Van Blokland,
Michael Mannstadt, Carla Pieterman, Wouter De Herder, Bas
Havekes, Eric Fliers, Ad Hermus, Menno Vriens, Marc
Timmers, Elsken Van der Wall, Myles Brown, Rob Van der
Luijt, Paul van Diest, Gerlof Valk.
11.
12.
302
1282
Genetic basis of hereditary gastric cancer:
Beyond the CDH1 locus. Samantha Hansford, Hector
LiChang, Pardeep Kaurah, Michelle Woo, Karey Shumansky,
David F. Schaeffer, Giovanni Corso, George Zogopoulos,
Steven Gallinger, Hugo Pinheiro, Franco Roviello, Carla
Oliveira, David Huntsman.
1290
Survival in familial breast cancer: Novel
findings based on a nationwide prospective cohort
study. Elham Kharazmi, Asta Försti, Kristina Sundquist, Kari
Hemminki.
Poster Abstract
Board Number
13.
1292
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia. Anna
Marie D. Tuazon, Carolina Ramírez, Mabel Bohorquez,
Rodrigo Prieto, Jorge Castro, Gilbert Mateus, Alejandro
Velez, Magdalena Echeverry, Luis G. Carvajal-Carmona.
14.
1293
Familial melanoma by histology and age
guiding clinical genetic counseling: joint data from five
Nordic countries. Mahdi Fallah, Eero Pukkala, Kristina
Sundquist, Steinar Tretli, Jørgen H. Olsen, Laufey
Tryggvadottir.
15.
1294
A pilot study of FBRSL1 and melanoma: What’s
the connection. Jenna M. Lilyquist, Pedro Lee, Marianne
Berwick, Danny Reinberg.
16.
1295
The association between asthma and pediatric
brain tumors in neurofibromatosis type 1. Kimberly J.
Johnson, Nancy Mueller, Evelyn Sharkey, Qian Liu, David H.
Gutmann.
17.
1296
Family history of cancer and
rhabdomyosarcoma in children: a report from the
Children’s Oncology Group. Philip J. Lupo, Heather E.
Danysh, Sharon E. Plon, David Malkin, Simone Hettmer,
Douglas S. Hawkins, Stephen X. Skapek, Logan G. Spector,
Karin Papworth, Beatrice Melin, Erik B. Erhardt, Seymour
Grufferman.
18.
1297
The heritability of melanoma differs between
light- and dark-skinned individuals of European
descent. Imge Hulur, Andrew Skol, Kenan Onel.
19.
1298
Evidence for a genetic contribution to nonsmoking-related lung cancer. Lisa A. Cannon-Albright,
Shamus Carr, Wallace Akerley.
20.
1299
Effect of family history of cancer on the risk of
multiple myeloma: Differences by ancestry and age of
onset. Gwendolyn I. Pruitt, Howard W. Weiner, Racquel D.
Innis-Shelton, Donna Salzman, Kelly N. Godby, Vishnu B.
Reddy, Fady M. Mikhail, Andrew J. Carroll, Elizabeth E.
Brown.
21.
1300
Exploration of rare variants from exome
sequencing in families with Waldenstrom
macroglobulinemia (WM). Mary L. McMaster, Lynn R.
Goldin, Melissa Rotunno, Ji He, Laurie Burdette, Amy
Hutchinson, Joseph Boland, Meredith Yeager, Margaret A.
Tucker, Stephen J. Chanock, Neil E. Caporaso.
22.
1301
Gene panel testing for inherited kidney cancer
risk. Christina Rybak, Veda N. Giri.
23.
1302
Genetic analysis in a patient with nine primary
malignant neoplasms: A rare case of Li-Fraumeni
syndrome. Xiaoyuan Li, Juan Kang, Qi Pan, Wenwei Yin,
Shiwen Tong, Dachun Zhao, Changting Meng, Chunmei Bai,
Hong Ren, Keyue Ding.
24.
1303
Genetic cancer incidence. Min Kyu Kim, Soo
Youn Bae, Jee Yeon Lee.
1291
High and moderate penetrance germline
mutations in a number of genes are responsible for a
small proportion of familial breast cancer risk in BRCAx
families. Kara N. Maxwell, Lucia Guidugli, Kasmintan
Schrader, Steven Hart, Vijai Joseph, Tinu Thomas, Xianshu
Wang, Bradley Wubbenhorst, Robert Klein, Susan M.
Domchek, Csilla Szabo, Susan Neuhausen, Jeffrey Weitzel,
Katherine L. Nathanson, Kenneth Offit, Fergus Couch.
POSTER SESSION
Molecular and Cellular Biology 16
Cell Cycle 1
Poster
Section
Poster Abstract
Board Number
1.
1304
Cyclin D:Cdk4/6 activates RB by monophosphorylation during early G1 phase. Steven F. Dowdy,
Manuel Kaulich.
2.
1305
Basal level of FANCD2 monoubiquitination is
required for the maintenance of a sufficient number of
licensed-replication origins to fire at a normal rate.
Panneerselvam Jayabal, Anna Pickering, Han Bing, Fei
Peiwen.
3.
1306
Synergistic function of a novel cell cycle
regulator, Ecdysoneless with oncogenic Ras in the
regulation of cell cycle and transformation. Aditya Bele,
Sameer Mirza, Riyaz Mir, Shakur Mohibi, Hamid Band, Vimla
Band.
4.
1307
c-Myc is a key mediator of glypican-1 (GPC1)dependent deregulation of the cell cycle. Dianhua Qiao,
Kristy Meyer, Andreas Friedl.
5.
1308
Functional inhibition of HSP90 induces G0/G1
arrest and downregulates thymidylate synthase in
colorectal cancer. Ganji P. Nagaraju, Field F. Willingham,
Kevin E. Woods, Patrick Sullivan, Jerome C. Landry, Roberto
Diaz, Bassel F. El-Rayes.
6.
1309
Identification of aurora kinase a as an
unfavorable prognostic factor and potential treatment
target for metastatic gastrointestinal stromal tumors.
Chun-Nan Yeh, Chueh-Chuan Yen, Yeng-Yang Chen, ChiTung Cheng, Shih-Chiang Huang, Ting-Wei Chang, Fang-Yi
Yao, Yung-Chan Lin, Yao-Shan Wen, Kun-Chun Chiang, JenShi Chen, Ta-Sen Yeh, Cheng-Hwai Tzeng, Ta-Chung Chao,
Jonathan A. Fletcher.
7.
1310
Increased cytoplasmic CDC25A phosphatase in
cutaneous squamous cell carcinoma leads to 14 –3-3
relocalization and suppression of apoptosis. Jenan
Almatouq, Kristen Ho, Laura A. Hansen.
8.
1311
Notch1 inhibits retinoblastoma (RB) via direct
interaction with RB pocket domain. Filomena T. Papa,
Ingrid Espinoza, Nicole Darack-Gutyon, Antonio Giordano,
Antonio De Luca, Christian R. Gomez, Lucio Miele.
9.
1312
Buformin, an anti-diabetic biguanide, inhibits
proliferation, invasion and adhesion, and acts
synergistically with paclitaxel in endometrial cancer cell
lines. Joshua Kilgore, Amanda Jackson, Haifeng Qiu,
Chunxiao Zhou, Paola Gehrig, Victoria Bae-Jump.
10.
11.
1313
Anti-tumorigenic effects of phenformin in
human endometrial cancer cells. Amanda L. Jackson,
Joshua E. Kilgore, Haifeng Qiu, Chunxiao Zhou, Paola A.
Gehrig, Victoria L. Bae-Jump.
1314
Aberrant expression of beta-catenin and cyclin
D1 in endometrial cancer. Yuji Ikeda, Katsutoshi Oda,
Takahiro Koso, Daichi Maeda, Osamu W. Hiraike, Tomoko
Kashiyama, Aki Miyasaka, Kei Kawana, Tetsu Yano,
Yoshihiro Kikuchi, Masashi Fukayama, Yutaka Osuga,
Tomoyuki Fujii.
Poster Abstract
Board Number
12.
1315
CtIP is regulated by the APC/C-Cdh1 to mediate
cell cycle-dependent control of DNA repair. Harmen R.
de Boer, Lorenzo Lafranchi, Christine Neugebauer, Rudolf S.
Fehrmann, Elisabeth G. de Vries, Alessandro A. Sartori,
Marcel A. van Vugt.
14.
1317
The metaphase checkpoint complex is
controlled by events downstream to spindle assembly
and microtubule attachment to the kinetochore. Theresa
Austria, David Hinton, Louis Dubeau.
15.
1318
Mps1 is modified by sumoylation during the
cell cycle. Agnese Restuccia, Feikun Yang, Yao Yixin, Wei
Dai.
16.
1319
Vulnerability and resistance in glioblastoma to
G2-specific drugs. Harshil D. Dhruv, Andrew D. Nelson,
Brock Armstrong, Julie L. Boerner, Jann N. Sarkaria, Nhan
L. Tran, Michael Berens.
17.
1320
Diversified roles of cyclin E1 isoforms in liver
cancer. Yan Yan Chan, Kin Tak Chan, Nikki Pui Yue Lee.
18.
1321
Identification of markers of sensitivity and
resistance to palbociclib (PD0332991) in melanoma.
Erika M. von Euw, Dylan Conklin, Hong-Mei Rong, Ke-Wei
Gong, Richard S. Finn, Dennis J. Slamon.
19.
1322
Novel CDK4/6 inhibitors provide robust
antitumor activity in a murine model of luminal breast
cancer. Patrick J. Roberts, David B. Darr, John E. Bisi, Jay
C. Strum.
20.
1323
Lack of cyclin D3 enhances the CDK6dependent skin tumor susceptibility to malignant
progression. Sung Hyun Lee, Xian Wang, Marcelo L.
Rodriguez-Puebla.
21.
1324
Dual targeting of CDK4 and ARK5 using a novel
kinase inhibitor ON123300 is effective in vitro and in
vivo in Multiple Myeloma. Deepak Perumal, Venu
Thirukonda, Zewei Jiang, Violetta V. Leshchenko, Pei-yu
Kuo, Samira Shahnaz, Jennifer Rubel, Weijia Zhang, Hearn
Jay Cho, M.V. Ramana Reddy, E. Premkumar Reddy, Samir
Parekh.
22.
1325
Profilin-1 overexpression downregulates
phosphorylation of p27kip1 leading to its nuclear
accumulation in breast cancer cells. Chang Jiang, William
Veon, Partha Roy.
23.
1326
Regulation of AKT phosphorylation by a CDK
inhibitor purvalanol A in breast cancer cells. Hong Yin.
24.
1327
Targeting the RB-pathway in sarcoma: Utility of
CDK4/6 inhibitors. Ashleigh M. Francis, Jason P. Carey,
Angela Alexander, Khandan Keyomarsi, Kelly K. Hunt.
14
14
303
POSTER SESSION
Poster
Section
15
15
Death Signaling in Apoptosis, Necrosis, and Autophagy
Poster Abstract
Board Number
1.
1328
Differential autophagy responses in nontumorigenic and malignantly transformed lung epithelial
cells. Clayton A. Wright.
2.
1329
Sensitization of non-small cell lung cancer cells
(NSCLC) to radiation by Vitamin D (EB 1089). Khushboo
Sharma, David Gewirtz.
3.
1330
Immunotherapy targeting folate receptor
induces autophagy in ovarian cancer. Yun-Fei Wen,
Whitney S. Graybill, Department of Gyneocologic Oncology,
Anil Sood.
4.
1331
MonoD, a novel analogue of digitoxin, induces
superoxide mediated autophagic cell death in H460 lung
cancer cells. Yogesh Kulkarni, Vivek Kaushik, Clayton
Wright, George O’Doherty, Neelam Azad, Anand Iyer.
5.
1332
Inhibition of G9a induces DUSP4-dependent
autophagic cell death in head and neck squamous cell
carcinoma. KAI-CHUN LI, KUO-TAI HUA, CHING-TING TAN,
MIN-LIANG KUO.
1333
Combining Afatinib and Cetuximab
synergistically increases their cytotoxicity for EGFR
T790M-harboring cells. Nobuyuki Tanaka, Zenta Watanuki,
Tatsuro Fukuhara, Makoto Maemondo.
6.
7.
15.
1342
RIP3 is downregulated in human myeloid
leukemia cells and modulates apoptosis and caspasemediated p65/RelA cleavage. Anne-Lucie Nugues, Hassiba
Bouafia, Dominique Hetuin, Celine Berthon, Anne Loyens,
Elisabeth Bertrand, Nathalie Jouy, Thierry Idziorek, Bruno
Quesnel.
16.
1343
Non-apoptotic death induced in glioma cells by
the indole-based chalcone, MOMIPP, involves disruption
of endolysosomal trafficking and ER stress. Nneka E.
Mbah, Andrew D. Trunk, Bryan A. Dewitt, Jean H.
Overmeyer, William A. Maltese.
17.
1344
Downregulation of mortalin increased
mitochondrial fragmentation and dysfunctions. So Jung
Park, Dong-Hyung Cho.
18.
1345
Role of AMP-activated protein kinase in
crosstalk between apoptosis and autophagy in human
colon cancer. Xinxin Song, Seog-Young Kim, Lin Zhang,
Yong J. Lee.
19.
1346
Osteopontin-b and Osteopontin-c splicing
isofoms activate prostate cancer cells prosurvival
features. Kivvi D. Mello, Tatiana M. Tilli, Ana Carolina S.
Ferreira, Claudete E. Klumb, Luiz E. Nasciutti, Etel R. Gimba.
20.
1347
The role of cell-cell contacts in the survival of
extracellular matrix detached mammary epithelial cells.
Raju Rayavarapu, Nicholas Pagani, Brendan Heiden, Zachary
T. Schafer.
21.
1348
Suppressor of cytokine signaling (SOCS)-1
suppresses a proliferation of malignant melanoma cells
via the suppression of JAK/STAT and the activation of
p53 signaling pathways. Naoko Tagami, Satoshi Serada,
Minoru Fujimoto, Atsushi Tanemura, Ichiro Katayama, Tetsuji
Naka.
8.
1335
Lack of casein kinase 1 delta induces DNA
damage, inhibition of mTORC1 signaling and
nucleophagy. Yoshimi E. Greer, Bo Gao, Yingzi Yang,
Jeffrey S. Rubin.
22.
9.
1336
Bortezomib induces the degradation of FLT3ITD tyrosine kinase in acute myeloid leukemia through
an autophagy-dependent mechanism. Clément Larrue,
Estelle Saland, Marion David, Jean-Emmanuel Sarry,
Stéphane Manenti, Christian Récher.
1349
Chemosensitization of breast cancer cell lines
by Ell3. Hee-Jin Ahn, Sun-Hee Heo, Gwangil Kim, KyungSoon Park.
23.
1337
BH3-mimetic gossypol promotes autophagy to
inhibit the proliferation of mutant BRAF melanoma cells
with high expression of p21Cip1. Michael Lee, Gun-Hee
Jang, Jun-Ho Ahn, Na-Yeon Kim.
1350
Mitogen activated protein kinase activated
protein kinase 2 (MK2) signaling in non-small cell lung
carcinoma. Oscar Paniagua-Morales, Laura Johnston,
Leonid Serebreni, Gigi Liu, Paul Hassoun, Mahendra
Damarla.
24.
1351
Expression of klotho enhances the apoptotic
response of cancer cells to anticancer agents. Yujin
Kudo, Jitsuo Usuda, Hideyuki Furumoto, Sachio Maehara,
Keishi Ohtani, Tatsuya Inoue, Taichiro Ishizumi, Yasufumi
Kato, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira,
Norihiko Ikeda.
25.
1352
Cytoplasmic galectin-7 has an antiapoptotic
function by decreasing p53 nuclear translocation in
breast cancer cells. Andrée-Anne Grosset, Donald Gagné,
Marilyne Labrie, Maria Vladoiu, Louis Gaboury, Nicolas
Doucet, Yves St-Pierre.
26.
1353
Protein tyrosine phosphatases PTP-1B, SHP-2
and PTEN facilitate Rb/E2F-associated apoptotic
signaling. Liza D. Morales, Mario Capetillo, Edgar Casillas
Pavon, Jun W. Shin, Alexander Garcia, Jonathan H. Lieman,
Dae J. Kim.
27.
1354
Relevance of Sp1 and survivin expression in
epithelial ovarian cancer patients and their usefulness
as potential therapeutic targets. Umesh T. Sankpal, Susan
B. Ingersoll, Vadiraja B. Bhat, Sarfraz Ahmad, Robert W.
Holloway, Riyaz M. Basha.
10.
11.
1338
Blockage of nucleocytoplasmic transport by
wheat germ agglutinin (WGA) induces autophagy and
cell death. Tsung-Lin Tsai, Chun-Hua Hung, Hao-Chen
Wang, Dar-Bin Shieh, Wu-Chou Su, Chien-Chung Lin.
12.
1339
Endoplasmic reticulum stress mediates
Tanshinone I induced apoptosis in mesothelioma cells.
JiHyun Lee, Bonglee Kim.
13.
1340
Induction of necroptosis in ovarian cancer cells
as a therapeutic strategy. Katelyn E. McCabe, Karl Bacos,
Dan Lu, Joe R. Delaney, Mitchell Vamos, Nicholas D.
Cosford, Dwayne G. Stupack.
14.
304
1334
Induction of autophagy by ormeloxifene and
mevastatin through Protein Kinase D1 in prostate
cancer cells. Rishi K. Gara, Sonam Kumari, Aditya Ganju,
Murali M. Yallapu, Ankita Shah, Sheema Khan, Man M.
Singh, Subhash C. Chauhan, Meena Jaggi.
Poster Abstract
Board Number
1341
Rapid decrease of ATP followed by necrosislike cell death in bladder cancer cells after exposure to
high-dose chemotherapeutics used in intravesical
therapy. Takahiro Yoshida, Hiroaki Okuyama, Masashi
Nakayama, Kazuo Nishimura, Norio Nonomura, Masahiro
Inoue.
POSTER SESSION
Epigenetic Markers of Cancer
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1355 Clinical utility of DNA methylation markers for
prostate cancer detection and prognosis: Towards lessinvasive molecular diagnostic tests. Mia Moller, Christa
Haldrup, Michael Borre, Soren Hoyer, Torben Orntoft, Karina D.
Sorensen.
1356 Frequent H3F3A K27M mutations in thalamic
gliomas from young adult patients. Akitake Mukasa, Koki
Aihara, Kengo Gotoh, Kuniaki Saito, Genta Nagae, Shingo Tsuji,
Kenji Tatuno, Shogo Yamamoto, Shunsaku Takayanagi,
Yoshitaka Narita, Soichiro Shibui, Hiroyuki Aburatani, Nobuhito
Saito.
1357 Clinical, pathological and prognostic value of LINE1 methylation in hepatocellular carcinoma. kazuto harada,
Yoshirumi Baba, Akira Chikamoto, Takatsugu Ishimoto, Keisuke
Kosumi, Asuka Murata, Naoya Yoshida, Toru Beppu, Hideo
Baba.
1358 Promoter hypermethylation of KISS1R, KiSS1,
SEPT9 and CSAD as a prognostic biomarker panel to assess
the metastatic potential of muscle invasive bladder tumors.
Beatrice Stubendorff, Kerstin Wilhelm, Kathleen Posselt, James
Catto, Arndt Harmann, Susanne Fuessel, Vladimir Novotny,
Mieczyslaw Gajda, Heiko Wunderlich, Marc-Oliver Grimm,
Kerstin Junker.
1359 Identification of a novel hypermethylated tumor
suppressor gene in human bladder cancer. Chia-Ming Yeh,
Pi-Che Chen, Wen-Yu Huang, Cheng-Huang Shen, Cheng-Da
Hsu, Michael W. Chan.
1360 DNA methylation analysis in self-sampled material
as a triage test in hrHPV positive women. Aniek Boers,
Remko P. Bosgraaf, Roland W. van Leeuwen, Ed Schuuring,
Leon F. Massuger, Johan Bulten, Willem J. Melchers, Ate G. van
der Zee, Ruud L. Bekkers, Bea Wisman.
1361 The clinicopathological significance of LSD1 in
esophageal cancers. Keisuke Kosumi, Yoshifumi Baba, Ryuichi
Karashima, Satoshi Ida, Yu Imamura, Takatsugu Ishimoto, Shiro
Iwagami, Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida,
Akihisa Sakamoto, Shinjiro Hino, Mitsuyoshi Nakao, Hideo Baba.
1362 Nuclear morphometry measures progressive atypia
in the development of pancreatic carcinoma. Evan S. Glazer,
Kimberly A. Hill, Hao (Helen) Zhang, Peter Bartels, Joseph
Watkins, David S. Alberts, Robert S. Krouse.
1363 Epigenetic inactivation of VGF in urothelial cell
carcinoma and its potential as a non-invasive biomarker
using urine. Masamichi Hayashi, Heike Bernert, Luciane T.
Kagohara, Mariana Brait, Mark Schoenberg, Trinity Bivalacqua,
George Netto, Wayne Koch, David Sidransky, Mohammad O.
Hoque.
1364 Epigenetic regulation of SPARC in ovarian cancer.
Dylan P. Matthews, Sherine Taylor, Neveen A. Said.
1365 Epigenetic modification of LY6K in CGI shore and
CGI regulates LY6K gene activation and metastatic function
in breast cancer. Hyun Kyung Kong, Sae Jeong Park, Ye Sol
Kim, Jong Hoon Park.
1366 Discovery of biomarkers for antitumor drug
resistance using 450K methylation data of NCI60. Vanesa
Nogales, Catia Moutinho, Anna Martinez-Cardús, Sudhir Varma,
J. K. Killian, William C. Reinhold, Paul S. Meltzer, Yves
Pommier, Manel Esteller.
1367 An epigenetic screen unmasks metallothioneins as
putative contributors to renal cell carcinogenesis. Hans
Krause, Imad Al-Kamal, Odiljon Ikromov, Kurt Miller, Carsten
Kempkensteffen.
1368 Genome-wide screening of DNA methylation
markers to predict the presence of lymph node metastasis
in esophageal squamous cell carcinoma. Ken-ichi Kozaki,
Hiroaki Nagata, Kousuke Tanimoto, Naoto Fujiwara, Seiya Imoto,
Daisuke Ichikawa, Satoru Miyano, Tatsuyuki Kawano, Eigo
Otsuji, Johji Inazawa.
1369 miR-645 inhibits apoptosis of AGEJ. Xiaoshan Feng,
Ying Wang, Zhikun Ma, Ruina Yang, Mengxi Zhang, Shuo Liang,
Shuoguo Li, Gang Liu, Fanming Dai, Shegan Gao.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1370 Epigenetic clustering of gastric carcinoma based
on DNA methylation profiles at the precancerous stage: its
correlation with tumor aggressiveness and patient outcome.
Kazuhiro Yamanoi, Eri Arai, Yoriko Takahashi, Sayaka Miyata,
Ryoji Kushima, Hitoshi Katai, Michiie Sakamoto, Yae Kanai.
1371 Histone lysine trimethylation or acetylation in
sporadic breast tumor and matched normal tissue.
Dominique J. Gallon-Bernard, Gaëlle Judes, Aslihan Dagdemir,
Maureen Echegut, Seher Karsli-Ceppioglu, Marjolaine Ngollo,
Andre Lebert, Frederique Penault-Llorca, Yves-Jean Bignon.
1372 The methylome of ER-negative tumors is
predominantly hypermethylated. Maria J. Worsham,
Dhananjay Chitale, Kang Mei Chen, George Divine.
1373 Comprehensive analysis of HBV DNA methylation in
liver tissues of hepatitis B, cirrhosis and hepatocellular
carcinoma patients. Surbhi Jain, Sitong Chen, Batbold
Boldbaatar, Selena Y. Lin, Ran Yan, Chi-Tan Hu, Haitao Guo,
Timothy M. Block, Wei song, Ying-Hsiu Su.
1374 Identification of a transcription factor driving BET
dependency in SCLC. Susan Wee, Tai Wong, BMS.
1375 Epigenetic changes associated with resistance to
sunitinib in human clear cell renal cell carcinoma models.
REMI ADELAIYE, Kiersten M. Miles, Eric Ciamporcero, Dylan
Conroy, Swathi Ramakrishnan, Ashley Orillion, Sheng Yu Ku,
May Elbanna, Li shen, Sreenivasulu Chintala, Roberto Pili.
1376 EpCAM-mediated hypomethylation of BMP and cell
adhesion genes is associated with advanced endometrial
cancer. Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu,
Jianhua Ruan, Rui-Lan Huang, Chiou-Miin Wang, Chun-Liang
Chen, Rohit R. Jadhav, Yao Wang, Victor X. Jin, Hung-Cheng
Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson,
Nameer B. Kirma, Tim H. Huang.
1377 Transcriptional silencing of MST1/Hippo by a
coordinated MYC and EZH2 signaling in prostate cancer.
Gamze Kuser Abali, Ahmet Alptekin, Bekir Cinar.
1378 The histone methyltransferase adaptor WDR5 is a
novel cofactor in neuroblastoma. Yuting Sun, Pei Y. Liu,
Daniel Carter, Nicolas Sokolowski, Karen L. MacKenzie, Glenn
M. Marshall, Tao Liu.
1379 Identification of global DNA methylation signatures
in glioblastoma-derived cancer stem cells. Eun Joon Lee,
Prakash Rath, Jimei Liu, Dungsheng Ryu, Alan Free, Lirong Pei,
Douglas C Anthony, Suash Sharma, Mark D Kirk, John J.
Laterra, Duck Hwan Ryu, Jeong-Hyeon Choi, Huidong Shi,
Douglas C. Miller, N. Scott Litofsky, Qi Feng.
1380 Genome-wide fingerprinting of regulatory
chromatin to evaluate the tissue specific origins of highgrade serous ovarian cancer. Howard C. Shen, Simon
Coetzee, Dennis J. Hazelett, Gerhard A. Coetzee, Houtan
Noushmehr, Simon A. Gayther.
1381 Somatic DNA demethylation and epigenetic
reprogramming of SST1 pericentromeric repeats associate
with genomic damage in colorectal cancer. Johanna
Samuelsson, Gabrijela Dumbovic, Sergio Alonso, Sonia Forcales,
Manuel Perucho.
1382 Developmental exposure to BPA increases the
prostate cancer susceptibility via reprogramming of
androgen-responsive genes via increased H3K4me3
methylation. Quan Wang, Rebecca L. Wong, Donna F. Kusewitt,
Maarten C. Bosland, Jing Chen, Mario Medvedovic, Gail S. Prins,
Kurunthachalam Kannan, Shuk-Mei Ho, Cheryl L. Walker.
1383 Evolution of the NCOR1 and NCOR2/SMRT
cistromes in prostate cancer progression. Prashant K. Singh,
Mark D. Long, Vineet K. Dhiman, Qianqian Zhu, Lara SuchestonCampbell, Dominic Smiraglia, Moray J. Campbell.
1384 Promoter methylation of tumor suppressor genes
in convalescent saliva samples from patients with head and
neck squamous cell carcinoma. Semra Demokan, Jatinder
Kaur, Alice Y. Chuang, Wojciech K. Mydlarz, Kavita M. Pattani,
Wayne M. Koch, David Sidransky, Nejat Dalay, Joseph A.
Califano.
16
16
305
POSTER SESSION
Poster
Section
17
17
Gene Expression and Transcriptional Control 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
306
1385
Orphan nuclear receptor estrogen-related
receptor alpha (ERR␣) characterized as a novel
transcriptional regulator of the oncogenic fusion gene
TMPRSS2:ERG in prostate cancer. Zhenyu Xu, Shan Yu,
Franky L. Chan.
1386
Enhanced expression of HMGA1 and THY1 in
human hepatocellular carcinoma correlates with poor
prognosis. Mariacarla Andreozzi, Luca Quagliata, David
Benz, Francesca Trapani, Serenella Eppenberger-Castori,
Christian Ruiz, Pierlorenzo Pallante, Markus Heim, Luigi
Tornillo, Alfredo Fusco, Salvatore Piscuoglio, Luigi Maria
Terracciano.
1387
Convergent CREB1/FoxA1 transcriptional activity
defines castration-resistant prostate cancer gene
expression profile. Benjamin D. Sunkel, Dayong Wu,
Xiangtao Liu, Zhenqing Ye, Victor Jin, Qianben Wang.
1388
Biological role of novel NQO2 inhibitors in
cancer therapeutics. Elham Santina, Amy Chadwick,
Soraya Al Nabulsi, Sally Freeman, Constantinos Demonacos,
Ian Stratford.
1389
Insights into the invasiveness of triple-negative
breast cancer from genome-wide profiling of AP-1.
Chunyan Zhao, Yichun Qiao, Karin Dahlman-Wright.
1390
Interferon-gamma potentiates the targeted
phenotypic reversion of erbb2/her2/neu transformed
human tumor cells. Edwin A. Runkle, Peter Young,
Yasuhiro Nagai, Hiromichi Tsuchiya, Hongtao Zhang, Mark I.
Greene.
1391
SOX2-p63 interaction and genomic colocalization in squamous cell carcinomas. Hideo
Watanabe, Qiuping Ma, Shouyong Peng, Guillaume
Adelmant, Danielle Swain, Wenyu Song, Cameron Fox,
Joshua M. Francis, Chandra Sekhar Pedamallu, David S.
Deluca, Angela N. Brooks, Jianwen Que, Anil K. Rustgi,
Kwok-kin Wong, Keith L. Ligon, X. Shirley Liu, Jarrod A.
Marto, Matthew Meyerson, Adam J. Bass.
1392
The Pursuit of p73 Regulation: interaction
partners tell many different stories. Yatendra K. Satija,
Sanjeev Das.
1393
Correlating the expression of protein kinase C
isozymes with the transformed phenotype in colorectal
cancer. Catríona M. Dowling, Jennifer Hanly, Tara Dalton,
Patrick A. Kiely.
1394
Role of non-coding RNA in regulation of
stemness and differentiation via notch signaling
pathway in glioblastoma. Keisuke Katsushima, Keiko
Shinjo, Fumiharu Ohka, Atsushi Natsume, Tatsuhiro Shibata,
Yutaka Kondo.
1395
Identification of genes and pathways related to
lymphovascular invasion in axillary-node negative
breast cancer: A bioinformatic analysis of gene
expression data. Mathieu Blais, Dushanthi Pinnaduwage,
Sheley Bull, Irene L. Andrulis.
1396
Musashi 1 stabilizes TAC1 transcript in breast
cancer cells to increase the production of oncosubstance P. George R. Nahas, Raghav G. Murthy, Shyam
A. Patel, Steven J. Greco, Pranela Rameshwar.
1397
Simultaneous down-regulation of WWOX and
DOK1 genes in non-small cell lung cancer (NSCLC)
patients. Onur Baykara, Seda Ekizoglu, Esin Tuna, Ahmet
Demirkaya, Kamil Kaynak, Hikmet Kose, Nur Buyru.
1398
Targeting novel co-activators of androgen
receptor in castration resistant prostate cancer. Rohit
Malik, Amjad P. Khan, John R. Prensner, Matthew K. Iyer,
Dmitry Borkin, Xiaoju Wang, Xia Jiang, Shruthi
Subramaniam, Yang Shi, Rachell Stender, Yi-Mi Wu, Xuhong
Cao, Jolanta Grembecka, Tomasz Cierpicki, Arul Chinnaiyan.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1399
NRF2 mutations are frequent in early rat
preneoplastic hepatic lesions and in human
hepatocellular carcinomas positive for the
stem/progenitor cell marker KRT-19. Patrizia Zavattari,
Andrea Perra, Marta A. Kowalik, Maddalena M. Angioni,
Silvia Menegon, Annalisa Petrelli, Luca Quagliata, Giovanna
M. Ledda-Columbano, Luigi Terraciano, Silvia Giordano,
Amedeo Columbano.
1400
Extended concurrent gene signatures of ER,
HER2 and disease-free survival in breast cancers. ChiCheng Huang, Shih-Hsin Tu, Ching-Shui Huang, Heng-Hui
Lien, Liang-Chuan Lai, Eric Y. Chuang.
1401
Transcription of angiogenin and ribonuclease 4
is regulated by RNA polymerase III elements and a
CTCF-dependent intragenic chromatin loop. Jinghao
Sheng, Chi Luo, Yuxiang Jiang, Philip W. Hinds, Zhengping
Xu, Guo-fu Hu.
1402
Regulation of Id2 In the proliferation of gliomainitiating neural progenitor cells. Jaclyn Sullivan, Matthew
Havrda, Brenton Paolella, Arminja Kettenbach, Scott Gerber,
Mark A. Israel.
1403
TRIM16 inhibits cell growth through direct
interaction and modulation of TDP43 protein stability in
cancer cells. Patrick Y. Kim, Owen Tan, Toby Trahair, Tao
Liu, Glenn M. Marshall, Belamy B. Cheung.
1404
An EGFR-Stat3-IL6 pathway contributes to NF1
tumor initiation and maintenance. Jianqiang Wu, Nancy
Ratner.
1405
Knockdown ARID5A suppresses proliferation of
LNCaP prostate cancer cell through the inhibition of
global protein synthesis. Chao Sun, Viktor Chesnokov,
Keiichi Itakura.
1406
Evoking potent RNAi response using novel 2’OMe-phosphorodithioated modified siRNAs. Sherry Wu,
Xianbin Yang, Martin Egli, Kshipra Ghaupure, Hiroto
Hatakeyama, Michael McGuire, Rajesha Rupaimoole,
Takahito Miyake, Morgan Taylor, Sunila Pradeep, Archana
Nagaraja, Malgorzata Sierant, Richa Singhania, Cristian
Rodriguez-Aguayo, Nigel McMillan, Gabriel Lopez-Berestein,
Prahlad Ram, Barbara Nawrot, Anil K. Sood.
1407
The influence of EWS-FLI1 on the Rho/Actin/
MRTF circuit in Ewing sarcoma. Anna M. Katschnig,
Raphaela Schwentner, Stephan Niedan, Maximilian O. Kauer,
Elizabeth R. Lawlor, Dave N. Aryee, Heinrich Kovar.
1408
p53-directed translational control can shape
and expand the universe of p53 target genes. Sara
Zaccara, Toma Tebaldi, Yari Ciribilli, Alessandra Bisio,
Alberto Inga.
1409
The BP1 homeobox gene is dysregulated in
triple negative breast cancer. Saurabh Kirolikar, Mandeep
Gill, Silma Pereira, Svetlana Ghinbouschi, Luciane Cavalli,
Patricia Berg.
1410
Gnaq/11 mutant uveal melanoma is susceptible
to Brd4 inhibition by JQ1. Grazia Ambrosini, Gary K.
Schwartz.
1411
Regulation of osteoprotegerin expression in
breast cancer cells by nuclear factor-kappaB. Michael
Weichhaus, Linda Connelly.
1412
Capturing c-Myb target genes in adenoid cystic
carcinoma. KATHRYN BRAYER, Scott Ness.
1413
RUNX3 plays an oncogenic role in Ewing
sarcoma cells. Krista L. Bledsoe, Meghan E. McGeeLawrence, Emily T. Camilleri, Andre M. Oliveira, Andre J.
van Wijnen, Jennifer J. Westendorf.
1414
Race-associated variation in the airway
transcriptome response to cigarette smoke. Anna
Tassinari, Duncan Whitney, Kate Porta, Marc Lenburg,
Avrum Spira, Jennifer Beane.
POSTER SESSION
Metabolic Pathways 1
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
1415
Prostate cancer: An integrated evaluation of
metabolomics, transcriptomics, and proteomics
expression data. Ulrike Rennefahrt, Hellmuth-A. Meyer,
Beate Kamlage, Regina Reszka, Philipp Schatz, Carsten
Stephan, Klaus Jung, Dimo Dietrich, Glen Kristiansen.
1416
CB-839, a novel potent and selective
glutaminase inhibitor, has broad antiproliferative activity
in cell lines derived from both solid tumors and
hematological malignancies. Francesco Parlati, Susan D.
Demo, Matthew I. Gross, Julie R. Janes, Evan R. Lewis,
Andy L. MacKinnon, Mirna L. Rodriguez, Peter J. Shwonek,
Taotao Wang, Jinfu Yang, Dong Zhang, Frances Zhao, Mark
K. Bennett.
1417
Stimulation of fatty acid synthesis by Spot14
enhances tumor cell proliferation but decreases
metastasis in vivo. Elizabeth A. Wellberg, Michael C.
Rudolph, Andrew Lewis, Steven M. Anderson.
1418
Induction of autophagy and apoptosis with
polyamine synthesis inhibition and metformin in human
melanoma and colon cancer cells. Yanping Zhang,
Guangyong Peng, Eddy C. Hsueh.
1419
Oncogenic Myc disrupts NAMPT circadian
oscillation in mouse hepatocellular carcinoma cell line.
Annie L. Hsieh, Brian J. Altman, Anand Venkataraman,
David I. Bellovin, Dean W. Felsher, John B. Hogenesch, Chi
V. Dang.
1420
RRx-001 inhibits glucose erythrocyte and tumor
glucose 6-phosphate dehydrogenase. Pedro Cabrales,
Bryan Oronsky, Jan Scicinski.
1421
Overexpression of the pro-glycolytic
transcription factor MondoA enhances malignant
potential of ALL in vivo. Alexandra A. Sipol, Günther H.
Richter, Caroline M. Wernicke, Thomas G. Grunewald,
Stefan Burdach.
1422
Validation of primary non-small cell lung
cancer model: Stable isotope-resolved metabolomics
(SIRM) reveals functional biochemistry. Connor J.
Kinslow, Teresa W. Fan, Jin L. Tan, Pawel K. Lorkiewicz,
Ramya Balasubramaniam, Yihua Cai, Jun Yan, Andrew N.
Lane.
1423
Resistance to LDHA inhibitors requires signaling
through the AMPK/mTOR/S6K pathway leading to
increased oxidative phosphorylation. Aaron Boudreau,
David Peterson, John Moffat, Bonnie Liu, Mandy Kwong,
Min Gao, Hans Purkey, Thomas O’Brien, Georgia
Hatzivassiliou, Anneleen Daemen, Marie Evangelista.
1424
Enhanced pyruvate carboxylation is crucial to
non-small cell lung cancer proliferation and anabolism.
Katherine E. Sellers, Matthew P. Fox, Michael Bousamra,
Jun Yan, Mariia Yuneva, Richard M. Higashi, Andrew N.
Lane, Teresa W. Fan.
1425
Diagnostic identification and characterization of
glutaminase-dependent tumors. Bonnie Liu, Kyung Song,
Anneleen Daemen, Mandy Kwong, Min Gao, Rebecca Hong,
David Peterson, Michelle Nannini, Deepak Sampath, Marcia
Belvin, Ron Firestein, Marie Evangelista, Georgia
Hatzivassiliou.
1426
Fumarate hydratase and deuterium depletion
control oncogenesis via NADPH-dependent reductive
synthesis: mitochondrial matrix water, DNA deuteration
and epigenetic events. László G. Boros, Emmanuelle J.
Meuillet, Ildikó Somlyai, Gábor Jancsó, György Jákli,
Krisztina Krempels, László G. Puskás, István L. Nagy, Miklós
Molnár, Keith R. Laderoute, Patricia A. Thompson, Gábor
Somlyai.
1427
Liver selective Acetyl-CoA Carboxylase
inhibition by ND-654 decreases hepatocellular
carcinoma development in cirrhotic rats. Danielle K.
DePeralta, Lan Wei, Geraldine Harriman, Jeremy Greenwood,
Sathesh Bhat, William Westlin, H. J. Harwood, Rosana
Kapeller, Kenneth K. Tanabe, Bryan C. Fuchs.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
1428
Targeting metabolic alteration in cisplatinresistant lung cancer. Medhi Wangpaichitr, Chunjing Wu,
Ying Ying Li, Shumei Chen, Min You, Vy Dinh, Lynn G. Feun,
Macus T. Kuo, Niramol Savaraj.
1429
Bioluminescent methods for investigating
metabolic pathways. Donna Leippe, Mary Sobol, Jolanta
Vidugiriene, Wenhui Zhou, Gediminas Vidugiris, Troy Good,
Laurent Bernad, Poncho Meisenheimer, James Cali.
1430
Identification of distinct metabolic subtypes
within pancreatic ductal adenocarcinoma through broad
metabolite profiling. Anneleen Daemen, David Peterson,
Nisebita Sahu, Ron McCord, Kaska Kowanetz, Anna Hitz,
Xiangnan Du, Bonnie Liu, Min Gao, John Moffat, Rebecca
Hong, Deepak Sampath, Mark Merchant, Thomas O’Brien,
Bob Yauch, Jeff Settleman, Jing Qing, Georgia
Hatzivassiliou, Marie A. Evangelista.
1431
Gene expression analysis of argininosuccinate
synthetase loss and the effects of pegylated arginine
deiminase in malignant pleural mesothelioma. Rosalind
Cutts, Puthen V. Jithesh, Barbara Delage, Phuong Luong,
Gareth Thomas, Claude Chelala, Peter W. Szlosarek.
1432
Understanding the roles of Choline kinase-␣ in
lipid metabolism of breast cancer cells. Noriko Mori,
Flonné Wildes, Kristine Glunde, Zaver M. Bhujwalla.
1433
Omental derived adipose stromal cells regulate
nitric oxide homeostasis to maintain tumorigenicity in
ovarian cancer cells. Bahar Salimian Rizi, Ann H. Klopp,
Deepak Nagrath.
1434
Metformin-induced metabolic changes are kras-dependent in animal models of pancreatic cancer.
Mary Jo Cantoria, Laszlo G. Boros, Hitendra Patel, Haiyong
Han, Natalia Ignatenko, Emmanuelle J. Meuillet.
1435
Exploiting obligate arginine auxotrophy in tumor
cells lacking arginino-succinate synthetase (ASS)
expression to develop targeted molecular therapy for
non-small cell lung cancer (NSCLC). Min You, Medhi
Wangpaichitr, Jonathan D. Nguyen, Jennifer R. Chapman,
Maureen Cioffi-Lavina, Niramol Savaraj, Dao M. Nguyen.
1436
Investigating the NAD metabolome in Ewing
sarcoma. Cornelia N. Mutz, Jozef Ban, Stephan Niedan,
Maximilian O. Kauer, Dave N. Aryee, Dietmar Fuchs,
Andreas Heitger, Heinrich Kovar.
1437
PTEN deficiency in prostate epithelial cells is
associated with increased CAD phosphorylation and is
inhibited by fisetin. Mohammad Imran Khan, Vaqar
Mustafa Adhami, Omar Mohammad Haidar, Bilal Bin Hafeez,
Ajit Kumar Verma, Hasan Mukhtar.
1438
Targeting metabolic enzyme with locked nucleic
acids in non-small cell lung cancer. Wen Cai Zhang, Bing
Lim.
1439
Combination of metformin plus orlistat prevents
tumor progression: novel role of the metabolic hormone
fibroblast growth factor 21 (FGF21). Shobika Sivaram,
Erdene Baljinnyam, Kousaku Iwatsubo, Lydia I. Puricelli,
Mariana S. De Lorenzo.
1440
Metabolic therapy reduces expression of
PECAM-1/CD31 and decreases peritumoral edema in a
mouse model of malignant glioma. Eric C. Woolf, Julie A.
Charlton, Qingwei Liu, Gregory Turner, Mark C. Preul,
Adrienne C. Scheck.
1441
Induction of cancer cachexia by inflammatory
molecules in directed complementation tumor models.
Qing Liu, Lorena Lerner, Zakir Siddiquee, Lucia Huang,
Ruojie Wang, Nianjun Tao, Brian Krieger, Isabel Chiu, Jeno
Gyuris.
1442
Effects of selective and broad glucose
transporter (GLUT) inhibition on glucose distribution in
tumor bearing mice. Melanie Heroult, Wolfram Steinke,
Anna-Lena Frisk, Sandra Borkowski, Kirstin Meyer, Heike
Petrul, Iring Heisler, Maria Quanz, Roland Neuhaus, Bernd
Buchmann, Thomas Mueller, Marcus Bauser, Andrea
Haegebarth, Michael Brands, Karl Ziegelbauer.
18
18
307
POSTER SESSION
Poster
Section
19
19
MicroRNAs and Metastasis
Poster Abstract
Board Number
1.
2.
3.
4.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
308
1443
A systematic approach to the metastatically
relevant microRNA landscape. Giridhar Mudduluru,
Mohammed Abba, Jasmin Batliner, Nitin Patil, Taral R.
Lunavat, Maike Scharp, Jörg Leupold, Olga Oleksiuk, Ivo
Buchhalter, Wilko Thiele, Melanie Rothley, Axel Benner,
Jonathan Sleeman, Heike Allgayer.
1444
Sensitivity to trastuzumab for gastric cancer is
regulated by miR-223/FBXW7 pathway. Kojiro Eto,
Masaaki Iwatsuki, Takatsugu Ishimoto, Hideo Baba.
1445
Thyroid hormone receptor represses microRNA130b to enhance cell metastasis. Yang Hsiang Lin, MengHan Wu, Yung-Hsin Yeh, Angel Chao, Kwang-Huei Lin.
1446
Isolation of a novel metastasis-related
microRNA, miR-518c-5p, induced by the stromal cellderived factor (SDF)-1/CXCR4 system in oral cancer.
Makoto Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi,
Tetsuya Tamatani, Hirokazu Nagai, Youji Miyamoto.
1448
Disseminated tumor cell formation promoted by
lysophosphatidic acid (LPA) involves ZEB1/miR21dependent activation pathway. Debashish Sahay, Raphaël
Leblanc, Johnny Ribeiro, Philippe Clézardin, Olivier
Peyruchaud.
1449
p70 S6 kinase signals tristetraprolin/Dicermediated maturation of microRNA-145 to regulate tumor
metastasis . Sophia S. Lam, Carman K. Ip, Alice S. Wong.
1450
MicroRNAs in myxoid/round cell liposarcomas:
FUS-CHOP regulated miR-497 and miR-30a target the
insulin-like growth factor receptor pathway. Caroline M.
Gits, Patricia F. van Kuijk, Wilfred F. van IJcken, Ron H.
Mathijssen, Michael A. den Bakker, Jaap Verweij, Stefan
Sleijfer, Erik A. Wiemer.
1451
MicroRNAs regulated by ESE3/EHF control
important mediators of epithelial cell differentiation and
stemness in prostate tumors. Cecilia Dallavalle, Domenico
Albino, Gianluca Civenni, Paola Ostano, Davide Genini,
Ramon Garcia-Escudero, Laura Curti, Sandra Pinton,
Manuela Sarti, Giovanna Chiorino, Carlo V. Catapano,
Giuseppina M. Carbone.
1452
MicroRNA-375 impairs head and neck
squamous cell carcinoma invasion by suppressing
invadopodia activity. Lizandra Jimenez, Ved P. Sharma,
Jihyeon Lim, Ruth Angeletti, John Condeelis, Thomas Harris,
Michael B. Prystowsky, Geoffrey Childs, Jeffrey E. Segall.
1453
MicroRNA replacement and RNAi-mediated
silencing of ALK as combined targeted therapies for
neuroblastoma. Patrizia Perri, Daniela Di Paolo, Leslie
Priddy, Annarita Di Fiore, Chiara Brignole, Fabio Pastorino,
David Brown, Mirco Ponzoni.
1454
MiR-517a mediates cisplatin sensitivity in
bladder cell carcinoma. Ahmed Ibrahim, Arnab
Chakravarti, Tim Lautenschlaeger.
1455
Therapeutic synergy between novel tumor
suppressor miR-520d-3p and EphA2-targeting siRNA in
ovarian cancer. Maitri Shah, Gabriel Berestein Lopez, Anil
Sood, George Calin.
1456
MicroRNA improves the efficacy of imatinib on
the treatment of chronic myeloid leukemia. Bin Yi, Ruixia
Ma, Xiangling Feng, Zhiwei Xing, Xiaoguo Zhang, Gary
Piazza, Yaguang Xi.
1457
Development of miRNA-loaded polymeric
nanoformulation for pancreatic cancer therapy. Sumit
Arora, Suresh K. Swaminathan, Sanjeev K. Srivastava,
Seema Singh, Jayanth Panyam, Ajay P. Singh.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1458
The precursor miR-138/2, but not miR-138/1,
targets p53 mRNA and contributes to the acquisition of
melanoma metastatic phenotype: Are the miRNAs
precursors important to direct mature miRNA to mRNA
targets. Adriana T. Da Cruz, Aline Hunger, Genevieve Paré,
Dulcie Lai, Fabiana H. Melo, Bryan E. Strauss, Victor Tron,
Miriam G. Jasiulionis.
1459
miR-221: A potential therapeutic target for
hepatocellular carcinoma. Edmund C. Lee, Jessica Xu,
Thomas Vincent, Jie Chen, Michael Nelson, Xinqiang Huang,
Eric Marcusson, John Androsavich, Scott Davis, Adam
Pavlicek, Neil Gibson, Sonya Zabludoff.
1460
Tumor suppressor miR-137 inhibits colorectal
cancer progression by negatively regulating cancer
stem cell marker, Musashi-1. Amber R. Smith, Rebecca
Marquez, Bryan Tsao, Lan Lan, Surajit Pathak, Xiao-Feng
Sun, Kristi Neufeld, Liang Xu.
1461
A miR-221 multigene pharmacodynamic
signature for assessing miR-221 inhibition. Adam
Pavlicek, Thomas Vincent, Oivin Guicherit, Nelson Chau,
Sonya Zabludoff, Neil Gibson, Edmund C. Lee.
1462
Tandem genome-wide and functional screening
reveals that MiRNA-29 regulates the proteasome
activator PSME4 to promote therapeutic resistance in
myeloma. James J. Driscoll, Sajjeev Jagannathan.
1463
Long non-coding RNA RoR and microRNA-145
regulate tumor cell invasion in triple-negative breast
cancer via targeting of ADP-ribosylation factor 6. Gabriel
L. Eades, Qun Zhou.
1464
Identification of metastasis-associated
microRNAs in oral squamous cell carcinoma using highthroughput sequencing. Patricia Severino, Liliane S.
Oliveira, Natalia Torres, Otavio A. Curioni, Patricia M. Cury,
Victor Wunsch-Filho, Head and Neck Genome Project
GENCAPO.
1465
Phase specific microRNA deregulation of
oncogenesis and stemness in a mouse model of
sporadic CRC. Mariangela De Robertis, Eva Bandrés, Maria
Luana Poeta, Luisa Loiacono, Giuseppe Lamorte, Massimo
Sanchez, Luigi Marchionni, Maria Grazia Diodoro, Edoardo
Pescarmona, Angelo Luigi Vescovi, Jesus Garcia-Foncillas,
Vito Michele Fazio.
1466
Regulation of colon cancer metastasis by
sprouty-2. Qiong Zhang, Vivek Vaish, Sharad Khare.
1467
The miR-23b/-27b cluster decreases metastasis
of aggressive prostate cancer. Meghan A. Rice, Reema
Ishteiwy, Thirupandiyur Udayakumar, Derek Dykxhoorn,
Kerry L. Burnstein.
1468
The KRAS-variant, a miRNA disrupting inherited
mutation in the 3’UTR of KRAS, causes EMT and unique
cell biology. Joanne B. Weidhaas, David Salzman, Michelle
Dookwah, Sunitha Nallur, Elcie Chan, Trupti Paranjape.
1469
Functional roles of SCAL1 expression in lung
cancer and progression. Sarah Statt, Philip Thai, ChingHsien Chen, Ya-Wen Cheng, Steven Belinsky, Reen Wu.
1470
The association of miR-21, HER-2/neu, and
PTEN expression and clinical outcome of breast cancer.
Hsiao-Ching Lin, Ya-Wen Cheng, Nan-Yung Hsu.
1471
HER2 regulated miRNA expression in letrozole
resistant breast cancer. Armina A. Kazi, Gauri Sabnis, Qun
Zhou, Saranya Chumsri, Amanda Schech, Preeti Shah,
Angela Brodie.
1472
The differential expression of miRNAs in breast
cancer cell lines. Checo J. Rorie, Brianna L. Arrington,
Sherette S. Godfrey, Armeshia S. McCoy, Kashenya M.
Gurley.
POSTER SESSION
MicroRNAs and Solid Tumors 2: Diagnostics/Prognostics
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
1473
Indentification of microRNA signature and
deregulation in breast, lung and colon cancer through
next generation sequencing and quantitative reverse
transcriptase PCR. Chunmei Liu.
1474
Integrated microRNA network analyses identify
a poor prognosis subtype of gastric cancer
characterized by the miR-200 family. Fengju Song, Kexin
Chen.
1475
Plasma circulating miRNAs: a new potential
biomarker for prostate cancer diagnosis. Simona Giglio,
Cosimo De Nunzio, Roberto Cirombella, Stefano Volinia,
Emidio Luciani, Andrea Tubaro, Andrea Vecchione.
1476
Hypermethylation of a TGF-␤ regulated microRNA, miR-193a, predicts prognosis in ovarian cancer.
Frank H. Cheng, Gary C. Chen, Jian-Liang Chou, Ya-Wen
Lin, Lin-Yu Chen, Hung-Cheng Lai, Chin Li, Michael W.
Chan.
1477
Evaluation of microRNA-10b prognostic
significance in a prospective cohort of breast cancer
patients. Paola Parrella, Raffaela Barbano, Barbara Pasculli,
Andrea Fontana, Massimiliano Copetti, Vanna Maria Valori,
Maria Luana Poeta, Giuseppe Perrone, Michelina Coco,
Teresa Balsamo, Fabio Pellegrini, Andrea Onetti Muda,
Evaristo Maiello, Roberto Murgo, Vito Michele Fazio.
1478
Decreased expression of miR-506 induced
epithelial-mesenchymal transition and poor prognosis in
gastric cancer patients. Shotaro Sakimura, Junji
Kurashige, Keishi Sugimachi, Masami Ueda, Hidenari Hirata,
Yoshiaki Shinden, Etsuko Sakimura, Tae Matsumura, Yuki
Takano, Ryutaro Uchi, Hiroki Ueo, Hidetoshi Eguchi, Tomoya
Sudo, Sumio Hoka, Koshi Mimori.
1479
A miRNA signature distinguishing low-grade
and high-grade gliomas shows miR-21 and 210 as
promising biomarkers of aggressive phenotype and
prognosis. Raffaela Barbano, Barbara Pasculli, Orazio
Palumbo, Marco Galasso, Stefano Volinia, Vincenzo
D’Angelo, Michelina Coco, Lucia Dimitri, Massimiliano
Copetti, Vanna Maria Valori, Evaristo Maiello, Massimo
Carella, Vito Michele Fazio, Paola Parrella.
1480
Long noncoding RNAs in the postmenopausal
breast and their role in cancer prevention. Maria Barton,
Julia Santucci-Pereira, Ricardo Lopez de Cicco, Irma H.
Russo, Eric A. Ross, Michael Slifker, Suraj Peri, Pal Bordas,
Per Lenner, Göran Hallmans, Paolo Toniolo, Jose Russo.
1481
miR-296 as prognostic and predictive molecular
marker for recurrence in early-stage laryngeal
carcinoma treated with definitive radiotherapy. Danielle
C. Maia, Ana Carolina de Carvalho, Maria Aderuza Horst,
Cristovam Scapulatempo Neto, Andre Lopes Carvalho, Andre
L. Vettore.
1482
MicroRNA expression profiles classify renal cell
carcinoma subtypes. Sven Wach, Elke Nolte, Theil Anne,
Christine Stoehr, Tilman T. Rau, Arndt Hartmann, Arif B.
Ekici, Bastian Keck, Helge Taubert, Bernd Wullich.
1483
Biological and clinical significance of miR-224
in colorectal cancer. HUI LING, George Calin, Milena
Nicoloso, Mariko Ikuo.
1484
CD57 defines a novel maker of glioblastoma
stem cells that have greater invasive potential than
CD133ⴙ tumor cells. Lin Qi, Yu-lun Huang, Mari Kogiso,
Hua Mao, Patricia Baxter, Jack M. Su, Laszlo Perlaky, Ching
C. Lau, Murali Chintagumpala, Xiao-Nan Li.
1485
Biomarker development for lung cancer
diagnosis using integrative microRNA and gene
expression networks. Ana Pavel, Joshua Campbell, Gang
Liu, Sherry Zhang, Hanqiao Liu, Steven Dubinett, David
Elashoff, Kate Porta, Duncan Whitney, Marc Lenburg, Avrum
Spira.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
30.
1486
Bladder cancer exosomes contain tumorassociated mRNA and long non-coding RNA and
facilitate tumor progression. Jayme Olsen, Jonathan D.
Flax, Edward M. Messing, Carla J. Beckham.
1487
Identification of oral carcinoma miRNA
signature and control OSCC tumorigenesis through Wnt/
␤-catenin signaling. Wei-Min Chang, Yuan-Ming Hsu,
Sung-Tau Chou, Yi-Shing Shieh, Michael Hsiao, Jenn-Ren
Hsiao, Jang-Yang Chang, Shine-Gwo Shiah.
1488
Association between microrna binding site
polymorphism and susceptibility to colorectal cancer in
Korean population. Byung Woog Kang, Hyosung Jeon, Yee
Soo Chae, Soo Jung Lee, Jong Gwang Kim, Hyunchul Lee,
Eun-Jin Lee, Myung Hoon Lee, Jae Yong Park, Gyu Seog
Choi, Jun Seok Park.
1489
Pri-let-7a-2 rs629367 associated with increased
risk and poor survival of gastric cancer in Chinese by
up-regulated let-7a expression. Qian Xu, Yuan Yuan.
1490
MiR-21 has strong prognostic implications and
functions as an oncogenic miR by modulating PI3K/Akt
pathway at multiple levels in diffuse large B cell
lymphoma. Heounjeong Go, Ji-Young Jang, Soo Jeong
Nam, Young-Goo Kim, Jin Ho Paik, Tae Min Kim, Dae Seog
Heo, Chul-Woo Kim, Yoon Kyung Jeon.
1491
Tissue miRNA as a predictive marker for
recurrence of Dukes B colorectal cancer. Nobuyoshi
Yamazaki, Yoshikatsu Koga, Norio Saito, Yasuhiro
Matsumura.
1492
Prediction of cancer progression in Barrett’s
esophagus patients using miRNA profiling. Josef Srovnal,
Ondrej Slaby, Jiri Ehrmann, Jan Gregar, Lenka Radova,
Michaela Sedlackova, Marian Hajduch.
1493
Specific miRNA signatures characterize
different metastatic sites in clear cell renal cell
carcinoma. Joana Heinzelmann, Franzsika Stolzenbach,
Robert Schneeweiss, Ulrike Wickmann, Sophie Baumgart,
Mieczyslaw Gajda, Michael Stöckle, Kerstin Junker.
1494
MicroRNAs encoded at the 14q32 cluster are
associated with poor outcome in lung adenocarcinoma.
Ernest Nadal, Jules Lin, Rishindra M. Reddy, Nithya
Ramnath, Mark B. Orringer, Andrew C. Chang, David G.
Beer, Guoan Chen.
1495
Identification of markers for the presence of
lymph nodes metastasis in patients with oral squamous
cell carcinomas. Fernando T. Zamunér, Danielle Calheiros
Campelo Maia, André Lopes Carvalho, André Luiz Vettore.
1496
MicroRNA signature associated with poor
outcome of glioblastoma patients. Jiri Sana, Radek
Lakomy, Pavel Fadrus, Martin Smrcka, Pavel Slampa, Leos
Kren, Marketa Hermanova, Marek Svoboda, Ondrej Slaby.
1497
A novel long non-coding RNA associated with
poor prognosis in epithelial ovarian cancer. Kate
Lawrenson, Tassja Spindler, Simon A. Gayther.
1498
Long non-coding RNA in situ hybridization
signal patterns correlate with breast tumor pathology.
Zhouwei Zhang, Zhihua Peng, Daniel Olsen, James deKay,
Donald L. Weaver, Mark F. Evans.
1499
Expression and prognostic significance of
microRNAs in Korean patients with myelodysplastic
syndrome. Yunsuk Choi, Eun-Hye Hur, Ju Hyun Moon, BonKwan Goo, Dae Ro Choi, Je-Hwan Lee.
1500
The difference of serum RNA profile: RNA
detection method. Satoshi Kondo, Satoko Takizawa, Hideo
Akiyama.
1501
Optimizing small RNAseq of archived serum
samples from the Janus Serum Bank - a search for
cancer biomarkers. Trine B. Rounge, Robert Lyle, Marianne
Lauritzen, Kristina Kjaerheim, Tom Grotmol, Tom K.
Grimsrud, Randi E. Gislefoss, Steinar Tretli, Giske Ursin,
Hilde Langseth.
Poster
Section
20
20
309
POSTER SESSION
Poster
Section
21
21
Mutation Detection Methods
Poster Abstract
Board Number
1.
2.
1503
Rapid detection of somatic mutations in cancer
genes. Michael J. Powell, Larry Pastor, Rachel Diaz, Lily
Chen, George Wu, Claudia Li, Aiguo Zhang.
3.
1504
Usefulness of peripheral blood for monitoring of
acquired resistance to EGFR tyrosine kinase inhibitors
in NSCLC. Naomi Kobayashi, Naoko Sueoka-Aragane, Hitomi
Umeguchi, Tomomi Nakamura, Akemi Sato, Kazutoshi
Komiya, Yuji Takeda, Shinichiro Hayashi, Eisaburo Sueoka,
Shinya Kimura.
4.
1505
Targeted sequencing for the assessment of
intratumor heterogeneity. Eugene G. Izumchenko, Xiaofei
Chang, Mariana Brait, William Westra, David Sidransky.
5.
1506
Mutant enrichment by ICE COLD-PCR prior to
the next-generation sequencing enables high sensitivity
and high throughput detection of cancer biomarkers in
patient samples. Rui Lin, Sarah Cherubin, Courtney
Cubrich, Grant Wu, Ben Legendre, Katherine Richardson.
6.
1507
Highly sensitive and specific digital
quantification of cancer genetic aberrations. Laura K.
Miotke, Billy Lau, Rowza Rumma, Hanlee Ji.
7.
1508
A highly sensitive and reliable methodology
(ARMS-PM system) for detection of K-ras mutations in
FFPE samples. Wei-Tao Duan, Xiujuan Wang, Lihong Hu,
Feng Zhu, Dehua Yu.
8.
1509
A ARMS-PNA PCR assay for detection of EGFR
mutations in FFPE tumor samples. Shanshan Zhao, Xiao
Guo, Ziwen Long, Dehua Yu.
10.
310
1502
A rapid and fully automated multiplex assay for
KRAS-BRAF mutations with high mutation sensitivity
using novel selective amplification and detection
technologies. Ina Vandenbroucke, Katrien Vermeiren, Elisa
Mokany, Lit Yeen Tan, Nicole Lima, Samantha Walker,
Geneviève Vandercruyssen, Bart Claes, Inky De Baere,
Pascale Holemans, Evelien Rondelez, Alison Todd, Geert
Maertens, Erwin Sablon.
1511
A highly sensitive, repaid and reliable assay for
detection of human B-raf (V600) mutations. Xiujuan
Wang, Hui Lan, Qi-Lin Chen, Wei-Tao Duan, Shanshan Zhao,
Dehua Yu.
11.
1512
Detection of somatic alterations in plasma from
lung cancer patients. Jose L. Costa, Ana Justino, Ana
Barroso, Barbara Parente, Jose C. Machado.
12.
1513
Use of complex oligonucleotide libraries for
concurrent high-resolution fluorescence imaging of both
DNA and RNA in various sample types. Robert A. Ach,
Peter Tsang, Alicia Scheffer-Wong, Laurakay Bruhn, Weston
Powell, Jesse Engreitz, Janine LaSalle, Mitchell Guttman,
Alice Yamada.
Poster Abstract
Board Number
13.
1514
An AC electrokinetic microarray device for
isolation of cell circulating free nucleic acid from the
blood of cancer patients. Jennifer Marciniak, Avery
Sonnenberg, Laura Rassenti, Emanuela Ghia, George
Widhopf, Elaine Skowronski, Sareh Manouchehri, Thomas J.
Kipps, Michael J. Heller, David J. Charlot, Rajaram Krishnan.
14.
1515
Simultaneous detection of KRAS and TP53
mutations in human cancer cell lines using multiplex
qPCR. Sunali Patel, Cora Woo, Joyce Wilde, Sundiep
Phanse.
15.
1516
Automated circulating DNA purification from
large volumes of plasma. Sydnor T. Withers, Mary
Dressler, Cristopher A. Cowan.
16.
1517
Detection of SMAD4, MAP2K4, RB1 and CDKN2A
gene deletions in human tumor cells by multiplex qPCR.
Cora Woo, Joyce Wilde, Sunali Patel.
17.
1518
A new multiplex genotyping assay using PNA
clamping-assisted fluorescence melting curve analysis.
Yongtae Kim, Jin W. Kim, Sung-Kee Kim, Goon Ho Joe.
18.
1519
Targeted enrichment and next generation
sequencing of non-small cell lung carcinoma FFPE
samples. Rusla du Breuil, Tatiana Shvetsova, Kruti Patel,
Troy Moore, Gwen Fewell.
19.
1520
Development of low-cost high throughput
screening pipeline for detecting germline cancer
causing mutations in Hispanic populations. Paul Lott,
Ruta Sahasrabudhe, Anna Marie Tuazon, John Williamson,
Ana Estrada, Mabel Bohorquez, Rodrigo Prieto, Angel Criollo,
Alejandro Velez, Jorge Castro, Gilbert Mateus, María
Magdalena Echeverry, Luis Carvajal-Carmona.
20.
1521
Quantitation of HER2 gene amplification using
digital PCR. Kelly Li, Devin Do, Patricia Hegerich, Bruno
Ping, David Keys, Nivedita Majumdar, Stephen Jackson,
Francisco Cifuentes, Caifu Chen.
21.
1522
Direct quantitative PCR of LINE repeats to
quantify CFC-DNA in serum. David J. Charlot, Megha
Bhalla, Raj Krishnan, Gene Tu.
22.
1523
Molecular typing of Chinese gastrointestinal
stromal tumors using a multigene next generation
sequencing panel. Zhi Xu, Zhibin Hu, Xinying Huo,
Chuanning Tang, Si-Yi Chen, Jinfei Chen.
POSTER SESSION
Oncogenomics
Poster
Section
Poster Abstract
Board Number
Poster Abstract
Board Number
1.
1524
The molecular landscape of breast ductal
carcinoma in situ (DCIS). C. Marcelo Aldaz, Martin C.
Abba, Ting Gong, Yue Lu, Jaeho Lee, Jianjun Shen, Marcos
R. Estecio, Aysegul A. Sahin.
13.
1536
Whole genome sequencing of high-grade
treatment-naïve prostate tumors. Brennan J. Decker,
Danielle M. Karyadi, Eric Karlins, Brian W. Davis, Lori S.
Tillmans, Stephen N. Thibodeau, Elaine A. Ostrander.
2.
1525
Exome sequencing to identify permissive
mutations representing acquired vulnerabilities in lung
cancer. Jill E. Larsen, Caleb F. Davis, Kenneth Huffman,
Luc Girard, David A. Wheeler, Richard A. Gibbs, John D.
Minna.
14.
3.
1526
Integrative and comparative genomic analysis
of East-Asian lung squamous cell carcinomas.
Youngwook Kim, Peter S. Hammerman, Jaegil Kim, Gad
Getz, Matthew Meyerson, Keunchil Park.
1537
Prospective mutational characterization of
Japanese patients with non-small cell lung cancer by
next-generation sequencing. Hirotsugu Kenmotsu,
Yasuhiro Koh, Masakuni Serizawa, Mitsuhiro Isaka,
Tomohiro Maniwa, Haruyasu Murakami, Keita Mori,
Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde, Toshiaki
Takahashi, Nobuyuki Yamamoto.
15.
1538
Molecular characterization of uterine
leiomyomas, histopathological uterine leiomyoma
subtypes, and uterine leiomyosarcomas. Netta Mäkinen,
Kati Kämpjärvi, Ralf Bützow, Pia Vahteristo.
16.
1539
Fusion events in NSCLC cell lines identified by
whole transcriptome analysis. Seung-Hyun Jung, YeunJun Chung.
17.
1540
CCCTC-binding factor (CTCF) mutation in
endometrioid endometrial carcinoma (EEC): Master
epimutator contributing to biologic aggressiveness.
Christopher J. Walker, Mario A. Miranda, David G. Mutch,
Paul Goodfellow.
18.
1541
Co-mutations define major subsets of KRASdriven lung adenocarcinoma with implications for
targeted cancer therapy. Ferdinandos Skoulidis, Kevin R.
Coombes, Lixia Diao, Pan Tong, Maria A. Cortez, Uma Giri,
Chao Yang, You Hong Fan, John N. Weinstein, Vassiliki
Papadimitrakopoulou, John D. Minna, Jing Wang, Lauren A.
Byers, John V. Heymach.
19.
1542
Comprehensive genome and transcriptome
analyses on small cell lung cancer. Julie George, Martin
Peifer, Lynnette Fernandez-Cuesta, Roman Thomas.
20.
1543
Systematic functional assessment of driver
mutations for individual ovarian cancers. Seiichi Mori,
Takako Yokomizo, Takeshi Fujiwara, Osamu Goto, Haruko
Iwase, Kazuyoshi Kato, Tokuichi Kawaguchi, Tetsuo Noda.
21.
1544
The clinical behavior of endometrioid and
serous endometrial carcinomas is governed by distinct
biological processes. Britta Weigelt, Christophe Lemetre,
Charlotte K. Ng, Salvatore Piscuoglio, Jorge S. Reis-Filho.
22.
1545
Identification of microRNA targets in triplenegative breast cancer. Mandeep Gill, Bruna Sugita, Silma
R. Pereira, Catalin Marian, Xi Li, Yuriy Gusev, Enilze M.
Ribeiro, Iglenir J. Cavalli, Luciane R. Cavalli.
23.
1546
The research of the mechanism of lung cancer
carcinogenesis and the target gene of microRNA-20a in
lung cancer small cells. Tan Xiaogang, Hu Mu, Zhi Xiuyi,
Jin Shimeng.
24.
1547
Identification of somatic mutations and copy
number alterations in metastatic high-grade ovarian
cancer. Jung-Yun Lee, Jung-Ki Yoon, Duhee Bang, YongSang Song.
25.
1548
Genomic and molecular profiling of NSCLC
formalin-fixed paraffin-embedded tumors. Dana S.
Gaffney, Katherine Bell, Gabriela Martinez, Yashoda
Rajpurohit, Jayaprakash Karkera, Christopher Moy, Suso
Platero.
5.
1528
Identification of FGFR3 as a potential
therapeutic target gene for human clear cell ovarian
cancer by global genomic analysis. Tsun Yee Tsang,
Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok,
Michael J. Birrer.
6.
1529
Ovarian low grade serous cancer: Mutation
analysis with a comprehensive 409 cancer gene panel.
Yvonne T. Tsang, Daisy Izaguirre, Suet-Yan Kwan, Samuel
C. Mok, David Gershenson, Kwong-Kwok Wong.
7.
1530
Identification of vulnerabilities in lung cancer
via pooled short hairpin RNA screening. Suzie Hight,
Ryan Carstens, Luc Girard, David Mangelsdorf, John D.
Minna.
8.
1531
Cross-entity mutation analysis of lung
neuroendocrine tumors sheds light into their molecular
origin and identifies new therapeutic targets. Lynnette
Fernandez-Cuesta, Martin Peifer, Xin Lu, Danila Seidel,
Thomas Zander, Frauke Leenders, Luka Ozretić, Odd-Terje
Brustugun, John K. Field, Gavin Wright, Benjamin Solomon,
Reinhard Buettner, Christian Brambilla, Elisabeth Brambilla,
Roman K. Thomas.
9.
10.
11.
12.
1532
Exome and transcriptome profiling of lung
adenocarcinoma in female never-smokers. Sanghyuk
Lee, Pora Kim, Yukyung Jun, Charny Park, Suyeon Kim,
Hee-Young Lee, Juhee Keum, Yeonhwa Jung, Yeonjoo Jung,
Chaehwa Seo, Kyoohyoung Rho, Jong-Eun Lee, Wankyu
Kim, Jaesang Kim, Jhingook Kim.
1533
A time course study of genomic instability in
breast cancer patients receiving neoadjuvant therapy
with or without bevacizumab. Elen K. Møller, Silje Nord,
Hans Kristian Moen Vollan, Hedda von der Lippe Gythfeldt,
Hege Edvardsen, Laxmi Silwal- Pandit, Marit Krohn, Thomas
Fleischer, Ellen Schlitchting, Elin Borgen, Øystein Garred,
Anne Fangberget, Marit M. Holmen, Helle Skjerven, Steinar
Lundgren, Erik Wist, Bjørn Naume, Anne-Lise Børresen-Dale,
Ole Christian Lingjærde, Olav Engebråten, Vessela N.
Kristensen.
1534
Identification of LMX1B as a novel oncogene in
human ovarian cancer. Gayatry Mohapatra, Lei He, Lankai
Guo, Vinod Vathipadiekal, Petra Sergent, Whitfield Growdon,
Bo Rueda, David Engler, Sandra Orsulic, Michael Birrer.
1535
Immunohistochemistry predicts presence and
type of TP53 mutation in high-grade serous carcinoma.
Martin Köbel, Anna Piskorz, Shuhong Liu, James D. Brenton.
22
22
311
POSTER SESSION
Poster
Section
23
23
Tumor Suppressors 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
312
1549
Ectopic expression of a glutamate receptor
gene, glur6, induces growth arrest and senescence in
breast and ovarian tumor cells. Raghbir S. Athwal,
Vikramjit K. Zhawar, Gurpreet Kaur.
1550
Differential angiogenic roles of serum amyloid
A 1 (SAA1) isoforms in esophageal squamous cell
carcinoma (ESCC). ON YING MAN, Maria Lung, Hong Lok
Lung.
1551
p53 mutant regulates a network of cellular
anoikis through activation of AKT and suppression of
BMF. Boon Shing Tan, Kai Hung Tiong, Ivan K. Yap, Rozita
Rosli, Soon-Keng Cheong, Chee-Onn Leong.
1552
CCN5/wisp-2 induced growth arrest of
aggressive triple negative breast cancer cells is
promoted through accumulation and trafficking of
p27kip1. Inamul Haque, Snigdha Banerjee, Archana De,
Gargi Maity, Sandipto Sarkar, Douglas McGragor, Sushanta
K. Banerjee.
1553
Rho guanine nucleotide exchange factor
(ARHGEF) 10 is a putative tumor suppressor in
pancreatic ductal adenocarcinoma. Joella Joseph,
Nikolina Radulovich, Ming-Sound Tsao.
1554
Identification of BRCA1 and BRCA2 somatic
mutations in breast cancer tumors with loss of BRCA1
nuclear expression. Carolina Alvarez, David Wiener,
Patricia Gajardo, Wanda Fernandez, Valeria Cornejo, Jorge
Gamboa, Pilar Carvallo.
1555
TP53 oncomorphic mutations are associated
with resistance to platinum- and taxol-based standard
chemotherapy in advanced serous ovarian cancer
patients. Pavla Brachova, Donghai Dai, Mathew Carlson,
Michael Goodheart, Kristina Thiel, Eric Devor, Kimberly
Leslie.
1556
Regulation of cellular apoptosis via a novel
protein-protein interaction of tumor suppressor p53 with
the xenobiotic pregnane X receptor (PXR) in colon
cancer cells. Delira F. Robbins, Jing Wu, Taosheng Chen.
1557
Overexpressions of ALEX1 gene play a negative
role in human colorectal tumorigenesis. Akihiko Takeda.
1558
TP53 codon 72 polymorphism association with
prognosis in Puerto Rican head and neck squamous cell
carcinoma patients. Bianca L. Rivera, Ricardo López,
Roger Vázquez, Yarilis Castro, Adriana Báez.
1559
TTC36, a novel chaperone of heat shock protein
70, functions as a tumor suppressor in hepatocellular
carcinoma. Lingxi Jiang, Ming Liu, Yan Li, Xinyuan Guan.
1560
Loss-of-function JAK1 mutations reveal a new
role of protein tyrosine kinase mutations in human
cancer. Yuan Ren, Yonghong Zhang, Richard Z. Liu, David
A. Fenstermacher, Kenneth L. Wright, Jamie K. Teer, Jie
Wu.
1561
AJAP1 is dysregulated at an early stage of
gliomagenesis and suppresses invasion through
cytoskeleton reorganization. Lei Han, Kai-Liang Zhang,
Jun-Xia Zhang, Liang Zeng, Chun-Hui Di, Brian Fee, Miriam
Rivas, Tao Jiang, Darrell Bigner, Chun-Sheng Kang, David
Cory Adamson.
1562
Proteomic analysis of citrullinated targets
regulated by the p53-PADI4 pathway. Chizu Tanikawa,
Koji Ueda, Hidewaki Nakagawa, Yusuke Nakamura, Koichi
Matsuda.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
1563
Damage-induced BRCA1 phosphorylation
contributes to the timing of end resection. Yanfen Hu,
Balaji Parameswaran, Huai-Chin Chiang, Yunzhe Lu.
1564
Spanxa1 is a novel mediator of epithelialmesenchymal transition in lung cancer. Shih-Chun Hsu,
Yi-Jing Hsiao, Sing-Liang Yu, Ming-Shyue Lee.
1565
Novel RhoGAP independent pathway of tumor
suppressor DLC1 regulates cancer invasion and
metastasis. Frankie C. Ko, Yin-Shan Yeung, Xiaowen Mao,
Judy Wai Ping Yam.
1566
Notch-1 regulation of the PTEN - mTOR axis in
prostate. Jennifer M. Nutter, C W. Angus, Fred E. Bertrand.
1567
A cancer-associated BRCA2 mutation reveals
masked nuclear export signals controlling localization.
Anand D. Jeyasekharan, Yang Liu, Hiroyoshi Hattori, Venkat
Pisupati, Ashok R. Venkitaraman.
1568
Cellular mechanisms of tumor regression
following Myc inhibition. Dan Lu, Deborah L. Burkhart,
Julian L. Griffin, Trevor D. Littlewood, Gerard I. Evan.
1569
The nuclear export signal (NES) within CALM is
necessary for CALM-AF10-induced leukemia. Mai Suzuki,
Kazutsune Yamagata, Yukiko Aikawa, Toshio Watanabe,
Issay Kitabayashi.
1570
ARID1A regulation of ATAD2 in gynecologic
cancer. Yutaka Shoji, Kelly A. Conrads, Rusheeswar Challa,
Brian L. Hood, Guisong Wang, Kathleen M. Darcy, Chad A.
Hamilton, George L. Maxwell, Thomas P. Conrads, John I.
Risinger.
1571
The tumor suppressor Liver Kinase B1 inhibits
triple-negative breast cancer cell metastasis via
regulation of AP-1 signaling. Lyndsay V. Rhodes, Chandra
R. Tate, Hope E. Burks, Van T. Hoang, Diari Gilliam,
Elizabeth C. Martin, Steven Elliott, David F. Miller, Aaron
Buechlein, Douglas Rusch, Haixu Tang, Kenneth P. Nephew,
Matthew E. Burow, Bridgette M. Collins-Burow.
1572
Dystrophin Is a tumor suppressor in human
cancers with myogenic programs. Yuexiang Wang, Adrian
Marino-Enriquez, Richard Bennett, Meijun Zhu, Grant Eilers,
Cristina Antonescu, Christopher Fletche, Chandrajit Raut,
Matt van de Rijn, Louis Kunkel, George Demetri, Jonathan
Fletcher.
1573
TUSC4 functions as tumor suppressor by
regulating BRCA1 stability and functions. Yang Peng,
Shiaw-Yih Lin.
1574
CDK5 negatively regulates Rho by
phosphorylating and activating the Rho-GAP and tumor
suppressor functions of DLC1. Brajendra K. Tripathi,
Xiaolan Qian, Philipp Mertins, Dunrui Wang, Alex
Papageorge, Steven Carr, Douglas R. Lowy.
1575
ARF regulates the stability of p16 protein via
REG␥-dependent proteasome degradation. Takashi
Kobayashi, Osamu Ogawa, Cory Abate-Shen.
1576
Characterization of a mouse line lacking the
PDZ-binding domain of PTEN. Andrew M. Chan, Hong
Guan, Alex M. Many.
1577
Inside-out regulation of ectodomain protease
accessibility in the release of cytokines. Monika
Hartmann, Liseth Parra, Sandra Schubert, Yong Li, Helen
Morrison, Christoph Kaether, Andreas Herrlich, Peter
Herrlich.
POSTER SESSION
Carcinogenesis 2
Chemical and Physical Carcinogenesis
Poster
Section
Poster Abstract
Board Number
1.
2.
1579
Induction of cytotoxicity by soluble chromium
(VI) compounds in cultured C3H/10T1/2 Cl 8 mouse
embryo cells effects of ascorbate and
dehydroascorbate. Sophia A. Shahin, William Liao, Laureen
Tran, Qasim A. Akinwumi, Farn-shuan Tseng, Alyssa
Mathew-Joseph, Joseph R. Landolph.
1580
Age-related difference in the susceptibility
phthalate-induced injury in Sprague-Dawley rat. Kassim
Traore.
3.
1581
Ethanol overrides DNA synthesis inhibition in
response to PAHs (tobacco smoke carcinogens): a
mechanistic explanation. Jagat J. Mukherjee, Subodh
Kumar.
4.
1582
Comparative transforming effects of ultra low
tar (ULT) and full flavor low tar (FFLT) cigarette smoke
particulate extracts on human oral epithelial cells.
Tianzhen Han, Peter Sacks, Joseph B. Guttenplan.
5.
1583
Western diet enhances benzo(a)pyrene [B(a)P]induced colon tumorigenesis in the PIRC rat model via
proinflammatory mechanisms. Kelly L. Harris, Stephanie
R. Pulliam, Mohammad S. Niaz, Mary K. Washington,
Samuel E. Adunyah, Aramandla Ramesh.
6.
1584
Lead toxicity and oxidative stress: Possible
causes of complications and grave prognosis in acute
leukemic Nigeria patients. Oluyemi Akinloye, Mary Bolanle
Ajadi, Adebayo M. Adegbenro, Ganiyu O. Arinola.
7.
1585
Chronic induction of breast cell carcinogenesis
by multiple environmental and dietary carcinogens.
Lenora A. Pluchino, Hwa-Chain R. Wang.
8.
1586
Toxicity screening, apoptosis hallmark events
and nitro reduction of novel quinolinium salts (BQS) on
lymphoma cells. Karoline Rios-Rodriguez, Jessica Soto,
Christian Velez, Osvaldo Cox, Juan P. Rivera, Beatriz Zayas.
9.
10.
1587
Mechanistic role of cytochrome P4501B1 in
DNA adduct formation by 3-methylcholanthrene in mice:
Implications for lung cancer in humans. Bhagavatula
Moorthy, Guodong Zhou, Lihua Wang, Sudha R. Kondraganti,
Weiwu Jiang.
1588
Detection in vivo of a novel endogenous etheno
DNA adduct derived from arachidonic acid and the
effects of antioxidants on its formation. Ying Fu, Marcin
Dyba, Jishen Pan, Casey Schultz, Peiying Yang, Dhimant
Desai, Shantu Amin, Fung-Lung Chung.
11.
1589
Olive oil alters benzo(a)pyrene
biotransformation and reduces oxidative DNA damage in
colon of ApcMin mouse. Leah D. Banks, Priscilla Amoah,
Mohammad S. Niaz, Mary K. Washington, Samuel E.
Adunyah, Aramandla Ramesh.
12.
1590
Expression and function of Sirt6 in muscle
invasive bladder cancer. Minghui Wu, Shohreh Dickinson,
Jingsong Zhang.
13.
1591
Src is activated in cervical adenocarcinoma.
Masato Nishimura, Natsumi Tanimura, Takako Kawakita,
Kanako yoshidaa, Minoru Irahara.
14.
1592
Frequent BrafV637E mutation in
hepatocarcinogenesis induced by neonatal treatment
with diethylnitrosamine (DEN) in B6C3F1 mice. Masahiro
Yamamoto, Hiroki Tanaka, Yuji Nishikawa, Keiko Shimizu,
Katsuhiro Ogawa.
Poster Abstract
Board Number
15.
1593
GSK3␤ mediated arsenite induction of spindle
abnormalities. Tz-Chi Lin, Ren-Meei Chen, Hsiao-Hui Kuo,
Ling-Huei Yih.
16.
1594
Transgenic overexpression of NanogP8 in the
mouse prostate does not initiate tumorigenesis nor
promotes tumor development in the Hi-Myc mouse
model. Shuai Gong, Bigang Liu.
17.
1595
Human mammary tumor virus (HMTV) detection
in surgical specimens and metastases of human breast
cancer by the Nanostring nCounter system and FISH
analysis. Stella M. Melana, Polly Etkind, Teiko Nartey,
Yetunde Agbaje, James F. Holland, Beatriz G. Pogo.
18.
1596
CXCL13 as a mediator of oncogenic PKC␧ in
prostate cancer. Rachana Garg, Martin Abba, Marcelo G.
Kazanietz.
19.
1597
Transcriptomic architecture of the field of
cancerization in the adjacent normal-appearing airway:
Early mechanisms in lung carcinogenesis. Yuho Maki,
Junya Fujimoto, Suk-Young Yoo, Melinda Garcia, Adam
Gower, Li Shen, Chi-Wan Chow, Carmen Behrens, Neda
Kalhor, Cesar Moran, Jing Wang, Avrum Spira, Kevin R.
Coombes, Ignacio I. Wistuba, Humam Kadara.
20.
1598
Grainyhead-like 2 (GRHL2) regulates the
expression of forkhead box transcription factor M1
(FoxM1) in human oral cancer cells and determines
tumorigenicity. Wei Chen, Jin-Kyu Yi, Ki-Hyuk Shin,
Reuben Kim, Shebli Mehrazarin, No-Hee Park, Mo K. Kang.
21.
1599
Elevated expression of ZEB1 upregulates VEGF
expression and induces tumor angiogenesis in breast
cancer. Qi Tong, Lingjia Liu, Lin Liang, Yang Gao, Shuang
Yang.
22.
1600
Keeping glioblastoma (GBM)in check by
targeting the CHK1-STAT3-CIP2A axis. Anchit Khanna,
Brett Stringer, Bryan Day, Kathleen Ensbey, Han Shen,
Andrew Boyd, Kerrie McDonald, John E. Pimanda.
23.
1601
Human colorectal cancer marker PC(16:0/16:1)
induces cell growth by activating Akt and Erk
pathways. Nobuya Kurabe, Toshio Nakamura, Kiyotaka
Kurachi, Tomoaki Kahyo, Kazuya Shinmura, Mitsutoshi
Setou, Haruhiko Sugimura.
24.
1602
Clobetasol treatment of vulvar carcinoma cell
lines influences growth rates. Jani E. Lewis, Mehek
Mehta, Alison Treichel, Sean Colligan, Vinh Nguyen, David
C. Foster.
25.
1603
Estrogen metabolites and colorectal cancer risk
in postmenopausal women in the Breast and Bone
Follow-up to the Fracture Intervention Trial (B⬃FIT).
Roni T. Falk, Cher M. Dallal, James V. Lacey, Douglas C.
Bauer, Diana S. Buist, Jane A. Cauley, Trisha F. Hue,
Andrea LaCroix, Jeffrey A. Tice, Ruth M. Pfeiffer, Xia Xu,
Timothy D. Veenstra, Louise A. Brinton.
26.
1604
Evaluation of chronic lung fibrosis following
total irradiation in C57B1/6 mice with hemaotpoeiticacute radiation syndrome. Kelsey P. Lipking, Ethan
Ferguson, Rajendran Sellamuthu, Christie M. Orschell,
George E. Sandusky.
27.
1605
Pterostilbene, a natural phytoalexin, effectively
protects against UVB-induced skin carcinogenesis by
increasing antioxidant cellular defenses and preventing
mutagenesis. J. Antoni Sirerol, Ines Pulido, Miguel Asensi,
Angel Ortega, Jose M. Estrela.
25
25
313
POSTER SESSION
Chemistry 1
Poster
Section
26
26
Proteomics and Signaling Networks
Poster Abstract
Board Number
1.
1606
Global mapping of tyrosine kinase signalling in
breast cancer by combined use of RNAi and SILAC
quantitative proteomics. Hua Zhang, Justin Stebbing,
Yichen Xu, Georgios Giamas.
2.
1607
Quantitative membrane proteome profiling to
discover therapeutic targets for adult T-cell leukemia
(ATL). Makoto Ishihara, Natsumi Araya, Tomoo Sato, Risa
Fujii, Ayako Tatsuguchi, Naomi Saichi, Hidewaki Nakagawa,
Yoshihisa Yamano, Koji Ueda.
3.
1608
Profiling c-Met and EGFR kinase inhibitor
resistance pathways in non-small lung cancer cells.
Ryan D. Bomgarden, Ryan Jacobs, Jason Fong, David
Moravec, Gregory M. Botting, Michael Blank, Rosa I. Viner,
John C. Rogers, Neelu Puri.
4.
1609
Proline-directed kinase signaling in human
hepatocellular carcinomas developed on non-fibrotic
liver. Saïd Taouji, Kristen Leong, Lee A. Beausang, Daniela
Arma, Violaine Moreau, Charles Balabaud, Paulette BioulacSage, Jessica Zucman-Rossi, Martin Latterich, Jean
Rosenbaum, Eric Chevet.
5.
1610
MAPK inhibitor resistance leads to ligandindependent Ephrin A2 receptor signaling and the
formation of new melanoma metastases. Kim H. Paraiso,
Meghna Das Thakur, Jobin K. John, Bin Fang, John M.
Koomen, Inna V. Fedorenko, Hensin Tsao, Keith T. Flaherty,
Jane L. Messina, Elena M. Pasquale, Alejandro Villagra,
John M. Kirkwood, Friedegund Meier, Sarah Sloot, Geoffrey
T. Gibney, Darrin Stuart, Hussein Tawbi, Keiran S. Smalley.
6.
314
1611
4-protein signature predicts outcome to
tamoxifen treatment in estrogen receptor positive
recurrent breast cancer. Tommaso De Marchi, NingQing
Liu, Mila Tjoa, Christoph Stingl, Marcel Smid, Maxime P.
Look, Mieke A. Timmermans, Rene B. Braakman, Mark
Opdam, Sabine Linn, Paul Span, Fred C. Sweep, John W.
Martens, Theo M. Luider, John A. Foekens, Arzu Umar.
Poster Abstract
Board Number
7.
1612
Gene expression and proteomic analysis to
identify predictive biomarkers of response in the
ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of
Concept study evaluating first-line ganetespib
monotherapy in women with metastatic HER2 positive
or triple negative breast cancer (TNBC). Emanuel F.
Petricoin, Julia Wulfkuhle, Tamas Hickish, Iman El-Hariry,
Vienna Reichert, Vojislav M. Vukovic, David A. Cameron,
Ahmad Awada, Neil Spector.
8.
1613
Characterization of the Src-regulated kinome by
chemical proteomics. Luxi Zhang, Jianmin Wu, Roger J.
Daly.
9.
1614
Kinases in lung squamous cell carcinoma and
inhibitor matching using quantitative activity-based
protein profiling. Bin Fang, Elizabeth R. Wood, Jiannong Li,
Y. A. Chen, Stephen G. Brantley, Fumi Kinose, Wei Guan,
Andrew R. Myers, Steven A. Eschrich, Eric B. Haura, John
M. Koomen.
10.
1615
Enrichment of EGFR/PI3K/AKT/PTEN proteins
using immunoprecipitation and analysis with mass
spectrometry-based proteomics. Bhavinkumar Patel, Scott
Meier, Kay Opperman, Paul Haney, Barbara Kaboord, John
Rogers.
11.
1616
Phosphoprotein enrichment pathway analysis
tools for studying cancer signaling. Danica Wiredja, Yu
Liu, Daniela Schlatzer, Giridharan Gokulrangan, Goutham
Narla, Mark Chance.
12.
1617
Quantification of pancreatic cancer proteome &
phosphorylome: Indicates molecular events likely
contributing to cancer & activation status of drug
targets. David Britton, Yoh Zen, Stefan Selzer, Vikram Mitra,
Alberto Quaglia, Debashis Sarker, Leandro Castellano, Justin
Stebbing, Julia Gee, Rob Nicholson, Nigel Heaton, Ian Pike.
POSTER SESSION
Chemistry 2
Small Molecule Design, Identification, and Optimization 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
9.
10.
11.
12.
13.
14.
15.
1618
New peptide-linked anilino-maytansinoid
antibody-drug conjugates (ADCs) for the treatment of
cancer. Wayne C. Widdison, Joe Ponte, Jennifer Coccia,
Yulius Setiady, Ling Dong, Anja Skaletskaya, Nathan Fishkin,
Yelena Kovtun, Rui Wu, Rajeeva Singh, Luke Harris, Greg
Jones, Leanne Lanieri, Erin Maloney, Charlene Audette,
Andre Dandeneau, Ravi Chari, Juliet Costoplus, Karen Veale,
Sharon Wilhelm.
1619
Hsp90 inhibitor drug conjugates (HDCs):
Construct design and preliminary evaluation. Weiwen
Ying, Dinesh Chimmanamada, Junyi Zhang, Teresa
Przewloka, Jun Jiang, Genliang Lu, Sami Osman, James
Loch, Dharma Vutukuri, Shoujun Chen, Robert Stein, John
Chu, David Proia, Pat Rao, Takayo Inoue, Luisa Shin Ogawa,
Ritu Singh, Noriaki Tatsuta.
1620
Synthesis and preclinical evaluation of novel
6-substituted pyrrolo[2,3-d]pyrimidines as targeted
antifolates. Lalit K. Golani, Aleem Gangjee, Christina
Cherian, Steven Orr, Shermaine Mitchell-Ryan, Lisa Polin,
Adrianne Wallace, Larry H. Matherly.
1621
Discovery of pyridyl pyrrolopyridinones as
potent and selective CK1␥ inhibitors. Hongbing Huang,
Lisa Acquaviva, Howard Bregman, John Buchanan,
Nagasree Chakka, Erin F. DiMauro, Jennifer Dovey, Hakan
Gunaydin, Zihao Hua, Xin Huang, Liyue Huang, Vinod F.
Patel, Matthew W. Martin, Randy Serafino, Cindy Wilson.
1622
Design and preclinical evaluation of single
agents with tubulin and multiple receptor tyrosine
kinase inhibition. Aleem Gangjee, Roheeth K. Pavana,
Michael Ihnat, Ernest Hamel.
1623
1,4,5,8-Tetrakis-[(2-N,N-dimethylaminoethyl)
amino]anthraquinone as a potential anticancer agent:
its synthesis, characterization and anticancer
properties. Don R. Ishmael, Orn Adelsteinsson.
1624
A fragment-based approach to the development
of small-molecule STAT3 transcription factor inhibitors.
Kazi S. Nahar, Christopher Chamberlain, Aanchal Grover,
Paul Jackson, Khondaker M. Rahman, David E. Thurston.
1626
Novel trisubstituted triazoles modeled from
naltrindole inhibit the proliferation of human multiple
myeloma cells. William J. Welsh, Youyi Peng, Jyoti Joshi
Mundra, Julianne F. Avrutik, Thomas C. Yoon, Andrew M.
Meillier, Richard D. Howells.
1627
The novel camptothecin analog and
antiapoptotic protein inhibitor FL118 appears to be a
great backbone platform for development of
personalized anticancer drugs. Fengzhi Li, Xiang Ling,
David Westover, Xiaojun Liu, Chunyang Jin, Mansukh Wani.
1628
Direct anti-cancer effects of zoledronic acid on
human cancer cell. Pengfei Jiang, Rajesh Mukthavavam,
Natsuko Nomura, Sandeep C. Pingle, Santosh Kesari.
1629
Identification and biological characterization of
a novel class of small molecules to inhibit c-myc
transcription. Kenneth M. Felsenstein, John K. Simmons,
Peter Gareiss, Beverly A. Mock, John ’Jay’ S. Schneekloth.
1630
C8-linked pyrrolobenzodiazepine (pbd)benzofused conjugates with low-picomolar in vitro
cytotoxicity. Julia Mantaj, Paul J. Jackson, Chris Pepper,
David E. Thurston, Khondaker M. Rahman.
1631
Structural activity relationship studies of azapodophyllotoxin derivatives on breast cancer cell line.
Ajay Kumar, Vineet Kumar, Antonio E. Alegria, Sanjay V.
Malhotra.
1632
Discovery of a novel series of androgen
receptor antagonists with potential therapeutic
applications in castration-resistant prostate cancer.
Huifang Li, Mohamed D. Hassona, Nathan A. Lack, Peter
Axerio-Cilies, Eric Leblanc, Emma T. Guns, Paul S. Rennie,
Artem Cherkasov.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
1633
Novel specific- and dual- tryptophan-2,3dioxygenase (TDO) and indoleamine-2,3-dioxygenase
(IDO) inhibitors for tumor immunotherapy. Mario R.
Mautino, Richard A. Metz, Firoz Jaipuri, Jesse Waldo,
Sanjeev Kumar, Agnieszka Marcinowicz-Flick, Hima Potturi,
James T. Adams, Clarissa Van Allen, Nicholas N. Vahanian,
Charles J. Link.
1634
A novel small molecule inhibitor of IRE1alpha
reverses endocrine resistance in breast cancer cells.
Ayesha N. Shajahan-Haq, Jacqueline Smith, Siva
Dakshanamurthy, Difei Wang, Ahreej E. Eltayeb, Milton L.
Brown, Robert Clarke.
1635
Discovery of novel SMAC mimetics as selective
IAP inhibitors. Jin Wang, Wei Li.
1636
NMR discovery and molecular-basis of small
molecule inhibitors of STAT3. Andrew T. Namanja, Ralf
Buettner, Richard Jove, Yuan Chen.
1637
Discovery of ATR kinase inhibitors from natural
products. Hui-Chun Wang, Alan Yueh-Luen Lee, Chin-Chung
Wu, Yang-Chang Wu.
1638
Effect of the phytochemical crinumaquine on
prostate mesenchymal type cells. Kristo Marvyin, Run-hui
Liu, Huizi Jin, Yaping Hua, Yi Qu, Xisong Ke, Karl-Henning
Kalland, Wei-dong Zhang, Anne Margrete Oyan.
1639
Development of novel thiobarbituric acid
derivatives as potential cancer therapeutics. Srinivasa R.
Ramisetti, Sang Y. Lee, Manoj K. Pandey, Shantu G. Amin,
Arun K. Sharma.
1640
A novel small molecule inhibitor of
lysophosphatidic acid acyltransferase-beta inhibits
pancreatic cancer cell proliferation and mTOR signaling.
Michelle A. Blaskovich, Yunting Luo, Yiyu Ge, Saïd M. Sebti,
Harshani R. Lawrence, Nicholas J. Lawrence, Gregory M.
Springett.
1641
Structure-based design and development of
pyrazolopyridine-based inhibitors of Mcl-1. Fardokht A.
Abulwerdi, Ahmed S. Mady, Andrej Perdih, Jeanne A.
Stuckey, Hollis D. Showalter, Zaneta Nikolovska-Coleska.
1642
Bryostatin 1 and the simplified analog Merle 23
have similar and opposing properties on mouse
epidermal cells and mouse skin. Jessica Kelsey, Noemi
Kedei, Christophe Cataisson, Mark Petersen, Stuart Yuspa,
Gary Keck, Peter Blumberg.
1643
BMS-983970, an oral pan-Notch inhibitor for the
treatment of cancer. Ashvinikumar V. Gavai, Yufen Zhao,
Daniel O’Malley, Brian Fink, Claude Quesnelle, Derek Norris,
Libing Chen, Soong-Hoon Kim, Wen-Ching Han, Patrice Gill,
Weifang Shan, Aaron Balog, Andrew Tebben, Richard
Rampulla, Dauh-Rurng Wu, Yingru Zhang, Arvind Mathur,
Haiqing Wang, Zheng Yang, Qian Ruan, Robin Moore, David
Rodrigues, Asoka Ranasinghe, Celia D’Arienzo, Ching K. Tye,
Ching Su, Gerry Everlof, Melissa Yarde, Mary E. Cvijic, Krista
Menard, Mei-Li Wen, George Trainor, Bruce Fischer, John
Hunt, Gregory Vite, Richard Westhouse, Francis Lee.
1644
Design and discovery of PWT33597 (VDC-597),
a dual inhibitor of PI3-kinase alpha and mTOR. Gordon
W. Rewcastle, Jack U. Flanagan, Anna C. Giddens, Swarna
A. Gamage, Sophia K. Tsang, Jackie D. Kendall, Bruce C.
Baguley, Christina M. Buchanan, David J. Matthews, Marie
O’Farrell, Stephen M. Jamieson, William A. Denny, Peter R.
Shepherd.
1645
Discovery of AMG 232, an inhibitor of the
MDM2-p53 interaction: From lead to a clinical
candidate. Zhihong Li.
1646
Synthesis of [11C]onapristone for clinical
investigation. Olivier Madar, Julien Fouque, Stefan Proniuk,
Keyvan Rezai, Samuel Huguet, Alexander Zukiwski, Erard M.
Gilles, Alice S. Bexon, François Lokiec.
Poster
Section
27
27
315
POSTER SESSION
Immunology 3
Poster
Section
28
28
Inflammation and the Tumor Microenvironment
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
316
1647 Favourable diffuse prognostic pattern of FOXP3ⴙ and
CD69ⴙ T cells in follicular lymphoma demonstrated using
automated imaging and analysis. James Mansfield, Lilli Nelson,
Roslyn Lloyd, Chris van der Loos, Ken Oguejiofor, Lia Menasce, Kim
Linton, Chris Rose, Richard J. Byers.
1648 Interleukin-6 expression is restricted to the prostate
stromal compartment and is not expressed by either primary or
metastatic prostatic adenocarcinoma cells. Shu-Han Yu, Qizhi
Zheng, Jun Luo, Anne Macgregor-Das, Emmanuel S. Antonarakis,
Angelo M. De Marzo, Karen Sfanos.
1649 Extent and location of tumor infiltrating lymphocytes
in colon cancer predicts outcome to adjuvant active specific
immunotherapy. Erik Hooijberg, Annelies W. Turksma, Marc
Shamier, Kevin Lam, Veerle M. Coupe, Vincent A. de Weger, Jeroen
A. Belien, Alfons J. van den Eertwegh, Gerrit A. Meijer, Chris J.
Meijer.
1650 Prognostic importance of both stage of the disease
and immune infiltrate in the outcome of NSCLC patients. MarieCaroline Dieu-Nosjean, Jeremy GOC, Claire GERMAIN, Samantha
KNOCKAERT, Marco Alifano, Audrey LUPO, Diane Damotte, Pierre
Validire, Scott S. HAMMOND, Wolf-Herman Fridman, Catherine
Sautes-Fridman.
1651 Profiling immune cells within the tumour
microenvironment for optimal model selection for pre-clinical
investigations. Andrew Leishman, Olivia Harris, Jane Coates
Ulrichsen, James Harper, Amy Popple, Marianna Papaspyridonos,
Geoff Williams, Stefanie Mullins, Viia Valge-Archer, Ross Stewart,
Richard Sainson, Michelle Morrow, Robert Wilkinson.
1652 Immune infiltration of normal and benign breast
lobules varies in breast tissues based on cancer risk. Rushin D.
Brahmbhatt, Daniel W. Visscher, Tanya L. Hoskin, Derek C. Radisky,
Linda M. Murphy, Melody L. Stallings Mann, Erin Miller, Vernon S.
Pankratz, Lynn C. Hartmann, Marlene H. Frost, Amy C. Degnim.
1653 Complement roles in endometriosis and
endometriosis-associated ovarian cancer. Swati M. Suryawanshi,
Xin Huang, Raluca Budiu, SungHwan Kim, George Tseng, Esther
Elishaev, Marcia Klein-Patel, Ted Lee, Suketu Mansuria, Robert
Edwards, Anda Vlad.
1654 Immune repertoire amongst subpopulations of tumor
infiltrating lymphocytes (TILs) in colorectal cancer:
Oligoclonality is predominantly observed in cytotoxic CD8ⴙ
TILs. Si Lin Koo, Rachel Rui Xian Ten, Thin Zar Aung, Dennis Koh,
Who Whong Wang, Wei Qiang Leow, Kiat Hon Lim, Suk Peng Chew,
Ju Yuan, Bing Lim, Salvatore Albani, Iain Beehuat Tan.
1655 Human immune cell infiltration of tumors in a PBMChumanized NSG mouse xenograft model changes with treatment
of an anti-tissue factor antibody. Hillary Millar-Quinn, Brenda
Hertzog, Rebecca Hanson, Jeffrey Nemeth, John Alvarez.
1656 CXCR4 antagonist-expressing liposomes reduce lung
metastases and deliver drugs to CXCR4 expressing cells: a new
drug-targeting device. Caterina Ierano, Sara Lusa, Crescenzo
D’Alterio, Giuseppina Salzano, Maria Napolitano, Maria Buoncervello,
Massimo Spada, Daniele Macchia, Antonio Barbieri, Antonio Luciano,
Lucia Gabriele, Giuseppe De Rosa, Stefania Scala.
1657 How does the tumor microenvironment affect
macrophage aggressiveness. Evita G. Weagel, Ping Guo Liu, Wei
Meng, Curren D. Smith, Richard A. Robison, Kim L. O’Neill.
1658 Enhanced shedding of extracellular vesicles from
amoeboid prostate cancer cells: Potential effects on the tumor
microenvironment. Jayoung Kim, Samantha Morley, Minh Le, Denis
Bedoret, Dale Umetsu, Dolores Di Vizio, Michael Freeman.
1659 Characterizing cytokine secretion in response to
dsRNA treatment in ovarian cancer cells. Maria Muccioli, Michelle
Pate, Fabian Benencia.
1660 Retroviral replicating vector transduced alloresponsive
T lymphocytes retain mobility and cytotoxic functionalities. Kate
L. Erickson, Colin C. Malone, Michelle J. Hickey, Geoffrey C. Owens,
Yuki Kato, Robert M. Prins, Noriyuki Kasahara, Carol A. Kruse.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
1661 The pro-inflammatory role of the putative oncogene
Bcl-3. Wanhu Tang, Hongshan Wang, Estefania Claudio, Ulrich
Siebenlist.
1662 Towards automated analysis of prostate inflammatory
state: Assessing density and distance of infiltrating T-cells
(CD3ⴙ) to glandular structures in prostate biopsies by a new
software. Radu Rogojanu, Bogdan Boghiu, Georg Schaefer, Theresia
Thalhammer, Georg Steiner, Rupert Ecker, Bettina Schlick, Thomas
Szekeres, Isabella Ellinger.
1663 CD40 agonists drive the anti-tumor functions of
macrophages and induce systemic immune activation survival
the Pan02 orthotopic pancreatic model. Nadia Luheshi, James
Harper, Jane Coates-Ulrichsen, Richard Sainson, Robert W.
Wilkinson, Gareth Davies, James W. Legg.
1664 Cancer progression: The failure to resolve. Megan L.
Sulciner, Dayna K. Mudge, Diane R. Bielenberg, Ofra Benny,
Jesmond Dalli, Sui Huang, Charles N. Serhan, Mark W. Kieran, Dipak
Panigrahy.
1665 Biopsy induced metastasis: Role of SOX4/TGF-␤ driven
EMT and immunosuppressive microenvironment. Edward G.
Mathenge, Cheryl Dean, Derek Clements, Ahmad Vagharkashani,
Steffany Photopoulos, Krysta Coyle, Benjamin A. Malueth, Mike
Giacomantonio, Anna Nunokawa, Julie Jordan, Shashi Gujar, Paola
Marcato, Partick Lee, Carman A. Giacomantonio.
1666 Suppression of cyclooxygenase-2 by dual-specificity
phosphatase-2 ameilorates cancer malignancy. Yo-Hua Li, ShihChieh Lin, Shaw-Jenq Tsai.
1667 Prostatitis related mitogenic stimuli cause loss of
NKX3.1: Increased risk for prostate cancer. Josua Decker, Garima
Jain, Philip Harazim, Tina Kießling, Peter Möller, Ralf Marienfeld.
1668 Stabilin-1 is expressed on tumor-associated
macrophages in breast cancer and supports tumor growth in
animal model of breast adenocarcinoma by clearance of SPARC.
Vladimir Ryabov, Ilja Ovsij, Aida Avdic, Kai Schledzewski, Alexei
Gratchev, Nan Wang, Bernd Arnold, Sergij Goerdt, Frederick Pfister,
Alexander Marx, Limin Zheng, Julia Kzhyshkowska.
1669 Characterization of B-cells infiltrating human breast
cancer and their presence in peritumoral tertiary lymphoid
structures. Soizic Garaud, Laurence Buisseret, Chunyan Gu, Edoardo
Migliori, Jean-Nicolas Lodewyckx, Hugues Duvillier, Ligia Craciun,
Denis Larsimont, Karen Willard-Gallo.
1670 Collagen matrix deposition by hepatic stellate cells
protects hepatocellular carcinoma from NK-mediated
cytotoxicity. Adam W. Mailloux, Pearlie K Epling-Burnette.
1671 Immunosuppressive myeloid-derived suppressor cells
expressing PDL1 are increased in human melanoma tumor
tissue. Kimberly R. Jordan, Virginia Borges, Martin D. McCarter.
1672 Tumor educated B cells acquire immune suppressive
function and promote tumor growth. Yu Zhang, Richard Morgan,
Seung-uon Shin, Hyun-Mi Cho, Ahmed Albayati, Augustin Pimentel,
Joseph D. Rosenblatt.
1673 Alternative NF-␬B signaling promotes inflammatory
cell recruitment and lung tumor formation. Jamie A. Ausborn,
Dong-Sheng Cheng, Vasiliy Polosukhin, Wei Han, Fiona Yull, Timothy
Blackwell.
1674 Humanized mouse models for personalized preclinical
testing of monoclonal antibodies targeting immune checkpoints.
Gilson S. Baia, David Vasquez, Daniel Ciznadija, Brandy Wilkinson,
David Sidransky, Amanda Katz, Keren Paz.
1675 Variations in the composition of inflammatory
infiltrates are associated with persistence or regression of
bronchial dysplasia. Mary C. O’Keefe, Lori Dwyer-Nield, Michael
Edwards, Robert L. Keith, Wilbur A. Franklin, Michio Sugita, York E.
Miller, Micah Friedman, Meredith Tennis, Kevin S. Choo, Gregory
Hickey, Jeannine Porter, Storey Wilson, Andrea Osypuk, Mary Weiser,
Adrie van Bokhoven, Mark Geraci, Raphael Nemenoff, Daniel T.
Merrick.
POSTER SESSION
Experimental and Molecular Therapeutics 10
Combination Therapy to Overcome Resistance
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1676 The HSP90 inhibitor 17-AAG improves chemoresistance
of cisplatin-resistant esophageal squamous cell carcinoma cell
lines. Takashi Ui, Kazue Morishima, Shin Saito, Yuji Sakuma,
Hirofumi Fujii, Yoshinori Hosoya, Yoshikazu Yasuda, Toshiro Niki.
1677 Preclinical activity of Vintafolide/MK-8109
monotherapy and in combination with standard of care therapy
in triple-negative breast cancer models. Brian B. Haines, Jennifer
O’Neil, Marlene C. Hinton, Christopher Ware, Tammie C. Yeh,
Tianxiao Sun, Kristen L. Picard, Theresa Zhang, Emmett V. Schmidt,
Isabelle Dussault.
1678 Combined effects of olaparib and cytotoxic agents to
triple negative breast cancer cells. Yuki Takashima, Jun
Hashimoto, Yuka Kitamura, Shuichi Shimma, Yasuhiro Fujiwara,
Fumiaki Koizumi, Kenji Tamura, Akinobu Hamada.
1679 Inhibiting KRAS-reprogrammed glutamine metabolism
sensitizes pancreatic cancer to NQO1-bioactivatable drugs.
Gaurab Chakrabarti, David A. Boothman.
1680 Modulation of MDM2 in context of DNA damage
enhances cell death in a metastatic breast-to-lung xenograft
model. Eva Tonsing-Carter, Harlan E. Shannon, Barbara J. Bailey,
Anthony L. Sinn, Kacie M. Peterman, Lindsey D. Mayo, Karen E.
Pollok.
1681 Iron chelation therapy increased the anticancer effect
of sorafenib in hepatocarcinoma. Shinichi Urano, Toshiaki Ohara,
Ryoichi Katsube, Shinichiro Watanabe, Kazuhiro Noma, Yasuko
Tomono, Hiroshi Tazawa, Kazuhiro Nouso, Yasuhiro Shirakawa,
Toshiyoshi Fujiwara.
1682 Metformin synergistically enhances antitumor efficacy
of sorafenib in vitro. YUNMI KO, Bo Ra Choi, Jun Ah Lee.
1683 Novel combination approach using platinum drugs and
mitochondrial division inhibitor 1 (mdivi-1) overcomes platinum
resistance by synergistically inducing mitochondrial outer
membrane permeabilization (MOMP) and apoptosis independent
of Drp1. Wei Qian, Jingnan Wang, Vera Roginskaya, Lee McDermott,
Robert Edwards, Donna Stolz, Fabien Llambi, Douglas Green, Bennett
Van Houten.
1684 Histone deacetylase inhibition enhances Pemetrexed
cytotoxicity through induction of apoptosis and autophagy in
non-small cell lung cancer models. Daniela Trisciuoglio, Marianna
Desideri, Teresa De Luca, Marta Di Martile, Chiara Gabellini, Adriana
Eramo, Ruggero De Maria, Michele Milella, Donatella Del Bufalo.
1685 HER2 upregulation induced by gemcitabine treatment
augments antitumor effect of trastuzumab emtansine against
pancreatic cancer. Shin Kan, Shigeo Koido, Masato Okamoto,
Kazumi Hayashi, Masaki Ito, Yuko Kamata, Hideo Komita, Eijiro
Nagasaki, Sadamu Homma.
1686 Synergistic combination of Trabectedin and Olaparib in
breast cancer tumor cell lines. Sonia Avila, Marta Martínez,
Victoria Moneo, Juan F. Martínez-Leal, Carmen Cuevas, Luis F.
Garcia-Fernández, Carlos M. Galamarini.
1687 A BRCA2-targeting antisense oligodeoxynucleotide
enhances cisplatin effectiveness by decreasing human tumor
cell proliferation, metastatic frequency, and metabolic response.
Mateusz Rytelewski, Jessica Tong, Adrian Buensuceso, Hon Leong,
Peter Ferguson, Saman Maleki Vareki, Christine Di Cresce, Larissa
Romanow, Trevor Shepherd, Bonnie Deroo, Ann Chambers, Mark
Vincent, James Koropatnick.
1688 Overcoming drug resistance to gemcitabine in
pancreas cancer cells by targeting activated PI3K/mTOR
pathway. Yuichi Murakami, Ai Shinoda, Kosuke Watari, Hiroshi
Nabeshima, Akihiko Kawahara, Daisuke Nagayama, Yoshiki Naito,
Koichi Higaki, Masako Inoue, Michihiko Kuwano, Mayumi Ono.
1689 Synergistic effect of JQ1 and rapamycin for treatment
of human osteosarcoma. Dhong Hyun T. Lee, Jun Qi, James
Bradner, Jonathan Said, Ngan Doan, Charles Forscher, H Phillip
Koeffler.
1690 Attacking EGFR mutant lung cancer by combined EGFR
and c-Met inhibition. Sandra Ortiz-Cuarán, Jakob Schöttle, Ilona
Dahmen, Martin Peifer, Caroline Wieczoreck, Mirjam Koker, Michaela
A. Ihle, Alexandra Florin, Berit Pinther, Lukas C. Heukamp, Roland T.
Ullrich, Roman K. Thomas.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1691 Synergistic anti-tumor activity of lenalidomide with the
BET bromodomain inhibitor CPI203 in bortezomib-resistant
mantle cell lymphoma. Alexandra Moros, Vanina Rodriguez, Ifigenia
Saborit-Villarroya, Arnau Montraveta, Patricia Balsas, Peter Sandy,
Antonio Martinez, Emmanuel Normant, Patricia Perez-Galan, Elias
Campo, Dolors Colomer, Gael Roue.
1692 Dalantercept, an ALK1 inhibitor of angiogenesis, in
combination with cisplatin inhibits tumor growth in a xenograft
model of squamous cell carcinoma of the head and neck. Marat
Alimzhanov, Michael Lee, Nicolas Solban, Scott Pearsall, Susan
Pandya, Matthew L. Sherman, Ravindra Kumar.
1693 The combination of romidepsin and bendamustin is
synergistically cytotoxic and reverses the malignant phenotype
in preclinical models of T-cell lymphoma. Cristiana Carniti, Silvia
Gimondi, Antonio Vendramin, Sara Rizzitano, Paolo Corradini.
1694 Combination of Indolizino[6,7-b]indole and Gefitinib
synergistically suppresses the growth of EGFR-mutant NSCLC
cells. Chi-Wei Chen, Satishkumar Tala, Tsann-Long Su, Te-Chang
Lee.
1695 CKD-581, a novel histone deacetylase inhibitor,
synergistically enhances Bortezomib cytotoxicity in multiple
myeloma cells. Chansu Lee, Kwang-Sung Ahn, Woo June Jung,
Youngil Koh, Hyo Jung Kim, Hyun Jung Lee, Hwi-Joong Yoon, SungSoo Yoon.
1696 Selective nuclear export inhibitor kpt330 enhances the
antitumor activity of gemcitabine in human pancreatic cancer.
Sabiha Kazim, Mokenge P. Malafa, Kazim Husain, Michael Kauffman,
Shacham Sharon, Amit Mahipal.
1697 CPI-169, a novel and potent EZH2 inhibitor, synergizes
with CHOP in vivo and achieves complete regression in
lymphoma xenograft models. Vidya Balasubramanian, Priya Iyer,
Shilpi Arora, Patrick Troyer, Emmanuel Normant.
1698 Identification of drugs with eribulin combinatorial
activity that kill both eribulin-sensitive and eribulin-insensitive
tumor cells. Toshimitsu Uenaka, Richard Rickles, Yasuhiro
Funahashi, Ping Zhu, Jill M. Grenier, Janine Steiger, Nanding Zhao,
Bruce A. Littlefield, Junji Matsui, Kenichi Nomoto.
1699 Delta-tocotrienol potentiates the antitumor activity of
standard chemotherapy with gemcitabine and abraxane in
metastatic pancreatic cancer. Kazim Husain, Said M. Sebti,
Mokenge P. Malafa.
1700 A combination of two tropical spice compounds
potentiates chemotherapy response in castration-resistant
prostate cancer cells. Taaha A. Mendha, Shamaladevi Nagarajarao,
Balakrisha L. Lokeshwar.
1701 A synthetic flavonoid abrogates doxorubicin resistance
through inhibition of focal adhesion kinase and P-glycoprotein
activity in breast cancer cells. Amrita Datta, Barbara J. Rider,
Zakaria Y. Abd Elmageed, Hogyoung Kim, Debasis Mondal, Asim B.
Abdel Mageed.
1702 High-throughput cell-based screening of drug library
identifies albendazole as a sensitizer with combination of
bortezomib for treatment multiple myeloma. Min Kyeong Kim,
Sunshin Kim, So Jin Park, Hyewon Lee, Tae Sik Kim, So Youn Jung,
Hyun Guy Kang, Hyeon-Seok Eom, Kong Sun-Young.
1703 Nicotine-induced gemcitabine resistance is reversed
by gamma-aminobutyric acid but enhanced by baclofen in
pancreatic cancer xenografts and in pancreatic cancer cells in
vitro. Jheelam Banerjee, Hussein A. Al-Wadei, Mohammed H. AlWadei, Koami Dagnon, Hildegard M. Schuller.
1704 Combination of Pirfenidone and Cisplatin as a
potential therapeutic strategy in NSCLC. Melanie Mediavilla-Varela,
David Noyes, Kingsley Boateng, Scott Antonia.
1705 Combinatorial therapeutics with targeting head and
neck cancer initiating cells using active components from
antrodia cinnamomea and conventional chemotherapy. ChingWen Chang, Jeng-Fan Lo.
Poster
Section
29
29
317
POSTER SESSION
Poster
Section
30
30
Drug Resistance 2: Proteosome Inhibitors, mTOR Inhibitors, and Other
Targeted Agents
Poster Abstract
Board Number
1.
2.
13.
1718
Schlafen 11 (SLFN11) is a critical determinant
of cellular sensitivity to PARP inhibitors. Junko Murai,
Rozenn Josse, James H. Doroshow, Yves Pommier.
14.
1719
Down-regulation of IGFBP2 is associated with
resistance to IGF1R therapy in rhabdomyosarcoma.
Zhigang Kang, Yunkai Yu, Yuelin J. Zhu, Lee Helman, Paul
Meltzer, Liang Cao.
15.
1720
MSK1 mediates PI3K inhibition resistance by
induction of ␤-catenin phosphorylation in glioblastoma.
Shaofang Wu, Jun Fu, Siyuan Zheng, Roel G. Verhaak, W. K
Yung, Dimpy Koul.
16.
1721
BRD4 antagonist-based therapy exerts lethal
activity against FLT3 mutation expressing AML cells
resistant to FLT3 tyrosine kinase inhibitors. Melissa
Rodriguez, Warren Fiskus, Sunil Sharma, Jun Qi, Leasha J.
Schaub, Bhavin Shah, Santhana G. Devaraj, Ka Liu,
Swaminathan Iyer, James E. Bradner, Kapil N. Bhalla.
17.
1711
Proteasomal alterations in a newly created
model of FLT3-ITD positive AML with acquired pan-TKI
resistance. Katie Wilson, Mary E. Irwin, Joya Chandra.
1722
Investigating resistance to AZD9291. Cath
Eberlein, Laura Ratcliffe, Lucy O’Brien, Katie Al-Khadimi,
Henry Brown, Paul Fisher, Daniel Stetson, Zhongwu Lai,
Gayle Marshall, Claire Barnes, Kenneth Thress, Brian
Dougherty, William Pao, Darren Cross.
18.
1712
Sunitinib-resistant ccRCC cell lines subjected to
TKI/mTOR inhibitors as a model for sequence therapy.
Gerhard Unteregger, Darja Schendel, Joana Heinzelmann,
Anne Weiland, Simone Ernst, Michael Stoeckle, Kerstin
Junker.
1723
Effect and mechanism of PF299804 alone and
in combination with STAT3 inhibitor in human sarcoma
cell lines. Xiaochun Wang, David Goldstein, Philip Crowe,
Jia-Lin Yang.
19.
1724
Genomic mechanisms of exquisite sensitivity
and acquired resistance to everolimus in a patient with
anaplastic thyroid carcinoma. Nikhil Wagle, Brian C.
Grabiner, Eliezer M. Van Allen, Ali Amin-Mansour, Scott C.
Carter, Nathanael Gray, Justine A. Barletta, Scott J.
Swanson, Daniel Ruan, David J. Kwiatkowski, Glenn J.
Hanna, Robert I. Haddad, David Sabatini, Pasi A. Janne, Levi
A. Garraway, Jochen H. Lorch.
20.
1725
Increased phosphorylation of eIF4E induces
resistance to treatment with mTOR inhibitors alone or
together with AR antagonists in advanced prostate
cancer. Leandro S. D’Abronzo, Ryan Beggs, Swagata Bose,
Paramita Ghosh.
21.
1726
Acquired resistance to rapamycin and mTOR
kinase inhibitors is mediated by non-overlapping
mutations in distinct sites in the mTOR protein. Vanessa
S. Rodrik-Outmezguine, Zhan Yao, Radha Mukherjee, Liqun
Cai, Derek Barratt, Richard Ward, Teresa Klinowska, Elisa
De Stanchina, Michael Berger, Jose Baselga, Neal Rosen.
22.
1727
Development of novel TAK1 inhibitors for
pancreatic cancer. Paul J. Chiao, Zhuonan Zhuang,
Qianghua Xia, Paul T. Schuber, Duoli Sun, Zhenghong Peng,
David S. Maxwell, William G. Bornmann.
1707
Accelerated proteasome turnover as a potential
mechanism of acquired resistance to carfilzomib in
BxPC3 pancreatic cancer cells. Lin Ao, Jieun Park, Di Hu,
Hyun Young Jeong, Kyung Bo Kim, Wooin Lee.
3.
1708
Heparanase regulates response to
chemotherapy in myeloma. Vishnu Prakash C. Ramani,
Fenghuang Zhan, Guido Tricot, Ralph D. Sanderson.
4.
1709
Reovirus synergy with proteosome inhibitor
carfilzomib and Akt inhibitor perifisone overcomes
therapy resistance of multiple myeloma: promising
preclinical activity. Chandini M. Thirukkumaran, Zhong
Qiao Shi, Paola Neri, Nizar Bahlis, Don Morris.
5.
1710
Bortezomib and lenalidomide resistant myeloma
cells overexpress the hepatocyte growth factor/MET
signaling axis and respond to MET kinase inhibitors.
Shadia Zaman, Christine M. Stellrecht, Robert Z. Orlowski,
Varsha Gandhi.
6.
7.
8.
1713
PDK1 and hexokinase 2 are downstream
effectors of PTEN loss and regulate response to
targeted therapies in multiple tumor types. Evangelos
Pazarentzos, Trever G. Bivona.
9.
1714
Erk inhibitor overcomes type II interleukin 1
receptor, a decoy receptor, associated Regorafenib
resistance in colorectal carcinoma. Ai-Chung Mar, ChunHo Chu, Te-Chang Lee.
10.
11.
12.
318
1706
Individualized therapy identified using
simulation for bortezomib resistant patient with ex-vivo
validation. Nicole A. Doudican, Shireen Vali, Annette Leon,
Ansu Kumar, Neeraj K. Singh, Anuj Tyagi, Shweta Kapoor,
Zeba Sultana, Taher Abbasi, Amitabha Mazumder.
Poster Abstract
Board Number
1715
Elucidating mechanisms of resistance to FGFR
inhibitors in endometrial cancer. Leisl M. Packer, Sara
Byron, David Loch, Farhad Dehkhoda, Andreas Wortmann,
Xinyan Geng, Katia Nones, Sean Grimmond, John Pearson,
Nic Waddell, Pamela Pollock.
1716
Targeting the insulin-like growth factor
receptor/Insulin receptor and Src signaling network for
the treatment of non-small cell lung cancer. Hye-Young
Min, Hye Jeong Yun, Hyo-Jong Lee, Jaebeom Cho, Hyun-Ji
Jang, Kyung Min Kim, Woo-Young Kim, Seung-Hyun Oh,
Diane Liu, J. Jack Lee, Waun Ki Hong, Ignacio I. Wistuba,
Ho-Young Lee.
1717
Downregulation of miR-217 correlates with
resistance of phⴙ leukemia cells to ABL tyrosine kinase
inhibitors. Takayuki Ikezoe, Chie Nishioka, Jing Yang,
Akihito Yokoyama.
POSTER SESSION
Kinase Inhibitors 2
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
1728 ASP8273, a novel mutant-selective irreversible EGFR
inhibitor, inhibits growth of non-small cell lung cancer (NSCLC)
cells with EGFR activating and T790M resistance mutations. Hideki
Sakagami, Satoshi Konagai, Hiroko Yamamoto, Hiroaki Tanaka,
Takahiro Matsuya, Masamichi Mori, Hiroyuki Koshio, Masatoshi Yuri,
Masaaki Hirano, Sadao Kuromitsu.
1729 KL-ON113, a novel orally available dual EGFR kinase
inhibitor targeting EGFR-activating and T790M mutants. Vijaybaskar
Lakshmikanthan, Venkateswarlu Sommepalli, Ramamohan Lekkala,
Kondababu Rasamsetti, Rama R. Gokaraju, Kiran Bhupathiraju,
Sudhakar Kasina.
1730 A study on EGFR gene amplification and protein
expression in Chinese esophagus cancer patients and antitumor
effect of an EGFR inhibitor in patient-derived esophagus cancer
models. Yongxin Ren, Jianming Zheng, Linfang Wang, Wei Zhang,
Fang Yin, Jinghong Zhou, Xuelei Ge, Shiming Fan, Renxiang Tang,
Junen Sun, Weiguo Qing, Weiguo Su.
1731 Dual inhibition of EGFR and HER2 in sublethally
irradiated Lewis lung carcinoma cells suppresses MMP-9
production and cell invasiveness. Wei-Lin Liu, Tommy Wei-Hsien
Hou, Jason Chia-Hsien Cheng.
1732 Biomarker-driven inhibition of MET and EGFR pathways
in hepatocellular and cholangiocarcinoma models with increased
efficacy in a sorafenib-tolerant model. Annemilai Tijeras-Raballand,
Maria Serova, Matthieu Martinet, Ivan Bièche, Valérie Paradis, Eric
Raymond, Sandrine Faivre, Armand de Gramont.
1733 EGF816, a novel covalent inhibitor of mutant-selective
epidermal growth factor receptor, overcomes T790M-mediated
resistance in NSCLC. Shailaja Kasibhatla, Jie Li, Celin Tompkins, MeiTing Vaillancourt, Jennifer Anderson, AnneMarie C. Pferdekamper, Chun
Li, Oliver Long, Mathew McNeill, Robert Epple, Debbie Liao, Eric
Murphy, Steve Bender, Yong Jia, Gerald Lelais.
1734 In vitro characterization of EGF816, a third-generation
mutant-selective EGFR inhibitor. Yong Jia, Jose Juarez, Mari Manuia,
Gerald Lelais, Shailaja Kasibhatla, Oliver Long, Matthew McNeill,
Michael DiDonato, Badry Bursulaya, Debbie Liao, Eric Murphy, Robert
Epple, Thomas Marsilje, Nuzhat Pathan, Pierre-Yves Michellys, Steven
Bender, Jennifer Harris.
1735 Discovery of novel and selective reversible inhibitors of
EGFR containing the T790M drug resistance mutation with activity
in vitro and in vivo. Gabriele Schaefer, Emily J. Hanan, Emily Chan,
Lily Shao, Yuan Chen, Jamie Knight, Robert L. Yauch, Stephen
Schmidt, Steven Sideris, Shiva Malek, Timothy P. Heffron.
1736 A novel Mer tyrosine kinase inhibitor mediates increased
cell killing in combination with FGFR inhibition. Timothy P. Newton,
Christopher T. Cummings, Gregory D. Kirkpatrick, Trista K. Hinz,
Deborah DeRyckere, Weihe Zhang, Xiaodong Wang, Stephen Frye, H.
Shelton Earp, Lynn Heasley, Douglas K. Graham.
1737 Allosteric FGFR2 inhibitor RPT835 impacts on tumor
growth and neovascularization. Ilya Tsimafeyeu, Evgenia Stepanova,
Eliso Solomko, Dmitry Kochenkov, Nina Peretolchina, Oxana Ryabaya,
Mikhail Byakhov, Sergey Tjulandin.
1738 JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with
nanomolar affinity for targeted therapy. Timothy Perera, Eleanora
Jovcheva, Jorge Vialard, Tinne Verhulst, Norbert Esser, Berthold
Wroblowski, Ron Gilissen, Eddy Freyne, Peter King, Suso Platero, Olivier
Querolle, Laurence Mevellec, Christopher Murray, Lynsey Fazal, Gordon
Saxty, George Ward, Matthew Squires, Neil Thompson, David Newell,
Patrick Angibaud.
1739 Preclinical profile of BAY 1163877 - a selective panFGFR inhibitor in phase 1 clinical trial. Melanie Heroult, Peter
Ellinghaus, Christian Sieg, Dirk Brohm, Sylvia Gruenewald, Marie-Pierre
Collin, Ulf Boemer, Mario Lobell, Walter Huebsch, Matthias Ocker,
Stuart Ince, Andrea Haegebarth, Rolf Jautelat, Holger Hess-Stumpp,
Michael Brands, Karl Ziegelbauer.
1740 Development of a novel small molecule MER tyrosine
kinase inhibitor with therapeutic activity in cell culture and mouse
models of acute lymphoblastic leukemia. Deborah A. DeRyckere,
Amanda A. Hill, Xiaodong Wang, Weihe Zhang, Michael A. Stashko,
Susan Sather, Christopher Cummings, Dmitri Kireev, William P. Janzen,
Stephen V. Frye, H. Shelton Earp, Douglas K. Graham.
Poster Abstract
Board Number
14.
15.
16.
17.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1741 Inhibition of type 1 insulin-like growth factor receptor
(IGF-1R) influences processing of replication-associated DNA
double-strand breaks (DSBs) and induces schedule-dependent
sensitization of human melanoma to temozolomide (TMZ). Roger N.
Ramcharan, Tamara Aleksic, Shan Gao, Jordan Tanner, Nicholas
Darvill, Esther Bridges, Ruth Asher, Amanda J. Watson, Geoffrey P.
Margison, Emmanouela Repapi, Ji-Liang Li, Mark R. Middleton,
Valentine M. Macaulay.
1742 Inhibition of Mer tyrosine kinase with a novel small
molecule inhibitor is efficacious in pre-clinical models of nonsmall cell lung cancer. Christopher T. Cummings, Kurtis D. Davies,
Jacqueline Carrico, Deborah DeRyckere, Weihe Zhang, Xiaodong Wang,
Stephen Frye, H. Shelton Earp, Douglas K. Graham.
1743 A dual FLT-3 and MER tyrosine kinase small molecule
inhibitor in acute myeloid leukemia cell lines and patient samples.
Alisa Lee Sherick, Kelly Menachof, Amanda Hill, Sean Rinella, Deborah
DeRyckere, Jing Liu, Xiaodong Wang, Stephen Frye, H. Shelton Earp,
Douglas Graham.
1744 ACP-196: A second generation Btk inhibitor
demonstrates biologic activity in a canine model of B-cell nonHodgkin lymphoma. Heather L. Gardner*, Bonnie K. Harrington*,
Raquel Izumi, Ahmed Hamdy, Allard Kaptein, Bart Van Lith, Cheryl A.
London, John C. Byrd, Amy J. Johnson, William C. Kisseberth.
1746 Novel and selective Axl inhibitors. Zaihui Zhang, Rick Li,
Erica Lee, Yuxiang Hu, Jun Yan, Jasbinder Sanghera.
1747 BGB324, a selective small molecule Axl kinase inhibitor
to overcome EMT-associated drug resistance in carcinomas:
Therapeutic rationale and early clinical studies. Katarzyna WnukLipinska, Crina Tiron, Gro Gausdal, Tone Sandal, Robin Frink, Stefan
Hinz, Monica Hellesøy, Lavina Ahmed, Hallvard Haugen, Xiao Liang,
Magnus Blø, David Micklem, Murray Yule, John Minna, Longen Zhou,
Rolf Brekken, James Lorens.
1748 Novel Ig1 inhibitors of the Axl tyrosine kinase that block
Gas6-inducible receptor activation. William J. Welsh, Vladyslav
Kholodovych, Raymond Birge, Tom Comollo, Stanley Kimani, Kamal
Singh.
1749 Preclinical characterization of SEL24-B489, a dual PIM/
FLT3 inhibitor for the treatment of hematological malignancies.
Wojciech Czardybon, Renata Windak, Izabela Dolata, Magdalena
Salwińska, Maciej Szydlowski, Tomasz Sewastianik, Emilia
Białopiotrowicz, Elżbieta Ma˛dro, Ewa Lech-Marańda, Bożena K.
Budziszewska, Katarzyna Borg, Przemysław Juszczynski, Krzysztof D.
Brzózka.
1750 Combined blockade of Aurora A and JAK2 kinase is
highly effective at inhibiting malignant transformation. Said M.
Sebti, Hua Yang, Harshani Lawrence, Aslamuzzaman Kazi, Harsukh
Gervaria, Ronil Patel, Yunting Luo, Uwe Rix, Ernst Schonbrunn, Nicholas
Lawrence.
1751 Preclinical development of a novel multi-targeted kinase
inhibitor, MG516, for the treatment of sarcoma. Kathryn S. Ivy,
Parag P. Patwardhan, Gary K. Schwartz.
1752 Search for effective therapies for canine and human
osteosarcoma using novel therapeutic agents. Yating Yang, Ewa
Bartczak, Vilma Yuzbasiyan-Gurkan.
1753 GLPG1790: The first Ephrin (EPH) receptor tyrosine
kinase inhibitor for the treatment of triple negative breast cancer.
Philippe Pujuguet, Filip Beirinckx, Carole Delachaume, Jacques Huck,
Ellen Van der Aar, Reginald Brys, Luc Van Rompaey, Piet Wigerinck,
Laurent Saniere.
1754 Cycloartane anticancer activity. Henry I. Lowe, Ngeh J.
Toyang, Charah Watson, Joseph Bryant.
1755 CT053PTSA, a novel c-MET and VEGFR2 inhibitor,
potently suppresses angiogenesis and tumor growth. Ning Xi,
Yingjun Zhang, Zhaohe Wang, Yanjun Wu, Tingjin Wang.
1756 Novel irreversible EGFR tyrosine kinase inhibitor,
DBPR112, as a therapeutic candidate for lung adenocarcinoma.
Hui-Yi Shiao, Tsu-An Hsu, Wen-Hsing Lin, Tsong-Toh Yang, Hui-Fang
Hsieh, Chiung-Tong Chen, Teng-Kuang Yeh, Hsing-Pang Hsieh.
1757 The novel BTK inhibitor CC-292 exerts in vitro and in
vivo antitumor activity, interferes with adhesion, cell migration,
and synergizes with lenalidomide in MCL models. Anna VidalCrespo, Vanina Rodríguez, Alba Matas-Céspedes, Elías Campos,
Armando López-Guillermo, Gael Roué, Dolors Colomer, Patricia PérezGalán.
31
31
319
POSTER SESSION
Poster
Section
32
32
New Targets and Agents 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
320
1758
Targeting EphB4 with a novel antibody in acute
leukemia. Miriam Y. Kim, Aparna Jorapur, Amy R.
McManus, Ren Liu, Valery Krasnoperov, Kranthi Naga,
Parkash S. Gill, Akil Merchant.
1759
Targeting GLI-dependent transcription by
GANT61 in human colon carcinoma cells (CC); a new
therapeutic approach. Akwasi Agyeman, Babal K. Jha,
Tapati Mazumder, Janet A. Houghton.
1760
Tumor-specific targeting of the NAD
metabolome with ␤-lapachone and NamPT inhibition.
Zachary Moore, David A. Boothman.
1761
PDE10, a novel therapeutic target for lung
cancer. Bing Zhu, Nan Li, Veronica Ramirez-Alcantara,
Joshua Canzoneri, Evrim Gurpinar, Alexandra Fajardo, Kevin
Lee, Sara Sigler, Bernard Gary, Meagan Thomas, Adam
Keeton, Xi Chen, William Grizzle, Gary Piazza.
1762
Phosphodiesterase 10, a novel target for
colorectal cancer therapeutics. Kevin J. Lee, Nan Li, Xi
Chen, Bing Zhu, Larry Yet, Gary Piazza.
1764
Inhibition of R-spondin (RSPO) signaling
reduces the growth of multiple human tumors. Austin
Gurney, Fumiko Axelrod, Chris Bond, Jennifer Cain, Cecile
Chartier, Marcus Fischer, May Ji, Chris Murriel, Janak
Raval, Jalpa Shah, Min Wang, Wan-Ching Yen, Ann Kapoun,
John Lewicki, Timothy Hoey.
1765
Ras and EF-hand domain containing as a novel
tissue biomarker and a therapeutic target for lung
cancer. Yataro Daigo, Atsushi Takano, Yusuke Nakamura.
1766
Growth modulation of head and neck cancer
via Sgk-1 inhibition: a novel modality of local control.
Henrik O. Berdel, Hongyu Yin, Jun Liu, Chris Middleton,
Nathan Yanasak, Rafik Abdelsayed, Wolfgang E. Berdel,
Mahmood Mozaffari, Jack C. Yu, Babak Baban.
1767
Oncocidia: a small molecule dual targeting pananticancer theragnostic strategy. Yicheng Ni.
1768
A novel PDE10 inhibitor suppresses tumor
growth in an orthotopic mouse model of lung cancer.
Veronica Ramirez-Alcantara, Michele A. Schuler, Bing Zhu,
Nan Li, Evrim Gurpinar, Joshua Canzoneri, Adam Keeton,
Bernard Gary, Suzanne Russo, Lori Coward, Gregory S.
Gorman, William Grizzle, Xi Chen, Gary A. Piazza.
1769
A novel potential cancer marker and
therapeutic target. Matteo Parri, Susanna Campagnoli,
Alberto Grandi, Elisa De Camilli, Valentina Farini, Serenella
Eppenberger, Paola Chiarugi, Paolo Sarmientos, Boquan Jin,
Guido Grandi, Giuseppe Viale, Luigi Terracciano, Piero Pileri,
Renata Maria Grifantini.
1770
Viral-based nanoparticles: a new therapeutic
approach for anticancer therapy. Rhonda Kines, Debaditya
Bhattacharya, John R. MacDougall, Diane Milenic, Martin W.
Brechbiel, Elisabet de los Pinos, John T. Schiller.
1771
Novel small molecule pak4 allosteric
modulators with activity against pancreatic cancer.
Asfar S. Azmi, William Senapedis, Yosef Landesman, Erkan
Baloglu, Ori Kalid, Jack Wu, Bin Bao, Amro Aboukameel,
Sharon Shacham, Michael Kauffman, Ramzi M. Mohammad.
1772
Overcoming drug-resistance in multiple
myeloma by CRM1 inhibitor combination therapy. Joel G.
Turner, Kenneth H. Shain, Yun Dai, Jana L. Dawson,
Christopher L. Cubitt, Sharon Shacham, Michael Kauffman,
Steven Grant, Daniel M. Sullivan.
Poster Abstract
Board Number
16.
17.
18.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1773
Phosphodiesterase 10A: A novel target for
selective inhibition of colon tumor cell growth and Wnt/
␤-catenin signaling. Nan Li, Kevin Lee, Yaguang Xi, Bing
Zhu, Bernary D. Gary, Verónica Ramírez-Alcántara, Evrim
Gurpinar, Joshua C. Canzoneri, Alexandra Fajardo, Sara
Sigler, John T. Piazza, Xi Chen, Joel Andrews, Wenyan Lu,
Yonghe Li, Suzanne Russo, Larry Yet, Adam B. Keeton,
William E. Grizzle, Gary A. Piazza.
1774
Polysialyltransferase ST8SiaII: a new target for
the treatment of metastatic tumours. Virginie Viprey,
Bradley R. Springett, Yousef Al-Saraireh, Matthew Northrop,
Mark Sutherland, Rida Saeed, Paul M. Loadman, Laurence
H. Patterson, Steven D. Shnyder, Robert A. Falconer.
1775
Identification of small molecule inhibitors of
HSF1 stress pathway activation in cancer cells.
Emmanuel de Billy, Nicola Chessum, Robert Te Poele,
Jennifer Smith, Lorenzo Zani, Swee Sharp, Mark Stubbs,
Wynne Aherne, Keith Jones, Paul Workman.
1778
Characterization and anti-tumor functionality of
a neuroblastoma-specific peptide, either free or
conjugated to nanocarriers. Alice Bartolini, Monica Loi,
Daniela Di Paolo, Laura Emionite, Angelina Sacchi, Flavio
Curnis, Gianluca Bottoni, Michela Massollo, Cristina Gagliani,
Silvia Bruno, Alessandro Gori, Renato Longhi, Michele Cilli,
Carlo Tacchetti, Angelo Corti, Gianmario Sambuceti, Mirco
Ponzoni, Serena Marchiò, Fabio Pastorino.
1779
CYP2W1 as a novel therapeutic target in colon
cancer. Klaus Pors, Paul M. Loadman, Sandra Travica,
Steven D. Shnyder, Mark Sutherland, Helen Sheldrake, Mark
Searcey, Inger Johansson, Souren Mkrtchian, Magnus
Ingelman-Sundberg, Laurence H. Patterson.
1780
Identification and characterization of L524 –
0366 as a small molecule inhibitor that disrupt TWEAKFn14 signaling in glioblastoma. Harshil D. Dhruv, Joseph
C. Loftus, Pooja Narang, Joachim L. Petit, Donald Chow,
Holly Yin, Michael Berens, Nathalie Meurice, Nhan L. Tran.
1781
Identification of focal adhesion and actin
cytoskeleton regulation family genes as druggable
target for gastric cancer. Hae Ryung Chang, Seungyoon
Nam, Myeong-Cherl Kook, Hee Seo Park, Hae Rim Jung,
Youme Gim, Han Liang, Garth Powis, Yon Hui Kim.
1782
The ubiquitin protease UBP43 is a target for
KRAS mutant lung cancers. Lisa Maria Mustachio, Fadzai
Chinyengetere, Yun Lu, Shanhu Hu, Masanori Kawakami,
Laura J. Tafe, Alexey Danilov, David J. Sekula, Tian Ma,
Sarah J. Freemantle, Ethan Dmitrovsky.
1783
Puupehenol natural product inhibits STAT3
signaling and induces antitumor cell effects in vitro
against human glioblastoma cells. Tyvette S. Hilliard,
Christopher Chock, Philip Williams, James Turkson.
1784
The impact of the natural (6S) isomer of 5formyltetrahydrofolate on the activities of pralatrexate
and methotrexate in vitro. Michele Visentin, Ersin S. Unal,
I D. Goldman.
1785
Distinct effect of aldehydes in anthracycline
cytotoxicity in S. cerevisiae. Jana S. Miles, Tryphon Mazu,
Selina Darling-Reed, Hernan Flores-Rozas.
1786
Development and pharmacological properties of
PEGylated glucuronide-auristatin linkers. Patrick
J. Burke, Joseph Z. Hamilton, Joshua H. Hunter, Scott C.
Jeffrey, Svetlana O. Doronina, Nicole M. Okeley, David W.
Meyer, Peter D. Senter, Robert P. Lyon.
1787
Prevention of skin cancer in xeroderma
pigmentosum: A long-term study of fourteen patients. W
Clark Lambert, Randal Anderson, Muriel W. Lambert.
POSTER SESSION
Novel Targets 1
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
14.
15.
1788 19-Substituted benzoquinone ansamycins. Hsp90
inhibitors with decreased off-target toxicity. Chuan-Hsin Chang,
Derek A. Drechsel, Russell R. Kitson, David Siegel, Qiang You,
Donald S. Backos, Cynthia Ju, Christopher J. Moody, David Ross.
1789 Profiling HSP90 inhibitors in cellular extracts on a
mass spectrometry chemoproteomics platform. Tyzoon K.
Nomanbhoy, Brian E. Nordin, Jonathan Rosenblum, Yongsheng Liu.
1790 Small molecule inhibitors of QSOX1 suppress tumor
cell growth and invasion. Paul D. Hanavan, Douglas O. Faigel,
Chen-Ting Ma, Eduard Sergienko, Nathalie Meurice, Joachim L. Petit,
Yvette W. Ruiz, Benjamin A. Katchman, Douglas F. Lake.
1791 19-Substituted benzoquinone ansamycin Hsp90
inhibitors: Effects on Hsp90 co-chaperones and Hsp90-Hsf1
complexes in cellular systems. Derek A. Drechsel, Chuan-Hsin
Chang, Russell Kitson, David Siegel, Christopher J. Moody, David
Ross.
1792 Identification of synergistic drug combinations with
the oral HSP90 inhibitor Debio 0932 in non-small cell lung
cancer and renal cell cancer. Casey G. Langdon, Norbert
Wiedemann, Hélène Maby-El Hajjami, Mathew A. Held, James T.
Platt, Grégoire Vuagniaux, Marcus W. Bosenberg, David F. Stern,
Frédéric Lévy.
1793 Emergence of novel purine scaffold HSP90 inhibitor
PU-H71 as potent therapeutic in lung cancer. Nicolas Lecomte,
Andre L. Moreira, Tony Taldone, Elizabeth Peguero, Robert J.
Downey, Gabriela Chiosis, Malcolm A. Moore.
1794 The HSP90 inhibitor, AT13387, combined with erlotinib
improves response in EGFR-driven xenograft models of NSCLC.
Tomoko Smyth, Jon Lewis, Keisha Hearn, Neil Thompson, John
Lyons, Nicola G. Wallis.
1795 Small molecule SBI-601 inhibits Siah1/2 ubiquitin
ligases, attenuates HIF1␣ expression and growth of melanoma
and prostate cancer cells. Yongmei Feng, Tal Varsano, Hampton
Sessions, Michael Davies, Greg Roth, Ze’ev Ronai.
1796 Novel triazole nucleoside inhibits heat shock factor 1
and androgen receptor to fight against prostate cancer. Yi Xia,
Eliana Beraldi, Amina Zoubeidi, Ling Peng, Martin Gleave.
1797 Discovery of NVP-CGM097, a highly potent and
optimized small molecule inhibitor of Mdm2 under evaluation in
a Phase I clinical trial. Sébastien Jeay, Joerg Berghausen, Nicole
Buschmann, Patrick Chène, Robert Cozens, Dirk Erdmann, Stéphane
Ferretti, Pascal Furet, Tobias Gabriel, François Gessier, Diana GrausPorta, Francesco Hofmann, Philipp Holzer, Moriko Ito, Edgar Jacoby,
Michael Jensen, Joerg Kallen, Marc Lang, Joanna Lisztwan, Masato
Murakami, Carole Pissot-Soldermann, Stephan Ruetz, Caroline Rynn,
Dario Sterker, Stefan Stutz, Thérèse Valat, Marion Wiesmann, Keiichi
Masuya.
1798 Mechanistic study of NVP-CGM097: a potent, selective
and species specific inhibitor of p53-Mdm2. Thérèse Valat, Keiichi
Masuya, Frédéric Baysang, Geneviève Albrecht, Nicole Buschmann,
Dirk Erdmann, Pascal Furet, Tobias Gabriel, François Gessier,
Francesco Hofmann, Philipp Holzer, Joerg Kallen, Carole PissotSolderman, Stefan Stutz, Patrick Chène, Sébastien Jeay.
1799 Targeted murine double minute 2 (MDM2) inhibition
results in dramatic tumor regression in an MDM2-amplified
glioblastoma multiforme (GBM) xenograft model. Ann C. Mladek,
Isabelle Meaux, Katrina Bakken, Pascal Pannier, Cedric Barriere,
James W. Watters, Laurent R. Debussche, Jann N. Sarkaria.
1801 APR-246, a clinical-stage mutant p53-reactivating
compound, resensitizes ovarian cancer cells to platinum
compounds and doxorubicin. Nina Mohell, Jessica Alfredsson, Åsa
Fransson, Vladimir Bykov, Mikael von Euler, Klas Wiman, Ulf
Björklund.
1802 Small molecule compound NCI-8 induces mutant p53
degradation via inhibition of the MDM2-Hsp90 axis. Shengliang
Zhang, Lanlan Zhou, Christina Leah B. Kline, David T. Dicker, Wafik
S. El-Deiry.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1803 A new spectrum-selective cathepsin inhibitor, VBY825, inhibits bone destruction in a syngeneic 5TGM1 multiple
myeloma mouse model. Mari I. Suominen, Johanna Tuomela, Esa
Alhoniemi, Katja M. Fagerlund, Jukka P. Rissanen, Jussi M. Halleen,
Leslie J. Holsinger.
1804 New insights in the induction of cell death by the
imidazolium based compound YM155. David Danielpour, Eswar
Shankar, Sarah L. Corum.
1805 Characterization of pyoluteorin derivatives as Mcl-1
antagonists. Kenichiro Doi, Krishne Gowda, Qiang Liu, Shen-Shu
Sung, Jyh Ming Lin, Shantu Amin, Thomas P. Loughran, Hong-Gang
Wang.
1806 Birinapant, a bivalent SMAC-mimetic, promotes
efficient cellular IAP E3 ligase activity and formation of a proapoptotic RIPK1:caspase-8 complex while monovalent IAP
inhibitors are less efficient - implications for therapeutic utility.
Yasuhiro Mitsuuchi, Christopher A. Benetatos, Thomas Haimowitz,
Yijun Deng, Angeline C. Mufalli, Martin E. Seipel, Jennifer M. Burns,
Gurpreet S. Kapoor, C. Glenn Begley, Stephen M. Condon.
1807 Pre-clinical evaluation of Mcl-1 inhibition through
maritoclax in acute myeloid leukemia. Qiang Liu, Kenichiro Doi,
Krishne Gowda, Brian M. Barth, David Claxton, Shantu Amin, Thomas
P. Loughran, Hong-Gang Wang.
1808 Potentiation of proteasome inhibitor cytotoxicity by
co-treatment with novel ␤1i-selective immunoproteasome
inhibitors. Zachary C. Miller, Ying Wu, Na-Ra Lee, Shuo Zhou,
Kyung-Bo Kim.
1809 Marizomib (NPI-0052) activity as a single agent in
malignant glioma. Kaijun Di, Xing Gong, Dana M. Curticiu, Michael
A. Palladino, Daniela A. Bota.
1810 PI-1840, a novel non-covalent and rapidly reversible
proteasome inhibitor with anti-tumor activity. Said M. Sebti,
Aslamuzzaman Kazi, Sevil Ozcan, Awet G. Tecleab, Ying Sun,
Harshani Lawrence.
1811 Evaluation of anti-CXCR2 small molecule inhibitors as
novel chemotherapy targeting the Interleukin-8 pathway in
colorectal cancer. Yinghui Jane E. Huang, Kevin J. Gaffney, Ethan
Gerdts, Nicos A. Petasis, Heinz-Josef Lenz, Melissa J. LaBonte.
1812 XCE853: A novel PDI inhibitor that inhibits proliferation
of human tumor cells in vitro, ex-vivo and in vivo. Gregoire P.
Prevost, Shili Xu, Marine Garrido, Maria Serova, Olivier DE Vewer,
Christian Gespach, Jean-François Briand, Annemilaï TijerasRaballand, Mathieu Gutmann, An Hendrix, Michele Sabbah, Anne
Chachereau, Armand de Gramont, Nouri Neamati, Denis Carniato,
Marc-Henry Pitty, Paul Foster.
1813 A novel designed small peptide enhances
chemotherapy sensitivity of leukemia cells in stromal
microenvironment. Xiaojin Li, Hua Guo, Yanlian Yang, Jie Meng,
Jian Liu, Chen Wang, Haiyan Xu.
1814 Harnessing the potential of idiotypic peptide therapy
for the treatment of multiple myeloma. Enrico Iaccino, Selena
Mimmi, Cristina Falcone, Eleonora Vecchio, Roberta Crescenzo,
Giuseppina Maggisano, Cesare Carvelli, Samuela Russo, Annamaria
de Laurentiis, Marilena Pontoriero, Antonio Pisano, Simona Ceglia,
Francesca Fasanella Masci, Annarita Scialdone, Annalisa Rossi,
Giuseppe Fiume, Camillo Palmieri, Ileana Quinto, Giuseppe Scala.
1815 Efficacy of FASN-selective small molecule inhibitors in
preclinical tumor models. Timothy S. Heuer, Richard Ventura,
Joanna Waszczuk, Kasia Mordec, Julie Lai, Russell Johnson, Lilly Hu,
Haiying Cai, Allan Wagman, Douglas Buckley, Stanley T. Parish,
Elizabeth Bruckheimer, George Kemble.
1816 Assessment of anti-tumour activity of the cathepsin L
inhibitor, KGP94. Thomas R. Wittenborn, Michael Stratford, Mary
Lynn Trawick, Kevin G. Pinney, David J. Chaplin, Dietmar W.
Siemann, Michael R. Horsman.
1817 Development of claudin-3 and claudin-4-targeted
antiprostate cancer prodrug. Victor Romanov, Terry Whyard,
Wayne C. Waltzer, Theodore Gabig.
33
33
321
POSTER SESSION
Poster
Section
34
34
Resistance to Inhibitors of ErbB Proteins
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
322
1818
ERBB3/HER2 signaling limits the effectiveness
of EGFR blockade in head and neck and colorectal
cancer models. Li Zhang, Carla Castanaro, Bo Luan, Katie
Yang, Amy Fan, John Rudge, Nicholas Papadopoulos, Gavin
Thurston, Christopher Daly.
1819
Heterogeneity of triple-negative breast cancer
response to neoadjuvant treatment: tumor EGFR, HER3
and MET expressions can provide clues for therapy
tailoring. Nina Radosevic-Robin, Catherine Abrial, MarieMelanie Dauplat, Matthieu Roche, Anne Cayre, Maud Privat,
Fabrice Kwiatkowski, Nassera Chalabi, Marie-Ange MouretReynier, Yves-Jean Bignon, Philippe Chollet, Jean-Marc
Nabholtz, Frederique Penault-Llorca.
1820
Dynamics of HER-2 loss in mammary
carcinoma of human HER-2 trangenic mice. Patrizia
Nanni, Arianna Palladini, Lorena Landuzzi, Massimiliano
Dall’Ora, Marianna Ianzano, Valentina Grosso, Dario Ranieri,
Giordano Nicoletti, Roberta Laranga, Carla De Giovanni,
Manuela Iezzi, Pier-Luigi Lollini.
1821
HER3 activation by MET contributes to
trastuzumab resistance in HER2-positive breast cancer.
Kenji Hashimoto, Valentine Macaulay, Anthony Kong.
1822
HER2/PIK3CAH1047R transgenic tumors develop
acquired resistance to triple therapy with trastuzumab,
pertuzumab, and PI3K inhibitors via multiple
mechanisms. Ariella B. Hanker, Christian D. Young, Thomas
P. Stricker, Rebecca S. Cook, Carlos L. Arteaga.
1823
Novel regulation of Jagged1 by ErbB2 in breast
cancer: implications for anti-ErbB2 therapy. Clodia Osipo,
Kinnari Pandya, Debra Wyatt.
1824
Hypoxia induces lapatinib resistance in ErbB2positive breast cancer cells via regulation of DUSP2.
Sergey Karakashev.
1825
Jab1/Csn5 a new target in the resistant
mechanism to HER2-targeted therapies for breast
cancer. Francois X. Claret, Thuy Vu, Terry J. Shackleford,
Jennifer Allensworth, Qingxiu Zhang, Ling Tian, Ronghua
Zhang.
1826
Altered expression of miRNAs in acquired
trastuzumab resistance. Karen Howe, Alex J. Eustace,
Giuseppe Gullo, Brigid Browne, Sinead Aherne, John Crown,
Norma O’Donovan.
1827
Inhibition of Src, HER2, and EGFR by the multikinase inhibitor KD019 overcomes trastuzumab
resistance in breast cancer. Rigen Mo, Nishta Rao, James
Tonra, Samuel Waksal, Masha Poyurovsky.
1828
A genomic-transcriptomic-phosphoproteomic
study to interrogate lapatinib resistance in an HER2
over expressing SKBR3 human breast cancer cell line
model. Parames Thavasu, Robert Te Poele, Mark Hughes,
Adam Stewart, Paul Workman, Udai Banerji.
1829
Regulation of Mixed Lineage Kinase-3 activity
by Her2 and its implication in death or survival.
Subhasis Das, Gautam Sondarva, Navin Viswakarma,
Rakesh Sathish Nair, Clodia Osipo, Basabi Rana, Ajay Rana.
1830
Antibody-drug conjugates with modified linkerpayloads overcome resistance to a trastuzumabmaytansinoid conjugate in multiple cultured tumor cell
models. Xingzhi Tan, Bingwen Lu, Guixian Jin, Fang Wang,
Jeremy Myers, Sylvia Musto, My-Hanh Lam, William Hu,
Kiran Khandke, Kim Arndt, Hans-Peter Gerber, Frank
Loganzo.
1831
Interrogating HER2ⴙ plasticity and lapatinib
resistance with MicroEnvironment MicroArrays. Spencer
Watson, James Korkola, Juha Rantala, Joe Gray.
1832
Combined EGFR and MEK inhibition prevents
the emergence of drug resistance in EGFR mutant nonsmall cell lung cancer (NSCLC). Erin M. Tricker, Chunxiao
Xu, Dalia Ercan, Atsuko Ogino, Kwok-kin Wong, Pasi Janne.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1833
De novo EGFR T790M mutation in lung cancer
patients harboring sensitive EGFR mutations. Youngjoo
Lee, Geon Kook Lee, Yeon-Su Lee, Wenji Zhang.
1834
The molecular characters of acquired resistant
non-small cell lung cancer cells to afatinib. Shinsuke
Hashida, Shinichi Toyooka, Tomoaki Ohtsuka, Ken Suzawa,
Kazuhiko Shien, Hiromasa Yamamoto, Junichi Soh, Hiroaki
Asano, Kazunori Tsukuda, Shinichiro Miyoshi.
1835
Transcriptome and metabolome reprogramming
in EGFR-mutant NSCLC early adaptive drug-escape
against erlotinib. Patrick C. Ma, Praveena S. Thiagarajan,
Patrick Leahy, Rakesh Bagai, Ivy Shi, Wei Zhang, Yan Feng,
Martina L. Veigl, Daniel Lindner, David Danielpour, Lihong
Yin.
1836
Erlotinib induces NF-kappa B dependence that
promotes EGFR tyrosine kinase inhibitor resistance in
lung adenocarcinoma. Collin M. Blakely, Evangelos
Pazarentzos, Saurabh Asthana, Victor Olivas, Irena Tan,
Timothy Fouts, Jeffrey Meshulam, Trever G. Bivona.
1837
A HSP90 inhibitor, AUY922, is effective to
overcome the MET- and AXL-mediated resistance to
EGFR-TKI in lung cancer. Jin Kyung Rho, Yun Jung Choi,
Seon Ye Kime, Gwang Sup So, Se Hoon Choi, Chang-Min
Choi, Jae Cheol Lee.
1838
Mechanism of EGFR and c-Met TKI resistance
and role of co-expression of EGFR and c-Met in nonsmall cell lung cancer patients. Gregory M. Botting,
Kymberly Harrington, Caleb Shearrow, Zachary Crees,
Jennifer Girard, Kavin Arasi, Neelu Puri.
1839
LKB1 deficiency enhances sensitivity to
energetic stress induced by erlotinib treatment in nonsmall cell lung cancer (NSCLC) cells. Young Mi Whang,
Serk In Park, Irina A. Trenary, Changki Lee, Jacob M.
Kaufman, David P. Carbone, Jamey D. Young.
1840
Contribution of miR-205 in gefitinib-resistant
lung cancer cell lines. Toshihiro Suzuki, Ikuko Nagasawa,
Toshimitsu Yamaoka, Tohru Ohmori, Kazuto Nishio, Kiyotaka
Koyama, Yuki Ogasawara.
1841
A miR551b/catalase/MUC1/EGFR cascade for
acquired apoptosis resistance and chemoresistance in
lung cancer cells. Xiuling Xu, Alexandria Wells, Mabel T.
Padilla, Kwang Chul Kim, Yong Lin.
1842
Synergistic inhibition of ALK inhibitor-resistant
lung cancer cells by dual-targeting EGFR and ALK
pathways. Soyeon Kim, Tae Min Kim, Yong-Oon Ahn,
Bhumsuk Keam, Se-Hoon Lee, Dae Seog Heo, Dong-Wan
Kim.
1843
Primary and acquired resistance to HERs
inhibition in colorectal cancer cells: All HERs go to RAS.
Mariangela Russo, Alessandra Riggio, Carlotta Cancelliere,
Federica Di Nicolantonio, Alberto Bardelli.
1844
Novel HER3 neutralizing antibody, patritumab
abrogates cetuximab resistance mediated by a
heregulin-autocrine loop in colorectal cancer. Hisato
Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio
Okamoto, Kiyoko Kuwata, Yume Morita, Haruka Yamaguchi,
Kazuto Nishio, Kazuhiko Nakagawa.
1845
Sensitivity of PC9 cells to erlotinib is affected
by extracellular matrix. Halina M. Onishko, Jie Zhao,
Katherine L. Jameson, Peter L. Frick, Darren R. Tyson, Vito
Quaranta, Thomas E. Yankeelov, Erin C. Rericha.
1846
Co-treatment with simvastatin and cetuximab in
KRAS mutant LoVo cells decreases PTK activity
effectively and increases STK activity to overcome the
anti-EGFR resistance. Lisanne Krens, Renee Pablo-Baak,
Monique Mommersteeg, Maria Hilhorst, Rob Ruijtenbeek,
Henk-Jan Guchelaar, Tahar van der Straaten.
1847
Influence of growth factors on resistance to
EGFR inhibitor treatment in HNSCC - Temsirolimus as a
potential concept. Susanne R. Tepper, Zhixiang Zuo, Arun
Khattri, Jana Heitmann, Jochen Heß, Tanguy Seiwert.
POSTER SESSION
Clinical Research 4
Diagnostic and Cancer Risk Markers
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
1848
Evaluation of the frequency of RNASE L in 462
and 541 variants in Iranian prostate cancer patients.
Sirweh Molla, Massoud Ghaffarpour, Somayeh Saeeda,
Seyed Werya Hossieni, Sina Mirzaahmadi, Mohammad Reza
Rahmany.
1849
High nuclear expression of the p53 target Wig-1
is associated with poor prognosis in cervical carcinoma.
Lidi Xu, Susanne Muller, Mikael Lerner, Svetlana
Lagercrantz, Dan Grandér, Keng-Ling Wallin, Klas G. Wiman,
Sonia Andersson, Catharina Larsson.
1850
The detection of methylated Septin 9 in tissue
and plasma of colorectal neoplasia and its relationship
to the amount of free circulating DNA. Alexandra Kalmar,
Kinga Toth, Reinhold Wasserkort, Ferenc Sipos, Barnabas
Wichmann, Gabor Valcz, Zsolt Tulassay, Bela Molnar.
1851
Colorectal adenomatous polyps and
mitochondrial DNA variants. Felix O. Aikhionbare, Sharifeh
Mehrabi, Shakeria Cohen, Xuebiao Yao, Osatohamwen
Iyamu.
1852
Enhancing specificity in predication of human
papillomavirus associated oropharyngeal squamous cell
carcinoma by combining biomarkers p16 and ␤-catenin.
Guoqing Qian, Hong Xu, Zhongliang Hu, Sungjin Kim,
Dongsheng Wang, Hongzheng Zhang, Zhengjia Chen, Susan
Muller, Nabil Saba, Dong M. Shin, Andrew Wang, Zhuo G.
Chen.
1853
Piwi-like 1 and -4 gene transcript levels are
associated with clinicopathological parameters in renal
cell carcinomas. Omar Al-Janabi, Sven Wach, Elke Nolte,
Katrin Weigelt, Tilman T. Rau, Christine Stöhr, Wolfgang
Legal, Stefan Schick, Thomas Greither, Arndt Hartmann,
Bernd Wullich, Helge W. Taubert.
1854
P16 immunoreactivity in endocervical tuboendometrial metaplasia (TEM) and correlation with high
risk HPV (HRHPV) status by chromogenic in-situ
hybridization (HPV-CISH) and hybrid capture 2 assay.
Shobhana Talukdar, Gomez-Gelvez Juan, Thomas E
Buekers, Ziying Zhang.
1855
SCT methylation is a potential cancer
biomarker for lung cancer. Yu-An Zhang, Xiaotu Ma,
Junya Fujimoto, Ignacio Wistuba, Stephen Lam, Victor
Stastny, Boning Gao, Jill Larsen, Xiaoyun Liu, John D.
Minna, Michael Q. Zhang, Adi F. Gazdar.
1856
DNA damage and repair markers (H2AX and
RAD51) improve accuracy of prostate cancer diagnosis
and improve identification of aggressive disease. Amit
M. Algotar, Anne E. Cress, Raymond B. Nagle, Dan
Drinkwitz, Naran S. Lodhia, Patricia A. Thompson, Steven P.
Stratton.
1857
Prognostic biomarker for SNP (-617C>A) in
ARE-like loci of the NRF2 gene in lung adenocarcinoma.
Yasuko Okano, Yasushi Ichikawa, Yohei Miyagi, Keiichi
Kondo, Yutaka Natsumeda.
1858
Genetic variations in acid phosphatase 1 (ACP
1) gene and cancer risk. Radhika G. Andavolu, Jean-Luc
Cardenas, Svetlana Rubakovic, Sina J. Torabi, Patrick
Herling, James MacMurray, Murthy V. Andavolu.
1859
Potential impact on the biology and biomarker
utility of ERG-typing in the context of ethnic differences
of prostate cancer. Albert Dobi, Yongmei Chen, Amina Ali,
Denise Young, Philip Rosen, James Farrell, Michael Degon,
Sudhir Srivastava, Jacob Kagan, Jocelyn Lee, Jennifer
Cullen, Gyorgy Petrovics, David G. McLeod, Isabell A.
Sesterhenn, Shiv Srivastava.
1860
An epigenetic biomarker panel for detection of
early stage lung cancer using serum DNA. Christina
Michailidi, Luciane Kagohara, Tal Hadar, Mohammad Hoque,
Rajani Ravi, Mariana Brait, William Rom, Harvey Pass, David
Sidransky.
1861
S100P is a potential biomarker in distinguishing
mucinous from non-mucinous pancreatic cysts and
predicting invasive adenocarcinoma. Wenyi Mi, David L.
Diehl, Jianhi Shi, Joseph Blansfield, Marie Hunsinger,
Wannian Yang, Fan Lin.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
1862
Menstrual blood TAP1 I333V and D637G gene
polymorphisms are associated with less risk to develop
high-grade cervical intraepithelial neoplasia. Sze Chuen
C. Wong, Thomas Chi Chuen Au, Sammy Chung Sum Chan,
Charles Ming Lok Chan, Nancy Bo Yin Tsui, Lawrence Wing
Chi Chan, Benjamin Yat Ming Yung.
1863
Androgen receptor CAG repeat length and
TMPRSS2:ETS prostate cancer risk: results from the
Prostate Cancer Prevention Trial. Douglas K. Price, Cindy
H. Chau, William D. Figg, Catherine A. Till, Phyllis J.
Goodman, Yonggon Cho, Marileila Garcia, Juergen
Reichardt, Catherine M. Tangen, Robin J. Leach, Adrie van
Bokhoven, Alan R. Kristal, Ian M. Thompson, M S. Lucia.
1864
Reptin as a tumor-associated antigen of
epithelial ovarian cancer. Eun-ju Lee, Hanbyoul Cho, HaYeon Shin, Wookyeom Yang, Hyunja Kwon, Sol Kim, JaeHoon Kim.
1865
Circulating microRNA expression profile: miR1246 and miR-185 profile as a novel diagnostic
biomarker for melanoma. Virginie Armand-Labit, Nicolas
Meyer, Anne Casanova, Stephane Verdun, Marie Bruillard,
Gilles Favre, Anne Pradines.
1866
Detection of early-stage lung cancer using a
novel ELISA for thymidine kinase 1. Madison K. Ramsden,
Melissa M. Alegre, Michael J. Weyant, Daine T. Bennett,
Jessica A. Yu, Atif Elnaggar, Richard A. Robison, Kim L.
O’Neill.
1867
Application of oxylipin metabolomics to a
celecoxib intervention in men at risk for colorectal
neoplasia recurrence. Jessica A. Miller, Jun Yang, Bruce
Hammock, Peter Lance, Erin Ashbeck, Patricia A.
Thompson.
1868
Clinical significance of cathepsin L and B
expression in pediatric acute myeloid leukemia. Garima
Pandey, Sameer Bakhshi, Ratnakar Singh, Shyam S.
Chauhan.
1869
Using Nanoparticle Tracking Analysis (NTA) to
characterize cellular microvesicles. Sonja Capracotta,
Pauline Carnell, Andrew Malloy, Patrick Hole, Bob Carr.
1870
Development of a standard operating procedure
for exosome isolation and analysis using clinical
samples: Application to cancer biomarker discovery.
Robert A. Setterquist, Alex J. Rai, Emily Zeringer, Mu Li,
Tim Barta, Jeoffrey Schageman, Susan Magdaleno,
Alexander V. Vlassov.
1871
“Capturing the elusive foe”: A novel telomerase
promoter-based approach to detect melanoma
circulating tumor cells. Melody Ju, Gary D. Kao, Charles
B. Simone, David Steinmetz, Xiangsheng Xu, Louise Aguarin,
Wei Xu, Edmund Bartlett, Stephen M. Hahn, Jay F. Dorsey,
Giorgos Karakousis.
1872
A novel method for efficient and hands-free
purification of circulating DNA from human plasma.
Douglas White, Douglas Horejsh, Zhiyang Zeng, Tetsuo
Uyeda, Poncho Meisenheimer, Marjeta Urh.
1873
Plasma heat shock protein 90kDa beta member
1 levels predict both early stage and advanced stage
ovarian cancer independently from cancer antigen 125
in patients with an indeterminate adnexal mass.
Matthew S. Block, Matthew J. Maurer, Krista Goergen,
Kimberly R. Kalli, Courtney L. Erskine, Marshall D. Behrens,
Keith L. Knutson.
1874
Investigation of the cerebrospinal fluid
proteome from central nervous system pediatric tumors
using bait loaded hydrogel nanoparticles and mass
spectrometry. Ruben Magni, Paolo Verderio, Lance Liotta,
Filippo Spreafico, Maura Massimino, Alessandra Luchini,
Italia Bongarzone.
1875
HPV16 detection by PCR in serum of HNSCC
patients and comparison with primary tumour tissue.
Daniela Vivenza, Martino Monteverde, Nerina Denaro, Mirella
Fortunato, Alberto Comino, Marco C. Merlano, Cristiana Lo
Nigro.
36
36
323
POSTER SESSION
Clinical Research 5
Poster
Section
37
37
New Diagnostics, Therapeutic Targeting, and Response Assessments
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
324
1876 Combination of PI3KCA targeting with irradiation: A
preclinical study on head and neck cancer cell lines. Laura
Lattanzio, Federica Tonissi, Martino Monteverde, Luca Gianello, Elvio
Russi, Marco C. Merlano, Cristiana Lo Nigro, Gerard Milano.
1877 Non-small cell lung cancer histological sub-typing by
gene expression analysis from FFPE tissue. Eva Wang, Zhenqiang
Lu, Krishna Moddula, Mark Schwartz, Chris Roberts, Mary-Beth
Joshi, David Harpole, Vijay Modur.
1878 Performance comparison of BRAF V600E detection
assays in malignant melanoma and colorectal cancer
specimens. Inger Marie Loes, Heike Immervoll, Halfdan Sorbye, JonHelge Angelsen, Arild Horn, Per Eystein Lonning, Stian Knappskog.
1879 Dual function HDAC and PI3K inhibitor, CUDC-907
affects cancer cells and the tumor microenvironment in
hematological malignancies. Anna W. Ma, Ruzanna Atoyan, Anas
Younes, Ian W. Flinn, Yasuhiro Oki, Amanda Copeland, Jesus G.
Berdeja, Robert Laliberte, Jaye Viner, Maria Elena S. Samson, Steven
Dellarocca, Ling Yi, Mylissa Borek, Brian Zifcak, Guangxin Xu, Jing
Wang.
1880 Pathologic response pattern of breast cancer after
neoadjuvant chemotherapy: its correlation with molecular
subtypes. In-Hye Song, Hee Jin Lee, Gyungyub Gong.
1881 New therapeutic options for CLL treatment: Src/c-abldirected molecular re-engineering of chlorambucil and
bendamustine. Lilian Amrein, Anne-Laure Larocque, David
Davidson, Lisa Peyrard, Daniel Borrelli, Bertrand Jean-Claude,
Lawrence Panasci.
1882 The expression phenotype of SNPs linked to the risk
for prostate cancer. Xin Chen, Zhenyu Jia, Michael McClelland,
Farah Rahmatpanah, Dan Mercola.
1883 Clinical and molecular genetic analysis of squamous
cell carcinoma of the oral tongue. Raju S. Adduri, Viswakalyan
Kotapalli, Rajender K K, Swarnalata Gowrishankar, Saumyadipta
Pyne, Mukta Srinivasulu, Subramanyeshwar Rao, Shantveer G. Uppin,
Mohammed M. Ali, Umanath K. Nayak, Snehalatha Dhagam, Mohana
V. Chigurupati, Murali D. Bashyam.
1884 Treatment with Hedgehog inhibitor PF-913 attenuates
leukemia-initiation potential in acute myeloid leukemia cells.
Yosuke Minami, Nobuaki Fukushima, Anil Sadarangani, Hironobu
Minami, Catriona Jamieson, Tomoki Naoe.
1885 Quantitative Textural Analysis (QTA) in CT imaging:
Identifying markers for genetic instability and overall survival in
cohort of previously treated metastatic pancreatic cancer (mPC).
David H. Campbell, Michael Barrett, Ramesh K. Ramanathan, Daniel
D. Von Hoff, Ronald Korn.
1886 Highly sensitive detection of circulating tumor DNA in
plasma as a biomarker of colorectal cancer. Matthew Wiggin,
Jaryn Perkins, Laura Mai, Valentina Vysotskaia, Andre Marziali.
1887 Global gene expression analysis of tamoxifen-resistant
breast cancer cell lines identified a gene signature predictive of
clinical outcome of breast cancer patients treated with
endocrine therapy. Daniel Elias Roro, Henriette Vever, Anne
Lykkesfeldt, Henrik Ditzel.
1888 Target sequencing of papillary renal cell carcinoma,
type 2, using custom-made kidney cancer panel. Ji-Yeon Kim,
Se-Hoon Lee, Jong-Il Kim, Jong-Yeon Shin, Dae seog Heo.
1889 Next-generation neuropathology - Improving diagnostic
accuracy for brain tumors using DNA methylation array-based
molecular profiling. David T. Jones, David Capper, Martin Sill,
Volker Hovestadt, Leonille Schweizer, Roger Fischer, Matthias Schick,
Melanie Bewerunge-Hudler, Axel Benner, David Zagzag, Peter
Lichter, Matthias A. Karajannis, Kenneth D. Aldape, Andrey
Korshunov, Andreas von Deimling, Stefan M. Pfister.
1890 Activated SphK1 and export of S1P via ABCC1 shorten
disease free survival in breast cancer. Akimitsu Yamada,
Masayuki Nagahashi, Tomoyoshi Aoyagi, Wei C. Huang, Krista P.
Terracina, Jeremy C. Allegood, Santiago Lima, Sheldon Milstien,
Sarah Spiegel, Kumiko Kida, Takashi Ishikawa, Itaru Endo, Kazuaki
Takabe.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
28.
29.
30.
1891 Mutations in polymerase ␧ as key molecular alteration
of the novel ultramutator phenotype do not define a clinically
distinct entity of colorectal cancer. Albrecht Stenzinger, Endris
Volker, Nicole Pfarr, Roland Penzel, Lina Jansen, Esther Herpel,
Wilfried Roth, Hendrik Bläker, Jenny Chang-Claude, Hermann
Brenner, Michael Hoffmeister, Wilko Weichert.
1892 Development of a clinical targeted next generation
sequencing test for challenging formalin-fixed paraffinembedded (FFPE) cancer samples. Wenge Shi, Christine Chin,
Tingdong Tang, Loretta Hipolito, Preethi Srinivasan, Derek Chiang,
David Peng, Emmanuelle Di Tomaso, Shabnam Tangri, Jelveh
Lameh, Reinhold Pollner.
1893 A computational method for somatic versus germline
variant status determination from targeted next-generation
sequencing of clinical cancer specimens without a matched
normal control. James X. Sun, Garrett Frampton, Kai Wang, Jeffrey
S. Ross, Vincent A. Miller, Philip J. Stephens, Doron Lipson, Roman
Yelensky.
1894 Extensive genomic profiling of a rare extranodalfollicular dendritic cell sarcoma: Implications for future
individualized therapy. Jaime I. Davila, Jason Starr, Steven Attia,
Chen Wang, Xue Wang, Brian Necela, Casler John, David Menke,
Vivek Sarangi, Gavin Oliver, Richard Joseph, John Copland,
Alexander Parker, E. Aubrey Thompson, Robert Smallridge, Yan W.
Asmann.
1895 Identifying clonal T-cell receptor sequences and
monitoring recurrent/persistent disease by T-cell receptor
repertoire profiling in patients with mature T-cell neoplasms.
Anna M. Sherwood, Harlan Robins, Jonathan R. Fromm, Harvey A.
Greisman, Daniel E. Sabath, Ryan O. Emerson, Mark Rieder, Brent
Wood, David Wu.
1896 Clinicopathologic characteristics for elevated
microsatellite alterations at selected tetranucleotie repeats
(EMAST) in colorectal cancer of Korean patients. Myong Hoon
Ihn, Duck-Woo Kim, Hye Seung Lee, Kyoung Un Park, Soo Young
Lee, Heung-Kwon Oh, Sung-Bum Kang.
1897 Application of a novel DNA methylation analysis
method (MSE) for mucin expression in pancreatic juices for
diagnosis of pancreatic neoplasms. Suguru Yonezawa, Seiya
Yokoyama, Michiyo Higashi.
1898 The combination of gemcitabine/nab-paclitaxel and
anti-DLL4 (demcizumab) produces synergistic growth inhibition,
delays tumor recurrence and reduces tumor initiating cells in
pancreatic cancer. Wan-Ching Yen, Marcus Fischer, John Lewicki,
Austin Gurney, Timothy Hoey.
1899 Predictive factors of anthracycline or taxan based
chemotherapy: Analysis from a randomized phase II trial
comparing docetaxel plus cyclophosphamide with epirubicin
plus cyclophosphamide followed by docetaxel as neoadjuvant
chemotherapy for hormone receptor-negative breast cancer.
Takashi Ishikawa, Kazutaka Narui, Kazuhiro Shimada, Kumiko Kida,
Sadatoshi Sugae, Yasushi Ichikawa, Mikiko Tanabe, Itaru Endo, Mari
S.Oba.
1900 Prognostic significance of genetic aberrations in
neuroblastoma. Alexander E. Druy, Grigory A. Tsaur, Egor V.
Shorikov, Alexander M. Popov, Leonid I. Saveliev, Larisa G. Fechina.
1901 Detection of EML4-ALK fusion gene expression in
circulating tumor cells (CTCs) captured from non-small cell lung
cancer (NSCLC) patients. Joo Kyung Park, Ji Kon Ryu, Se-Hoon
Lee, Eun-Hye Kim, Byung-Chul Kim.
1903 Personalized diagnostics: Receptor specific gold
nanorods used for accurate diagnosis of EGFR expression in
human tumor tissues. Chuck Caldwell, Ajit Zambre, Dhananjay
Suresh, Gerald Arthur, Raghuraman Kannan.
1904 RNA expression based screening of ALK gene fusion
from formalin fixed non-small cell lung cancer samples. Krishna
Maddula, Mary-Beth Joshi, Vijay Modur, David H. Harpole.
1905 Defining a therapeutic classification of breast cancer
by actionable targets. Manuel Salto-Tellez, David P. Boyle, Darragh
McArt, Gareth Irwin, Charlotte Charlotte Wilhelm-Benartzi, Tong G.
LIoe, Martha Minter, Stephen McQuaid, Paul Mullan, Richard D.
Kennedy, Peter Hamilton, D P. Harkin.
POSTER SESSION
This session wil linclude clinical trials submitted at the Late-Breaking Abstract deadline. The full text of all abstracts
in this session will be available online through www.aacr.org and in the print Proceedings, Part 2 distributed to
registrants.
38
Clinical Trials
Early Phase Clinical Trials 1: Phase I
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
CT201 Phase I study of 5-azacytidine and oxaliplatin in
patients with advanced cancers relapsed or refractory to platinum
compounds. Apostolia M. Tsimberidou, Kirk Culotta, Ignacio Wistuba,
Siqing Fu, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Ralph
Zinner, Jaime Rodriguez-Canales, Guangan He, Zahid H. Siddik,
Jaroslav Jelinek, Woonbok Chung, Yang Ye, Rabih Said, Kenneth
Hess, David J. Stewart, Razelle Kurzrock, Jean-Pierre Issa.
CT202 A Phase I study of a first-in-man carbohydrate
mimetic-peptide vaccine in Stage IV breast cancer subjects. Laura
Hutchins, Issam Makhoul, Peter D. Emanuel, Eric R. Siegel, Fariba
Jousheghany, Behjatolah Monzavi-Karbassi, Thomas Kieber-Emmons.
CT203 Chemoprotective hematopoietic stem cell gene
therapy permits increased chemotherapy efficacy and survival
in poor-prognosis glioblastoma patients treated with a
methylguanine methyltransferase inhibitor and temozolomide.
Jennifer E. Adair, Maciej M. Mrugala, Barry Storer, Kristin R.
Swanson, Hans-Peter Kiem.
CT204 The pharmacokinetics and safety of idelalisib in
subjects with severe renal impairment. Feng Jin, Michelle
Robeson, Huafeng Zhou, Grace Hisoire, Srini Ramanathan.
CT205 A phase I dose-escalation study of trametinib (T) in
combination with continuous or intermittent GSK2126458
(GSK458) in patients (pts) with advanced solid tumors. Philippe
L. Bedard, Juneko E. Grilley-Olson, Mark Cornfeld, Leanne Cartee,
Susan Warwick, Albiruni A. Razak, Lee-Anne Stayner, Yuehui Wu,
Rebecca Greenwood, Veronica Viana-Gilmartin, Carrie B. Lee,
Johanna Bendell, Howard A. Burris, Luca Gianni, Cristiana Sessa,
Jeffrey R. Infante, Angelica Fasolo.
CT206 SN-38 antibody-drug conjugate (ADC) targeting Trop2, IMMU-132, as a novel platform for the therapy of diverse
metastatic solid cancers: Initial clinical results. Alexander N.
Starodub, Allyson J. Ocean, Manish A. Shah, Linda T. Vahdat, Ellen
Chuang, Michael J. Guarino, Vincent J. Picozzi, Sajeve S. Thomas,
Pius P. Maliakal, Serengulam V. Govindan, William A. Wegener,
Robert M. Sharkey, David M. Goldenberg.
CT207 Pharmacokinetic analysis of the HDAC inhibitor
belinostat (PXD-101) and metabolites in patients with hepatic
dysfunction. Brian Kiesel, Robert Parise, Yan Lin, Deborah Allen,
Guru Reddy, Shanta Chawla, Richard Piekarz, Percy Ivy, Shivaani
Kumar, Jan H. Beumer.
CT208 Absolute bioavailability of dacomitinib (PF-00299804):
Comparison of oral and intravenous administration in healthy
volunteers. Nagdeep Giri, Robert R. LaBadie, Yali Liang, Tanya
Boutros, Zelanna Goldberg, Carlo L. Bello.
CT209 A phase I study with the oral pan-CDK inhibitor BAY
1000394 in patients with advanced stage small cell lung or
ovarian cancer. Rastilav Bahleda, Fabrice Barlesi, Christine
Audebert, Maurice Perol, Isabelle Ray-Coquard, Dirk Strumberg,
Beate Schultheis, Ramaswamy Govindan, Grace K. Dy, Gerard
Zalcman, Annette O. Walter, Martin Kornacker, Matthias Ocker,
Jean-Charles Soria.
CT210 A phase 1 study of BIND-014, a PSMA-targeted
nanoparticle containing docetaxel, administered to patients with
refractory solid tumors on a weekly schedule. Monica Mita,
Howard Burris, Patricia LoRusso, Lowell Hart, Peter Eisenberg, Alain
Mita, Susan Low, Jason Summa, Gregory Berk, Jasgit Sachdev.
CT211 IMMU-130, an SN-38 antibody-drug conjugate (ADC)
targeting CEACAM5, is therapeutically active in metastatic
colorectal cancer (mCRC): Initial clinical results of two Phase I
studies. Neil H. Segal, Efrat Dotan, Jordan D. Berlin, Alexander N.
Starodub, Michael J. Guarino, Leonard B. Saltz, Pius P. Maliakal,
Serengulam V. Govindan, William A. Wegener, Robert M. Sharkey,
David M. Goldenberg.
CT212 Adoptive transfer of wild-type TCR gene transduced
T lymphocytes targeting MAGE-A4 antigen to patients with
refractory esophageal cancer. Shinichi Kageyama, Hiroaki Ikeda,
Naoko Imai, Mikiya Ishihara, Yoshihiro Miyahara, Shugo Ueda,
Takeshi Ishikawa, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi,
Naoki Inoue, Masashige Tanabe, Tomohide Kidokoro, Hirofumi
Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh
Takesako, Naoyuki Katayama, Hiroshi Shiku.
Poster
Section
38
Poster Abstract
Board Number
13.
14.
15.
16.
17.
18.
19.
21.
22.
23.
24.
25.
CT213 Arctigenin, an antiausterity agent shows high safety
and promising clinical response in phase I clinical trial in
patient with gemcitabine-refractory pancreatic cancer. Hiroyasu
Esumi, Satoshi Owada, Rumi Fujioka, Katsuya Tsuchihara, Atsushi
Ohtsu, Aihiro Sato, Masafumi Ikeda, Nobuo Mochizuki, Satoshi
Kishino, Takanori Kawashima, Satoshi Yomoda.
CT214 High purity and activity NK cells therapy in patients
with advanced gastrointestinal cancer: Phase I study. Tetsuya
Okayama, Satoshi Kokura, Takeshi ishikawa, Naoyuki Sakamoto,
Mitsuko Ideno, Fumiyo Sakai, Akiko Kato, Tatsuji Enoki, Junichi
Mineno, Hideyuki Konishi, Yuji Naito, Yoshito Itoh, Toshikazu
Yoshikawa.
CT215 A phase I trial of LY2874455, a fibroblast growth
factor receptor inhibitor, in patients with advanced cance.
Jeanne Tie, Yung-Jue Bang, Young Suk Park, Yoon-Koo Kang, David
Monteith, Kimberly Hartsock, Donald E. Thornton, Michael Michael.
CT216 Phase I dose escalating study of 2B3–101,
glutathione PEGylated liposomal doxorubicin, in patients with
solid tumors and brain metastases or recurrent malignant
glioma. Pieter J. Gaillard, Bojana Milojkovic Kerklaan, Philippe
Aftimos, Sevilay Altintas, Agnes Jager, Werner Gladdines, Fredrik
Lonnqvist, Patricia Soetekouw, Henk Verheul, Ahmad Awada, Jan
Schellens, Dieta Brandsma.
CT217 Pharmacokinetics and safety of idelalisib, a novel
PI3K␦ inhibitor, in Japanese and Caucasian subjects. Feng Jin,
Michelle Robeson, Huafeng Zhou, Candra Moyer, Srini Ramanathan.
CT218 Wilms= tumor gene 1 (WT1) peptide-based cancer
vaccine combined with gemcitabine for patients with advanced
pancreatic cancer. Shigeo Koido, Sumiyuki Nishida, Sadamu
Homma, Yutaka Takeda, Hideo Komita, Satoshi Morita, Toshinori Ito,
Soyoko Morimoto, Yoshihiro Oka, Satoru Yanagisawa, Yoichi Toyama,
Masahiro Ikegami, Hiroaki Nagano, Toshifumi Ohkusa, Hisao Tajiri,
Haruo Sugiyama.
CT219 Selenium counteracts carboplatin drug resistance
through Rad51-AP1 induction: A phase I trial in women with
gynecologic cancers. Lorna Rodriguez-Rodriguez, Mihae Song,
Neelakandan Muthukumaran, Murugesan Gounder, Darlene Gibbon,
Wilberto Nieves-Neira, Ami Vaidya, Mira Hellmann, Susan Goodin,
Brian Buckley.
CT221 The effect of food on the oral bioavailability of the
novel PARP 1/2 inhibitor BMN 673 in healthy male subjects.
Joshua Henshaw, Huiyu Zhou, Don Musson, Charles O’Neill, Randall
Stoltz, Andrew Dorr.
CT222 Differences in pharmacokinetics of TRC105 (antiendoglin antibody) when administered as a single agent versus in
combination with bevacizumab (Bev). Shawn D. Spencer, Lee S.
Rosen, Michael S. Gordon, Francisco Robert, Daniela Matei, Cody J.
Peer, Bonne Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer,
W. D. Figg.
CT223 Dendritic cells pulsed with Wilms= tumor gene 1
(WT1)-specific and MHC class I and II-restricted epitopes with
gemcitabine induce antitumor immune responses in patients
with advanced pancreatic cancer. Shigeo Koido, Sadamu Homma,
Masato Okamoto, Masako Mori, Shinji Yoshizaki, Kazuki Takakura,
Kazumi Hayashi, Shin Kan, Takafumi Ishidao, Sei-ichi Yusa,
Shigetaka Shimodaira, Kan Uchiyama, Mikio Kajihara, Hiroo Imazu,
Hiroshi Arakawa, Toshifumi Ohkusa, Hisao Tajiri.
CT224 Pilot study in patients with advanced solid tumors to
evaluate feasibility of ferumoxytol (FMX) as tumor imaging
agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI).
Ramesh K. Ramanathan, Ronald L. Korn, Jasgit C. Sachdev, Gerald
J. Fetterly, Katie Marceau, Vickie Marsh, John M. Neil, Ronald G.
Newbold, Natarajan Raghunand, Joshua Prey, Stephan G. Klinz, Eliel
Bayever, Jonathan B. Fitzgerald.
CT225 A phase I cancer clinical trial for 4-demethyl4cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) IND
68.876. Roy S. Weiner, Philip Friedlander, Craig Gordon, Yvonne
Saenger, Tallat Mohmood, Marcus Ware, AH Rogers, Gerard Bastian,
S Urien, LR Morgan.
325
POSTER SESSION
Hall A-E • Monday, 8:00 a.m.-12:00 p.m.
Advocates Poster Session 1
Poster
Section
1
1
Poster Abstract
Board Number
1.
ADV101 Advocate Poster. Jameisha Brown, Baylor
College of Medicine, Houston, TX.
8.
ADV108 Florence Kurttila: Survivorship to advocacy.
Florence Kurtitila, Fight Colorectal Cancer, Citrus Heights, CA.
2.
ADV102 Trifecta Effect: Scientifically trained survivor
advocates. Sandy Castillo, Independent Advocate,
Cypress, TX.
9.
ADV109 Malecare. Wendy A. Lebowitz, Malecare,
Brooklyn, NY.
3.
ADV103 Digital footprints on the sands of time. Cynthia
Chmielewski, Independent Advocate, Lawrenceville, NJ.
4.
10.
ADV110 CBCC as a resource for enrolling minority
participants in research studies. Wanda Lucas, Capital
Breast Care Center, Washington, DC.
ADV104 The secret life of an independent research
advocate. Laura Cleveland, Independent Advocate,
Powell, OH.
11.
ADV111 CANCER101: Personalizing the educational
experience...One patient at a time. Sarah Krug, Cancer 101,
New York, NY.
5.
ADV105 Navigating uncharted waters: Exploring the
tools patients use to manage long-term recurrent ovarian
cancer. Annie Ellis, Independent Advocate, White Plains, NY.
12.
ADV112 Taking advocacy efforts to the street. Cynthia
Ryan, University of Alabama at Birmingham, Birmingham, AL.
13.
6.
ADV106 Coming through cancer: Surviving and thriving
though advocacy. Valerie Fraser, University of Michigan,
Huntington Woods, MI.
ADV113 Advocate Poster. Sonia Baez-Hernandez, Florida
Breast Cancer Foundation, Fort Lauderdale, FL.
14.
ADV114 Advocate Poster. Ronald Halem, Independent
Advocate, Salinas, CA.
7.
326
Poster Abstract
Board Number
ADV107 On being a research advocate: How I became
a TWISTed sister. Virginia Hetrick, Independent Advocate,
Los Angeles, CA.
LATE-BREAKING POSTER SESSIONS
Monday, 8:00 a.m.-12:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 40
Late-Breaking Research: Tumor Biology 2
Poster Section 41
Late-Breaking Research: Molecular and Cellular Biology 1
Poster Section 42
Late-Breaking Research: Experimental and Molecular Therapeutics 1
327
PLENARY SESSION
Monday, 8:15 a.m.-10:15 a.m.
Hall F-G, San Diego Convention Center
Targeted Immunotherapy: Mobilizing the Immune System
Against Cancer
Chairperson: Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
The human immune system, comprised of adaptive (T and B cell) and innate (NK and myeloid)
components, is inherently capable of recognizing and destroying cancer cells but is held in check
by suppressive intratumoral factors. Tumors can thwart immune attack through the secretion of
soluble mediators and by cell surface display of inhibitory ligands. This session will explore
recently recognized immune-modulating pathways and potential clinical solutions that are in active
development, including genetic redirection of antitumor lymphocyte specificity, adoptive T cell
transfer technologies, and monoclonal antibody blockade of barriers to tumor elimination affecting
adaptive and innate antitumor immunity. These translational advances are converting the promise
of immunotherapy into a new reality for patients with cancer.
8:15 a.m.
8:45 a.m.
Investigating inhibition of the CD47 “don’t eat me” signal to
enable tumor phagocytic removal and augmented crosspresentation to T cells
Irving L. Weissman, Stanford University School of Medicine,
Stanford, CA
9:15 a.m.
9:45 a.m.
328
Engineering T cells for cancer: CARs in the clinic
Carl H. June, Abramson Cancer Center of the University of
Pennsylvania, Philadelphia, PA
The curative potential of T cell transfer therapy for
patients with cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD
Immune modulation for cancer therapy: Assessing
antagonists and agonists
Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center,
New York, NY
PROFESSIONAL ADVANCEMENT SESSION
Monday, 8:15 a.m.-10:15 a.m.
Marina Ballroom G, South Tower, San Diego Marriott
Marquis & Marina
WICR Career Mentoring Session
Organized by the Women in Cancer Research (WICR)
Council
Co-Chairpersons: Leslie Bernstein, City of Hope,
Duarte, CA, and Pearl S. Huang, GlaxoSmithKline, King
of Prussia, PA
The WICR Career Mentoring Session has become one of
the most popular Professional Advancement Sessions at
the Annual Meeting. This session is designed for
graduate students, medical students and residents, and
clinical and postdoctoral fellows. Following a keynote
address, attendees will meet, network, and learn from
many of the leading senior scientists in cancer research.
Attendees participate in roundtable discussions and
change tables halfway through the session if they
choose. This allows for additional networking
opportunities with more than one mentor. Topics will
include grant writing, work/life integration, careers in
industry, choosing a postdoctoral position, oral
presentations, and many more. Breakfast will be
provided.
For AACR members, all 2014 Professional Advancement
Sessions are free with your Annual Meeting registration
(except for the Grant Writing Workshop) and are an
added benefit of your membership. For nonmembers,
there is an additional fee of $50 ($95 for the Grant
Writing Workshop) for attendance at each session. If you
are not an AACR member, we strongly encourage you to
join and take advantage of the many benefits of
membership, which include attendance at these
sessions. Advance registration is only available for the
Grant Writing Workshop. Participation for all other
sessions is on a first-come, first-served basis, and space
is limited. Nonmembers are required to pay onsite.
8:15 a.m.
Welcome
Leslie Bernstein, City of Hope, Duarte, CA
8:20 a.m.
Keynote Address
Nancy E. Davidson, University of Pittsburgh
Cancer Institute, Pittsburgh, PA
8:40 a.m.
Roundtable Discussions
10:10 a.m.
Closing Remarks and Evaluations
Pearl S. Huang, GlaxoSmithKline, King of
Prussia, PA
Balancing Research and Clinical Practice
Patricia M. LoRusso, Barbara Ann Karmanos Cancer
Institute, Detroit, MI
Building a Laboratory
Danny R. Welch, University of Kansas Cancer Center,
Kansas City, KS
Careers in Academia
Varsha Gandhi, The University of Texas MD Anderson
Eileen P. White, Rutgers-The Cancer Institute of New
Jersey, New Brunswick, NJ
Careers in Government
Beverly D. Lyn-Cook, FDA-National Center for
Toxicological Research, Jefferson, AR
Careers in Industry
J. Carl Barrett, AstraZeneca Pharmaceuticals LP,
Waltham, MA
Cynthia A. Romerdahl, Framingham, MA
Family/Work/Life Integration
Margaret A. Tempero, University of California,
San Francisco, CA
Grant Writing - Postdoctoral Level
Kornelia Polyak, Dana-Farber Cancer Institute,
Boston, MA
How to Stand Out on a Job Application
Jessie M. English, Dana-Farber Cancer Institute,
Boston, MA
How to Transition to Independence
Donald L. Trump, Roswell Park Cancer Institute,
Buffalo, NY
How to Write a CV
Jonathan S. Wiest, National Cancer Institute-CCT,
Bethesda, MD
Interview Skills - Academia
James V. Lacey, Jr., City of Hope, Duarte, CA
Mentoring and Sponsoring
Elizabeth L. Travis, The University of Texas MD Anderson
Negotiations for Jobs, Salaries, and Promotions
Ethan Dmitrovsky, The University of Texas MD Anderson
Time Management
Carolyn Buser-Doepner, GlaxoSmithKline,
Collegeville, PA
329
FORUM
Monday, 9:30 a.m.-11:30 a.m.
MICR Forum: The Role of Training and Mentoring in
Navigating a Successful Cancer Research Career
Organized by the Minorities in Cancer Research (MICR) Council
Chairperson: Sanya A. Springfield, National Cancer Institute-Center to Reduce Cancer Health
Disparities (CRCHD), Bethesda, MD
The purpose of this session is to highlight the progress of trainees who have been supported
through the Continuing Umbrella of Research Experiences (CURE) program and the critical
elements to consider in developing a career path in cancer research. This session will present
training opportunities available to students and early-stage investigators across the academic
continuum. The speakers will address the intricacies of developing strong scientific research
proposals, including review of literature, significance of the research problem, definition of a
hypothesis-driven proposal, and grantsmanship. Common errors and pitfalls to avoid will be
discussed. The speakers will also examine the importance of networking, academic partnerships,
mentoring relationships, and strategies for successfully navigating obstacles on the journey to a
successful cancer research career. Panel members will include NCI Program Officers as well as a
successful former Center to Reduce Cancer Health Disparities (CRCHD) trainee.
9:40 a.m.
NCI Center to Reduce Cancer Health Disparities
H. Nelson Aguila, National Cancer Institute-CRCHD, Bethesda, MD
9:50 a.m.
CRCHD/DTB/CURE Program
Peter O. Ogunbiyi, National Cancer Institute-CRCHD, Bethesda, MD
Alison Lin, National Cancer Institute-CRCHD, Bethesda, MD
John O. Ojeifo, National Cancer Institute-CRCHD, Rockville, MD
Anil Wali, National Cancer Institute-CRCHD, Bethesda, MD
10:30 a.m.
Associate Professor, Former CURE Grantee
Elva Arredondo, San Diego State University, San Diego, CA
10:45 a.m.
Panel Discussion
330
CAREER CONVERSATIONS
Monday, 10:00 a.m.-11:00 a.m.
AACRcentral, Exhibit Hall A-E, San Diego Convention Center
Positions in the Biotechnology and Pharmaceutical Industry
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and scientists. This session will address the unique skills and experiences needed to be
successful in industry rather than academia. Open to all graduate students, medical students,
residents, and clinical and postdoctoral fellows, this session will take place in the Associate
Member Resource and Career Center located in AACRcentral; limited seating is available on a
first-come, first-served basis. #AACR14 #AACRCC
Speaker:
Jacob R. Haling, Genomics Institute of the Novartis Research Foundation, San Diego, CA
Michael Pourdehnad, Celgene Corp., San Francisco, CA
331
Monday, 10:30 a.m.-12:00 p.m.
Utilizing Existing Resources for Discovery or Validation of
Markers for Early Cancer Detection
Co-Chairpersons: Sheri Schully, National Cancer Institute, Bethesda, MD, and Danielle Carrick,
National Cancer Institute, Rockville, MD
Despite the large investment in biomarker discovery and validation for cancer screening, almost
no such cancer biomarkers have been approved for clinical use over the last 25 years. Many
initially promising biomarkers have not been validated because many study designs produce a
biased comparison in which results that appear “positive,” but the difference is due to bias - a
systematic difference between cases and controls or in handling of their specimens. In contrast,
strong sources of unbiased specimens have been produced by specimen collections from
longitudinal cohort studies (e.g., PLCO, CARET, WHI; and in some HMOs).
To accurately discover and/or validate cancer biomarkers, access to resources where serial
collections, epidemiological data, clinical data, and outcomes were assessed over time is
required. Specimens collected just-proximal to the diagnosis of cancer are ideal because they are
typically not biased by knowledge of the diagnosis or treatment of the disease. These include
serial blood samples (including plasma or serum) collected in a systematic and equivalent manner,
with appropriate epidemiological and clinical annotation; such samples are ideal for discovery
and/or validation of biomarkers for early detection.
While several NCI- and NIH-sponsored cohort studies and clinical trials have produced highquality specimens utilized to assess biomarker validity, much larger numbers are needed.
Consequently, it may be useful to aggressively leverage existing clinical and epidemiology cohort
resources since new collections are so expensive and time consuming.
The aim of this session is to discuss how existing studies and HMO infrastructures may be
leveraged for unbiased studies of biomarker study and validation for early detection. Speakers will
discuss challenges and opportunities for doing this type of research and provide examples of
successful studies in this arena. In addition the session will accomplish the following goals:
1) Facilitate sharing of methods, approaches, and lessons learned in performing this type of
research using existing clinical and epidemiology infrastructures, mainly for studies of cancer
early detection.
2) Identify obstacles or challenges that need to be addressed to perform this type of research.
3) Share knowledge about available resources to foster this research.
Discovery or validation of markers for early cancer detection: Current
landscape and outstanding issues
David F. Ransohoff, University of North Carolina, Chapel Hill, NC
Data quality and study design: Lessons learned from ovarian cancer
Steven J. Skates, Massachusetts General Hospital, Boston, MA
Leveraging cohort studies for discovery and validation of biomarkers
Susan E. Hankinson, University of Massachusetts, Amherst, MA
Leveraging healthcare delivery infrastructures for discovery and validation of
biomarkers
Lawrence H. Kushi, Kaiser Permanente Division of Research, Oakland, CA
332
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
Preventing Hereditable Cancers: Treating the Organ,
the Individual, and Their Families
Chairperson: Marcia R. Cruz-Correa, University of Puerto Rico Comprehensive Cancer Center,
San Juan, PR
Hereditary cancer syndromes constitute an opportunity for cancer prevention with implication to
the individual patient and their families. Recognizing those with hereditary cancer risk and
establishing targeted screening, surveillance, and prevention strategies require a systematic and
integrated health delivery approach. This session will discuss aspects of several hereditary cancer
syndromes including the diagnosis, the role of molecular pathology and genetic testing, and
specific medical/surgical management and chemoprevention strategies to reduce the burden of
cancer. This session is a primer for scientists focusing on hereditary cancers along the continuum
of cancer prevention, diagnosis, and treatment.
10:30 a.m.
Diagnostic and preventive strategies in hereditary colorectal cancer
Marcia R. Cruz-Correa, University of Puerto Rico Comprehensive Cancer Center,
San Juan, PR
10:50 a.m.
Discussion
10:55 a.m.
Surgical strategies for cancer prevention in patients with hereditary
cancer syndromes
Miguel A. Rodriguez-Bigas, The University of Texas MD Anderson Cancer Center,
Houston, TX
11:15 a.m.
Discussion
11:20 a.m.
Hereditary breast and ovarian cancer syndrome: Genetic spectrum,
surveillance, and prevention
Jeffrey N. Weitzel, City of Hope, Duarte, CA
11:40 a.m.
Discussion
11:45 a.m.
Hereditary pancreatic cancer: Genetic spectrum and surveillance
strategies for prevention?
Sapna Syngal, Dana-Farber Cancer Institute, Boston, MA
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
333
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
Radiation and Breast Cancer: Linking Genetics,
Epidemiology, and Biology
Chairperson: Kenan Onel, University of Chicago, Chicago, IL
Radiation exposure is nearly ubiquitous in modern society; yet, although it is one of only very few
complete carcinogens, able to both induce and promote cancer, surprisingly little is known about
radiation-induced carcinogenesis. Considerable work has been done to investigate the role of
radiation as a DNA-damaging agent, but recent data suggest that the relationship between radiation
and cancer may be considerably more complex. Using breast cancer as an exemplar, the purpose of
this session is to present a series of complementary studies that together provide new insights into
the etiology of radiation-induced cancer. Because it exists at the interface of genetics, biology, and a
clearly defined causative exposure, radiation-induced carcinogenesis provides a unique opportunity
to explore the contribution of each factor to cancer risk. As such, it may serve as a model for future
studies of gene-by-environment interactions in cancer and other complex diseases.
10:30 a.m.
The role of other exposures in radiogenic breast cancer risk
Roy E. Shore, Radiation Effects Research Foundation, Hiroshima, Japan
10:55 a.m.
Discussion
11:00 a.m.
Age-related differences in susceptibility to radiation-induced mammary
carcinogenesis in rats
Yoshiya Shimada, National Institute of Radiological Sciences, Chiba, Japan
11:25 a.m.
Discussion
11:30 a.m.
The genetic epidemiology of radiation-associated second primary breast
cancer
Jonine L. Bernstein, Memorial Sloan-Kettering Cancer Center, New York, NY
11:55 p.m.
Discussion
12:00 p.m.
Context matters: PRDM1 and risk for radiation-induced breast cancer
Kenan Onel, University of Chicago, Chicago, IL
12:25 p.m.
Discussion
334
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
Novel Approaches for Understanding
the Biology of Colorectal Cancer
Update on New Translational Findings
in Lymphoid Malignancies
Chairperson: Raju Kucherlapati, Harvard Medical
School, Boston, MA
Chairperson: John C. Byrd, Ohio State University
Comprehensive Cancer Center, Columbus, OH
Our understanding of the biology and genetics of
gastrointestinal cancers, especially colon and rectum
cancers, is changing rapidly. This session will highlight
some of approaches that are being used to study this set
of cancers and how these approaches are helping us
better understand the biology and develop therapeutic
approaches. Our understanding of the role of the
microbiome in many biological processes is advancing
rapidly and this session will explore the role of the
microbiota and their interaction with the genetics in the
initiation of colon cancer. Large-scale genomic studies
are also changing our understanding of the various
genetic factors in the progression of colorectal cancers.
All of the new information is also allowing new types of
clinical trials for treatment of this important cancer type.
All of these aspects will be discussed in this session.
The 2013 year of research has brought forth many novel
findings related to both B cell and T cell malignancies.
This session will review relevant findings related to
familial lymphoproliferative disorders where new genetic
findings are providing novel insight into pathogenesis of
these diseases. The role of tumor microenvironment in
mantle cell lymphoma will be reviewed and impact of
novel targeted therapies to agonize this. An update on
B cell receptor targeted therapies and new mechanisms
of resistance will be reviewed. Finally, novel T cell
lymphoma targets identified by next-generation
sequencing will be reviewed along with new strategies to
target these.
10:30 a.m.
Genetic lesions and the microbiota
contribute to site-specific development
of intestinal polyps
Sergio Lira, Icahn School of Medicine at
Mount Sinai, New York, NY
10:55 a.m.
Discussion
11:00 a.m.
Role of the microbiome in colorectal
cancer
Christian Jobin, Univerisity of Florida,
Gainesville, FL
11:25 a.m.
Discussion
11:30 a.m.
Rational drug combinations to improve
anti-EGFR targeted therapies in
metastatic colorectal cancer
*Andrea Bertotti, University of Turin,
Turin, Italy
11:45 a.m.
Discussion
11:50 a.m.
Genomics of colorectal cancer
Raju Kucherlapati, Harvard Medical School,
Boston, MA
12:15 p.m.
Discussion
12:20 p.m.
Panel Discussion
10:30 a.m.
Lessons from the investigation of
familial lymphoproliferative disorders
Jennifer R. Brown, Dana-Farber Cancer
Institute, Boston, MA
10:50 a.m.
Discussion
10:55 a.m.
The role of the tumor microenvironment
in mantle cell lymphoma
Adrian U. Wiestner, NIH National Heart,
Lung, and Blood Institute, Bethesda, MD
11:15 a.m.
Discussion
11:20 a.m.
Update on B-cell receptor targeted
therapies and mechanisms of resistance
John C. Byrd, Ohio State University
Comprehensive Cancer Center,
Columbus, OH
11:40 a.m.
Discussion
11:45 a.m.
Genomic studies of mature T-cell
lymphoma/leukemia
Megan S. Lim, University of Michigan,
Ann Arbor, MI
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
*NextGen Star, selected to give a talk by the AACR President and Annual
Meeting Program Chairperson through a competitive application process
designed to bring more visibility to early-career scientists. Abstract can be
found in the Invited Abstracts: NextGen Stars section of the Proceedings.
335
CLINICAL TRIALS SYMPOSIUM
Monday, 10:30 a.m.-12:30 p.m.
Biomarker-Driven Clinical Trials
Chairperson: David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX
10:30 a.m.
CT227 Neratinib plus standard neoadjuvant therapy for high-risk breast
cancer: Efficacy results from the I-SPY 2 TRIAL
John W. Park, University of California, San Francisco, CA
10:50 a.m.
Discussant: Lajos Putsztai, Yale Cancer Center, New Haven, CT
11:00 a.m.
CT228 A phase II study of afatinib (A) in patients (pts) with metastatic human
epidermal growth factor receptor (HER2)-positive trastuzumab (T)
refractory esophagogastric (EG) cancer
Yelena Y. Janjigian, Memorial Sloan-Kettering Cancer Center, New York, NY
11:20 a.m.
Discussant: Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN
11:30 a.m.
CT229 A phase II and biomarker study of an irreversible pan-human EGF
receptor (HER) tyrosine kinase inhibitor, dacomitinib, in patients with
recurrent and/or metastatic squamous cell carcinoma of head and neck
(R/M-SCCHN)
Han Sang Kim, Yonsei Cancer Center, Seoul, Republic of Korea
11:50 a.m.
Discussant: Barbara A. Burtness, Fox Chase Cancer Center, Philadelphia, PA
12:00 p.m.
CT230 Pediatric phase I trial of moxetumomab pasudotox: Activity in
chemotherapy refractory acute lymphoblastic leukemia (ALL)
Alan S. Wayne, Children’s Hospital of Los Angeles, University of Southern
California, Los Angeles, CA
12:20 p.m.
Discussant to be announced
336
MAJOR SYMPOSIA
Monday, 10:30 a.m.-12:30 p.m.
Ballroom 20A-C, San Diego Convention Center
The Bayard D. Clarkson Symposium:
Stem Cells and Cancer
Cancer Metabolism
Chairperson: Sean J. Morrison, UT Southwestern
Medical School, Dallas, TX
Two kinds of links have been demonstrated between
stem cell biology and cancer biology. First, cancer cells
hijack stem cell self-renewal mechanisms to enable
neoplastic proliferation. Consequently, an understanding
of the mechanisms that regulate stem cell self-renewal
can yield new therapeutic strategies. Second, some
cancers exhibit a hierarchical organization in which
tumorigenic cancer cells “differentiate” into
nontumorigenic cancer cells. In these cancers, the
tumorigenic cells are thought to drive tumor growth and
disease progression. Thus, insights into cancer biology
can potentially be gained of multiple levels by applying
the principles of stem cell biology.
10:30 a.m.
Introduction
10:40 a.m.
Genetic and nongenetic mechanisms
contribute to long-term clonal growth
dynamics and therapy resistance
John E. Dick, University of Toronto,
Toronto, ON, Canada
11:00 a.m.
Discussion
11:05 a.m.
Targeting the stem cells that give rise to
brain tumors
Robert J. Wechsler-Reya, SanfordBurnham Medical Research Institute,
La Jolla, CA
Chairperson: Lewis C. Cantley, Weill Cornell Medical
College of Cornell University, New York, NY
Observations that cancer cells have altered metabolism
compared to the surrounding normal tissue were made
by Otto Warburg approximately 90 years ago. The
enhanced glucose metabolism common to most tumors
is often exploited to visualize tumors with radioactive
glucose analogs (FDG-PET). The speakers in this session
will discuss the genetic, epigenetic, and biochemical
mechanisms by which metabolism is altered in cancer
cells. Importantly, the speakers will also discuss how
these changes in metabolism provide an advantage to
the cancer cell in regard to growth or survival.
10:30 a.m.
Introduction
10:40 a.m.
Understanding metabolic heterogeneity
in cancer
Ralph J. DeBerardinis, UT Southwestern
Medical Center, Dallas, TX
11:00 a.m.
Discussion
11:05 a.m.
PI3K regulation of nutrient uptake
Craig B. Thompson, Memorial SloanKettering Cancer Center, New York, NY
11:25 a.m.
Discussion
11:30 a.m.
Probing the IDH mutant metabolic
phenotype in vivo
Elizabeth Maher, UT Southwestern Medical
Center, Dallas, TX
11:25 a.m.
Discussion
11:50 a.m.
Discussion
11:30 a.m.
Signal pathways in prostate cancer
stem cells
Owen N. Witte, University of California,
Los Angeles, CA
11:55 a.m.
11:50 a.m.
Discussion
The role of metabolism for tumor
progression in vivo
Matthew G. Vander Heiden, MIT Koch
Institute for Integrated Cancer Research,
Cambridge, MA
11:55 a.m.
Stem cell self-renewal and cancer
Sean J. Morrison, UT Southwestern
Medical School, Dallas, TX
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
12:15 p.m.
General Discussion
12:20 p.m.
Discussion
337
MAJOR SYMPOSIA
Endogenous Immunity and Cancer
Functional Regulation of the
Cancer Genome
Chairperson: Robert D. Schreiber, Washington
University School of Medicine, St. Louis, MO
It is now clear that the endogenous immune system
plays important roles in controlling, shaping, and
promoting many types of cancer. As a consequence of
work from several laboratories, we have now obtained
significant mechanistic insights into these apparent
paradoxical roles of immunity and have begun to apply
our enhanced understanding of these processes towards
the development of effective cancer immunotherapies.
This session will focus on recent findings about the
effects of endogenous innate and adaptive immune
responses on developing tumors in mice and humans
and on the naturally occurring regulatory processes that
inhibit or promote these immune functions.
10:30 a.m.
Cancer immunoediting:
New mechanistic insights
Robert D. Schreiber, Washington University
School of Medicine, St. Louis, MO
10:55 a.m.
Discussion
11:00 a.m.
Mechanisms of recognition and
elimination of tumor cells by natural
killer cells
David H. Raulet, University of California,
Berkeley, CA
11:25 a.m.
Discussion
11:30 a.m.
Shaping the immune microenvironment
by and to human cancer
Wolf Hervé Fridman, Unité INSERM 255,
Paris, France
Chairperson: Bradley E. Bernstein, Massachusetts
General Hospital, Boston, MA
Malignant cellular properties are acquired through
combination of genetic and epigenetic changes. In
particular, the past several years have brought increasing
realization of the importance of epigenetic factors to
tumor proliferation, spread, and therapeutic resistance.
Chromatin regulators are frequent targets of mutations in
diverse tumor types, DNA methylation patterns undergo
characteristic changes in malignancy, and new classes
of drugs target the epigenome. This session will focus on
transcriptional and epigenetic programs that underlie
malignant cell phenotypes. It will focus in particular on
emerging technologies and approaches for capturing
comprehensive views of genome regulation in cancer
cells, along with associated insights into mechanisms of
transformation, tumor heterogeneity, and therapeutic
responses.
10:30 a.m.
Introduction
10:40 a.m.
Reactivation of early developmental
programs during oncogenesis
John Stamatoyannopoulos, University of
Washington, Seattle, WA
11:00 a.m.
Discussion
11:05 a.m.
Genetic and epigenetic mechanisms of
resistance to endocrine therapy
Myles A. Brown, Dana-Farber Cancer
11:25 a.m.
Discussion
11:30 a.m.
How deregulation of histone
methyltransferases drive malignant
transformation of B cells
Ari M. Melnick, Weill Cornell Medical
College of Cornell University, New York, NY
11:55 a.m.
Discussion
12:00 p.m.
Immune checkpoint blockade in cancer
therapy: New insights and possibilities
James P. Allison, The University of Texas
MD Anderson Cancer Center, Houston, TX
11:50 a.m.
Discussion
Discussion
11:55 a.m.
Epigenetic regulation and heterogeneity
in glioblastoma
Bradley E. Bernstein, Massachusetts
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
12:25 p.m.
338
Monday, 10:30 a.m.-12:30 p.m.
Pediatric Cancer Genomes
Senescence, Cancer, and Aging
Chairperson: Todd R. Golub, Broad Institute of MIT and
Harvard, Cambridge, MA
Chairperson: Norman E. Sharpless, Lineberger
Comprehensive Cancer Center, Chapel Hill, NC
The ability to comprehensively characterize tumor
genomes is now making it possible to gain new insights
into the disease. A number of international efforts are
focusing on deciphering the genomes of pediatric
cancers, which in general have a remarkably different
mutational spectrum compared to adult tumors. In this
session, speakers will present recent advances in
pediatric cancer genome research. Dr. Downing will
review recent progress in understanding pediatric acute
lymphoblastic leukemia and other cancers. Dr. Pfister will
present emerging insights into the pathogenesis of
pediatric brain tumors. Dr. Maris will present the
landscape of genomic alterations in neuroblastoma. Dr.
Janeway will present early views into the genomes of
pediatric sarcomas, and will review recent efforts to
bring pediatric cancer genomics to clinical care.
Cellular senescence represents an irreversible form of
growth arrest induced by a variety of stressors and is of
indisputable importance in tumor suppression. More
recently, the activation of senescence has been
suggested to be an important component of the
therapeutic response to some anticancer agents.
Additionally, the accumulation of senescent cells with
aging has been suggested to contribute to certain
common age-induced phenotypes such as decreased
immunity, sarcopenia, and type II diabetes. Therefore,
the senescence machinery appears to be a critical
organismal defense against cancer that is also a
principal determinant of how humans age. This session
will examine the implications for cancer research of a
modern understanding of cellular senescence.
10:30 a.m.
Introduction
10:40 a.m.
Measuring senescence during
cancer therapy
Norman E. Sharpless, Lineberger
Comprehensive Cancer Center,
Chapel Hill, NC
Discussion
11:00 a.m.
Discussion
11:05 a.m.
Genomics entering the clinical stage:
New concepts in pediatric oncology
Stefan M. Pfister, German Cancer Research
Center, Heidelberg, Germany
11:05 a.m.
11:25 a.m.
Discussion
Developmental senescence: A new
type of senescence that could be
relevant for cancer
Manuel Serrano, Spanish National Cancer
Center (CNIO), Madrid, Spain
11:30 a.m.
Neuroblastoma genomics to define new
therapies: Progress, opportunities, and
challenges
John Maris, Children’s Hospital of
Philadelphia, Philadelphia, PA
11:25 a.m.
Discussion
11:30 a.m.
Oncogene-induced senescence:
Mechanism and therapeutic opportunities
Daniel Simon Peeper, Netherlands Cancer
Institute, Amsterdam, The Netherlands
10:30 a.m.
Introduction
10:40 a.m.
The Pediatric Cancer Genome Project:
Lessons learned
James R. Downing, St. Jude Children’s
Research Hospital, Memphis, TN
11:00 a.m.
11:50 a.m.
Discussion
11:50 a.m.
Discussion
11:55 a.m.
Cancer genomics in the pediatric
oncology clinic
Katherine A. Janeway, Dana-Farber Cancer
11:55 a.m.
12:15 p.m.
Discussion
Regulation of normal and cancer
stem cell self-renewal and senescence
by USP16
Michael F. Clarke, Stanford University
School of Medicine, Stanford, CA
12:20 p.m.
Discussion
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
339
MAJOR SYMPOSIUM
Translating Preclinical Trials in
Genetically Engineered Mouse Models
toward Clinical Trials
Chairperson: Douglas Hanahan, Swiss Institute for
Experimental Cancer Research (ISREC), Lausanne,
Switzerland
Genetically engineered (immunocompetent) mouse
models (GEMMs) of human carcinogenesis have
produced new knowledge about mechanisms of tumor
development and progression, about the constitution
and functional importance of the tumor
microenvironment, and about tumor immunobiology,
revealing parameters not evident or incompletely
recapitulated in traditional transplant models. The
longstanding corollary hypothesis has been the promise
that such GEMMs will prove to have greater predictive
value than traditional models about the efficacy (or lack
thereof) of nouveaux therapeutic agents and regimens,
incentivizing and guiding the design of clinical trials that
change the standard of care. A generalized proof-ofconcept has been slow, although there have been
occasional demonstrative successes. The speakers in
this session will provide results and insights into their
efforts to develop – using various organ-specific GEMMs
– this new frontier in cancer therapeutics.
10:30 a.m.
Introduction
10:40 a.m.
The Co-Clinical Trial Project
Pier Paolo Pandolfi, Beth Israel Deaconess
Medical Center, Boston, MA
11:00 a.m.
Discussion
11:05 a.m.
Preclinical identification, modeling, and
validation of immune cells as targets for
therapy in breast and pancreas cancer
Lisa M. Coussens, OHSU Knight Cancer
Institute, Portland, OR
11:25 a.m.
Discussion
11:30 a.m.
Therapeutic exploitation of tumorassociated macrophages for cancer
immunotherapy through local irradiation
Philipp Beckhove, German Cancer
Research Center, Heidelberg, Germany
340
Monday, 10:30 a.m.-12:30 p.m.
11:50 a.m.
Discussion
11:55 a.m.
Case studies in translational therapeutic
oncology
Douglas Hanahan, Swiss Institute for
Experimental Cancer Research (ISREC),
Lausanne, Switzerland
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Monday, 10:30 a.m.-12:30 p.m.
Marina Ballroom E, San Diego Marriott Marquis & Marina
Networking in Action: Expanding and Utilizing Your Network
through Effective Communication
Organized by the Associate Member Council
This session will focus on developing your skills for effective networking-based communication –
both in person and through online networking tools. Learn how to form connections that can lead
to career development opportunities. For AACR members, Professional Advancement Sessions
are free with your Annual Meeting registration and are an added benefit of your membership. For
nonmembers, there is an additional fee of $50 for attendance at each session to be paid onsite.
#AACR14 #AACRnet
How to approach networking
Jonathan S. Wiest, National Cancer Institute-CCT, Bethesda, MD
The world wide web of networking
Kelly L. Covello, GlaxoSmithKline, Philadelphia, PA
How to utilize your network
Karen E. Knudsen, Thomas Jefferson University Kimmel Cancer Center,
Philadelphia, PA
The session will conclude with a networking activity involving attendees, members of the
Associate Member Council and speakers, panelists, and other distinguished members of the
cancer research field attending the Annual Meeting.
341
REGULATORY SCIENCE
AND SCIENCE POLICY
Monday, 10:30 a.m.-12:30 p.m.
Room 6E, San Diego Convention Center
Regulatory Considerations for Targeted Immunotherapies
Co-Chairpersons: Renzo Canetta, Bristol-Myers Squibb Co., Wallingford, CT, and Ke Liu, U.S.
Food and Drug Administration, Rockville, MD
Immunotherapies offer some of the most promising treatment options for long-term, sustained
antitumor activity in oncology today. The transformative potential of these therapies has already
been recognized by regulatory authorities and has resulted in approved treatment options for
patients. However, the variety of products (vaccines, cell-based therapies, immune checkpoint
inhibitors) coupled with the inherent variability of individual immune responses and tumor
heterogeneity present unique scientific and regulatory challenges. Some of these concerns are
unique to specific product subtypes such as vaccines; however, several overarching regulatory
concerns present opportunities to find evidence-based solutions that will benefit developers of all
immunotherapy products. These concerns include but are not limited to the following: a paucity in
official guidelines that specifically address development of immunotherapy products; an
assessment of currently available standards and tools to measure efficacy of these products and
development of new standards and tools if needed; the need for unique trial designs that
incorporate complexities and dynamics of immune system heterogeneity; the need for regulatory
standards that acknowledge the safety concerns unique to these therapies and provide means of
addressing and monitoring the same; developing validated biomarkers that can be used to select
patients who will benefit from targeted immune treatments and regulatory guidelines for combining
immunotherapies in a manner that protects patient safety while allowing for product innovation
and treatment options. A panel discussion moderated by Renzo Canetta, Bristol Myers Squibb,
and audience Q and A will follow the presentations.
Currently available regulatory guidances
Marc Theoret, U.S. Food and Drug Administration, Silver Spring, MD
Efficacy outcomes and clinical trial designs unique to immunotherapies
Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON,
Canada
Safety concerns unique to immunotherapies including manufacturing concerns,
which can become a bottleneck
Jeffrey S. Weber, Moffitt Cancer Center and Research Institute, Tampa, FL
Defining and validating biomarkers to select patients for specific immunebased treatments
Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
Combining immunotherapies and parsing out safety and efficacy contributions
of individual agents
Samir N. Khleif, Georgia Health Sciences University Cancer Center, Augusta, GA
342
SCIENCE POLICY SESSION
Monday, 10:30 a.m.-12:30 p.m.
Honoring the 50th Anniversary Surgeon General’s Report: The Health
Consequences of Smoking—50 Years of Progress
Chairperson: Roy S. Herbst, Yale Cancer Center, New Haven, CT
This year marks the 50th anniversary of the 1964 Surgeon General’s Report on Smoking and
Health. This landmark publication found a definitive, causal link between smoking and lung cancer
in men, and, along with subsequent reports, it motivated a series of important public health
initiatives that have stemmed the tide of tobacco-related death and disease in the United States.
Since the 1964 report there have been over 30 reports of the Surgeon General on tobacco,
including the most recent report, published in 2014: The Health Consequences of Smoking—50
Years of Progress. This session will address smoking patterns and the evolution of tobacco control
over the last 50 years and provide new findings on tobacco’s adverse health effects, including the
risks it poses to individuals with chronic diseases, highlighting the effects on cancer patients.
Speakers will also discuss challenges to future tobacco control efforts and federal research and
regulatory efforts aimed at further understanding and reducing the adverse health consequences
of smoking and other forms of tobacco use.
Fostering evidence-based tobacco control: AACR research and policy
initiatives
Roy S. Herbst, Yale Cancer Center, New Haven, CT
The Surgeon General’s Reports: From 1964 to 2014
Jonathan M. Samet, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Smoking and the cancer patient: Understanding the clinical, biologic, and
behavioral effects of tobacco to improve clinical cancer care and research
Graham W. Warren, Hollings Cancer Center, Charleston, SC
NCI-supported tobacco research priorities
Robert T. Croyle, National Cancer Institute, Bethesda, MD
The role of product regulation: FDA actions under the Family Smoking
Prevention and Tobacco Control Act
Mitchell Zeller, U.S. Food and Drug Administration, Rockville, MD
343
CICR TOWN MEETING
Monday, 12:00 p.m.-1:30 p.m.
Room 6D, San Diego Convention Center
Chemistry in Cancer Research (CICR) Town Meeting and
Networking Reception
The Chemistry in Cancer Research (CICR) Working Group brings together cancer-focused
scientists in chemistry and chemistry-related fields to discuss the present status and future
promise of chemistry in the advancement of the prevention and cure of cancer. All CICR members
are encouraged to attend and all interested Annual Meeting registrants are also invited. This event
will provide an opportunity to raise questions and contribute ideas to help shape future CICR
initiatives. Attendees can also learn about membership in CICR, meet the members of the Steering
Committee, and connect with colleagues. A networking reception will follow.
12:00 p.m.
Chairperson: Opening Remarks
Michael J. Luzzio, Novartis Institutes for BioMedical Research, Cambridge, MA
12:15 p.m.
CICR Editorial Board Co-Chairperson: Remarks
Klaus Pors, University of Bradford Institute of Cancer Therapeutics, Bradford,
United Kingdom
12:25 p.m.
Chairperson-Elect: Remarks
Stephen A. Munk, Ash Stevens Inc., Detroit, MI
344
GERTRUDE B. ELION LECTURE
Monday, 12:30 p.m.-1:00 p.m.
Tenth Annual Gertrude B. Elion Cancer Research Award Lecture
Identification of Disseminated Breast Tumor Cells that
Progress to Metastatic Disease
Sandra S. McAllister, PhD
Brigham and Women’s Hospital, Boston, MA
The AACR Gertrude B. Elion Cancer Research Award
provides a one-year grant to foster meritorious basic,
translational, or clinical cancer research by a tenuretrack scientist at the level of Assistant Professor. This
award honors the late Dr. Gertrude B. Elion, Scientist
Emeritus at Glaxo Wellcome Co. (now GlaxoSmithKline).
Her seminal research at the company revolutionized
cancer therapeutics and her prolific contributions to
biomedical science earned her the Nobel Prize in
Physiology or Medicine in 1988. The AACR is extremely
pleased to sponsor this award in the name of Dr. Elion, a
distinguished Past President and Honorary Member of
the AACR.
This year we honor Dr. Sandra S. McAllister, who is
taking innovative approaches to understand how breast
cancers progress to metastatic disease, which affects
approximately 30% of breast cancer patients and is
incurable. A particular challenge to preventing metastatic
breast cancer is that tumor cells have already
disseminated to the periphery in patients at the time of
their primary diagnosis. It is thought that less than 1% of
all disseminated tumor cells (DTCs) is able to form an
overt tumor, suggesting that successful DTCs are rare.
Nevertheless, these are the cells that claim the lives of
breast cancer patients with metastatic disease. Dr.
McAllister’s project was designed to identify DTCs with
life-threatening potential before they progress to
metastatic disease and to distinguish them from the vast
majority of DTCs that are inconsequential. Her lab used
novel molecular tagging and detection technologies that
were developed by her collaborators at the Broad
Institute. This technology enabled her lab to track the
fate of individual DTCs and to study rare progression
events in vivo, which was previously impossible to do.
By studying one of the most aggressive types of breast
cancer, triple-negative breast cancer, her group identified
DTCs that respond to pathophysiological cues and
learned how these DTCs are altered when they convert
from a state of indolence to one of malignant growth.
These studies should serve as a foundation for more
accurate identification of breast cancer patients who
would benefit from systemic adjuvant therapy to treat
potentially deadly DTCs before they develop into
incurable clinical metastatic disease.
Dr. McAllister is an Associate Scientist in the Hematology
Division at Brigham and Women’s Hospital and an
Assistant Professor of Medicine at Harvard Medical
School in Boston. She received her undergraduate
degree at the University of Michigan in Ann Arbor and
completed her PhD studies in molecular and cellular
biology at Washington University School of Medicine in
St. Louis. She joined Robert Weinberg’s laboratory at the
Whitehead Institute for Biomedical Research as a
postdoctoral fellow where she established new
preclinical models to study breast cancer
pathophysiology. She joined the faculty of Brigham and
Women’s Hospital and Harvard Medical School in 2009,
and is also an affiliate member of the Harvard Stem Cell
Institute, an associate member of the Broad Institute,
and a member of the Dana-Farber/Harvard Cancer
Center. Dr. McAllister studies cancer as a systemic
disease and focuses her research efforts on identifying
physiological processes that contribute to tumor
progression and finding ways to interdict their function.
Dr. McAllister is a recent recipient of the Presidential
Early Career Award for Scientists and Engineers, the
highest honor bestowed by the U.S. Government on
science and engineering professionals in the early stages
of their careers.
345
SPECIAL SESSION
Monday, 12:45 p.m.-2:00 p.m.
AACR Annual Business Meeting of Members
Moderator: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY
The AACR Officers and Directors invite all members to attend the Annual Business Meeting of
Members for an update on programs and new initiatives. The meeting’s agenda includes: reports
from the AACR President, Treasurer, and President-Elect; In Memoriam; Acknowledgments of 50year members, sustaining members, and major sponsors; 2014-2015 election results; Induction of
and remarks from the 2014-2015 AACR President; and open discussion of new business. Lunch
will be provided.
346
SPECIAL SESSION
Monday, 12:45 p.m.-2:15 p.m.
Realizing Patient Benefit: Four-Year Results From
the SU2C Dream Teams
Chairperson: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
In May 2009, Stand Up To Cancer (SU2C) announced its first round of “Dream Team” grants to five
multi-institutional, cross-disciplinary research teams. This open session, during which Dream
Team Leaders, Co-leaders, and members will give brief reports on their respective projects, is
available to all attendees. Dream Teams will discuss the cancer science driving the clinical trials,
the lessons learned, and what has been accomplished during the term of these grants. A brief
Q & A will follow the presentation of the Dream Team Reports.
Opening remarks from the SU2C Scientific Advisory Committee Chairperson
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
Bringing epigenetic therapy to the forefront of cancer management
Introduction: Stephen B. Baylin, Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins University, Baltimore, MD
Speaker: Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins University, Baltimore, MD
Combining a PI3K inhibitor and PARP inhibitor in high-grade serous ovarian
cancer and triple-negative breast cancer
Introduction: Gordon B. Mills, The University of Texas MD Anderson Cancer Center,
Houston, TX
Speaker: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, MA
Understanding cancer metastasis through circulating tumor cells
Introduction: Mehmet Toner, Massachusetts General Hospital, Charlestown, MA
Speaker: Daniel A. Haber, Massachusetts General Hospital Cancer Center,
Charlestown, MA
An integrated approach to targeting breast cancer molecular subtypes and
their "resistance" phenotypes
Introduction: Dennis J. Slamon, UCLA Jonsson Comprehensive Cancer Center,
Los Angeles, CA
Speaker: Joan S. Brugge, Harvard Medical School, Cambridge, MA
A new approach to the treatment of pancreatic cancer
Introduction: Daniel D. Von Hoff, Translational Genomics Research Institute,
Phoenix, AZ
Speaker: Rajesh Kumar NV, Johns Hopkins University School of Medicine,
Baltimore, MD
347
MEET THE RESEARCH ICON
Monday, 1:00 p.m.-1:30 p.m.
Meet the Research Icon:
Martine J. Piccart, MD, PhD
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the
Associate Member Council, provide early-career scientists with the opportunity to hear from an
esteemed senior researcher in a small-group setting to learn about the speaker’s professional and
personal experiences as well as key decisions that shaped their career path.
Martine J. Piccart, MD, PhD, is a Professor of Oncology at Université Libre de Bruxelles and
Director of Medicine at Institut Jules Bordet in Brussels, Belgium. Dr. Piccart is internationally
recognized as an advocate of worldwide scientific collaboration and is one of the foremost
researchers in the fields of clinical trials and drug development, primarily concerning breast
cancer. Her research interests include optimizing genetic profiling of breast cancer subtypes to
enhance cancer diagnosis techniques and to improve treatment strategies and regimens.
This session is open to all graduate students, medical students, residents, and clinical and
postdoctoral fellows and will take place in the Associate Member Resource and Career Center
located in AACRcentral. #AACR14 #AACRicon
348
SCIENCE POLICY SESSION
Monday, 1:00 p.m.-2:30 p.m.
The President’s Cancer Panel Report “Accelerating HPV Vaccine
Uptake: Urgency for Action to Prevent Cancer” - Scientific Advances
to Help Achieve Policy Goals
Chairperson: Abby Sandler, National Cancer Institute, Bethesda, MD
Vaccines that prevent infection with the two most prevalent oncogenic types of human
papillomavirus (HPV) are substantially underused in the U.S and elsewhere and have not yet
reached their cancer prevention potential. During 2012-2013, the President’s Cancer Panel (PCP)
examined underuse of HPV vaccines, identified key barriers to increasing vaccine uptake, and
provided recommendations for overcoming these obstacles in their report, released on February
10, 2014. Owen Witte, member of the PCP, will present the committee’s findings. Panelists will
discuss recent and ongoing scientific advances that are poised to facilitate implementation of the
PCP’s recommendations to increase HPV vaccine uptake. Discussion topics will include:
development of next-generation HPV vaccines, reducing the number of vaccine doses, and
progress in understanding the natural history of noncervical HPV infections, among others.
Speaker:
Owen N. Witte, University of California, Los Angeles, CA
Panelists:
Douglas R. Lowy, National Cancer Institute, Bethesda, MD
Maura L. Gillison, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Jennifer S. Smith, University of North Carolina, Chapel Hill, NC
Joel Palefsky, University of California, San Francisco, CA
Mary-Jo Murphy, The Farrah Fawcett Foundation, Beverly Hills, CA
Laurence Piro, The Angeles Clinic Research Institute, Los Angeles, CA
349
CLINICAL TRIALS SYMPOSIUM
Monday, 1:00 p.m.-3:00 p.m.
Novel Targets
Chairperson: Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN
1:00 p.m.
CT231 BET-bromodomain inhibitor OTX015 shows clinically meaningful activity
at nontoxic doses: Interim results of an ongoing phase I trial in
hematologic malignancies
Patrice E. Herait, Oncoethix, Lausanne, Switzerland
1:20 p.m.
Discussant: James E. Bradner, Dana-Farber Cancer Institute, Boston, MA
1:30 p.m.
CT232 Clinical activity of LY2835219, a novel cell cycle inhibitor selective for
CDK4 and CDK6, in patients with metastatic breast cancer
Amita Patnaik, South Texas Accelerated Research Therapeutics,
San Antonio, TX
1:50 p.m.
Discussant: Gary K. Schwartz, Columbia University Irving Comprehensive Cancer
Center, New York, NY
2:00 p.m.
CT233 A first-in-human phase I study of the safety and pharmacokinetic
(PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR)
antibody-drug conjugate (ADC), in patients with metastatic or
unresectable melanoma
Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN
2:20 p.m.
2:30 p.m.
CT234 Dabrafenib stimulates radioiodine uptake in BRAF V600E mutant
advanced papillary thyroid cancer
Stephen M. Rothenberg, Massachusetts General Hospital Cancer Center,
Charlestown, MA
2:50 p.m.
350
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
Systems Pharmacology: Measuring and Harnessing
Chemosensitivity on a Quantitative, Omics-Driven Basis
Chairperson: Peter K. Sorger, Harvard Medical School, Boston, MA
This session will address the challenge of understanding and ultimately predicting the sensitivities
of tumor cells to targeted and cytotoxic therapy based on quantitative analysis of cell signaling
networks. Beneficial and adverse drug responses are integrated properties of cells, tissues, and
organisms that are determined, in a multifactorial manner, by genotype, microenvironment, and
physiological state. Talks will highlight the use of multiplex biochemical measurement, quantitative
modeling, and clinical translation in delineating these factors. Tony Letai will describe “BH3
profiling” that predicts the sensitivity of cells to chemotherapy-induced apoptosis based on
measuring the priming of mitochondria. Peter Sorger will describe single-cell methods for
measuring and modeling cellular responses to kinase inhibitors, and Adolfo Ferrando will discuss
factors that control drug sensitivity and resistance in T cell acute lymphoblastic leukemia. Finally,
Peter Jackson will discuss how modeling protein networks can yield new therapeutic targets
related to cancer biology.
1:00 p.m.
Predicting in vivo chemosensitivity with BH3 profiling
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA
1:20 p.m.
Discussion
1:25 p.m.
Measuring and modeling drug responses in single cells
Peter K. Sorger, Harvard Medical School, Boston, MA
1:45 p.m.
Discussion
1:50 p.m.
Targeting of signaling drivers of chemotherapy resistance in acute
lymphoblastic leukemia
Adolfo Ferrando, Columbia University, New York, NY
2:10 p.m.
Discussion
2:15 p.m.
Protein network analysis reveals new regulators of the Chk1 DNA
damage pathway
Peter K. Jackson, Stanford University, South San Francisco, CA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
351
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
The Exposome: Future Promise for
Cancer Research
Long-Term Consequences in
Cancer Survivors
Chairperson: John D. Groopman, Johns Hopkins
University School of Public Health, Baltimore, MD
Chairperson: Smita Bhatia, City of Hope, Duarte, CA
The exposome is a conceptual project designed to
employ state-of-the-art technologies to understand
exogenous and endogenous exposures that contribute
to cancer risk and disease burden. Perhaps for a
majority of human cancers we still do not have a
comprehensive understanding of the etiological factors
that contribute to these tumors at different organ sites.
With the prospect of a near doubling of cancer incidence
worldwide over the next 25 years, there is a compelling
need to understand these hazards and risk factors in
order to implement prevention strategies. While our
knowledge of the underlying genetic bases and
pathways in cancer has increased dramatically over the
past 10 to 15 years, our knowledge of the exposure
component of these different tumors has lagged behind.
This is the challenge that the exposome project is
designed to address.
1:00 p.m.
The future of medicine, where
can technology take us in oncology
and beyond...
Daniel L. Kraft, Stanford University,
Stanford, CA
1:20 p.m.
Discussion
1:25 p.m.
Interrogating the exposome to discover
causes of cancer
Stephen M. Rappaport, UC Berkeley
School of Public Health, Berkeley, CA
1:45 p.m.
Discussion
1:50 p.m.
The airway transcriptome as a
biomarker for tobacco smoke exposure
and lung cancer risk
Avrum E. Spira, Boston University School
of Medicine, Boston, MA
2:10 p.m.
Discussion
2:15 p.m.
Prospects for the exposome project with
the increasing global cancer burden
John D. Groopman, Johns Hopkins
University School of Public Health,
Baltimore, MD
2:35 p.m.
Discussion
2:40 p.m.
352
Panel Discussion
Advances in early detection, supportive care, and
treatment have resulted in 5-year survival rates
exceeding 65% for all cancers. There are over 13.7
million cancer survivors, comprising about 4% of the
U.S. population, with this number expected to increase
by 2% annually. For many patients, these marked
improvements in survival have been countered by
serious therapy-associated adverse effects (e.g., second
malignant neoplasms and cardiovascular disease).
Survival rates for most pediatric cancers have markedly
improved over the past four decades, with the number of
U.S. survivors currently surpassing 420,000. This
population is particularly vulnerable, with an excess of
treatment-related mortality and morbidity. In fact, a
significant proportion has at least one serious or lifethreatening chronic health condition by 40 years of age.
Cardiac disease and second cancers have emerged as
leading causes of morbidity in cancer survivors largely
due to radiation and chemotherapy used to treat the
primary cancer. This presentation will describe the
burden of morbidity borne by the cancer survivors,
discuss the etiology and risk factors for cardiac disease
and second cancers, as well as interventions to
decrease morbidity related to these adverse outcomes.
1:00 p.m.
Burden of morbidity and premature
mortality in cancer survivors: Adultonset cancer perspective
Lois B. Travis, University of Rochester
Medical Center, Rochester, NY
1:20 p.m.
Discussion
1:25 p.m.
Burden of morbidity and premature
mortality in cancer survivors: Pediatric
cancer perspective
Leslie L. Robison, St. Jude Children’s
1:45 p.m.
Discussion
1:50 p.m.
Key therapy-related adverse events:
From etiology to risk-reduction
strategies – Cardiac morbidity
Saro Armenian, City of Hope, Duarte, CA
2:10 p.m.
Discussion
2:15 p.m.
Key therapy-related adverse events:
From etiology to risk-reduction strategies
– Cardiac morbidity, second cancers
Smita Bhatia, City of Hope, Duarte, CA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
The Dharma Master Jiantai Current
Concepts in Lung Cancer Session:
Novel Targets in Non-Small Cell
Lung Cancer
Genetic Lesions and Therapeutic
Opportunities in Acute Myeloid Leukemia
Chairperson: Thomas J. Lynch, Yale Cancer Center,
New Haven, CT
Chairperson: Benjamin Ebert, Brigham and Women’s
Hospital, Boston, MA
The therapeutic landscape for lung cancer has changed
dramatically over the past decade. This is principally
from the identification of driver oncogenes that are
druggable targets. EGFR mutations define a unique
subset of lung cancer where an increased understanding
of resistance mechanisms is defining active second-line
options that are practice changing. Lung tumors driven
by Alk translocations are similarly initially responsive to
crizotinib-based therapy. Several second-generation
ALK inhibitors will play a greater role in management.
Finally, this session will address approaches to defining
new targets that might be rare as a percentage of total
cases, but still represent important patient populations
that can benefit from a targeted therapy approach.
Identification of the major genetic drivers of acute
myeloid leukemia (AML) has yielded major insights into
disease biology, the development of improved animal
models, and the development of novel therapies that are
currently under investigation. The genetics, biology, and
therapeutic targeting of aberrantly activated kinase
signaling pathways are well advanced. Dr. Tyner will
review the genetics and biology of kinase dysregulation,
and Dr. Shah will discuss the clinical efficacy and
resistance mechanisms of kinase inhibitors in AML.
Many of the genetic lesions in AML are not
straightforward therapeutic targets. Dr. Ebert will discuss
the identification of novel therapeutic targets using
synthetic lethal screens, and Dr. Levine will speak about
the cellular consequences of mutations in epigenetic
regulators in AML.
1:00 p.m.
Introduction: Molecular profiling and
focus on EGFR-mutated lung cancer
Thomas J. Lynch, Yale Cancer Center,
New Haven, CT
1:00 p.m.
The genetic basis of kinase
dysregulation in AML
Jeffrey W. Tyner, OHSU Knight Cancer
Institute, Portland, OR
1:20 p.m.
Discussion
1:20 p.m.
Discussion
1:25 p.m.
Use of preclinical models to overcome
resistance to EGFR agents
Katerina A. Politi, Yale Cancer Center,
New Haven, CT
1:25 p.m.
1:45 p.m.
Discussion
Clinical application of tyrosine kinase
inhibitors and other targeted therapies
in AML
Neil P. Shah, UCSF School of Medicine,
San Francisco, CA
1:50 p.m.
Novel agent development in
ALK+ NSCLC
Alice T. Shaw, Massachusetts General
Hospital Cancer Center, Boston, MA
1:45 p.m.
Discussion
1:50 p.m.
Identification of novel therapeutic targets
in AML using synthetic lethal screens
Benjamin Ebert, Brigham and Women’s
Hospital, Boston, MA
2:10 p.m.
Discussion
2:15 p.m.
Mutations in epigenetic regulators in AML
Ross L. Levine, Memorial Sloan-Kettering
Cancer Center, New York, NY
2:10 p.m.
Discussion
2:15 p.m.
Targeted Rx of NSCLC - Non-Alk, nonEGFR, non-PD-1
Jean-Charles Soria, Institut GustaveRoussy, Villejuif, France
2:35 p.m.
Discussion
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
2:40 p.m.
Panel Discussion
353
MAJOR SYMPOSIA
Aneuploidy
Blocking the PD-1/PD-L1 Pathway in
Cancer Therapy
Chairperson: Angelika Amon, Massachusetts Institute of
Technology, Cambridge, MA
Aneuploidy, a karyotype that is not a multiple of the
haploid complement, is a hallmark of cancer. Ninety
percent of all solid human tumors harbor an incorrect
karyotype. Thus, determining how aneuploidy arises and
how it impacts cellular behavior is critical for our
understanding of tumorigenesis. Talks in this session will
describe new findings on the molecular mechanisms
governing chromosome segregation and how aneuploidy
impacts cell proliferation. Specifically, speakers in this
session will describe exciting new findings on how
chromosome mis-segregation and the ensuing
aneuploidy impact genome stability and discuss how
this genome-instability-inducing property of aneuploidy
could contribute to tumorigenesis.
Chairperson: Charles G. Drake, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
This session will begin with an introduction to immune
checkpoint molecules and their physiological relevance,
followed by an in-depth discussion of the basic cellular
biology and immunology of the PD-1/PD-L1 interaction.
Subsequent presentations will discuss the encouraging
clinical results observed in clinical trials of PD-1 and PDL1 blocking antibodies in patients with melanoma, as
well as resulting toxicities. Innovative combination
therapy regimens centered on PD-1 blockade will also
be presented. Finally, the role of PD-1 blockade in other
tumor types will be reviewed, with a focus on kidney
cancer and non-small cell lung cancer (NSCLC).
1:00 p.m.
Introduction
1:10 p.m.
Introduction to PD-1 and related
molecules
Charles G. Drake, Johns Hopkins
Kimmel Comprehensive Cancer Center,
Baltimore, MD
1:00 p.m.
Introduction
1:10 p.m.
Pten suppresses tumorigenesis by
guarding against aneuploidization
Jan M. Van Deursen, Mayo Clinic,
Rochester, MN
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
Guarding the genome: Centromeres,
aneuploidy, and tumorigenesis
Don W. Cleveland, University of California
San Diego, La Jolla, CA
1:35 p.m.
Basic biology of the PD-1/PD-L1 pathway
Arlene Sharpe, Dana-Farber Cancer
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
2:00 p.m.
How chromosome segregation errors
shape cancer genomes
David Pellman, Dana-Farber Cancer
PD-1 blockade in melanoma:
Monotherapy and novel combinations
F. Stephen Hodi, Dana-Farber Cancer
2:20 p.m.
Discussion
2:20 p.m.
Discussion
2:25 p.m.
2:25 p.m.
The impact of aneuploidy on
tumorigenesis
Angelika Amon, Massachusetts Institute of
Technology, Cambridge, MA
The rapidly evolving role of PD-1
pathway inhibition in other tumor types
Mario Sznol, Yale Cancer Center,
New Haven, CT
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
354
Monday, 1:00 p.m.-3:00 p.m.
The Cancer Cell Niche
New Cancer Models
Chairperson: Andreas Trumpp, German Cancer
Research Center, Heidelberg, Germany
Chairperson: Hans Clevers, Hubrecht Institute, Utrecht,
The Netherlands
Cancer and metastatic cells are embedded in a
microenvironment comprised of normal tissue. Tumor
cell seeding, survival, and outgrowth requires the
formation of distinct anatomic microenvironments or
niches which form a complex cellular network including
tumor cells, stromal cells, immune and inflammatory
cells, as well as tumor vasculature. This leads to the
activation of cell adhesion networks combined with the
secretion of cytokines and chemokines within such
cancer cell-niche units that are mediating and promoting
oncogenesis, stemness, dormancy, chemoresistance,
and metastasis. This symposium will cover recent
progress in identifying cancer niche components,
uncovering tumor cell niche cross-talks, characterizing
specific cancer pathways controlled by niche signals,
and outline possibilities to target the disease by
disrupting the cancer cell-niche unit.
Progress in the development of drug treatment of cancer
has been steady, yet slow. The majority of current
patients do not benefit from their initial therapy.
Experimental laboratory strategies to develop drugs and
to predict patient response have typically involved
cancer-derived cell lines and transgenic mouse models.
These approaches have been useful but have inherent
limitations. In this session, several experimental
strategies will be discussed that involve the direct “live”
propagation and testing of tumor cells from individual
patients. These approaches include xenografting in
mice, in vitro propagation of the tumor in “smart”
3-cultures systems that are supplied with the crucial
growth factors for each tumor type, and the use of iPS
technology to efficiently immortalize primary human
tumor cells. These technologies complement deepsequencing analyses by allowing functional tests of
tumor cells from individual patients as a step towards
personalized medicine.
1:00 p.m.
Introduction
1:10 p.m.
Mesenchymal and MDS stem cells
shape an interactive disease unit in the
bone marrow
Andreas Trumpp, German Cancer Research
Center, Heidelberg, Germany
1:30 p.m.
Discussion
1:35 p.m.
The inflammatory cancer cell niche
Mikala Egeblad, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY
1:55 p.m.
Discussion
2:00 p.m.
Brain metastasis stem cells and niches
Joan Massagué, Memorial Sloan-Kettering
2:20 p.m.
Discussion
2:25 p.m.
Niche control of cellular states
associated with malignancy
Thea D. Tlsty, UCSF Helen Diller
Family Comprehensive Cancer Center,
San Francisco, CA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
1:00 p.m.
Introduction
1:10 p.m.
Building biobanks of Lgr5/Rspondinbased organoids from primary human
cancers
Hans Clevers, Hubrecht Institute, Utrecht,
The Netherlands
1:30 p.m.
Discussion
1:35 p.m.
Patient-derived tumor grafts as models
for breast cancer metastasis
Alana L. Welm, University of Utah Huntsman
Cancer Institute, Salt Lake City, UT
1:55 p.m.
Discussion
2:00 p.m.
Modeling cancer in primary organoid
culture
Calvin J. Kuo, Stanford University School
of Medicine, Stanford, CA
2:20 p.m.
Discussion
2:25 p.m.
Conditional reprogramming for the realtime analysis of tumor biopsies
Richard Schlegel, Georgetown University
School of Medicine, Washington, DC
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
355
MAJOR SYMPOSIA
Next-Generation Sequencing Analysis
as a Tool to Define the Biologic Basis of
Drug Sensitivity
Chairperson: David B. Solit, Memorial Sloan-Kettering
This session will focus on the use of novel sequencing
methods to identify the genomic basis for the
heterogeneity of outcomes characteristically observed in
human cancers. Talks will discuss efforts to use wholegenome, exome, and transcriptome methods to identify
the basis of drug sensitivity in outlier responders and the
use of novel profiling methods to screen patients
prospectively for targeted therapy trials. Efforts to initiate
broad genomic characterization of all patients with
cancer will also be reviewed and discussed.
1:00 p.m.
Introduction
1:10 p.m.
The application of integrative
sequencing for precision medicine
Arul M. Chinnaiyan, University of Michigan,
Ann Arbor, MI
1:30 p.m.
Discussion
1:35 p.m.
Translation of cancer genomics
knowledge to the clinic
John D. Carpten, Translational Genomics
Research Institute, Phoenix, AZ
1:55 p.m.
Discussion
2:00 p.m.
Genomics of therapy response
Elaine R. Mardis, Washington University
School of Medicine, St. Louis, MO
2:20 p.m.
Discussion
2:25 p.m.
Use of whole-genome sequencing to
identify occult biomarkers of drug
response
David B. Solit, Memorial Sloan-Kettering
subdivided into several elementary processes: local
invasion, intravasation, transport to distant organs,
extravasation, micrometastasis formation, and
colonization. These steps can be achieved by the
changes in both the cancer epithelium and in their
microenvironments. In contrast to the oncogenic
alterations in the primary tumors, however, few key
mutations were reported that are specific to and
responsible for metastasis. Although many pieces of
information have been reported to affect cancer
metastasis, we still wait for a more comprehensive
picture of the metastatic mechanisms. Here, we will have
presentations of new progress in the field of metastasis
research and discuss their relevance to clinical therapies.
1:00 p.m.
Role of Notch signaling in colon cancer
invasion and metastasis
Makoto Mark Taketo, Kyoto University
Graduate School of Medicine, Kyoto,
Japan
1:20 p.m.
Discussion
1:25 p.m.
Insights into mechanisms of breast
cancer metastasis
Nancy E. Hynes, Friedrich Miescher
Institute for Biomedical Research,
Basel, Switzerland
1:45 p.m.
Discussion
1:50 p.m.
Genomic characterization of 101 brain
metastases and paired primary tumors
reveals patterns of clonal evolution and
selection of driver mutations
*Priscilla K. Brastianos, Massachusetts
2:05 p.m.
Discussion
2:10 p.m.
Nuclear-mitochondrial cross-talk: A key
determinant of cancer metastasis
Danny R. Welch, University of Kansas
Cancer Center, Kansas City, KS
2:45 p.m.
Discussion
2:30 p.m.
Discussion
2:50 p.m.
General Discussion
2:35 p.m.
Mechanisms of malignant progression
Robert A. Weinberg, MIT Whitehead
Institute for Biomedical Research,
Cambridge, MA
2:55 p.m.
Discussion
Novel Mechanisms of Metastasis
Chairperson: Makoto Mark Taketo, Kyoto University
Graduate School of Medicine, Kyoto, Japan
The major cause of death by solid cancer is its
metastasis to the vital organs. Metastasis can be
356
*NextGen Star, selected to give a talk by the AACR President
and Annual Meeting Program Chairperson through a
competitive application process designed to bring more
visibility to early-career scientists. Abstract can be found in the
Invited Abstracts: NextGen Stars section of the Proceedings.
Monday, 1:00 p.m.-3:00 p.m.
Tumor Microenvironment: Composition
and Consequence
Chairperson: Clare Isacke, The Institute of Cancer
Research, London, United Kingdom
The tumor microenvironment is characterized by the
infiltration and activation of stromal cells and
reorganization of the extracellular matrix. The focus of
this session will be on the crosstalk between these
components and their impact on tumor progression.
Speakers will address (a) the composition of the tumor
extracellular matrix and how it can be manipulated
experimentally, (b) the mechanisms by which cells sense
and respond to changes in their extracellular
environment, and how this in turn drives matrix
reorganization, and (c) how these interactions impact on
stromal cell activation, particularly the activation of
cancer-associated fibroblasts, to promote tumor cell
migration, invasion, and metastasis.
1:00 p.m.
Introduction
1:10 p.m.
Engineering biomimetic cell-matrix
interactions
Christopher S. Chen, Harvard University,
Boston, MA
1:30 p.m.
Discussion
1:35 p.m.
Extracellular matrix density, alignment,
and tumor progression
Patricia J. Keely, University of Wisconsin
School of Medicine, Madison, WI
1:55 p.m.
Discussion
2:00 p.m.
Fibroblast recruitment and activation in
breast cancer progression
Clare Isacke, The Institute of Cancer
Research, London, United Kingdom
2:20 p.m.
Discussion
2:25 p.m.
Imaging drug-tolerant and -resistant
tumor microenvironments
Erik Sahai, Cancer Research UK, London,
United Kingdom
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
357
REGULATORY SCIENCE
AND SCIENCE POLICY
Monday, 1:00 p.m.-3:00 p.m.
The Role of Research Biopsies in Trials of Molecularly Targeted
Agents: Scientific, Ethical, and Practical Considerations
Chairperson: Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA
In the current age of molecularly targeted cancer therapy, the inclusion of research biopsies in
clinical trials is becoming increasingly common. Tissue biopsies play a key role in evaluating
pharmacodynamic effects of targeted agents, validation of biomarkers and assays in drugdiagnostic codevelopment studies, and dissecting mechanisms of therapeutic resistance.
Research biopsies may be focused on questions directly related to the therapy being tested in the
trial (for example, to evaluate a biomarker for response) for correlative studies relevant in the trial
population (for example, mechanisms of endocrine resistance in patients with ER-positive breast
cancer), and even for questions outside of the oncology arena. Biopsies may be performed as a
one-time, stand-alone procedure or multiple times during the course of the study depending on
the ultimate purpose and the study design. Historically, biopsies have been optional, and there
was been wide variation in the proportion of patients who consented to biopsies. Increasingly,
biopsies are becoming mandatory. This may be in the context of an integral biomarker, in which
results of assays on biopsy material will be used to determine eligibility or treatment assignment.
Mandatory biopsies are also increasingly common for correlative studies, in order to maximize the
likelihood of sufficient statistical power for scientific questions. There remains ongoing debate on
the proper place of research biopsies in studies of patients with cancer and their inclusion
presents scientific, ethical, and practical challenges. Speakers will discuss the key considerations
for conducting tumor biopsies and banking of tissue/biospecimen for prognostic or retrospective
pathologic analysis including: informed consent for research biopsies, ethics of research biopsies
and potential for coercion, use of limited tissue to answer meaningful scientific questions, need for
biopsies at tumor progression, how to account for tumor heterogeneity, costs of biopsies and
genomic profiling, optimal biopsy procedures such that sufficient tissue is collected, properly
prepared, and banked, potential impact of biopsies on assessment of the trial’s primary end point,
possibility of central tissue and data repositories such that patients can be channeled to
appropriate trials and sites as studies open up.
Introduction including physician attitudes and IRB challenges
Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA
Optimizing tissue procurement and banking considerations
W. Fraser Symmans, The University of Texas MD Anderson Cancer Center,
Houston, TX
The utility and ethical considerations of biospies in early drug development
Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON,
Canada
Patient advocate perspectives including data from patient surveys
Elizabeth Frank, Dana-Farber/Harvard Cancer Center, Lexington, MA
Use of biopsies for clinical and regulatory decision making in late-stage
drug development
Tatiana Prowell, U.S. Food and Drug Administration, Silver Spring, MD, and
Johns Hopkins Kimmel Cancer Center, Baltimore, MD
358
Monday, 1:00 p.m.-3:00 p.m
NCI Resources for Accessing and
Improving Research Biospecimens
Part I: Next Generation Tools for Accessing Human
Biospecimens for Research: NCI Clinical Trials
Network (NCTN) Biospecimen Navigator and NCI
Specimen Resource Locator (75 min)
The availability of human biospecimen resources is
critical to the study and fundamental understanding of
the biology of cancer (discovery, translational and clinical
research). The National Cancer Institute (NCI) supports
human biospecimen resources and recently funded the
development of two next-generation informatics tools
(NCTN Biospecimen Navigator and NCI Specimen
Resource Locator) with a goal to improve the awareness
of and access to valuable specimen resources for the
research community.
The NCTN Biospecimen Navigator is an integral part of
NCTN Biospecimen Banks (a.k.a. Cooperative Group
Banks) that supports specimen collection, storage, and
distribution on the Phase III and large Phase II NCI
Clinical Trials. It provides a consolidated inventory of
biospecimens across all NCTN Group Trials; connects
biospecimen inventory data with associated trial data
and selected clinical data to allow assessment of
biospecimen availability based on trial design and
clinical data end points; provides tools and standard
definitions to facilitate automated data loading from
multiple systems (biorepositories, data centers, CTRP);
provides a secure, role-based, highly functional user
interface for performing data queries and reporting as
needed by stakeholders including the NCI “Front Door
concierge” service, NCI staff, NCTN Group, Bank staff,
and research investigators; and provides a user interface
and data model for tracking requests,
utilization/distribution of biospecimens, and monitoring
scientific productivity. The NCTN Biospecimen Navigator
search engine for researchers will be demonstrated and
the access to available NCTN biospecimens will be
discussed.
The NCI has developed an expanded Specimen
Resource Locator website (SRL) in order to make
researchers aware of existing resources that have
biospecimens available for distribution to or sharing with
the research community. Researchers are able to search
the SRL database, then request and retrieve a list of
resources likely to meet their needs. If no direct match of
resource to investigator is achieved, the SRL refers
researchers to the Tissue Expediter. The Tissue
Expediter is an individual who helps the investigator
locate appropriate resources. Also, the Tissue Expediter
helps identify potential collaborations between
researchers and those specimen resources that are not
easily accessible to the research community. The SRL
will lead cancer research investigators directly to the
resource. The SRL search engine and website will be
demonstrated.
The use of the NCTN Biospecimen Navigator and NCI
Specimen Research Locator by the research community
should spread knowledge of the availability of
appropriate biospecimen resources and accelerate
scientific discovery.
Part 2: NCI’s Biospecimen Science and Best
Practices Programs: Moving Toward Biospecimen
Evidence-Based Practices (45 min)
Human biospecimens are critical foundations for basic
and translational cancer research as well as patient
diagnosis. A high degree of variability pervades the
collection, processing, and storage of biospecimens,
raising the concern about the reproducibility of research
results and clinical tests performed on biospecimens.
The National Cancer Institute’s (NCI) Biorepository and
Biospecimen Research Branch (BBRB; formerly known
as OBBR) has developed several initiatives to
understand the effect of pre-analytical factors on
biospecimen molecular integrity and to develop
evidence-based best practices for biospecimen handling
from collection to analysis. This session will provide an
update on BBRB’s programs and available resources.
• Introduction to BBRB’s Activities: This session will
provide an overview of the NCI’s “Best Practices for
Biospecimen Resources,” the Biospecimen Research
Network (BRN), and the Biospecimen Research
Database (BRD). Current investigations into the
economics of biobanking, as well as the provision of
high-quality postmortem tissues for research, will be
briefly described.
• Assessing the Impact of NCI’s Best Practices for
Biospecimen Resources: The NCI’s “Best Practices
for Biospecimen Resources” defines state-of-thescience practices to promote the collection of high
quality biospecimens and to encourage harmonization
of biospecimen practices, including guidance on
ethical, legal, and social issues related to biospecimen
resources. This session will describe recent efforts
undertaken to examine the impact of the NCI’s “Best
359
Monday, 1:00 p.m.-3:00 p.m
Practices for Biospecimen Resources” and its value as
a resource to the research community.
• Biospecimen Science Research to Support the
Development of Biospecimen Evidence-Based
Practices: This session will present an overview of the
NCI Biospecimen Research Network (BRN), designed
to support Biospecimen Science research to assess
the effects of pre-analytical factors involved in the
collection, handling and processing on biospecimen
molecular integrity. This research has been conducted
through research contracts which fund programs
regarding biospecimen quality and integrity. A high
level description of the funded work will be provided.
• Translating Biospecimen Science results into
Biospecimen Evidence-Based Practices: This
session will describe pathways for utilizing the results
of Biospecimen Science research to develop evidencebased practices for biospecimen collection,
processing, and storage. Discussion will be invited as
to how the research community can best encourage
the development and adoption of evidence-based
biospecimen practices for use in research and clinical
biomarker research.
Part II
Introduction to BBRB’s Activities
Co-Chairperson: Helen M. Moore, National Cancer
Institute, Bethesda, MD
Assessing the impact of NCI’s best practices for
biospecimen resources
Latarsha Carithers, National Cancer Institute-DCTD,
Rockville, MD
Biospecimen science research to support the
development of biospecimen evidence-based
practices
Abhi K. Rao, National Cancer Institute-DCTD,
Rockville, MD
Translating biospecimen science results into
biospecimen evidence-based practices
Helen M. Moore, National Cancer Institute,
Bethesda, MD
Part I
NCI Clinical Trials Network (NCTN) Biospecimen
Navigator
Co-Chairperson: Irina Lubensky, National Cancer
Institute-DCTD, Rockville, MD
Speakers:
Mark A. Watson, Washington University, St. Louis, MO
Dave Billiter, The Research Institute at Nationwide
Children's Hospital Biopathology Center, Columbus, OH
NCI Specimen Resource Locator (SRL)
Moderator: Aniruddha Ganguly, National Cancer
Institute-DCTD, Rockville, MD
Speaker: Steven Marroulis, Information Management
Services, Inc. (IMS), Calverton, MD
360
POSTER SESSION
Hall A-E, Poster Section 1 • Monday, 1:00 p.m.-5:00 p.m.
Tumor Biology 19
Cancer Stem Cell Phenotype and Function 1
Poster
Section
Poster Abstract
Board Number
1.
1906
FOXC1 regulates cancer stem cells properties
via inducing SMO-independent Gli activation and
confers anti-Hedgehog drug resistance in basal-like
breast cancer. Bingchen Han, Yanli Jin, Shikha Bose, Xiao
Zhang, Ying Qu, Beth Y. Karlan, Armando E. Giuliano,
Xiaojiang Cui.
2.
1907
Wnt pathway antagonist OMP-54F28 (FZD8-Fc)
inhibits tumor growth and reduces tumor-initiating cell
frequency in patient-derived hepatocellular carcinoma
and ovarian cancer xenograft models. Pete Yeung, Lucia
Beviglia, Belinda Cancilla, Cristina Dee-Hoskins, James W.
Evans, Marcus M. Fischer, Wan-Ching Yen, Austin Gurney,
John Lewicki, Timothy Hoey, Ann M. Kapoun.
3.
4.
1908
The Wnt-target Prox1 promotes colorectal
cancer stem cell survival to fuel tumor growth. Zoltan
Wiener, Ville Hyvönen, Jenny Högström, Tanja Holopainen,
Arja Band, Pauliina Kallio, Olli Dufva, Caj Haglund, Olli
Kruuna, Guillermo Oliver, Yinon Ben-Neriah, Kari Alitalo.
1909
Identification and characterization of microRNA134 as a novel receptor tyrosine kinase-regulated tumor
suppressive hub in glioblastoma. Ying Zhang, Jungeun
Kim, Adam C. Mueller, Bijan Dey, Yanzhi Yang, Daehee Lee,
Jan Hachmann, Sanjo Finderle, Deric M. Park, James
Christensen, David Schiff, Benjamin Purow, Anindya Dutta,
Roger Abounader.
5.
1910
Evolution of preleukemia stem cells to
lymphoma initiating cells requires thymus in msh2-/mice. Yulan Qing, Stanton L. Gerson.
6.
1911
NF-␬B mediated CD47 upregulation promotes
sorafenib resistance and its blockade synergizes the
effect of sorafenib in hepatocellular carcinoma. Jessica
Lo, Eunice Yuen Ting Lau, Irene Oi Lin Ng, Terence Kin Wah
Lee.
7.
8.
9.
11.
1912
ADAR1-mediated microRNA regulation and blast
crisis leukemia stem cell generation in chronic myeloid
leukemia. Maria Zipeto, Qingfei Jiang, Leslie Crews
Robertson, Catriona H. Jamieson.
1913
C/EBPdelta links hypoxia and inflammation to
the promotion of tumor cell stemness through inhibition
of FBXW7: A molecular target for HDAC inhibitor action.
Kuppusamy Balamurugan, Glenn H. Summers, Shikha
Sharan, Esta Sterneck.
1914
Functional characterization of oncogenicinduced dedifferentiation in neurons and astrocytes
using DP-seq. Dinorah Friedmann-Morvinski, Vipul
Bhargava, Shakti Gupta, Inder M. Verma, Shankar
Subramaniam.
1916
␤3 integrin/KRAS/RalB complex drives tumor
stemness and resistance to EGFR inhibition. Laetitia J.
Seguin, Shumei Kato, Aleksandra Franovic, Maria Fernanda
Camargo, Katrhyn Elliott, Mayra Yebra, Jacqueline
Lesperance, Ainhoa Mielgo, Jay Desgrosellier, Sudarshan
Anand, Sara Weis, David Cheresh.
12.
1917
Re-thinking the concept of cancer stem cells:
Polyploid giant cancer cells as mother cancer stem
cells. Jinsong Liu, Imelda Mercado-Uribe, Na Niu, Baocun
Sun, Jian Kuang, Shiwu Zhang.
13.
1918
Synergy between epithelial and mesenchymal
cells in breast cancer: from mammospheres to
predicting patient outcomes. Anne Grosse-Wilde, Aymeric
d’Herouel, Rolf Kuestner, Gokhan Ertaylan, Alexander
Skupin, Sui Huang, Adrian Ozinsky.
Poster Abstract
Board Number
14.
1919
Profiling of cancer cell lines demonstrates a
dynamic relationship between epithelial, mesenchymal
and cancer stem states. James R. Hernandez, Steven M.
Mooney, Takumi Shiraishi, James E. Verdone, Calvin A.
Harberg, Donald Vindivich, Kenneth J. Pienta.
15.
1920
Stem-like triple negative breast cancer cells
exhibit a distinct response to selectin/selectin ligand
interactions. Grady E. Carlson, Luis F. Delgadillo, Emily A.
Blaha, Fabian Benencia, Monica M. Burdick.
16.
1921
The effect of Hoechst 33342 and Hoechst 33258
on side population (SP) cells or stem cell-like
population. Naimei Tang, Crystal Zhang, Cyndi Noraian, Anil
Wali, Harvey Pass, Michael Harbut, Xinbo Zhang.
17.
1922
Elasticity of stem-like and non-stem-like breast
cancer cells studied by micropipette aspiration
technique. Ameneh Mohammadalipour, Fabian Benencia,
Monica M. Burdick, David F. Tees.
18.
1923
NF-␬B signaling supports a sub-population of
ovarian cancer tumor-initiating cells. Carrie D. House,
Christina M. Annunziata.
19.
1924
Discovery and characterization of EMT positive
and chemo-resistant novel population of HCC like stem
cells. Abhisek Mitra, Arun Satelli, Xueqing Xia, Shulin Li.
20.
1925
CK2 phosphorylates and inhibits tumor
suppressor TAp73 function to promote cancer stem cell
gene expression and phenotype in head and neck
cancer. Hai Lu, Carol H. Yan, Yansong Bian, Zhong Chen,
Carter Van Waes.
21.
1926
Identification of stem cell by
immunohistochemistry in benign and malignant human
esophageal mucosa. Kim Vaiphei, Saroj K. Sinha, Rakesh
Kochhar.
22.
1927
Tumor suppressor PTEN regulates cancer stem
cells of glioblastoma multiforme: identification of
signaling pathways as targets of therapy. Michael
LaBagnara, Keith Lambert, Sudeepta Sridhara, Michael
Tobias, Raj Murali, Meena Jhanwar-Uniyal.
23.
1928
Reporter construct for functional and real-time
evaluation of cytokeratin 14ⴙ bladder cancer stem
cells. Philip L. Ho, Antonina Kurtova, Jing Xiao, Ross
Krasnow, Erica Lay, Senthil Pazhanisamy, Seth P. Lerner,
Keith S. Chan.
24.
1929
Tyrosine kinase inhibition with sorafenib but
not pazopanib enriches for sarcoma cancer stem cells
in diverse models of soft tissue sarcoma. Robert J.
Canter, Erik Ames, Stephanie Mac, Steve K. Grossenbacher,
Mingyi Chen, Joe Tellez, Arta M. Monjazeb, William J.
Murphy.
25.
1930
Low surface Gal3 expression in breast cancer
stem cells is associated with chemoresistance,
tumorigenesis, and decreased overall patient survival.
Matthias Illmer, Nachman Mazurek, James Byrd, Jody
Vykoukal, Robert S. Bresalier.
26.
1931
Tumor spheres growing from circulating tumor
cells exhibiit stem cell features. Katharina Pachmann,
Monica Pizon, Dorothea Zimon.
1
1
361
POSTER SESSION
Tumor Biology 20
Poster
Section
2
2
Developmental Pathways in Cancer
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
362
1932
Parallel functions of the endoplasmic reticulum
chaperone protein GRP78 in tumorigenesis and the
induction of pluripotency. Athanasia D. Panopoulos, Yuriko
Hishida, Min-Zu Wu, Sergio Ruiz, Erika Batchelder, Tomoaki
Hishida, Jonathan A. Kelber, Peter C. Gray, Juan Carlos
Izpisua Belmonte.
1933
Novel roles of receptor tyrosine kinase AXL in
the control of stem cell pluripotency and
reprogramming. Yee Sook Cho, Mi-Young Son, Binna Seol.
1934
Role of CDK1 in human stem cell biology. Xiao
Qi Wang, Lin Chen, Chris Norbury.
1935
Transformation of epithelial cells through
recruitment leads to polyclonal intestinal cancers. Alyssa
A. Leystra, Dustin A. Deming, Amanda M. Wisinger,
Christopher D. Zahm, Chelsie K. Sievers, Kristina A.
Matkowskyj, Dawn M. Albrecht, Michael A. Newton, Richard
B. Halberg.
1936
The ETS factor ESE3/EHF controls Lin28A and
Lin28B and acts as a barrier for stemness in prostate
epithelial cells. Domenico Albino, Gianluca Civenni, Mahnaz
Nikpour, Carlo V. Catapano, Giuseppina M. Carbone.
1937
RBM3 overexpression increases ␤-catenin
signaling activity to induce a cancer stem cell
phenotype. Anand Venugopal, Julia Balmaceda, Deep
Kwatra, Dharmalingam Subramaniam, Shahid Umar,
Shrikant Anant.
1938
Inhibition of both physiological and aberrant
Wnt/␤-catenin signaling activities associated with
stemness in nasopharyngeal carcinoma. Yue Cheng, Yee
Peng Phoon, Maria L. Lung.
1939
Calcineurin/NFAT signaling regulates tumor
initiating cell properties in non-small cell lung cancer.
Zhi-Jie Xiao, Jing Liu, Vicky P. Tin, Maria P. Wong.
1940
Short (S) isoform of cancer-stem-cell marker,
DCLK1, is critically required to maintain proliferative/
tumorigenic potential of colon cancer cells:
identification of associated molecular pathways.
Malaney R. O’Connell, Shubhashish Sarkar, Pomila Singh.
1941
GSK3 signaling is critical to glioma stem cell
growth and survival. Angel Alvarez, Andrey Ugolkov, Irina
Gaisina, Alan P. Kozikowski, Kaushal Joshi, Sunghak Kim,
Ichiro Nakano, Jeffrey J. Raizer, Andrew P. Mazar, Bo Hu,
Shi-Yuan Cheng.
1942
Lgl1 loss promotes stemness and invasion in
EGFRvIII-driven gliomas. Sandra Gomez-Lopez, Robin G.
Lerner, Claudia Petritsch.
1943
Exploring cancer stem cells heterogeneity via
single cell multiplex gene expression analysis. Ebrahim
Azizi, Shamileh Fouladdel, Yadwinder S. Deol, Jonathan
Bender, Sean McDermott, Hui Jiang, Mary Sehl, Shawn G.
Clouthier, Sunitha Nagrath, Max S. Wicha.
1944
Divergent effects of BRAF activation in neural
stem and progenitor-like glioblastoma cells. Robin G.
Lerner, Yuichiro Ihara, Kate Lewis, Amelie Griveau, Brian
Reichhold, Dian Qu, Martin McMahon, David Rowitch,
Charles D. James, Claudia Petritsch.
1945
TORC inhibitors increase the cancer stem cell
(CSC) population and Notch signaling in triple negative
breast cancer. Neil E. Bhola, Valerie Jansen, Carlos
Arteaga.
1946
Inhibition of IKK/NF-␬B impairs glioma stem
cell function. Amanda L. Rinkenbaugh, Patricia C.
Cogswell, Albert S. Baldwin.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
1947
Plasticity of CD44ⴙ colorectal cancer stem
cells depends on TGF-beta-induced epithelial
mesenchymal transition(EMT): Evidences from an ex
vivo culture. Michitaka Nakano, Hiroshi Ariyama, Shingo
Tamura, Taichi Isobe, Kohta Miyawaki, Yuta Okumura,
Hitoshi Kusaba, Eishi Baba, Koichi Akashi.
1948
Human papillomavirus enhances oral cancer
stem cell phenotype by regulating microRNA-181. Sung
Hee H. Lee, Nicole Rigas, Chang-Ryul Lee, Jiho Han,
Reuben Kim, Mo Kang, No-Hee Park, Ki-Hyuk Shin.
1949
P38MAPK plays a tumor suppressive role
through differentiation of ALDHhigh/CD44high tumour
iniating cells in primary human lung adenocarcinoma.
Jing Liu, Lai-han Leung, Zhi-jie Xiao, Vicky PC Tin, Maria P.
Wong.
1950
SMURF1 inhibition reduces cancer stem celllike population in head and neck squamous cell
carcinoma. Ali Khammanivong, Raj Gopalakrishnan, Erin B.
Dickerson.
1951
Role of embryonic signaling pathways in lung
cancer. Samer Singh, Dao M. Nguyen, Anthony J.
Capobianco, David J. Robbins.
1952
Notch-1 regulated stemness and EMT in
colorectal cancer. Alex Fender, Makenzie Nutter, Timothy
Fitzgerald, Fred Bertrand, George Sigounas.
1953
The role of NR5a2 in pancreas development and
carcinogenesis. Sahar Nissim, Julia Wucherpfennig, XiaoXu Wang, Alec Kimmelman, Wolfram Goessling.
1954
RNA-binding protein Musashi1 activates STAT3
signaling via PKR phosphorylation and promotes
tumorigenicity of glioblastoma cells. Hsiao-yun Chen,
Shih-Hwa Chiou.
1955
Regulatory role of miRNA-1246 and Wnt/␤catenin pathway interaction in CD133ⴙ liver cancer
stem cells-driven hepatocellular carcinoma. Stella Chai,
Kai Y. Ng, Man Tong, Xin Y. Guan, Stephanie Ma.
1956
The basic helix-loop-helix (bHLH) transcriptional
factor ATOH8 promotes the stemness of breast cancer
cells via Oct4 and Nanog. Antao Chang, Yanan Chen,
Wenzhi Shen, Ruifang Gao, Wei Zhou, Yunping Luo, Na Luo,
Dwayne Stupack, Rong Xiang.
1957
Slug regulates SOX9 stability in lung carcinoma
and its involvement in the regulation of cancer stem
cells and lung metastasis. Sudjit Luanpitpong, Liying
Wang, Yon Rojanasakul.
1958
Interrogating hedgehog pathway and
smoothened inhibition by PF-04449913 in patientderived acute myeloid leukemia models. Amy JacksonFisher, Pamela Whalen, Mark Elliott, Melissa McMahon,
Enhong Chen, Xianxian Zheng, Mark Ozeck, Donghui Huang,
Paul Lira, Joseph Lee, Cathy Zhang, Justine Lam, Mary
Spilker, Shibing Deng, Patrick Lappin, Penny Venne, Cynthia
Heinlein, Annelie Schairer, Karen McLachlan, Todd
VanArsdale.
1959
Lgr5 marks an enriched population of fetal
mammary stem cells. Christy L. Trejo, Ben Spike, Geoff
Wahl.
1960
Sox10 expression labels mammary stem cell
activity in fetal, adult, cultured, and male mammary
tissues and is attenuated by FGF signaling inhibition.
Christopher Dravis, Geoff Wahl.
1961
Embryonic stem cells antigens: expression in
acute myeloid leukemia cells. Lydia Campos, TIPHANIE
PICOT, CARMEN AANEI, PASCALE FLANDRIN-GRESTA,
EMMANUELLE TAVERNIER, DENIS GUYOTAT.
POSTER SESSION
Hall A-E, Poster Section 3 • Monday, 1:00 p.m-5:00 p.m.
Tumor Biology 21
Impact of Tissue Context on Tumor Progression and Treatment
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1962
Macrophages mediate gemcitabine resistance
of pancreatic adenocarcinoma by up-regulating cytidine
deaminase. Moran Amit, Noam Weizman1, Yoav
Binenbaum, Ayelet Shabtay-Orbach, Richard J. Wong, Ziv
Gil.
1963
Toll-like receptor activation in bacterial
pneumonia increases lung cancer cell adhesion and
metastasis formation. Stephen D. Gowing, Simon C. Chow,
Jonathan J. Cools-Lartigue, Crystal B. Chen, Betty Giannias,
France Bourdeau, Simon Rousseau, Salman T. Qureshi,
Lorenzo E. Ferri.
1964
Masitinib antagonizes ATP-binding cassette
subfamily c member 10-mediated paclitaxel resistance:
a preclinical study. Rishil Kathawala, Kamlesh Sodani,
Kang Chen, Atish Patel, Alaa Abuznait, Nagaraju Anreddy,
Yue-Li Sun, Amal Kaddoumi, Charles R. Ashby, Zhe-Sheng
Chen.
1965
Inhibiting SIAH2 E3 ligase function disrupts
focal adhesion and cell junction, inhibits cell mobility
and attachment, and blocks tumor invasion and
metastasis in oncogenic K-Ras-driven tumors. Ming
Bian, Yang Liao, Rebecca L. Schmidt, Monicah M. Njogu,
Rie Takahashi, Zandra E. Walton, Amy H. Tang.
1966
A unique cross-talk between HER2 and sonic
hedgehog signaling promotes anoikis resistance in
breast cancer cells. Parul Gupta, Sanjay K. Srivastava.
1967
A-803467, a sodium channel blocker, reverses
ABCG2-mediated MDR. Nagaraju Anreddy.
1968
Breast cancer cells escape from chemotherapy
and hypoxia by distinct mechanisms. Siobhan O’Brien,
Liang Chen, Wenyan Zhong, Douglas Armellino, Maximillian
Follettie, Marc Damelin.
1969
Overexpression of specific CD44 variants
mediate endocrine insensitivity and invasion in breast
cancer cells. Rebecca L. Bellerby, Christopher Smith, Julia
Gee, Tracey Martin, Peter Barrett-Lee, Stephen Hiscox.
1970
Co-culture of 3D tumor spheroids with
fibroblasts as an in vitro model for drug resistance
study. Sun-Ah Kim, Hyo-Jeong Kuh.
1971
Inhibition of CXCR4 pathway augments
trastuzumab sensitivity in HER2 positive breast cancer
cells with intrinsic and acquired trastuzumab
resistance. Arjun Mehta, Gloria Yang-Kolodji, Debu Tripathy.
1972
The sodium channel auxiliary subunit SCN1B
promotes breast tumor growth and metastasis. Michaela
Nelson, Rebecca Millican-Slater, Lorna C. Forrest, William J.
Brackenbury.
1973
Influences of extracellular matrix protein
tenascin-c on glioblastoma stem cell growth and
invasion through tumor-microenvironment interactions.
Shervin Wang, Bachchu Lal, Brian Tung, John Laterra, Shuli
Xia.
1974
Ovulatory wound: the site of origin for ovarian
serous carcinoma. Yang Yang-Hartwich, Marta Gurrea,
Natalia Sumi, Jennie Holmberg, Vinicius Craveiro, Ayesha
Alvero, Gil Mor.
1975
Real-time FUCCI imaging demonstrates
targeting dormant cancer cells. Shuya Yano, Ming Zhao,
Hiroshi Tazawa, Robert M. Hoffman, Toshiyoshi Fujiwara.
1976
MDR expression/ activity may serve as potential
biomarker in developing therapeutic drug s for AML
therapy. Nandini Rudra-Ganguly, Christine Lowe, Mukta
Shiwalkar, Claudia I. Guevara, Christopher Kemball, Min
Michelle Wu, Cyrus Virata, Alla Verlinsky, Ssucheng J Hsu,
Michael Mattie, William Yeh, Peng Yang, Sung-Ju Moon,
Ingrid Joseph, David R. Stover, Daniel S. Pereira, Dowdy
Jacksosn.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
1977
Therapeutic miRNAs targeted selectively to
tumors by mesenchymal stem cell derived
microparticles. Marianna Prokopi, Agamemnon Epenetos,
Andreas Anayiotos, Costas Pitsillides, Konstantinos Kapnisis,
Christina Kousparou.
1978
The tyrosine kinase Syk plays a role in the
maintenance of intercellular adhesive junctions in
human breast cancer cells. Toufic Kassouf, Philippe
Montcourrier, Romain Larive, Nadir Bettache, Anne Morel,
Fabrice Merezegue, Serge Urbach, Peter J. Coopman.
1979
Three-dimensional Gelfoam® histoculture
enables cancer cells to mimic in vivo cancer cell
cycling as visualized with FUCCI imaging. Shuya Yano,
Shinji Miwa, Sumiyuki Mii, Yukihiko Hiroshima, Fuminari
Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Ming Zhao,
Toshiyoshi Fujiwara, Robert M. Hoffman.
1980
Role of lysyl oxidase and lysyl oxidase-like 2 in
gastric carcinoma. Hiroaki Kasashima, Masakazu Yashiro,
Yukie Go, Go Masuda, Haruhito Kinoshita, Mao Tokumoto,
Tamami Morisaki, Tatsunari Fukuoka, Takahiro Toyokawa,
Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Masaichi
Ohira, Kosei Hirakawa.
1981
Drug-tolerant gastric cancer cell subpopulation
enriched by 5-fluorouracil acquires malignant
phenotype. Kaoru Ishida, Satoshi S. Nishizuka, Kohei Kume,
Mamoru Nukatsuka, Kei Sato, Fumitaka Endo, Hirokatsu
Katagiri, Takashi Kobunai, Teiji Takechi, Keisuke Koeda, Go
Wakabayashi.
1982
Invading cancer cells are mostly in G0/G1 and
resist chemotherapy demonstrated by real-time FUCCI
imaging of cell-cycle kinetics in Gelfoam® histoculture.
Shuya Yano, Shinji Miwa, Sumiyuki Mii, Yukihiko Hiroshima,
Fuminari Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Ming
Zhao, Michael Bouvet, Toshiyoshi Fujiwara, Robert M.
Hoffman.
1983
Real-time imaging of exosomes dynamic of
cross-talking and cell trafficking in 3D Gelfoam®
histoculture. Mako Yamamoto, Shinji Miwa, Yukihiko
Hiroshima, Shuya Yano, Fuminari Uehara, Yasunori
Matsumoto, Atsushi Suetsugu, Kimi Homma, Robert M.
Hoffman.
1984
Role of nectin-4 in the progression of ovarian
cancer. Kristin L. Boylan, Adam Meyer, Petra C. Buchanan,
Melissa S. DeRycke, Amy P. Skubitz.
1985
Vitronectin expression in primary lung cancers.
Lina M. Salazar-Pelaez, Ivan Martinez-Forero.
1986
The role of APC in chemotherapeutic
responsiveness of breast cancer. Katia Fernandez Soto,
Monica K. VanKlompenberg, Jenifer R. Prosperi.
1987
The role of lipolysis-stimulated lipoprotein
receptor in directing breast cancer cell behavior and
subtype. Jodie M. Fleming, Denise K. Reaves, Katerina D.
Fagan-Solis, Karen Dunphy, Shannon D. Oliver.
1988
MenaINV interaction with ␣5␤1 promotes tumor
cell invasion in response to gradients of growth factors
and fibronectin. Madeleine J. Oudin, Liliane C. Broye,
Alisha Lussiez, Sreeja B. Asokan, Miles A. Miller, Douglas A.
Lauffenburger, James E. Bear, Frank B. Gertler.
Poster
Section
3
3
363
POSTER SESSION
Tumor Biology 22
Poster
Section
4
4
364
Metastasis Regulating Genes
Poster Abstract
Board Number
1.
1989
SRRM4 and the loss of REST may promote the
emergence of the neuroendocrine /neuronal phenotype
in castration resistant prostate cancer. Xiaotun Zhang,
Ilsa Coleman, Roger Coleman, Lisha Brown, Lori Kollath,
Lisly Chéry, Jared Lucas, Eva Corey, Martine Roudier, Paul
Lange, Celestia Higano, Lawrence True, Peter Nelson,
Robert Vessella, Colm Morrissey.
2.
1990
Identification and biochemical characterization
of HMP19, a tumor/metastasis suppressor in pancreatic
cancer. Christopher R. Bohl, Hiroshi Kurahara, Shoji
Natsugoe, Yuka Nishizono, Sitaram Harihar, Tomoo
Iwakuma, Danny R. Welch.
3.
1991
Axl overexpression drives migration and
invasion in colon cancer. Diana J. Uribe, Lidia Bosurgi,
Nicola Gagliani, Leonel Joannas, Adam Watson, Jesse D.
Martinez, Carla V. Rothlin, Sourav Ghosh.
4.
1992
Y-box protein-associated acidic protein
promotes breast cancer progression and is a potential
molecular target. Olivia J. Scully, Aye Aye Thike, George
Wai-Cheong Yip, Puay Hoon Tan, Ken Matsumoto, Boon
Huat Bay.
5.
1993
The role of metabotropic glutamate receptor 5
on the lymph node metastases in oral cancer. Nobuyuki
Kuribayashi, Daisuke Uchida, Makoto Kinouchi, Tetsuya
Tamatani, Hirokazu Nagai, Youji Miyamoto.
6.
1994
Cd44s is of functional importance for
hepatocellular carcinoma (hcc) extra-hepatic
metastases through activation of sdf-1a/cxcr4 axis.
Wenwei Zhu, Lei Guo, Qinhai Ye.
7.
1995
The Functional analyses of Oct4 in metastasis
of human hepatocellular carcinoma. Qiongzhu Dong,
Chun Dai, Huliang Jia, Lunxiu Qin.
8.
1996
Inhibitor of differentiation-1 (Id1) expression
deficiency in the tumor microenvironment impairs
experimental hepatic metastasis of lung cancer. Ignacio
Gil-Bazo, Eduardo Castanon, Inés López, Victor Segura,
Mariano Ponz-Sarvise, José M. López-Picazo, Maria
Collantes, Margarita Ecay, Isabel Gil-Aldea, Alfonso Calvo,
Fernando Vidal-Vanaclocha.
Poster Abstract
Board Number
14.
2002
A novel candidate metastasis-associated
protein, MAP40, differentially expressed in highly
metastatic breast cancer cells reveals an essential role
in tumor metastasis. Mijin Kim, Seong-Jin Kim.
15.
2003
CPE-delta-N promotes metastasis by regulating
Nedd9 and Yap1 expression. Saravana R. Murthy, Terence
K. Lee, Niamh X. Cawley, Stephen M. Hewitt, Peng Y. Loh.
16.
2004
S100A4 in colorectal cancer - biological
function of nuclear localization. Eivind V. Egeland, Kjetil
Boye, Kjersti Flatmark, Solveig J. Pettersen, Tove Oyjord,
Gunhild M. Maelandsmo.
17.
2005
Aberrant hedgehog signaling is responsible for
the highly invasive behavior of a subpopulation of
hepatoma cells. Yahan Fan, Jia Ding, Jian Wu.
18.
2006
The role of neuronal predominant gene
expression in breast cancer brain metastasis. Deepak P.
Kanojia, Purva Sarvaiya, Jian Qiao, Lingjiao Zhang, Irina
Balyasnikova, Maciej S. Lesniak.
19.
2007
Hypoxia induced TGF-␤ regulates
Semaphorin7A to promote a pro-tumorigenic
mesenchymal phenotype in mammary cells. Ramon A.
Garcia-Areas, Stephania Libreros, Samantha Amat, Camila
Castro-Silva, Kathy Schilling, Vijaya Iragavarapu-Charyulu.
20.
2008
CUL7 promotes non-small cell lung cancer cells
migration and invasion. Qiong Song, Lihui Wang, Yi Lu,
Jian Zhang, Jiejun Fu.
21.
2009
Role of kallikrein 6 secretion in metastatic
colon cancer. Bethany A. Skovan, Ritu Pandey, Raymond B.
Nagle, Haiyan Cui, Julie A. Buckmeier, Robert S. Krouse,
Patricia A. Thompson, Natalia A. Ignatenko.
22.
2010
SPHK1 promotes lung metastasis of breast
cancer. Sunil Acharya, Chenyu Zhang, Frank L. Lowery,
Qingling Zhang, Dihua Yu.
23.
2011
ETV4 promotes pancreatic cancer progression
and metastasis. Nikhil Tyagi, Sanjeev K. Srivastava, Arun
Bhardwaj, Sumit Arora, William E. Grizzle, Laurie B. Owen,
Ajay P. Singh, Seema Singh.
9.
1997
Glucose transporter isoform 1 (GLUT1)
expression determines tumorigenicity of melanoma cells
and their potential to form hepatic metastasis. Andreas
Koch, Anja Bosserhoff, Claus Hellerbrand.
24.
2012
GPNMB cooperates with Neuropilin-1 and
Integrin a5b1 to promote breast cancer tumorigenesis
and metastasis. Gordana Maric, Matthew Annis, April Rose,
Dru Perkins, Patricia Macdonald, Peter Siegel.
10.
1998
Deficient expression of oncogenic Wip1
(PPM1D) negatively regulates melanoma progression
and metastasis. Bo-Hyun Moon, Shubhankar Suman,
Henghong Li, Qian Yang, Steven J. Strawn, Janine LoBello,
Sharlyn J. Mazur, Ettore Appella, Suzie Chen, Albert J.
Fornace.
25.
2013
NEDD9 depletion leads to MMP14 inactivation
by TIMP2 and prevents invasion and metastasis. Elena
N. Pugacheva, Sarah McLaughlin, Ryan Ice, Anuradha
Rajulapati, Polina Kozyulina, Ryan Livengood, Varvara
Kozyreva, Yuriy Loskutov, Alexey Ivanov, Scott Weed.
26.
11.
1999
Role of peptidylarginine deiminase 2 enzyme in
mammary tumor progression. Sachi Horibata, Sunish
Mohanan, John L. McElwee, Dalton T. McLean, David
Sadegh, Scott Coonrod.
2014
SHP2 stabilizes EGFR and beta-catenin to
promote the transformation and tumorigenic potential of
basal-like and triple-negative breast cancer cells. Hua
Zhao, Yehenew M. Agazie.
27.
12.
2000
Lysyl oxidase-like 2 promotes hepatocellular
carcinoma metastasis by remodelling the tumor and
metastatic microenvironments. Carmen C. Wong, Irene
Oi-Lin Ng.
2015
Thrombospondin-1 is a targetable marker of
invasive, mesenchymal- like melanoma cells. Andreas
Behren, Aparna Jayachandran, Matthew Anaka, Christopher
Hudson, Jonathan Cebon.
28.
13.
2001
GATA2: Potential role as a prostate cancer
metastasis-driving gene. Yan Ting Chiang, Kendric Wang,
Francesco Crea, Colin Collins, Peter Gout, Yuzhuo Wang.
2016
Mst2 is required for tumor progression and Yap
activity. Carles Escriu, Klaas Mulder, Samuel Woodhouse,
Nathan Benaich, Simon Broad, Frances Richards, Duncan
Jodrell, Fiona Watt.
POSTER SESSION
Tumor Biology 23
Modeling Cancers in 3D Culture
Poster
Section
Poster Abstract
Board Number
1.
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
2017
Development of a novel 3D tri-culture system in
an in vitro non-small cell lung cancer (NSCLC) model.
Arno Amann, Marit Zwierzina, Julia M. Huber, Gabriele
Gamerith, Mario Bitsche, Elisabeth J. Pechriggl, Wolfgang
Hilbe, Heinz Zwierzina.
2018
A pipeline within the OncoTrack project for
generating Patient-tumor-derived 3D cell cultures
(PT3DC) and their application for individualized,
targeted drug sensitivity assays. Dirk Schumacher,
Karsten Boehnke, Martin Lange, Yvonne Welte, Cathrin
Davies, Maria Rivera, Marlen Keil, Ulrich Keilholz, Johannes
Haybaeck, Juan Angel Velasco, Marie-Laure Yaspo, Hans
Lehrach, David Henderson, Christoph Reinhard, Jens
Hoffmann, Reinhold Schaefer, Christian Regenbrecht.
2020
Spheroid culture of primary colorectal cancer
cells from liver metastases as an in vitro model of
patient tumors. Maria Jeppesen, Grith Hagel, Ben Vainer,
Henrik Harling, Ole Thastrup, Lars N. Jorgensen, Jacob
Thastrup.
2021
A novel model to study the stroma-induced
drug resistance in glioblastoma cells. Ning Yang,
Huaiyang Zhu, Tao Yan, Xiao Liang, Lina W. Leiss, Per Ø.
Enger, Xingang Li, Jian Wang.
2022
Importance of ECM and media permeation in 3D
modeling of breast cancer. Kayla F. Goliwas, Lauren E.
Marshall, Kun Yuan, Joel Berry, Andra R. Frost.
2023
Complex in vitro and in vivo prostate cancer
models for the PREDECT consortium. Suzana Vidic,
Norbert Esser, Ronald de Hoogt, Ingrid Verberne, Ira KoganSakin, Yan Stein, Varda Rotter, Michael Barbier, Yolanda
Chong, Sabine De Breucker, Karine Smans, Malin Akerfelt,
Matthias Nees, Peter King, Ian Hickson, Wytske van
Weerden, Ralph Graeser.
2024
Resistance of colorectal cancer cells to 5-FU
treatment in three dimensional cell culture models
under perfusion involves BCL-2. Christian Hirt, Adam
Papadimitropoulos, Evangelos Panopoulos, Valentina Mele,
Manuele Muraro, Eleonora Cremonesi, Raoul Droeser,
Chantal Mengus, Michael Heberer, Daniel Oertli,
Giandomenica Iezzi, Paul Zajac, Serenella EppenbergerCastori, Luigi Tornillo, Luigi Terracciano, Ivan Martin, Giulio
Spagnoli.
2025
Multicellular tumor spheroid 3D models to
decipher cancer cell biology and to evaluate anticancer
drugs. Bernard Ducommun, Valérie Lobjois.
2026
Analysis of the impact of compounds derived
from marine organisms on 3D co-spheroids generated
from multiple myeloma cells and stromal cell types.
Jayanthi Ganesan, Holger Weber, Sarah Umber, Oliver
Siedentopf, Daniel Feger, Luis F. García-Fernández, Miguel
Aracil Ávila, Michael H. Kubbutat, Jan E. Ehlert.
2027
Novel 3D tumor-immune cell spheroid models
for assessment of cancer immunotherapy agents. Laura
Morra, Inja Waldhauer, Christian Klein, Pablo Umana, Marina
Bacac.
2028
A novel human gastric primary cell culture
system for modelling Helicobacter pylori infection in
vitro. Philipp Schlaermann, Thomas F. Meyer.
2029
Insight of 3D multicellular tumor spheroids for
innovative culture models of potential relevance for the
screening of anti-CRC compounds. Silvio Däster, Nunzia
Amatruda, Diego Calabrese, Paul Zajac, Giulio C. Spagnoli,
Giandomenica Iezzi, Valentina Mele, Manuele G. Muraro.
2030
Culturing patient-derived prostate cancer
xenografts using a three-dimensional hydrogel system
for drug testing and mechanistic studies. Eliza L. Fong,
Mariane Martinez, Jun Yang, Leland M. Chung, Antonios G.
Mikos, Nora M. Navone, Daniel A. Harrington, Mary C.
Farach-Carson.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2031
HMGB1 regulates pancreatic cancer initiation
and pogression. Rui Kang, Qiuhong Zhang, Wen Hou,
Ruochan Chen, Michael Lotze, Herbert Zeh, Daolin Tang.
2032
TGF-␤ differentiates immortalized pancreatic
epithelial cells to form duct architecture in 3D culture.
Takashi Yamaguchi, Sanae Ikehara, Yuzuru Ikehara.
2033
A comprehensive 3D triple coculture model for
evaluating breast cancer progression. Gabriel J. Benton,
Jay George, Gerald DeGray, Irina Arnaoutova, Hynda K.
Kleinman.
2034
Development of 3D bioprinted human breast
cancer for in vitro drug screening. Shelby M. King,
Sharon C. Presnell, Deborah G. Nguyen.
2035
A 3-dimensional tumoroid model made up of
lung cancer cells, fibroblasts, and endothelial cells is
predictive of drug activity in animal models. Luciana F.
Macedo, Elizabeth Kaiser, Bradley Heidrich, Barbara Bushey,
Catherine Ferrante, Deborah Marshall.
2036
OncoPanel 3D: High-content characterization of
240 three-dimensional tumor spheroids for drug
response profiling and biomarker discovery. Katie Snead,
Jim Hnilo, Karen Bernards, Jonathan M. Crane, Brian
Nelson, Alison R. Angione, Keith McKinley, Kate Waikins, O.
Jameel Shah.
2037
A 3D model for lung cancer based on
decellularized lung scaffolds allows for in vitro testing
of viral oncolysis. Luis F. Tapias, Sarah E. Gilpin, Justin
Elliott, Roshini Zachariah, Haiyu Zhou, Bryan C. Fuchs, Lan
Wei, Danielle K. Deperalta, Kumudu D. Kuruppu, Kenneth K.
Tanabe, Harald C. Ott, Michael Lanuti.
2038
Establishment and analysis of an in vitro model
for hemangioblastomas of the central nervous system.
Ana Martins Metelo, Elizabeth Lockerman, Fred Barker,
Jeffrey Engelman, Othon Iliopoulos.
2039
Dynamic changes and regulation of circulating
tumor cells that govern the metastasis of colorectal
cancer. Ju-Yu Tseng, Chih-Yung Yang, Jeng-Kai Jiang, ChiHung Lin.
2040
Adenomatous polyposis coli mediated signaling,
self renewal and differentiation of breast epithelial cells.
Alyssa Lesko, Harikrishna Nakshatri, Manjushree Anjanappa,
Poornima Bhat-Nakshatri, Jenifer Prosperi.
2041
Development and analysis of mouse brain
tumor models derived from neural stem cells expressing
activated ALK. Nobuyuki Onishi, Oltea Sampetrean, Eiji
Sugihara, Hideyuki Saya.
2042
Deregulated TS promotes tumor progression in
diverse hematopoietic and mesenchymal cell lineages.
Min Chen, Akbar Nawab, Frederic J. Kaye, Maria ZajacKaye.
2043
Modeling the differential responses of cancer
stem cells (CSCs) as heterogeneous versus homogenous
populations in human cancers. Maria L. Mancini.
2044
Lin neg Sca-1high CD49f high prostate cancer
cells derived from Hi-Myc mice are tumor-initiating
cells with basal-epithelial characteristics and
differentiation potential in vitro and in vivo. Jorge M.
Blando, Achinto Saha, Irina Fernandez, Kaoru Kiguchi, John
DiGiovanni.
2045
Identifying key molecular events at the onset of
melanoma using a neural crest stem cell marker.
Charles K. Kaufman, Christian Mosimann, Richard M. White,
Dominic Matos, Leonard I. Zon.
2046
EZH2 inhibition targets a stem cell population in
a canine urothelial carcinoma model. Parthena
Foltopoulou, Monica Betancur-Boissel, Laurent Boissel,
Manar A. AbdelMageed, Philip N. Tsichlis, Elizabeth A.
McNiel.
5
5
365
POSTER SESSION
Tumor Biology 24
Poster
Section
7
7
Photoacoustics, MRI, and Translational Imaging Applications
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
366
2047
Molecular photoacoustic imaging and serum
diagnostics rapidly detect response to angiopoietin 1
and 2 blockade in ovarian cancer. Sarah E. Bohndiek,
Laura Sasportas, Steven Machtaler, Jesse V. Jokerst,
Sharon Hori, Sanjiv S. Gambhir.
2048
Characterization of tumor hypoxia by
photoacoustic imaging and limitations of
bioluminescence imaging in a Mia PaCa2-luc orthotopic
model of pancreatic carcinoma. Florian Raes, Thomas
Barre, Jithin Jose, Philippe Trochet, Stéphanie Lerondel,
Alain Le Pape.
2049
Identification of orthotopic pancreatic
adenocarcinoma using multispectral optoacoustic
tomography. Justin Huang, Charles W. Kimbrough, Shanice
V. Hudson, Wenyuan Yin, Jamie Rush, Brian P. Ceresa,
Hermann B. Frieboes, Lacey R. Mcnally.
2050
Novel approaches for dynamic tumor
microenvironment imaging by Multispectral
Optoacoustic Tomography (MSOT). Stefan Morscher, Neal
C. Burton, Thomas Sardella, Daniel Razansky, Vasilis
Ntziachristos, Wouter H. Driessen.
2051
Three-dimensional in vivo photoacoustic
tracking of targeted nanoparticles in a pancreatic
cancer model. Richard Bouchard, Tatiana Wolfe, Michael
Thornton, Timothy Morgan, Trevor Mitcham, Shanta
Bhattarai, Jonathan Grant, Jihyoun Lee, John Hazle, Sunil
Krishnan.
2052
Assessing lymphatic response to treatments in
head and neck cancer using near-infrared fluorescence
imaging. I-Chih Tan, Ron J. Karni, John C. Rasmussen, Eva
M. Sevick-Muraca.
2053
Dynamic 18F-FDG PET parameters variation in
patient-derived breast cancer xenograft and correlation
with outcome following treatment with cytotoxic agents.
Alexandr Kristian, Mona-Elizabeth Revheim, Hong Qu,
Gunhild Mælandsmo, Olav Engebraaten, Eirik Malinen.
2054
Patient relevant preclinical in vivo models using
image-guided small animal irradiation for drug
discovery. Rajendra Kumari, Andrew McKenzie, Nektaria
Papadopoulou, Yinfei Yin, Martin Page, Henry Li, Ian Wilson.
2055
Modulated near-infrared fluorescence light
imaging of primary tumor margins, cancer positive
lymph nodes, and freshly excised human cancers with
imaging agent targeting EpCAM. Banghe Zhu, Barrett
Harvey, Melissa Aldrich, Grace Wu, Nathaniel Wilganowski,
Holly Robinson, Kenneth Pinkston, Gao Peng, Songlin Zhang,
Ron Karni, Eva M. Sevick-Muraca.
2056
Identification of microscopic ovarian tumor foci
utilizing a novel imaging device in a murine ovarian
cancer model, an opportunity to improve optimal
cytoreduction. Youngjeong Na, Tim Kwok, Christopher
Awtrey, David B. Strasfeld, Jorge M. Ferrer, David Lee,
Michael J. Birrer.
2057
The development and evaluation of a series of
novel in vivo imaging models of AML for the
assessment of drug efficacy. Michael A. Batey, Frida
Ponthan, Helen J. Blair, Olaf Heidenreich.
2058
Molecular imaging of glutaminolysis as a tool
for evaluating therapeutic response in preclinical
models of colorectal cancer. Matthew R. Hight, Michael L.
Schulte, Samir Saleh, Gregory D. Ayers, Frank L. Revetta,
M. Kay Washington, Robert J. Coffey, H. Charles Manning.
2059
In situ imaging of antibody drug conjugate
(ADC) binding and pharmacodynamic biomarkers of
response in models of human cancer. Jonathon Golas,
Andrea T. Hooper, Justin Lucas, Heather Jones, Timothy
Nichols, Kiran Khandke, Manoj Charati, Roger Conant,
Michael Cinque, Judy Lucas, Marc Damelin, Ken Geles,
Caiazzo Teresa, Frank Loganzo, Puja Sapra, Hans-Peter
Gerber, Chad May.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
2060
Quantifying vascular biomarkers with contrastenhanced molecular ultrasound imaging. Janet M.
Denbeigh, Brian A. Nixon, John J. Lee, Mirjana Jerkic, Philip
A. Marsden, Michelle Letarte, Mira C. Puri, F. Stuart Foster.
2061
Extended adjuvant temozolomide improves
survival in a glioblastoma mouse model. Hanxiao Wang,
Wajd Al-Holou, Kevin Heist, Craig J. Galbán, Ana C.
deCarvalho, Tom Mikkelsen, Brian D. Ross, Alnawaz
Rehemtulla.
2062
The biodistribution pattern depending on the
size of anti-tissue factor antibodies. Ryo Tsumura, Ryuta
Sato, Yoshikatsu Koga, Yoshiyuki Yamamoto, Yuki Fujiwara,
Masahiro Yasunaga, Yasuhiro Matsumura.
2063
Trojan horsing the blood-brain barrier with
nanocarriers aided by adenosine receptor agonists. Nasir
Al Awwad.
2064
Mass Spectrometry Imaging of therapeutic
antibodies: Distribution of unlabeled trastuzumab in
CB.17 SCID mice implanted with the human breast
BT474 xenograft. David Bonnel, Chassidy Hall, Robert J.
Mullin, Kathryn A. Simon, Jonathan Stauber.
2065
Magnetic resonance imaging with an iron oxide
nanoparticle demonstrates the preclinical feasibility of
predicting intratumoral uptake and activity of MM-398,
a nanoliposomal irinotecan (nal-IRI). Ashish V. Kalra,
Joseph Spernyak, Jaeyeon Kim, Arnold Sengooba, Stephan
Klinz, Nancy Paz, Jason Cain, Walid Kamoun, Ninfa
Straubinger, Yang Qu, Sheryl Trueman, Eliel Bayever, Ulrik
Nielsen, Daryl Drummond, Jonathan Fitzgerald, Robert
Straubinger.
2066
Comparison of ADC MRI, T2-weighted MRI and
combined T2-weighted/T1-contrast-enhanced/ADC MRI
quantification of cerebral edema in an intracranial
glioma model. Deanne Lister, Deepa Balagurunathan,
Meridith Baugher, Athena Flecha, Erin Trachet, Scott Wise,
W.R. Leopold, Patrick McConville.
2067
Hyperpolarized 13C-pyruvate MRS quantitatively
monitor the therapeutic efficacy of adjuvant metformin
combined RT in brain metastasis from triple negative
breast cancer. Young-suk Choi, Han-Sol Lee, Jung-Sung
Lee, Hyun-Jin Park, Ju-Hyun Lee, Eun-Kyung Wang, SeungWook Yang, Eunhae Joe, Soo Hyeon Lee, Dong-Hyun Kim,
Ho-Taek Song.
2068
RRx-001 oxidation of redox sensitive protein
thiols in tumors measured by Gd-LC7-SH enhanced MRI
In preclinical tumor models. Natarajan Raghunand, Jan
Scicinski, Bryan Oronsky, Gerald Guntle, Elizabeth
Bruckheimer, Ron Korn.
2069
Initial PET imaging and pharmacokinetic results
from a Phase I/II study of Zr-89-labeled anti-STEAP1
antibody in metastatic castrate-resistant prostate
cancer (mCRPC) patients. Jorge A. Carrasquillo, Daniel C.
Danila, Volkan Beylergil, Joseph A. O’Donoghue, Sarah M.
Cheal, Shutian Ruan, Neeta Pandit-Taskar, Josef J. Fox,
Stephen E. Fleming, Pat B. Zanzonico, Govind Ragupathi,
Serge K. Lyashchenko, Simon P. William, Steven M. Larson,
Howard I. Scher, Bernard M. Fine, Michael J. Morris.
2070
In vivo imaging of therapy response to novel
antibody mixtures targeted at the human epidermal
growth factor receptor family using FDG and FLT
positron emission tomography. Carsten H. Nielsen, Mette
M. Jensen, Helle J. Jacobsen, Thomas T. Poulsen, Ivan D.
Horak, Johan Lantto, Michael Kragh, Andreas Kjaer.
2071
The utility of FDG uptake as a surrogate
biomarker to monitor tumor cell metabolism in response
to anticancer therapy. Nanni Huser, Wenlin Li, Maruja Lira,
Patrick Lappin, Erick Kindt, Valeria Fantin, Gary Li, Cathy C.
Zhang.
2071A Anti-VEGF treatment in orthotopic breast cancer
xenografts: Dynamic contrast-enhanced micro-CT correlates
with 3D multispectral fluorescence histology. Thomas
Pöschinger, Anja Renner, Fabian Eisa, Michael Dobosz, Robert
Brauweiler, Willi A. Kalender, Werner Scheuer.
POSTER SESSION
Tumor Biology 25
Positive Modulators of Tumor Metastasis
Poster
Section
Poster Abstract
Board Number
1.
2072
Chitinase-3-like-1 protein expression associated
with pulmonary inflammation accelerates metastasis to
the lung. Stephania Libreros, Ramon Garcia-Areas, Vijaya
Iragavarapu-Charyulu.
2.
2073
Neutrophil serine proteases, cathepsin-G and
elastase, promote metastasis through cleavage of
thrombospondin-1. Tina El Rayes, Raul Catena, Sharrell
Lee, Dingcheng Gao, Marcin Stawowczyk, Nasser Altorki,
Vivek Mittal.
3.
2074
Metastasis prevention using fibroblast
activation protein-targeting prodrugs at the premetastatic niche. Meera Murgai, Amber Giles, Miki Kasai,
Yorleny Vicioso, Crystal Mackall, Rosandra Kaplan.
4.
2075
Resistin promotes MMP-2 production and
migration in human chondrosarcoma cells through
AMPK/p38/mir 519d pathway. Ho-Ning Huang, Chih-Hish
Tang, Yuan-Li Huang.
5.
2076 ␤III-tubulin is required for the tumorigenic
phenotype and resistance to anoikis via the PTEN/AKT
signaling axis in non-small cell lung cancer. Joshua A.
McCarroll, Pei Pei Gan, Rafael B. Erlich, Marjorie Liu, Tanya
Dwarte, Mia C. Akerfeldt, Melissa Chang, Michael S. Shum,
Frances Byrne, Maria Kavallaris.
14.
2085
Interleukin 33 promotes tumor development,
progression, and metastasis in colorectal cancer. Yu
Zhang, Celestia Davis, Maria M. Pena.
15.
2086
PLK1 promotes epithelial-to-mesenchymal
transition, confers oncogenic potential, and targets
metastasis in prostate cancer. Jianguo Wu, Andrei Ivanov,
Jinglei Zhang, Zheng Fu.
16.
2087
Multiple drug resistance-associated protein 4
(MRP4) may contribute to breast cancer metastasis by
exporting the COX-2 product PGE2. Tyler J. Kochel,
Namita Kundu, Xinrong Ma, Jocelyn Reader, Amy M. Fulton.
17.
2088
Kindlin-3 enhances breast cancer metastasis
through upregulation of Twist-mediated tumor
angiogenesis. Khalid Sossey-Alaoui, Elzbieta Pluskota,
Gangarao Davuluri, Katarzyna Bialkowska, Mitali Das, Daniel
Lindner, Edward F. Plow.
18.
2089
MMP7-mediated cleavage of nucleolin at the
Asp255 induces MMP9 expression to promote tumor
malignancy. Jan-Jong Hung, Wen-Chang Chang.
19.
2090
Novel role of STAT-3 in anoikis resistance and
metastasis in melanoma cells in vitro and in vivo. Neel
M. Fofaria, Sanjay K. Srivastava.
20.
2091
Metastatic oral cancer cell adhesion to vascular
and lymphatic endothelial cells is sialyl Lewis A/Xdependent. Ahmed Alkishi, Syed Ali Khurram, Martin
Thornhill, Craig Murdoch.
21.
2092
Elevated PKC␣ expression and its association
with Notch signaling in localized and metastatic
prostate cancers. Xinchun Zhou, He Zhu, Xu Zhang, Jack
Lewin, Lucio Miele.
22.
2093
LPP promotes ErbB2 overexpressing breast
cancer cell migration, invasion and metastasis. Elaine
Ngan, Peter M. Siegel.
23.
2080
Plasma membrane fluidity drives metastasis in
breast cancer. Weina Zhao, Michael Tisza, Jessie Sjol,
Sendurai Mani, Jeffrey T. Chang.
2094
Regulation of site-specific liver metastasis by
collagen IV-conveyed signals. Roni F. Rayes, Ni Wang,
Julia V. Burnier, France Bourdeau, Pnina Brodt.
24.
2081
FoxM1 transactivates PTTG1 and promotes
colorectal cancer cell migration and invasion. Jinjun
Guo, Yun Zheng, Yunguang Tong, H P. Koeffler.
2095
FAK mediates STAT3 activation, migration and
invasion in ovarian carcinoma cells. Fang Xiao, Denise C.
Connolly.
25.
2096
HIF-1␣ is a crucial factor in the development of
peritoneal dissemination via natural metastatic routes in
scirrhous gastric cancer. Shuusuke Miyake, Yoshihiko
Kitajima, Jun Nakamura, Keita Kai, Kazuyoshi Yanagihara,
Tomokazu Tanaka, Masatsugu Hiraki, Kohji Miyazaki,
Hirokazu Noshiro.
26.
2097
Distinct levels of circulating tumor cell counts
for the papillary thyroid cancer patients with distant
metastases and in disease-free status. Hung-Chih Lin,
Ju-Chien Cheng, Ching-Ping Tseng, Jen-Der Lin.
27.
2097A
The role of Lipocalin-2 in colorectal cancer
metastasis. Daniel T. Hughes.
6.
2077
Snail modulates stemness properties in hypoxic
Glioblastoma. Chitrangda srivastava, Khushboo Irshad, Arpit
Sahu, Parthaprasad Chattopadhyay, Chitra Sarkar, Deepak
K. Gupta, Subrata Sinha, Kunzang Chosdol.
7.
2078
High-fat diet feeding increases the expression
of chemokines in the target organs and their
corresponding receptors in tumor tissues of mice
injected with highly metastatic prostate cancer cells.
Gyoo Taik Kwon, Hyerim Song,, Jung Han Yoon Park.
8.
2079
EpHA2 is an essential driver of invasion and a
novel target in KRAS mutant colorectal cancer. Philip D.
Dunne, Darragh G. McArt, Jaine K. Blayney, Sonali
Dasgupta, Manuel Salto-Tellez, Patrick G. Johnston, Sandra
Van Schaeybroeck.
9.
10.
11.
2082
PHD3 regulates EMT and therapy response in
lung cancer. Jose Higinio Dopeso Gonzalez.
12.
2083
WNT5a/ROR1 axis in triple-negative breast
cancer progression and potential therapy. Nicholas
Borcherding, Magdalene Ameka, Ryan Kolb, Qing Xie,
Weizhou Zhang.
13.
Poster Abstract
Board Number
2084
RhoGDI2 is associated with HGF-mediated
tumor invasion through VEGF in stomach cancer. Sung
Ae Koh, Kyung Hee Lee, Eun Young Choi, Min Kyoung Kim,
Byung Ik Jang, Si Hyung Lee, Kyeong Ok Kim, Kook Hyun
Kim, Jae Ryong Kim, Sang Woon Kim, Se Won Kim.
8
8
367
POSTER SESSION
Endocrinology 2
Poster
Section
9
9
Molecular Endocrinology of Hormone-responsive Cancers
Poster Abstract
Board Number
1.
2098
Histone deacetylation underlying hMAPKinduced ER mRNA repression. Amy J. Plotkin, ClaudeHenry Volmar, Nagi Ayad, Dorraya El-Ashry.
2.
2099
Cellular and molecular determinants of retinoic
acid sensitivity in breast cancer. Enrico Garattini, Floriana
Centritto, Silvio K. Garattini, Gabriela Paroni, Marco Bolis,
Maddalena Fratelli, Mineko Terao.
3.
4.
5.
368
2100
Regulation of breast tumor kinase (Brk)
expression in triple negative breast cancer integrates
cell stress and cortisol signaling pathways. Tarah M.
Regan Anderson, Andrea R. Daniel, Carol A. Lange.
2101
Role of CDK8 in estrogen receptor signaling in
breast cancers. Martina McDermott, Balazs Gyorffy, Changuk Lim, Alexander Chumanevich, Zhengguan Yang,
Mengqian Chen, James F. Catroppo, Igor Roninson, Eugenia
V. Broude.
2102
Phenformin down-regulates mammary
aromatase expression via the AMPK pathway in
humanized aromatase expressing ERBB2 mice. Hong
Zhao, Robert T. Chatterton, Timothy Prajka, Lin Li, Serdar E.
Bulun.
Poster Abstract
Board Number
15.
2112
AR splice variants ARv7 and ARv567 utilize
different mechanisms of cytoplasmic trafficking and
nuclear translocation: Therapeutic implications for PC.
Luigi Portella, Paraskevi Giannakakou.
16.
2113
Androgen receptor splice variants activating the
full-length receptor in mediating resistance to
androgen-directed therapy. Yanfeng Qi, Bo Cao, Guanyi
Zhang, Duo Xu, Zhiyong Guo, Zhenggang Xiong, Stephen
Plymate, Oliver Sartor, Haitao Zhang, Yan Dong.
17.
2114
UGT2B17 is a unique co-regulator of the
androgen receptor and androgen receptor splice
variants in prostate cancer. Gang Liu, Shihua Sun,
Kathleen Haugk, Cynthia Sprenger, Xeusen Dong, Elahe
Mostaghel, Stephen R. Plymate.
18.
2115
Interrogation of mechanisms that underlie
augmented steroidogenesis in castration-resistant
prostate cancer. Kai-Hsiung Chang, Nima Sharifi.
19.
2116
Mapping peptides critical for association of the
androgen receptor with Elk1. Rayna Rosati, Mugdha Patki,
Venkatesh Chari, Manohar Ratnam.
20.
2117
Constitutively active androgen receptor variants
upregulate expression of mesenchymal markers in
prostate cancer cells. Félicie COTTARD, Irène ASMANE,
Eva ERDMANN, Jean-Pierre BERGERAT, Jean-Emmanuel
KURTZ, Jocelyn CERALINE.
21.
2118
Differential efficiency in the deletion of
estrogen receptor ␤ DNA binding domain generates
distinct phenotypes in the mouse ventral prostate and
ovary. Laure Maneix, Per Antonson, Sabrina S. Rochel-Maia,
Hyun-Jin Kim, Margaret Warner, Jan-Ake Gustafsson.
6.
2103
Utilizing ER target genes as biomarkers of
endocrine response in serous ovarian carcinoma.
Courtney L. Andersen, Matthew J. Sikora, Soumya Luthra,
Uma Chandran, Paul Haluska, Steffi Oesterreich.
7.
2104
Mechanisms for the inhibition of estrogen
receptors by estrogen related receptor beta and
oxysterols. Nicholas J. Starkey, Lu Yuan, Yufei Li, Dennis
B. Lubahn.
8.
2105
Regulation of estrogen receptor turnover by
lysine 302 methylation. Elizabeth L. Zoeller, Dalia BarsyteLovejoy, Peter J. Brown, Dafydd R. Owen, Cheryl H.
Arrowsmith, Paula M. Vertino.
22.
2119
Regulation of T-type calcium channel
expression during IL-6 induced neuroendocrine
differentiation of prostate cancer cells. Erika Weaver,
Jennifer L. Hearne, Miguel Martin-Caraballo.
9.
2106
Estrogen receptor alpha drives proliferation of
prostate cancer through PI3K and MAPK signaling.
Itsuhiro Takizawa, Mitchell Lawrence, Helen Pearson, John
Pedersen, Normand Pouliot, Australian Prostate Cancer
BioResource, Patrick Humbert, Luc Furic, Gail Risbridger.
23.
2120
Cdk5 involves in interleukin-6 induces AR
activation through phosphorylation of serine 727 Stat3
and serine 81 AR in prostate cancer cells. Jo-Hsin Wang,
Pei-Chi Li, Li-Chiung Lin, Fu-Ning Hsu, Mei-Chih Chen, Ho
Lin.
10.
2107
Aurora A kinase and progesterone receptor
cross talk in breast cancer. Katherine A. Leehy, Tarah M.
Regan Anderson, Andrea R. Daniel, Antonino B. D’Assoro,
Carol A. Lange.
24.
2121
Resveratrol regulates phospho-serine 81
androgen receptor and its stability to inhibit growth of
prostate cancer cells. Yu-Ting Peng, Tzu-Yin Chen, MeiChih Chen, Eugene Lin, Ho Lin.
11.
2108
Estrogen non genomic signalling is activated in
tamoxifen-resistant breast cancer. Coralie Poulard,
Juliette Rambaud, Pascale Cohen, Antimo Migliaccio, Laura
Corbo, Elisabetta Marangoni, Muriel Le Romancer.
25.
2122
Androgen decreases proliferation of thyroid
cancer cells. Melanie E. MacEwan, Timmy O’Connell, Hong
Zhao, Codrin Iacob, Nina Suslina, Augustine Moscatello,
Edward Shin, Raj Tiwari, Zbigniew Darzynkiewicz, Jan
Geliebter.
12.
2109
All trans-retinoic acid (ATRA) induces
redifferentiation of early transformed breast epithelial
cells. Maria F. Arisi, Rebecca A. Starker, Sankar Addya,
Yong Huang, Sandra V. Fernandez.
26.
2123
Her2 affects AR phosphorylation at serine 81
and suppresses cell proliferation of breast cancer cell
line MDA-MB-453. Pao-Hsuan Huang, Chen-Chuan Huang,
Yueh-Tsung Lee, Chia-Herng Yue, Ho Lin.
13.
2110
Molecular characterization of everolimusresistant cell lines established from estrogen depletionresistant MCF-7. Mariko Kimura, Toru Hanamura, Toshifumi
Niwa, Yuri Yamaguchi, Itaru Endo, Shin-ichi Hayashi.
27.
2124
Analysis of FAM111A, a newly identified AR
regulated gene, in prostate cancer. Maria Mudryj,
Stephen J. Libertini, Alan P. Lombard, Salma Saddiqui,
Paramita M. Ghosh.
14.
2111
Role of gene repression by estrogen in
invasiveness of breast cancer cells. Mugdha Patki,
Marcela d’Alincourt Salazar, Robert Trumbly, Manohar
Ratnam.
28.
2125
G-protein coupled receptors for cholecystokinin
regulate transactivation of EGF receptors in lung cancer
cells. Terry W. Moody, Suk Hee Lee, Paola Moreno Perez,
Robert T Jensen.
POSTER SESSION
Chemoprevention Studies
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2126 PIK3CA mutation status is not involved in the
response of nonsteroidal anti-inflammatory drugs in
colorectal cancer cell lines. Ester Borras-Flores, Kara
Calhoun, Gita Bhatia, Hong Wu, Eduardo Vilar-Sanchez.
2127
Silibinin modulates the inflammatory signals on
colon cancer stem cells and provides protective effect
against colitis-associated colon tumorigenesis. Alpna
Tyagi, Ranganatha Somasagara, Sushil Kumar, Komal Raina,
Chapla Agarwal, Rajesh Agarwal.
2128
The effects of Quercetin on prostate cancer.
Ashley B. Ward, Pranav Gupta, Gurpreet Kaur, Hina Mir,
James W. Lillard, Shailesh Singh.
2129
Effects of talactoferrin on lung adenoma
prevention in A/J mice. Donna Seabloom, Arthur Galbraith,
Anna Haynes, Jenny Antonides, Alisha Fujita, Beverly R.
Wuertz, Vernon Steele, Frank Ondrey, Lee Wattenberg.
2130
Oral intervention of Withaferin A (WA)
suppresses tumor growth and metastasis in TRAMP
model. Chendil Damodaran, Suman Suman, Trinath P. Das.
2131
Effects of black raspberries and their
constituents on rat prostate carcinogenesis and human
prostate cancer cell growth. Jillian N. Eskra, Michael J.
Schlicht, Maarten C. Bosland.
2132
Personalized prevention of colorectal rectal trial
(PPCCT). Qi Dai, Martha J. Shrubsole, Xinqing Deng,
Xiangzhu Zhu, Eugene Shubin, Tiffany McCray, Wei Zheng,
Harvey Murff, Douglas Seidner, Reid M. Ness, Chang Yu.
2133
Suppressing effect of a Kava fraction on two
lineages of prostate carcinogenesis in the transgenic
adenocarcinoma of mouse prostate model. Su-Ni Tang,
Palika Datta, Peixin Jiang, Pablo Leitzman, Cheng-guo Xing,
Cheng Jiang, Junxuan Lu.
2134
Black raspberries and protocatechuic acid
protectively alter gut bacteria and bile acid metabolism
Min/ⴙ
in Apc
mice. Chieh-Ti Kuo, Hsin-Tzu Wang, Jo-Hsin
Chen, Jibran Siddiqui, Matthew R. Young, Shakir Saud, Gary
Stoner, Li-Shu Wang.
2135
Chemoprevention of tobacco carcinogeninduced lung cancer by DFMO and Licofelone
administered individually or in combination in female
A/J mice. Jagan Mohan R. Patlolla, Levy Kopelovich, Li
Qian, Laura Biddick, Yuting Zhang, Michael K. Sadeghi,
Dhimant Desai, Shantu Amin, Stan Lightfoot, Vernon E.
Steele, Chinthalapally V. Rao.
2136
Long-term metformin use reduces gastric
cancer risk in type 2 diabetics without insulin
treatment: a nationwide cohort study. Soo-Jeong Cho,
Young-Il Kim, So Young Kim, Jong-Hyock Park, Il Ju Choi,
You Jin Lee, Eun Kyung Lee, Myeong-Cherl Kook, Chan
Gyoo Kim, Keun Won Ryu, Young-Woo Kim.
2137
Prevention of HER2 overexpressing early stage
breast disease progression by lapatinib. Jia Xu, Shalini
Jain, Dihua Yu.
2138
6-Shogaol from dried ginger inhibits growth of
prostate cancer cells both in vitro and in vivo. Achinto
Saha, Jorge Blando, Eric Silver, Linda Beltran, Jonathan
Sessler, John DiGiovanni.
2139
Pre-clinical chemopreventive efficacy of a novel
hybrid p-XSC-aspirin compound in a NNK-induced A/J
mouse lung cancer model. Daniel Plano, Cesar Aliaga,
Manoj K. Pandey, Arunangshu Das, Timothy K. Cooper,
Shantu Amin, Arun K. Sharma.
2140
Efficacy of aerosolized pioglitazone in lung
carcinogenesis in A/J mice. Donna Seabloom, Art
Galbraith, Beverly Wuertz, Anna Haynes, Jenny Antonides,
alisha fujita, Vernon Steele, Lee Wattenberg, Frank G.
Ondrey.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2141
Dietary feeding of Kava root extract inhibits
prostate carcinogenesis in the transgenic
adenocarcinoma of the mouse prostate (TRAMP) model.
Xuesen Li, Christopher A. Blair, Xiaolin Zi.
2142
Plumbagin, a medicinal plant-derived 1,4napthoquinone, inhibits prostate carcinogenesis in
intact and castrated Pten knockout mice by modulation
of tumor microenvironment. Bilal B. Hafeez, Joseph W.
Fischer, Ashok Singh, Ala Mustafa, Louise Meske, Ajit K.
Verma.
2143
Inhibiting fatty acid synthase for
chemoprevention of chemically induced colorectal
tumors. Hajime Orita, Sigekazu Tanaka, Hiroshi Maekawa,
Mutsumi Sakurada, Tomonori Kushida, Tomoaki Ito,
Masahiro Miyazaki, Toshihiko Shiroishi, Koichi Sato.
2144
Retinoid and carotenoid depletion in patients at
high-risk for liver cancer. Yachana Kataria, Erika Enk
Rueter, Ryan Deaton, Donald Jensen, Scott Cotler, Peter
Gann.
2145
Chemopreventive and immune-modulatory
effects of the Cucumaria frondosa extract, Frondanol A5
in the APCMin/ⴙ mice intestinal tumorigenesis. Naveena
B. Janakiram, Altaf Mohammed, Misty Brewer, Peter D.
Collin, Vernon E. Steele, Chinthalapally V. Rao.
2146
The chemo-preventive effect of ER-␤ agonist on
DMBA induced breast cancers. Young J. Choi, Yehwang
Cheong.
2147
The effects of artemisinin, dihydroartemisinin
and artemisinin-glycolipid on non-small cell lung cancer
induced bone destruction. Gwang-Taek Ma, Kwang-Kyun
Park, Won-Yoon Chung.
2148
Inhibitory effects of liensinine and nuciferine on
breast cancer-associated bone loss. Eun-Ji Kang, WonYoon Chung, Kwang-Kyun Park.
2149
Novel compound 1, 3-bis (3, 5-dichlorophenyl)
urea inhibits lung cancer progression. Sharad S. Singhal,
James Figarola, Jyotsana Singhal, Lokesh Nagaprashantha,
David Berz, Samuel Rahbar, Sanjay Awasthi.
2150
Chemopreventive effects of black raspberries in
endometrial cancer. Jo-Hsin Chen, Irene AguileraBarrantes, Chieh-Ti Kuo, Leena Hilakivi-Clarke, Gary D.
Stoner, Janet S. Rader, Yi-Wen Huang.
2151
Evaluation of a citrus flavonoid as a
chemopreventive agent against breast cancer. Jia-Yu Ke,
Min Tian, Kara L. Kliewer, Steve J. Schwartz, Ken M. Reidl,
Shin-yu Tsai, Lisa D. Yee, Martha A. Belury.
2152
Akt/survivin pathway inhibition synergizes the
apoptotic cell death induced by A-santalol in prostate
cancer cells. Ajay Bommareddy, Lauren Lockus, Jonathan
Seward, William Eggelston, Stacy Prelewicz, Andrea Antal,
Sarah Fillman, Christian Castro, Adam L. VanWert, Sreevidya
Santha, Chandradhar Dwivedi.
2153
Metformin and aspirin synergistically inhibit
mTOR and JAK/STAT3 signaling pathway and induce
cell death in pancreatic cancer cells. Wen Yue, Yong Lin,
Chunxia Chen, Darren R. Carpizo, Robert S. DiPaola, XiangLin Tan.
2154
Notoginseng suppresses azoxymethane/dextran
sulphate sodium-induced colitis and colitis-associated
colorectal carcinogenesis. Chong-Zhi Wang, Chun-Su
Yuan.
2155
Novel combinations of nano-formulated ferulic
acid and aspirin show high potential for
chemoprevention of pancreatic cancer. Arvind Thakkar,
Jeffrey Wang, Sunil Prabhu.
11
11
369
POSTER SESSION
Epidemiology 6
Poster
Section
12
12
Lifestyle Factors and Cancer Risk/Mortality
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
370
2156 Childhood exposure to secondhand smoke, nicotine
dependence, and DRD1 are associated with lung cancer risk.
Victoria A. Zigmont, Brid M. Ryan, Jin Jen, Ana I. Robles, Cain
McClary, Kara Calhoun, Elise D. Bowman, Kirsi Vähäkangas, K. Leigh
Greathouse, Wang Yi, Angela S. Wenzlaff, Bo Deng, Ping Yang, Ann
G. Schwartz, Curtis C. Harris, Susan Olivo Marston.
2157 Causal effects of delaying smoking initiation on
subsequent lung cancer risk. Orestis A. Panagiotou, Fangyi Gu,
Carolyn Reyes-Guzman, Maria-Teresa Landi, Michele Bloch, Neil E.
Caporaso, Sholom Wacholder.
2158 Smoking before first childbirth may explain some of
the increase in breast cancer diagnosed before 50 years of age.
Inger T. Gram, Melissa A. Little, Eiliv Lund, Tonje Braaten.
2159 A prospective study of non-steroidal anti-inflammatory
drug use and colorectal adenoma and colorectal cancer. Wen-Yi
Huang, L. Joseph Su, Christine C. Johnson, Mark P. Purdue, Sonja I.
Berndt.
2160 Metformin use is not associated with pancreatic
cancer risk in a clinic-based case-control study conducted in
the San Francisco Bay Area, California. Evan J. Walker, Andrew
H. Ko, Elizabeth A. Holly, Paige M. Bracci.
2161 Metformin and cancer risk: A cohort study in the UK
Clinical Practice Research Datalink analyzed like a randomized
trial. Konstantinos K. Tsilidis, Despoina Capothanassi, Naomi Allen,
Evangelos Rizos, David Lopez, Karin van Veldhoven, Carlotta
Sacerdote, Deborah Ashby, Paolo Vineis, Ioanna Tzoulaki, John
Ioannidis.
2162 Prior bone health history in breast cancer patients on
aromatase inhibitors. Marilyn L. Kwan, Joan C. Lo, Li Tang, Cecile
Laurent, Janise M. Roh, Malini Chandra, Theresa E. Hahn, Chi-Chen
Hong, Lara Sucheston-Campbell, Dawn L. Hershman, Bette J. Caan,
Charles P. Quesenberry, Barbara Sternfeld, Christine B. Ambrosone,
Lawrence H. Kushi, Song Yao.
2163 Height, weight and weight changes during adulthood
and thyroid cancer risk. Yunji Hwang, Kyu-Eun Lee, Young Joo
Park, Do Joon Park, Yeo-Kyu Youn, Yohwan Yeo, Seung-Hyun Ma,
Daehee Kang, Keun-Young Yoo, Sue K. Park.
2164 Age at attainment of adult height and risk of primary
brain tumors. Rebecca B. Little, Louis B. Nabors, Jeffrey J. Olson,
Zachary J. Thompson, Melissa H. Madden, Renato V. LaRocca, Peter
A. Forsyth, Reid C. Thompson, Kathleen M. Egan.
2165 Parents’ ages at birth and risk of hormone-related
cancer among women in the California Teachers Study. Yani Lu,
Jianning Luo, Sophia Wang, Huiyan Ma, Jane Sullivan-Halley, Peggy
Reynolds, Leslie Bernstein.
2166 A prospective study on oral contraceptive use and risk
of colorectal adenomas. Brittany M. Charlton, Ed Giovannucci,
Charles S. Fuchs, Stacey A. Missmer, Bernard A. Rosner, Kana Wu,
Karin B. Michels.
2167 Infertility and risk of incident endometrial carcinoma:
a pooled analysis from the Epidemiology of Endometrial Cancer
Consortium. Hannah P. Yang, Linda S. Cook, Elisabete Weiderpass,
Hans-Olov Adami, Kristin E. Anderson, Hui Cai, James R. Cerhan,
Tess Clendenen, Ashley S. Felix, Christine Friedenreich, Montserrat
Garcia-Closas, Marc T. Goodman, Xiaolin Liang, Jolanta Lissowska,
Lingeng Lu, Anthony M. Magliocco, Susan E. McCann, Kristen B.
Moysich, Sara H. Olson, Malcolm C. Pike, Silvia Polidoro, Fulvio
Ricceri, Harvey Risch, Carlotta Sacerdote, V. Wendy Setiawan, Xiao
Ou Shu, Amanda B. Spurdle, Britton Trabert, Penelope M. Webb,
Nicolas Wentzensen, Yong-Bing Xiang, Youming Xu, Herbert Yu, Anne
Zeleniuch-Jacquotte, Louise A. Brinton.
2168 Components of metabolic syndrome and total cancer
mortality. Wambui G. Gathirua-Mwangi, Jianjun Zhang.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
23.
24.
25.
26.
27.
28.
29.
30.
2169 Diabetes and pancreatic cancer survival: a prospective
cohort study. Adetunji T. Toriola, Lara Dalidowitz, David Linehan,
Rachael Stolzenberg-Solomon, Graham A. Colditz.
2170 Body mass index and non-Hodgkin lymphoma survival
in an ethnically diverse population: The Multiethnic Cohort
study. Qi Jie Nicholas Leo, Nicholas J. Ollberding, Lynne R. Wilkens,
Laurence N. Kolonel, Brian E. Henderson, Loic Le Marchand,
Gertraud Maskarinec.
2171 Weight change in relation to early breast cancer
events in breast cancer patients. Xuyian Kenéz, Andrea Markkula,
Maria Simonsson, Christian Ingvar, Carsten Rose, Helena C.
Jernström.
2172 Physical activity in relation to overall and colorectal
cancer specific survival in the Seattle Colon Cancer Family
Registry. Sheetal S. Hardikar, Polly A. Newcomb, Michael N.
Passarelli, Peter T. Campbell, Amanda I. Phipps.
2173 Survival time in pancreatic cancer patients with
metabolic syndrome varies by use of insulin and statins. Christie
Y. Jeon, Stephen J. Pandol, Marc T. Goodman.
2174 Association of diabetes and obesity with risk of
esophageal and gastric adenocarcinoma in the Iowa Women’s
Health Study (IWHS). Bryan P. LaBore, Anna E. Prizment, Frank G.
Ondrey, Kristin E. Anderson.
2175 Prospective association between obesity and statin
use with conversion from high-grade prostatic intraepithelial
neoplasia (HGPIN) to prostate cancer (PC). Jay H. Fowke, Saundra
Motley, Susan Byerly.
2176 Obesity and risk of colorectal cancer: A Mendelian
randomization study. Aaron P. Thrift, Sonja I. Berndt, Andrew T.
Chan, Jenny Chang-Claude, Martha L. Slattery, Michelle Cotterchio,
Graham Casey, John D. Potter, Polly A. Newcomb, Emily White,
Hermann Brenner, Ulrike Peters, Peter T. Campbell.
2178 Rotating night shift work and cancer mortality in the
nurses’ health study. Fangyi Gu, Jiali Han, Sue Hankinson, Eva
Schernhammer, Nurses’ Health Study Group.
2179 Relationship between daily habits and risk of death in
patients with biliary tract cancer: a large-scale cohort study in
Japan. Shinji Otani, Youichi Kurozawa, Takenobu Hosoda, Haosheng
Mu, Kazunari Onishi, Yae Yokoyama, Joji Watanabe, Teruhisa
Sakamoto, Kanenori Endo, Masahide Ikeguchi.
2180 Serum 25-hydroxyvitamin D, vitamin D binding protein,
and lung cancer survival in the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study. Gabriella M. Anic, Stephanie J. Weinstein,
Satu Männistö, Demetrius Albanes.
2181 Association of sleep duration, daytime napping, and
night shift work with breast cancer risk. Zefang Ren.
2182 Lifestyle factors are associated with late breast cancer
outcomes among 5-year survivors of estrogen-receptor positive
breast cancer. Sarah J. Nechuta, Wendy Y. Chen, Marilyn L. Kwan,
Elizabeth M. Poole, Shirley W. Flatt, John P. Pierce, Bette J. Caan,
Xiao Ou Shu.
2183 Serum alpha-tocopherol, beta carotene and cancer
survival in the ATBC Study. Kristin A. Moy, Stephanie Weinstein,
Satu Männistö, Demetrius Albanes.
2184 Past use of coal for cooking is associated with allcause mortality in the prospective Shanghai Women’s Health
Study. Christopher Kim, Xiao-Ou Shu, H. Dean Hosgood, Bryan A.
Bassig, Wei Jie Seow, Yongbin Xiang, Bu-Tian Ji, Wei Hu, Wong-Ho
Chow, Yutang Gao, Nathaniel Rothman, Qing Lan.
2185 Childhood obesity is associated with persistent
minimal residual disease (MRD) following induction therapy for
pediatric acute lymphoblastic leukemia. Etan Orgel, Jonathan
Tucci, Wassem Alhushki, David R. Freyer, Hisham Abdel-Azim,
Steven D. Mittelman.
POSTER SESSION
Epidemiology 7
Molecular and Genetic Epidemiology of Gastrointestinal Cancers
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2186 Inflammation- and angiogenesis- related genes: Interaction with
NSAID use, and serum inflammatory markers on colorectal cancer risk
within the Women’s Health Initiative. Nina Habermann, Elissa Brown, Reka
Toth, Dominique Scherer, Katharina Buck, Ting-Yuan David Cheng, Karen W.
Makar, Marian L. Neuhouser, Yingye Zheng, David J. Duggan, Shirley A.
Beresford, Mark Wener, Heather Ochs-Balcom, Adetunji Toriola, Cornelia M.
Ulrich.
2187 Colorectal cancer survival is not associated with genetic
variants related to risk of other cancers: The GECCO study. Jonathan M.
Kocarnik, Michael N. Passarelli, Amanda I. Phipps, Andrew T. Chan, Manish
Gala, Amit Joshi, Peter T. Campbell, Martha L. Slattery, John Potter, Emily
White, Sonja Berndt, Ulrike Peters, Polly A. Newcomb.
2188 Genetic variation in angiogenesis-related genes is associated
with colorectal cancer risk and prognosis. Dominique Scherer, Yesilda
Balavarca, Nina Habermann, Katharina Buck, Petra Seibold, Lisanne Kap, Katja
Butterbach, Katrin Pfütze, Axel Benner, Michael Hoffmeister, Hermann Brenner,
Barbara Burwinkel, Jenny Chang-Claude, Cornelia M. Ulrich.
2189 A rare copy number variant at chromosome 14q11 was
associated with sporadic colorectal cancer risk in Singapore Chinese. Peh
Yean Cheah, Lai Fun Thean, Yik-Ying Teo, Woon-Puay Koh, Jian-Min Yuan, Poh
Koon Koh, Min Hoe Chew, Choong Leong Tang.
2190 Fine-mapping of common genetic variants associated with
colorectal tumor risk identified potential functional variants. Mengmeng Du,
Shuo Jiao, Stephanie A. Rosse, Manish Gala, Goncalo Abecasis, Stephane
Bezieau, Hermann Brenner, Graham Casey, Jenny Chang-Claude, Steven
Gallinger, Thomas J. Hudson, Sébastien Küry, Loic Le Marchand, Suzanne M.
Leal, Polly A. Newcomb, Deborah A. Nickerson, John D. Potter, Martha L.
Slattery, Li Hsu, Andrew T. Chan, Emily White, Sonja I. Berndt, Ulrike Peters.
2191 Identification of functional risk alleles in colorectal cancerassociated regions in African Americans. Fabio Pibiri, Ricky Rechenmacher,
Rosa Xicola, Rick Kittles, Robert Sandler, Temitope Keku, Xavier Llor, John
Carpten, Sonia Kupfer, Nathan Ellis.
2192 Defective calcium signaling pathway highlights the mutational
landscapes of liver metastasis from colorectal and breast cancer. Fangfang
Song, Miao Li, Yuexin Liu, Fengju Song, Wei Zhang, Kexin Chen.
2193 Colorectal cancer risk associated with alcohol intake is
modified by common genetic variants in one-carbon metabolism: the
Multiethnic Cohort Study. Unhee Lim, Lynne R. Wilkens, Maarit Tiirikainen,
Carol J. Boushey, Laurence N. Kolonel, Loic Le Marchand.
2194 Genome-wide gene-environment interactions study on
colorectal cancer. Victor Moreno, Ulrike Peters, Li Hsu, Jian Gong, Yi Lin,
Bhramar Mukherjee, Graham Casey, Duncan Thomas, Stephen B. Gruber, Jim
Gauderman, on behalf of CORECT and CCFR.
2195 Genome-wide interaction analyses between genetic variants
and alcohol consumption and risk of colorectal cancer. Jian Gong, Carolyn
Hutter, Jenny Chang-Claude, Polly Newcomb, Sonja Berndt, Hermann Brenner,
Andrew T. Chan, Loic Le Marchand, Tabitha Harrison, Yi Lin, Martha L. Slattery,
Emily White, John Potter, Shuo Jiao, Mathieu Lemire, Li Hsu, Ulrike Peters.
2196 Two-phase study of PTH polymorphisms, calcium, magnesium
and colorectal adenoma risk. Zhu Xiangzhu, Martha J. Shrubsole, Reid M.
Ness, Qiuyin Cai, Walter E. Smalley, Todd L. Edwards, Edward Giovannucci, Wei
Zheng, Qi Dai.
2197 Interaction between genetic variants in one-carbon metabolism
and folate biomarkers on colorectal cancer risk: The Women’s Health
Initiative observational cohort. Ting-Yuan D. Cheng, Karen W. Makar, Marian
L. Neuhouser, Joshua W. Miller, Xiaoling Song, Elissa C. Brown, Shirley A.
Beresford, Yingye Zheng, David J. Duggan, Elizabeth M. Poole, Nina Habermann,
Reka Toth, Lynn B. Bailey, Marie A. Caudill, Cornelia M. Ulrich.
2198 A literature-based sum score of genetic variants in IGF genes
modifies associations between indicators of energy balance and colorectal
cancer risk. Colinda C. Simons, Leo J. Schouten, Roger Godschalk, FrederikJan van Schooten, Piet A. van den Brandt, Matty P. Weijenberg.
2199 CD14 gene polymorphisms associated with development of
colorectal cancer subtypes among atomic bomb survivors in Japan. Yiqun
Hu, Kengo Yoshida, Junko Kajimura, Seishi Kyoizumi, Yoichiro Kusunoki, John
Cologne, Waka Ohishi, Ikue Hayashi, Kei Nakachi, Tomonori Hayashi.
2200 Plasma Fetuin-a concentration, genetic variation in the AHSG
gene and risk of colorectal cancer. Katharina Nimptsch, Krasimira
Aleksandrova, Heiner Boeing, Jürgen Janke, Young-Ae Lee, Mazda Jenab, Bas
Bueno-De-Mesquita, Konstantinos K. Tsilidis, Elisabete Weiderpass Vainio,
Eugène H. Jansen, Timothy J. Key, Antonia Trichopoulou, Kim Overvad, Elio
Riboli, Tobias Pischon, European Prospective Investigation into Cancer
andNutrition (EPIC).
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2201 Long-term risk of colorectal cancer in patients with sessile
serrated adenomas, traditional serrated adenomas, and hyperplastic
polyps. John A. Baron, Rune Erichsen, Stephen J. Hamilton-Dutoit, Dale C.
Snover, Emina E. Torlakovic, Trine Frøslev, Lars Pedersen, Mogens Vyberg,
Stanley R. Hamilton, Henrik T. Sørensen.
2202 PIK3CA amplification was not associated with serrated polyps
but tubular adenomas in colorectal lesions. Jae-Ho Lee, Dae-Kwang Kim,
In-Jang Choi, IlSeon Hwang, Yu-Na Kang, Shin Kim.
2203 Pathway analysis of genome-wide association study data
highlights taste transduction and metabolic pathways and esophageal
squamous cell carcinoma susceptibility. Paula L. Hyland, Han Zhang, Qi
Yang, Shih-Wen Lin, Dennis Maeder, Nan Hu, Ze-Zhong Tang, Hua Su, Lemin
Wang, Chaoyu Wang, Ti Ding, Jin-Hu Fan, You-Lin Qiao, William Wheeler, Carol
Giffen, Laurie Burdett, Zhaoming Wang, Stephen J. Chanock, Sanford M.
Dawsey, Neal D. Freedman, Christian C. Abnet, Alisa M. Goldstein, Kai Yu, Philip
R. Taylor.
2204 Joint analysis of three genome-wide association studies of
esophageal squamous cell carcinoma in Chinese populations reveals new
susceptibility loci. Chen Wu, Zhaoming Wang, Xin Song, Xiao-Shan Feng,
Christian C. Abnet, Jie He, Nan Hu, Xian-Bo Zuo, Wen Tan, Xue-Jun Zhang, Neal
D. Freedman, Alisa M. Goldstein, Dongxin Lin, Philip R. Taylor, Li-Dong Wang,
Stephen J. Chanock.
2205 A three-gene signature predicts esophageal squamous cell
carcinoma prognosis. Huihui Cao, Enmin Li, Liyan Xu.
2206 Genetic variants in selenoprotein genes and risk of esophageal
squamous cell carcinoma and gastric cancer in a Chinese population.
Sharon Li, Paula L. Hyland, Neal D. Freedman, Nan Hu, Hua Su, Lemin Wang,
Chaoyu Wang, Ti Ding, Yuan Wang, Jin-Hu Fan, You-Lin Qiao, Xiaoqin Xiong, Kai
Yu, Alisa M. Goldstein, Sanford M. Dawsey, Philip R. Taylor, Christian C. Abnet,
Shih-Wen Lin.
2207 An analysis of circulating sex steroid hormones in relation to
Barrett’s esophagus. Michael B. Cook, Shannon Wood, Brooks D. Cash, Patrick
Young, Ruben D. Acosta, Roni T. Falk, Ruth Pfeiffer, Nan Hu, Carol Giffen,
Veronique Turcotte, Patrick Caron, Chantal Guillemette, Sanford M. Dawsey,
Christian C. Abnet, Paula L. Hyland, Philip R. Taylor.
2208 Detection of somatic mutations and gene amplifications using
amplicon sequencing with biopsy samples from patients with advanced
gastric cancer. Wataru Okamoto, Takeshi Kuwata, Shingo Matsumoto, Yoichi
Naito, Hideaki Takahashi, Kohei Shitara, Yasutoshi Kuboki, Hideaki Bando, Yoko
Yamada, Izumi Miki, Takeharu Yamanaka, Atsushi Ohtsu, Atsushi Ochiai,
Hiroyasu Esumi, Takayuki Yoshino, Katsuya Tsuchihara.
2209 Effects of IL10 haplotypes and atomic bomb radiation exposure
on risks of gastric cancer subtypes. Tomonori Hayashi, John B. Cologne,
Yiqun Hu, Kengo Yoshida, Waka Ohishi, Ikue Hayashi, Junko Kajimura, Seishi
Kyoizumi, Yoichiro Kusunoki, Kei Nakachi.
2210 Cumulative risks of gastric cancer by PSCA polymorphism,
Helicobacter Pylori infection and smoking history in Japan. Hidemi Ito, Isao
Oze, Satoyo Hosono, Miki Watanabe, Hideo Tanaka, Keitaro Matsuo.
2211 Viral subtypes in hepatocellular carcinoma are associated with
different mechanisms of WNT/CTNNB1 alteration. Kyle R. Covington,
Lawrence A. Donehower, Chad Creighton, Betty L. Slagle, John A. Goss, Ronald
T. Cotton, Marie-Claude Gingras, Eve Shinbrot, Jacfranz J. Guiteau, Thao N.
Nguyen, Theresa R. Harring, Donna M. Muzny, Kimberly Walker, HarshaVardhan
Doddapaneni, Richard A. Gibbs, Hiroyuki Aburatani, Tatsuhiro Shibata, David A.
Wheeler, Japan ICGC HCC Project.
2212 Urinary biomarkers of catechins in relation to risk of
hepatocellular carcinoma in the Shanghai Cohort Study. Joyce Y. Huang,
Lesley M. Butler, Renwei Wang, Chung S. Yang, Jian-Min Yuan, Yu-Tang Gao.
2213 Uncommon CHEK2 missense variant and reduced risk of
pancreatic cancer. Ghislaine Scelo, James McKay, Ivana Holcatova, Vladimir
Janout, Lenka Foretova, Eleonora Fabianova, Amelie Chabrier, Valerie Gaborieau,
Paul Brennan.
2214 Genome-wide gene-diabetes and gene-obesity interaction scan
in the pancreatic cancer case control consortium. Hongwei Tang, Eric J.
Duell, Harvey A. Risch Risch, Sara H. Olson, H. Bas Bueno-de-Mesquita, Steven
Gallinger, Elizabeth A. Holly, Gloria M. Petersen, Paige M. Bracci, Robert R.
McWilliams, Mazda Jenab, Elio Riboli, Anne Tjønneland, Marie Christine BoutronRuault, Rudolf Kaaks, Dimitrios Trichopoulos, Salvatore Panico, Malin Sund,
Petra H. M Peeters, Kay-Tee Khaw, Christopher I Amos, Donghui Li, Peng Wei.
2215 Association between single-nucleotide polymorphisms of BRAF
and papillary thyroid carcinoma in a Chinese population. Kexin Chen.
Poster
Section
13
13
371
POSTER SESSION
Poster
Section
15
15
Cancer Genetics and Genomics Studies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
372
2216 6q15 deletion impede development of ERG fusion in
prostate cancer. Martina Kluth, Maria Christina Tsourlakis, David
Meyer, Antje Krohn, Fabian Freudenthaler, Melanie Bauer, Georg
Salomon, Hans Heinzer, Uwe Michl, Stefan Steurer, Ronald Simon,
Guido Sauter, Thorsten Schlomm, Sarah J. Minner.
2217 Genomic alteration of bromodomain protein ATAD2 in
cancer. Tomoyo Takeda, Yuta Matsumura, Hirotoshi Nagasaki, Ken
Eguchi, Miki Takatsuka, Yoichi Shinkai, Hiroyuki Nakagawa, Hitoshi
Kawashima, Hiroyuki Ueno, Chiang J. Li.
2218 Genomic characterisation of 1015 cancer cell-lines.
Graham R. Bignell, Francesco Iorio, Andrew Futreal, Michael R.
Stratton, Peter Campbell, Ultan McDermott.
2219 STAT3 network dissection in ALK positive Anaplastic
Large Cell Lymphomas. Elisa Spaccarotella, Aldi Pupuleku, Elisa
Pellegrino, Cecilia Bandini, Manuela Ferracin, Daniela Cantarella,
Andrea Rinaldi, Paolo Provero, Ferdinando Di Cunto, Enzo Medico,
Francesco Bertoni, Giorgio Inghirami, Roberto Piva.
2220 Impact of single-nucleotide polymorphisms (SNPs) on
thymic hyperplasia and tumors outcome. Rossana Berardi, Silvia
Pagliaretta, Alessandro Brunelli, Vittorio Paolucci, Gaia Goteri, Majed
Refai, Cecilia Pompili, Agnese Savini, Giulia Marcantognini,
Mariangela Torniai, Michela Tiberi, Consuelo Ferrini, Francesca
Morgese, Miriam Caramanti, Silvia Rinaldi, Azzurra Onofri, Antonio
Zizzi, Paola Mazzanti, Stefano Cascinu.
2221 A new promoter of Casp 8 in an esophageal squamous
cell carcinoma susceptibility locus. Zhengwei Lin, Xiaohang Zhao,
Yang Xu, Zhimin Guo, Nan Zhao, Yulin Sun.
2222 Synergistic effects of NAT2 and GSTT1 null
polymorphism in lung cancer: a study from North India. Rajni K.
Shukla, Surya Kant, Sandeep Bhattacharya, Balraj K. Mittal.
2223 Genome-wide analysis of copy number alterations and
gene mutations in testicular germ cell cancer. Yusuke Sato, Aiko
Sato-Otsubo, Yasunobu Nagata, Kenichi Yoshida, Yuichi Shiraishi,
Hiromichi Suzuki, Masashi Sanada, Haruki Kume, Satoru Miyano,
Yukio Homma, Seishi Ogawa.
2224 Identification of molecular drivers of human
hemangioblastoma. Mianen Sun, Federico Monzon, Lijun Zhou,
Xiande Liu, Zhiyong Ding, Xuesong Zhang, Shanshan Bai, Peter
German, Sarathi Kalra, In Young Park, Ruhee Dere, Tia Berry, Xuefei
Tong, Cheryl Walker, Nizar Tannir, Surena Matin, Gregory Fuller, Ian
McCutcheon, Eric Jonasch.
2225 Comprehensive molecular characterization of
esophageal squamous cell carcinoma. Dechen Lin, Xuan Meng,
Liang Xu, Lingwen Ding, Manoj Garg, Henry Yang, Lizhen Liu, Jiajie
Hao, Mingrong Wang, Yasunobu Nagata, Yusuke Sato, Yusuke
Okuno, Seishi Ogawa, Phillip Koeffler.
2226 Loss of STAG2 in bladder cancer. Nithya Krishnan, Anna
Woloszynska-Read, Jianmin Wang, Song Liu, Carl Morrison, Khurshid
Guru, Evelyn Smit, Donald Trump, Candace Johnson.
2227 An automatic pipeline to find and annotate rare
subclonal somatic variants in a paired tumor/normal sample.
Anika Joecker, Nathan Pearson, Cecilie Boysen, Naomi Thomson,
Anne-Mette Hein, Bodil Oster, Anne Arens, Bjarne Knudsen, Thomas
Knudsen, Dan Richards, Roald Forsberg.
2228 Folate-related genes polymorphism and risk of
pediatric acute lymphoplastic leukemia. Nermin Raafat, Amal
Gharib, Usama Elsafy, Tamer Hassan.
2229 Whole exome sequencing reveals the landscape of
gene mutations and evolution in low-grade glioma. Hiromichi
Suzuki, Atsushi Natsume, Yusuke Sato, Yuichi Shiraishi, Yusuke
Shiozawa, Kenichi Yoshida, Yasunobu Nagata, Aiko Sato, Kazuya
Motomura, Masazumi Fujii, Masashi Sanada, Satoru Miyano,
Toshihiko Wakabayashi, Seishi Ogawa.
2230 Gene mutations and deletions inactivates PTEN tumor
suppressor in Chilean colon cancer patients. Gonzalo Encina,
Karin Alvarez, Paulina Orellana, Ana María Wielandt, Cynthia
Villarroel, Daniela Simian, Luis Contreras, Udo Kronberg, Francisco
López, Pilar Carvallo.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2231 The prevalence of EGFR and KRAS mutations in a
population of African immigrants in France is closer to that of
Asian populations than to white Europeans. Antoinette Lemoine,
Raphael Saffroy, Nelly Bosselut, Emmanuel Lecorche, Reza Etessami,
Marc A. Allard, Jean Tredaniel, Andre Balaton, Pierre Validire, Jean
F. Morere.
2232 Next generation sequencing of the EGFR signaling
pathway in colon cancer tumors from Chilean patients. Karin
Alvarez, Paulina Orellana, Cynthia Villarroel, Gonzalo Encina, Daniela
Simian, Camila Estay, Maki Kobayashi, Hiroshi Kawashi, Udo
Kronberg, Francisco Lopez, Pilar Carvallo.
2233 Rearrangement of ERG and CHD1 genes in prostate
cancer as a marker of tumor heterogeneity. Irina V.
Tereshchenko, Hua Zhong, Marina Chekmareva, Urmila Santanam,
Whitney Petrosky, Noriko Kane-Goldsmith, Jay A. Tischfield, Robert
DiPaola.
2234 Combined analysis of TERT, EGFR and IDH status
define distinct prognostic classes of GBM. Marianne Labussiere,
Blandine Boisselier, Karima Mokhtari, Anais Rahimian, Olivier
Saulnier, Yannick Marie, Marc Sanson.
2235 High frequency of fusion transcripts involving TCF7L2
in colorectal cancer: Novel fusion partner and splice variants.
Andreas M. Hoff, Torfinn Nome, Anne Cathrine Bakken, Torleiv O.
Rognum, Arild Nesbakken, Rolf I. Skotheim.
2236 The Biospecimen Methodological Study (BMS):
Identifying best practices for tissue preservation and
maintenance of RNA integrity. Abhi Rao, Latarsha Carithers, Helen
Moore.
2237 Acquisition of biospecimens to support the GenotypeTissue Expression (GTEx) project. Latarsha Carithers, Abhi Rao,
Helen Moore.
2238 Non-random genetic rearrangements driven highly
malignant tumor-cell population dictates the development of
high-risk neuroblastoma. Faizan H. Khan, Satish K. Ramraj,
Vijayabaskar Pandian, Sheeja Aravindan, Terence S. Herman, Mohan
Natarajan, Natarajan Aravindan.
2239 Macronodular adrenal hyperplasia due to mutations in
ARMC5: New mutations in humans and modeling in zebrafish.
Fabio R. Faucz, Mihail Zilbermint, Guillaume Assié, Maya B. Lodish,
Eva Szarek, Giampaolo Trivellin, Annabel Berthon, Ninet Sinaii,
Rossella Libé, Stéphanie Espiard, Ludivine Drougat, Bruno Ragazzon,
Benjamin Feldman, Jerome Bertherat, Constantine A. Stratakis.
2240 TERT promoter mutations are highly prevalent in
bladder cancer and represent a potential new urinary
biomarker. Carolyn D. Hurst, Fiona M. Platt, Margaret A. Knowles.
2241 SHH pathway in uterine mesenchymal tumors. Natalia
Garcia, Faila C. Souza, Nilo Bozzini, Glauco Baiocchi, Isabela W.
Cunha, Fernando A. Soares, Edmund C. Baracat, Kátia C. Carvalho.
2242 Comprehensive genome methylation and whole
genome expression analysis in penile carcinoma: Uncovering
new molecular markers. Hellen Kuasne, Ilce M. Colus, Hector
Hernandez-Vargas, Ariane F. Busso-Lopes, Mateus C. Barros-Filho,
Fabio A. Marchi, Christovan Scapulatempo-Neto, Eliney F. Faria,
Ademar Lopes, Gustavo C. Guimaraes, Zdenko Herceg, Silvia R.
Rogatto.
2243 Gene expression signature of aneuploidy in acute
myeloid leukemia. Giorgia Simonetti, Antonella Padella, Viviana
Guadagnuolo, Cristina Papayannidis, Francesca Volpato, Emanuela
Ottaviani, Serena Formica, Annalisa Astolfi, Ilaria Iacobucci, Giovanni
Capranico, Daniel Remondini, Giovanni Martinelli.
2244 SPOP mutations in prostate cancer across
demographically diverse patient cohorts. Mirjam Blattner, Daniel
Lee, Catherine O´Reilly, Kyung Park, Theresa Y. MacDonald,
Francesca Khani, Kevin Turner, Peter J. Wild, Haley Hieronymus,
Charles L. Sawyers, Ashutosh K. Tewari, Holger Moch, Ghil Suk
Yoon, Ove Andrén, Katja Fall, Juan M. Mosquera, Brian D. Robinson,
Andrea Sboner, Christopher E. Barbierie, Mark A. Rubin.
2244A Prion protein cross-talks with Notch1 to promote
pancreatic ductal adenocarcinoma progression. Yiwei Wang, Dan
Huang, Lan Zhou, Wei Xin.
POSTER SESSION
Hall A-E, Poster Section 16 • Monday, 1:00 pm.-5:00 p.m.
Cellular Senescence / Drug Responses
Poster
Section
Poster Abstract
Board Number
1.
2245
Mechanism of replicative senescence induced
by SNF5 loss. Darmood Wei, HoYoon Chung, Dennis A.
Simpson, William K. Kaufmann, Bernard E. Weissman.
2.
2246
Senescence as a result of impaired ribosome
biogenesis. Frédéric Lessard, Véronique Bourdeau, Xavier
Deschênes-Simard, Sebastian Igelmann, Marinieve Montero,
Gerardo Ferbeyre.
3.
4.
5.
6.
7.
11.
2255
DHA may enhance proteasome activity in
human cervical cancer cells: Indirect modulation of
proteasome by DHA. Kyu Lim, Kaipeng Jing, Soyeon Shin,
Soyeon Jeong, Soyeon Kim, Gi-Ryang Kweon, Seung-Kiel
Park, Tong Wu, Jong-Il Park.
12.
2256
p53 gene expression is epigenetically regulated
during replicative senescence in keratinocytes. Reuben
H. Kim, Mo K. Kang, Terresa Kim, Paul Yang, Christine
Hong, Ki-Hyuk Shin, No-Hee Park.
13.
2248
The implication of STAT3 degradation and its
mitochondrial functions in cellular senescence.
Sebastian Igelmann, Xavier Deschênes-Simard, Frédéric
Lessard, Véronique Bourdeau, Gerardo Ferbeyre.
2257
Divergent IRE1␣ endonuclease outputs dictate
the senescence response of mouse keratinocytes to
oncogenic HRAS. Nicholas Blazanin, Christian John, Alayna
Craig-Lucas, Adam Glick.
14.
2249
N- and C-terminal peptides of the tumor
suppressor protein IGFBP7 differentially induce growth
arrest or senescence in breast cancer cells. Tania C.
Benatar, Yutaka Amemiya, Valentina Evdokimova, Wenyi
Yang, Arun Seth.
2258
Tempol diet provides chemoprotection against
UV-induced skin cancer in mice with epidermal Smad4
deletion. Doyel Mitra, Bian Li, Qinghong Zhang, James B.
Mitchell, Xiao-Jing Wang.
15.
2250
Role of single strand binding protein 1 in TERT
recruitment to telomeres and in maintaining telomere
G-overhangs. Tej K. Pandita, Raj Pandita.
2259
Oxidative DNA damage causes premature
senescence in mouse embryonic fibroblasts deficient for
krüppel-like factor 4. Changchang Liu, Stephen La Rosa,
Engda Hagos.
16.
2251
nrf2-keap1 axis molecular profile in small cell
lung cancer cell lines. Lucia Anna Muscarella, Annamaria
la Torre, Angelo Sparaneo, Orazio Palumbo, Clelia Tiziana
Storlazzi, Teresa Balsamo, Domenico Trombetta, Fabio
Pellegrini, Raffaela Barbano, Barbara Pasculli, Paolo
Graziano, Montse Sanchez-cespedes, Maria Teresa Landi,
Paola Parrella, Vito Michele Fazio.
2260
c-Myc induced senescence is dependent on
transactivation of actin depolymerizing factor (ADF)/
cofilin to mediate potent bystander effect. Shih-Ting Lin,
Cheng-Han Tsai, Yi-Jang Lee, Chia-Chien Lo, Yen-Ting
Chou.
17.
2261
Natural redistribution of end-protection proteins
in aging cells as telomeres shorten. Michelle E. Baribault,
Mark J. Swanson, Nancy S. Bae.
18.
2262
Elevated peroxiredoxin expression in breast
cancer and its protective role in doxorubicin-resistance.
Jillian Muhlbauer, Gregg Perlmutter, Caitlin McDonald, Harry
Cintineo, Caterina Aiello, Shelley A. Phelan.
19.
2263
Change in miRNA by suberoylanilide
hydroxamic acid affects lung cancer cell death via
regulating thioredoxin. Bo Ra You, Bo Ram Han, Woo
Hyun Park.
2247
Histone H3 cleavage via Cathepsin L drives a
cellular senescence program. Luis F. Duarte, Andrew R.
Young, Hsan-Au Wu, Taniya Panda, Zichen Wang, Alexandre
G. Maia, Dan Hasson, Avnish Kapoor, Masashi Narita, Emily
Bernstein.
8.
2252
Gadd45b deficiency impairs G2/M cell cycle
progression leading to premature senescence. Andrew
Magimaidas, Barbara Hoffman, Dan Liebermann.
9.
2253
YAP nuclear accumulation involved in druginduced cellular senescence in vitro. Kai Ma, Shuren
Wang, Qing Xu, Mei Liu, Hongxia Zhu, Ningzhi Xu.
10.
Poster Abstract
Board Number
2254
Pro-angiogenic CXCL8 signalling underpins
microenvironment-induced relapse to anti-androgen
therapy of prostate cancer. Melanie McKechnie, Pamela J.
Maxwell, David J. J. Waugh.
16
16
373
POSTER SESSION
Poster
Section
17
17
Death Receptors and Death Signaling Upstream of the Mitochondria
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
374
2264
HIC (MDFIC) is a protein that interacts and
colocalizes with the RELT family of TNFRs. John K.
Cusick, Cara Sumida, Matthew Checketts, Mary E. Reyland,
Aaron T. Jacobs.
2265
Sub-fractions of conditioned medium, from
hypoxia-induced cells with multipotent potential, exhibit
a significant anti-oncogenic activity. Emmett Pinney,
Mayra Montes-Camacho, Kayler Brintle, Christian Posch,
Rhiana Menen, David Easter, Michael Bouvet, Robert
Hoffman, Gail Naughton.
2266
Investigating the role of the anti-apoptotic
protein ARC in breast cancer cell DNA repair. Eli
Grunblatt, Evanka Madan, Sweta Roy, Sumanta Goswami.
2267
Sulforaphane depresses proliferation and
induces cell death in glioblastoma multiforme (GBM)
cells, GBM stem cell-like spheroids, and tumor
xenografts through modulation of multiple cell signaling
pathways. Khadijeh Bijangi-Vishehsaraei, Mohammad R.
Saadatzadeh, Haiyan Wang, Malgorzata M. Kamocka,
Wenjing Cai, Aaron A. Cohen-Gadol, Stacey L. Halum, Karen
E. Pollok, Jann N. Sarkaria, Ahmad R. Safa.
2268
Augmentation of DR5 expression by calmodulin
antagonists sensitizes TRA-8-induced apoptosis in
pancreatic cancer. Kaiyu Yuan, Tong Zhou, Jay McDonald,
Yabing Chen.
2269
Combination of erlotinib and epigallocatechin-3gallate induces apoptosis of squamous cell carcinoma
of the head and neck through posttranslational
regulation of Bim and Bcl-2. Abedul Haque, Mohammad
A. Rahman, Zhuo G. Chen, Dong M. Shin, A.R.M. R. Amin.
2270
TRAIL-TZD combinatorial treatment induces
apoptosis in prostate cancer cells through modulation
of AMPK signaling pathway. Sreevidya Santha, Sunipa
Majumdar, Navin Viswakarma, Ajay Rana, Basabi Rana.
2271
Effective therapy for advanced renal cell
carcinoma using triptolide and TRAIL receptor agonists.
Thomas S. Griffith, Erik L. Brincks, Tamara A. Kucaba,
Britnie R. James, Veena Sangwan, Sulagna Banerjee, Ashok
Saluja.
2272
Understanding resistance to Trail and Trail
agonists. Hong Chen, Rosa A. Carrasco, Hui Feng, Robert
E. Hollingsworth, Zhan Xiao, David A. Tice.
2273
c-Rel is a critical mediator of NF-␬B-dependent
apoptosis resistance of pancreatic cancer cells against
TRAIL. Claudia Geismann, Frauke Grohmann, Gabriele
Wirths, Susanne Sebens, Anita Dreher, Robert Häsler,
Sebastian Zeissig, Stefan Schreiber, Philip Rosenstiel, Heiner
Schäfer, Alexander Arlt.
2274
RIP1-mediated sensitivity to SN38 induced by
TNF in colon adenocarcinoma cell lines. Lucia CabalHierro, Peter J. O’Dwyer.
2275
Characterization of the mechanistic basis of
Apo2L/TRAIL-AMG 655-dr5 interactions and cooperative
signaling in cancer cells. Tzu-Hsuan Huang, Wesley
Chang, Alexander Long, Xin Huang, Pamela Holland.
2276
Induction of apoptosis and inhibition of
angiogenesis by novel fusion protein - AD-O54.9 as a
new preclinical strategy in cancer treatment. Piotr
Rózga, Jerzy Pieczykolan, Bartłomiej Żerek, Anna
Pieczykolan, Marlena Gała˛zka, Katarzyna Bukato, Michał
Szymanik, Albert Jaworski, Sebastian Pawlak, Małgorzata
Teska-Kamińska, Anna Grochot-Prze˛czek.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
2277
TNF transactivation of EGFR protects EGFR-TKI,
gefitinib induced pulmonary epithelial cell apoptosis and
injury in TNF transgenic mice. Toshimitsu Yamaoka,
Yasunari Oki, Yasunori Murata, Sojiro Kusumoto, Hiroo
Ishida, Takao Shirai, Etsuko Toya, Motoi Ohba, Ken-ichi
Fujita, Satoru Arata, Tohru Ohmori, Tsukasa Ohnishi,
Hironori Sagara, Yasutsuna Sasaki.
2278
The SMAC-mimetic birinapant regulates
autocrine TNF production by caspase-8:RIPK1 complex
via p38MAPK pathway. Gurpreet S. Kapoor, Christopher A.
Benetatos, Yasuhiro Mitsuuchi, Eric M. Neiman, Guangyao
Yu, Mark A. Mckinlay, Jennifer Burns, John Silke, Stephen
M. Condon, Srinivas K. Chunduru.
2279
Adenine nucleotide translocase-2 is a key
molecule in the enhancement of TRAIL sensitivity by
flavonoids. Masakatsu Oishi, Yosuke Iizumi, Takashi Ueda,
Saya Ito, Terukazu Nakamura, Fumiya Hongo, Yoshio Naya,
Tsuneharu Miki, Toshiyuki Sakai.
2280
Role of apoptosis signal-regulating kinase 1 in
the cell apoptosis in oral leukoplakia. Xiaofei Tang, JianFei Zhang, Wen-wen Niu, Min Zhang.
2281
Molecular mechanisms by which cFLIP
overexpression regulates TRAIL-induced NF-␬B
activation and lymphoma survival. Hasem Habelhah,
Lauren Workman, Laiqun Zhang.
2282
Calmodulin binding to DR-5 and the role of
CaM-DR-5 binding in DR-5-mediated DISC formation in
breast cancer. Romone M. Fancy, Hong Wang, Tong Zhou,
Yuhua Song.
2283
Potent curcumin analog FLLL-12 targets both
intrinsic and extrinsic signaling pathways to induce
apoptosis in lung cancers. A.R.M. R. Amin, Abedul Haque,
Mohammad A. Rahman, James R. Fuchs, Zhuo G. Chen,
Dong M. Shin.
2284
Cytotoxic and genotoxic effects of PEG-coated
gold nanoparticles in HK-2 cells. Anita K. Patlolla, Tammy
Epting, Lisabeth Thrasher, Paul B. Tchounwou.
2285
PKC activation sensitizes certain basal breast
cancer cell lines to the Smac mimetic LBW242. Louise
Cornmark, Christian Holmgren, Katarzyna Masoumi, Christer
Larsson.
2286
Regulation of GSK3␤ axis by combination
treatment with TRAIL and Troglitazone in cancer cells.
Sunipa Majumdar, Sreevidya Santha, Ajay Rana, Basabi
Rana.
2287
Nuclear localization of N-myc downstream
regulated gene 4: A novel therapeutic target in
meningioma. Rama P. Kotipatruni, Xuan Ren, Robert P.
Vanderwaal, Dinesh Thotala, Jerry J. Jaboin.
2288
Pharmacological inhibition of B-Raf/MEK/ERK
signaling suppresses DR5 expression and impairs
cancer cell response to DR5 activation-induced
apoptosis. You-Take Oh, Ping Yue, Taofeek K. Owonikoko,
Fadlo R. Khuri, Shi-Yong Sun.
2289
Effects of TRAIL and ellagic acid on malignant
melanoma A375 in vitro and in vivo. Katherine Turner,
Daniel Lindner, Michael Kalafatis.
2290
Rational targeting of inhibitor of apoptosis
proteins (IAPs) for effective therapy of colorectal
cancer. Nyree T. Crawford, Philip D. Dunne, Patrick G.
Johnston, David J. Waugh, Daniel B. Longley.
2291
Arsenic trioxide induces cell cycle arrest,
apoptosis and MAPKinase signaling cascade in acute
promyelocytic leukemia cells. Sanjay Kumar, Clement
Yedjou, Paul B. Tchounwou.
POSTER SESSION
Epigenetics 3: DNA Methylation
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2292 Epigenetic alterations in Barrett’s esophagus and
esophageal adenocarcinoma: identification and evaluation of
potential biomarkers. Rachele M. Stockdale, Andrew M. Kaz, Shelli
M. Morris, Amitabh Chak, Joseph Willis, Dean Brenner, Sharmila
Anandabapasathy, Maria Westerhoff, Chao-Jen Wong, Jill BarnholtzSloan, Yanwen Chen, William M. Grady.
2293 A fast and simple method for whole-genome bisulfite
library preparation from ultra-low DNA inputs. Karolyn Giang,
TzuHung Chung, Xueguang Sun, Marc E. Van Eden, Xi Yu Jia.
2294 Pregnancy changes the DNA methylation profile of the
breast in postmenopausal women. Julia Santucci-Pereira, Colleen
O’Malley, Ricardo López de Cicco, Nameer B. Kirma, Tim H. Huang,
Joseph Liu, Eric A. Ross, Michael Slifker, Suraj Peri, Irma H. Russo,
Pal Bordas, Per Lenner, Göran Hallmans, Paolo Toniolo, Jose Russo.
2295 Epigenetic regulation of KLHL34 may be predictive of
pathologic response to preoperative chemoradiotherapy in rectal
cancer patients. Yejin Ha.
2296 IDH2 mutation induced histone and DNA
hypermethylation is progressively reversed by small molecule
inhibition. Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie
Schalm, Kimberly Straley, Camelia Gliser, Hua Yang, Jeremy Travins,
Stuart Murray, Marion Dorsch, Sam Agresta, David P. Schenkein,
Scott A. Biller, Shinsan M. Su, Wei Liu, Katharine E. Yen.
2297 15-Deoxy-⌬12,14-prostaglandin J2 upregulates the
expression of 15-hydroxyprostaglandin dehydrogenase through
DNA methyltrasferase 1 inactivation. Hye-Ok Jang, Ha-Na Lee,
Areumnuri Kim, Do-Hee Kim, Young-Joon Surh, Hye-Kyung Na.
2298 Methylated gene markers discovered in
nasopharyngeal carcinoma by differential methylation
hybridization (DMH) in high density CpG island DNA chips. Wai
Wai Cheng, Roger K.C. Ngan, Dora L.W. Kwong, Tim H.M. Huang,
Victor W.S. Ma, Stephen C.K. Law, Loretta Tse, Pierre Busson,
George S.W. Tsao, Maria Li Lung, Timothy T.C. Yip.
2299 An epigenetic study of DNA methylation and histone
modification of brain cancer Glioblastoma multiforme. Hirendra
N. Banerjee, GWYN HYMAN, Jeffrey Rousch, VINOD MANGALIK,
Deidre Vann, Christopher Krauss, sabrina sharpe, DAVID KLINKEBIEL,
SANTOSH MANDAL, MUKESH VERMA.
2300 Silencing of the transcription repressor HOXA2 by
aberrant hypermethylation enhances invasion via MMP-9
activation in NPC. Chen-Ching Peng.
2301 Cross validation of NGS methylated targets using
droplet digital PCR (ddPCR). Dawne N. Shelton, Claudia Litterst,
John F. Regan, Helen R. Moinova, Sanford D. Markowitz.
2302 CpG hypermethylation marks potentially curable acute
myeloid leukemia. Jaroslav Jelinek, Heike Kroeger, Jumpei
Yamazaki, Rodolphe Taby, Frank Neumann, Justin T. Lee, Rong He,
Shoudan Liang, Yue Lu, Matteo Cesaroni, Sherry A. Pierce, Steven
M. Kornblau, Carlos E. Bueso-Ramos, Farhad Ravandi-Kashani,
Hagop M. Kantarjian, Jean-Pierre J. Issa.
2303 Decitabine impact on immunohistochemistry scores for
tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human
tumor samples. David J. Stewart, Maria I. Nunez, Jaroslav Jelinek,
David Hong, Sanjay Gupta, C. Marcelo Aldaz, Jean-Pierre Issa,
Razelle Kurzrock, Ignacio I. Wistuba.
2304 Genomic and epigenomic characterization of DNA
hypomethylation in human epithelial ovarian cancer. Wa Zhang,
David Klinkebiel, Sanjit Pandey, Chitibabu Guda, Austin Miller, Stacey
Akers, Kunle Odunsi, Adam Karpf.
2305 Acute depletion reveals novel co-regulation of DNA
methylation at conserved loci by DNMT1 and DNMT3B. Rochelle
Tiedemann, Jeong-Hyeon Choi, Keith Robertson.
2306 Pre-clinical development of 4’-thio-2’-deoxycytidine
(TdCyd) as a DNA-demethylating agent for use in treating solid
tissue tumors. Robert J. Kinders, Melinda Hollingshead, Jaideep
Thottassery, William B. Parker, Thomas D. Pfister, Lawrence W.
Anderson, Joseph E. Tomaszewski, Jerry M. Collins, James H.
Doroshow.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2307 DNA methylation as a reprogramming modulator: An
epigenomic roadmap to induced pluripotency. Dong-Sung Lee.
2308 Heterogeneous and low-level methylation of novel
biomarker candidates for breast cancer clinical management.
Tomasz K. Wojdacz, Johanne A. Windeløv, Britta B. Thestrup, Tine E.
Damsgaard, Jens Overgaard, Lise Lotte Hansen.
2309 Identification of common and unique epigenetic
signatures of chronic hepatitis infection and alcohol abuse in
human liver disease. Ryan A. Hlady, Rochelle Tiedemann, William
Puszyk, Chen Liu, Jeong-Hyeon Choi, Keith D. Robertson.
2310 Epigenetic silencing of a potential tumor suppressor
NR4A3 by aberrant JAK/STAT signaling predicts prognosis in
gastric cancer. Michael W. Chan, Li-Han Zeng, Liang-Yu Chang,
Claudia Dittner, Jian-Liang Chou, Yao-Ting Huang, Alfred S. Cheng,
Jiayuh Lin, Kun-Tu Yeh.
2311 NDN, an imprinted tumor suppressor gene inhibits
ovarian cancer cell growth and motility and is downregulated
by genetic and epigenetic mechanisms. Hailing Yang, Partha Das,
Yinhua Yu, Keith Baggerly, Ying Wang, Weiqun Mao, Rebecca T.
Marquez, Zhen Lu, Jinsong Liu, Robert C. Bast.
2312 Mycoplasmal DNA methyltransferases induce aberrant
global hypermethylation and activate cancer-specific genes in
human cells. Andrei Chernov, Alex Y. Strongin.
2313 Dynamic expression of 5-alpha reductase 2 in aging
prostate is regulated by DNA methyltransferase 1. Ge Rongbin,
Zongwei Wang, Chin-Lee Wu, Shahin Tabatabaei, Aria Olumi.
2314 The combination of DNA methylation and H3K27me3 is
a cancer-specific dual epigenetic modification. Hideyuki
Takeshima, Mika Wakabayashi, Naoko Hattori, Satoshi Yamashita,
Toshikazu Ushijima.
2315 Demethylating therapy modulates expression of the
RON tyrosine kinase receptor in pancreatic cancer. Jeffery
Chakedis, Randall French, Dawn Jaquish, Evangeline Mose, Andrew
Lowy.
2316 Multilayer omics analyses in CpG island methylator
phenotype clear cell renal cell carcinomas. Eri Arai, Hiromi
Sakamoto, Masaya Ono, Yoriko Takahashi, Sayaka Miyata, Hiroyuki
Fujimoto, Masahiro Gotoh, Tesshi Yamada, Yae Kanai.
2317 SGI-110 alters ovarian cancer stem cells to prevent
recurrent and chemoresistant ovarian cancer. Yinu Wang, Horacio
Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Gavin
Choy, Mohammad Azab, Kenneth Nephew, Daniela Matei.
2318 The role of EZH2 as an epigenetic switch of the TGF␤/SMAD4 targets in regulating EMT in ovarian cancer. Jora M.
Lin, Jacqueline Shay, Jian-Liang Chou, Pearlly S. Yan, Tim H. Huang,
Hung Cheng Lai, Michael W. Chan.
2319 Dynamics of TET methylcytosine dioxygenases in 5methylcytosine and 5-hydroxymethylcytosine patterning in
human cancer cells. Emily L. Putiri, Rochelle L. Tiedemann, JeongHyeon Choi, Keith D. Robertson.
2320 Clinical epigenetic resensitization of platinumresistant, recurrent ovarian cancer patients with SGI-110, a
novel, second-generation, subcutaneously administered
hypomethylating agent (HMA). Gini Fleming, Sharad Ghamande,
Yvonne Lin, Angeles Alvarez Secord, John Nemunaitis, MerryJennifer Markham, Kenneth Nephew, Fang Fang, Shweta Gupta, Sue
Naim, Gavin Choy, Simone Jueliger, Pietro Taverna, Yong Hao,
Harold Keer, Mohammad Azab, Daniela Matei.
2321 SGI-110 SQ provides superior disposition profile for
active metabolite decitabine than decitabine IV infusion: Results
from mass balance and tissue distribution study in cynomolgus
monkeys and in vitro human studies. Aram Oganesian, Robert H.
McClanahan, Eric Solon, Mohammad Azab.
18
18
375
POSTER SESSION
Poster
Section
19
19
Gene Expression and Transcriptional Control 3
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
376
2322 ␤-catenin-dependent TCF/LEF transcriptional
regulation of phosphodiesterase expression in colon
cancer cells. Alexandra M. Fajardo, Bernard D. Gary, Kevin
J. Lee, Adam B. Keeton, Bing Zhu, Xi Chen, Ashraf H.
Abadi, Gary A. Piazza.
2323 Interferon regulatory factor-4 is
transcriptionally regulated by NF-␬B in peripheral T-cell
lymphomas. Rebecca L. Boddicker, N. Sertac Kip, Luciana
L. Almada, Julie C. Porcher, Deanna M. Grote, Stephen M.
Ansell, Martin E. Fernandez-Zapico, Andrew L. Feldman.
2324
Phospho-MED1 mediates the transcriptional
regulation of AR splice variants in castration-resistant
prostate cancer. Gang Liu, Cynthia Sprenger, Pin-Jou Wu,
Shihua Sun, Takuma Uo, Kathleen Haugk, Kathryn S.
Epilepsia, Stephen Plymate.
2325
The mechanistic basis of BMP2 activation in
NF1-deficient malignant peripheral nerve sheath tumors.
Sidra Ahsan, Daochun Sun, Michael A. Tainsky.
2326
Understand the telomerase-dependent
transcriptional regulation in cancer cells. TingDong Yan,
Chang-Ching Liu, Lai-Fong Poon, Xiaoran Chai, Melissa J.
Fullwood, Sujoy Ghosh, Shang Li.
2327
Defining the determinants of sensitivity and
resistance to BET bromodomain inhibition. Nicole
Follmer, Jennifer Mertz, Andrew Conery, Barbara Bryant,
Charlie Hatton, Richard Centore, Hon-Ren Huang, Kerry
Spillane, Robert Sims.
2328
COX-2 induce mediated multidrug resistance by
activating JNK signal transduction pathway in colorectal
cancer. Qi Li, Hua Sui.
2329
Restriction of androgen receptor and target
gene expression. Margrete R. Hellem, Jan Roger Olsen,
Yaping Hua, Yi Qu, Kristo Marvyin, Kari Rostad, Jie Liu,
Lisha Li, Varda Rotter, Biaoyang Lin, Xisong Ke, Anne
Margrete Oyan, Karl-Henning Kalland.
2330
Transcription factor MAZ promotes cell growth
and aggressive behavior of human pancreatic cancer
cells. Gargi Maity, Sandipto Sarkar, Kakali Dhar, Gopal
Dhar, Inamul Haque, Sushanta K. Banerjee, Snigdha
Banerjee.
2331
Transcriptional repressor PRDM1/Blimp-1
directly regulates transcriptional elongation factor ELL3
during terminal B-cell differentiation. Lou-Ella M.
Alexander, January M. Watters, Michelle Maurin, Kenneth L.
Wright.
2332
Oncogenic mutant KRAS modulates EZH2
expression through MEK-ERK signaling by remodeling
gene expression in NSCLC. Erick M. Riquelme, Li Shen,
Jing Wang, Carmen Behrens, John D. Minna, Ignacio I.
Wistuba.
2333
Nuclear EPS8 as a potential cooperative factor
for FOXM1 in cancer cell proliferation. Wan-Ling Ngan,
Kwok-Ming Yao.
2334
Identification of differentially expressed genes
and somatic mutations in esophageal adenocarinoma
cancer patients. Bodil Oster, Anika Joecker, Anne-Mette K.
Hein, Patrick Dekker, Robert O’Neill, Adam Krejci, Anne
Arens, Naomi Thomson, Cecilie Boysen, Søren Mønsted,
Roald Forsberg, Bjarne Knudsen, Thomas Knudsen, Richard
Lussier, Ted R. Hupp.
2335
Thymoquinone induces the MUC4 mRNAdestabilizing activity of Tristetraprolin. Hyun Hee Lee,
Se-Ra Lee, Sun-Hee Leem.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2336
Interplay of Fra-2/AP-1 and Ezh2/PRC2
orchestrates epidermal differentiation. Stefanie Wurm,
Juan Guinea-Viniegra, Jisheng Zhang, Elena Ezhkova, Erwin
F. Wagner.
2337
Loss of the LIM-only protein FHL2 enhances
TGF-␤ expression and fibrogenesis. Jennifer Dahan,
Florence Levillayer, Catherine Werts, Grégory Jouvion, Yann
Nouët, Minou Adib-Conquy, Anne-Marie Cassard-Doulcier,
Tian Xia, Ju Chen, Thierry Tordjmann, Marie-Annick
Buendia, Yu Wei.
2338
Functional investigation of the CRD-BP hnRNPK-Homology domains for C-myc messenger RNA
interaction. Gerrit van Rensburg, Mark Barnes, Chow Lee.
2339
Transcriptional basis for loss of cellular
differentiation in colon cancer. Ian Y. Luk, Hoanh Tran,
Janson W. Tse, Anderly C. Chueh, Fiona Chionh, Nicholas J.
Clemons, John M. Mariadason.
2340
Disentangling the Myc:Max from the Mad:Max
network. Ana Paula Rebocho, Trevor Littlewood, Gerard I.
Evan.
2341
CAPG inproves breast cancer metastasis
through competing with PRMT5 to activate STC-1
transcription. Sheng Huang, Yayun Chi, Jingyan Xue,
Zhimin Shao, Zhaohui Wu, Jiong Wu.
2342
Related study on the fat mass and obesity
associated FTO gene and melanoma. Tianhui Niu, Min
Xiong, Yan Tian.
2343
Role of calreticulin in the regulation of MALAT1 expression in mouse adenocarcinoma cells. Hamid
Massaeli, Divya Viswanathan, Dhanya Pillai, Nasrin Mesaeli.
2344
3D extracellular stiffness cues drive localized
changes in gene expression. Russell Bainer, Yoshihiro Yui,
Shannon Mumenthaler, Parag Mallick, Ondrej Podlaha,
Franziska Michor, Jan Liphardt, Jonathan Licht, Valerie
Weaver.
2345
A positive feedback loop for transcriptional
regulation of ␤-catenin that favors sustained colorectal
cancer cell invasion. Franziska Ehrmann, Linda Frank,
Peter Schirmacher, Karsten Brand, Obul R. Bandapalli.
2346
The expression of ASPP2 and its new isoform
delta-ASPP2 in HCC. Ying Shi, Kai Liu, Huiguo Ding,
Fudong Lv, Charles Lopez, Ning Li, Dexi Chen.
2347
PSA splice variants and their expression in
prostate cancer. Alice S. Yang, Thushari Alahapperuma,
James N. Mubiru, Magdalena Garcia-Forey, Robert E.
Shade.
2348
Low PU.1 expression not only attenuates
neutrophil differentiation of AML cells but also
increases resistance to cytotoxic therapies. Mario P.
Tschan, Aladin Haimovici, Daniel Brigger, Anna M. Schläfli,
Deborah Shan, Martin F. Fey.
2349
An RNA-based epigenetic network controls the
expression of E-cadherin in epithelial normal and
cancer cells. Sara Napoli, Giuseppina Pisignano, Ramon
Garcia-Escudero, Giuseppina Carbone, Carlo V. Catapano.
2350
Inhibition of Gli1 as a novel therapeutic target
for lung squamous cell carcinoma. Chunli Shao.
2351
MYC gene copy number determine MYC
expression and sensitivity to a MYC-inhibitor in multiple
myeloma cells. Toril Holien, Kristine Misund, Glenn Buene,
Oddrun E. Olsen, Katarzyna A. Baranowska, Anders Waage,
Anders Sundan.
POSTER SESSION
Gene Expression Profiling and Sequence Analysis
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
2352
Mapping the airway-wide molecular field of
injury in smokers with lung cancer. Rebecca Kusko,
Christina Anderlind, Gerald Wang, Sherry Zhang, W. Dean
Wallace, Tonya Wasler, Michael Ebright, Melinda M. Garcia,
Rosana Eisenberg, Gina Lee, Gang Liu, David Elashoff, Neda
Kalhor, Cesar Moran, Reza Mehran, Junya Fujimoto, Pierre
P. Massion, Steven Dubinett, Ignacio Wistuba, Marc
Lenburg, Humam Kadara, Avrum Spira.
2353
A comparative meta-analysis of prognostic
gene signatures for late-stage ovarian cancer. Levi
Waldron, Markus Riester, Michael Birrer, Giovanni
Parmigiani.
2354
Nasal gene expression reflects the physiologic
response to potentially reduced exposure products.
Kahkeshan Hijazi, Bozena Bomalysz, Katrina Steiling, Ji
Xiao, Gang Liu, Yuriy Alekseyev, Martine Dumas Yves,
Louise A. Hertsgaard, Joni Jensen, Rachel Isaksson Vogel,
Dorothy Hatsukami, George O’Connor, Daniel R Brooks,
Jennifer Beane, Avrum Spira.
2355
Risk prediction for late-stage ovarian cancer by
meta-analysis of 1,525 patient samples. Markus Riester,
Wei Wei, Aedin C. Culhane, Lorenzo Trippa, Franziska
Michor, Curtis Huttenhower, Giovanni Parmigiani, Michael
Birrer.
2356
Characterization of molecular signatures
predicting response to 5-FU based chemotherapy in
mouse models of colorectal cancer. Jamie N. Hadac,
Terrah J. Paul Olson, Alyssa A. Leystra, Dawn M. Albrecht,
Linda Clipson, Ruth Sullivan, Michael A. Newton, Richard B.
Halberg, William R. Schelman.
2357
Gene expression profiling robustly predicts the
outcome of patients diagnosed with early stage lung
adenocarcinoma. Yann Gaston-Mathé, CHARLES FERTE,
benoit gauthier, mathilde bateson, david planchard,
benjamin besse, Jean-Pierre Armand, jean-charles soria.
2358
Dissecting the cellular response to cisplatin
from RNA transcription to translation. Carlos Mackintosh,
Sergiy Konovalov, Ivan Garcia-Bassets.
2359
Bioinformatics analysis of an Ad-VEGF flank
angiogenesis model identifies vessel subtype gene
signatures: Implications for anti-VEGF therapy. Jiangang
Liu, Beverly L. Falcon, Janice A. Nagy, Shou-Ching S.
Jaminet, Dan Li, Thompson N. Doman, Sudhakar
Chintharlapalli, Bronek Pytowski, Mark T. Uhlik, Harold
Dvorak, Laura Benjamin, Anthony S. Fischl.
2360
Gene expression profile induced by pregnancy
in the breast of premenopausal women. Julia SantucciPereira, Anne Zeleniuch-Jacquotte, Yelena Afanasyeva, Hua
Zhong, Eric A. Ross, Michael Slifker, Suraj Peri, Ricardo
López de Cicco, Yubo Zhai, Irma H. Russo, Theresa Nguyen,
Fathima Sheriff, Alan A. Arslan, Pal Bordas, Per Lenner,
Janet Åhman, Anna-Stina L. Eriksson, Robert Johansson,
Göran Hallmans, Paolo Toniolo, Jose Russo.
2361
Identification and analysis of gene fusion and
splice variant events in the NCI sarcoma cell line panel.
Kazimierz O. Wrzeszczynski, Eric C. Polley, Curtis Hose,
Anne Monks, Beverly A. Teicher.
2362
Identification and characterization of
pathogenetic pathways and potential therapeutic targets
in tumors derived from histiocytes and follicular
dendritic cells. Pier-Paolo Piccaluga, Maura Rossi,
Giovanna Motta, Sylvia Hartmann, Claudia Doering, Fabio
Fuligni, Claudio Agostinelli, Maria Rosaria Sapienza, Maria
Antonella Laginestra, Federica Melle, Maryam Etebari,
Mohsen Navari, Anna Gazzola, Claudia Mannu, Clara
Bertuzzi, Claudio Tripodo, Martin L. Hansmann, Fabio
Facchetti, Stefano A Pileri.
2363
Large scale gene expression analysis identifies
key oncogenic pathways across hematological
malignancies. Thomas Liuksiala, Kaisa Teittinen, Kirsi
Granberg, Merja Heinäniemi, Matti Annala, Antti Ylipää,
Markku Mäki, Matti Nykter, Olli Lohi.
Poster Abstract
Board Number
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
2364
Pancreatic cancer stem-like cells display
aggressive behavior mediated through the activation of
FoxQ1. Bin Bao, Asfar Azmi, Aamir Ahmad, Shadan Ali,
Yiwei Li, Fazlul H. Sarkar.
2365
Analysis of angiogenesis pathway-related gene
expression impacted by MDM2 using PCR array.
Thiagarajan Venkatesan, Corine Stinson, Sivanesan
Dhandayuthapani, Appu Rathinavelu.
2366
Transcriptome analysis of human metastasis
prostate cancer cells deciphers new function of Esrrb.
Yuan Lu, Jilong Li, Jianlin Cheng, Dennis B. Lubahn.
2367
High expression of GAPDH is relevant to lung
adenocarcinoma with low expression of the tumor
suppressor gene Deleted in Liver Cancer-1 (DLC1).
Dunrui Wang, Guangxian Zhang.
2368
Differential gene expression in key oncolytic
pathways between node-matched Caucasian-American,
African-American and East African triple-negative breast
cancer patients. Julie Getz, Mary E. Ahearn, Carmen
Gomez, Mark Pegram, Peter Bird, John Carpten, Lisa L.
Baumbach-Reardon.
2369
Molecular biological characterization of newly
established epithelial ovarian cancer (EOC) cell lines:
The cyclin-dependent kinase 1 pathway. wookyeom
yang, hanbyoul Cho, hayeon Shin, eunju Lee, hyunja Kwon,
sol Kim, jaehoon Kim.
2370
Comparative evaluation of somatic mutations
calls on single nucleotide variants and structural
variants using breast cancer cell lines. Oliver A.
Hampton, Richard A. Gibbs, David A. Wheeler.
2371
Heterogeneity of resistance mechanisms in lung
adenocarcinoma patients with acquired resistance to
EGFR inhibitors. Xinmeng J. Mu, Eli V. Allen, Nikhil Wagle,
Curtis Chong, Mohit Butaney, Deborah Farlow, Gad Getz,
Pasi A. Jänne, Levi A. Garraway.
2372
Detecting driver genes based on tumor wholeexome sequencing studies. Xing Hua, Teresa M. Landi,
Jianxin Shi.
2373
Deep computational analysis of human and
mouse specific next-generation sequencing data
generated from PDX specimen. Roopika Menon, Petra
Schneider, Martin Peifer, Frauke Leenders, Johannes M.
Heuckmann.
2374
Discovering Cis-SAGe chimeric RNAs in prostate
cancer. Fujun Qin, Yansu Song, Henry F. Frierson, Hui Li.
2375
A method to identify copy number aberrations
(CNAs) from whole exome sequence (WES) data and its
application to multiple myeloma cell lines and patient
samples. Jeremiah D. Degenhardt, Kenneth B. Hoehn, Kevin
A. Kwei, Kristi Stephenson, Jonathan J. Keats, Chris J. Kirk,
Brian B. Tuch.
2376
MutationValidator: A computational method for
variant cross-validation in next-generation sequencing
data. Mara Rosenberg, Gad Getz, Adam Kiezun, Andrey
Sivachenko.
2377
Low frequency KRAS mutations in colorectal
cancer patients and the presence of multiple mutations
in oncogenic drivers in non-small cell lung cancer
patients. Christopher Morehouse, Liyan Jiang, Jiagi Huang,
Wei Zhu, Susana Korolevich, Xiaoxiao Ge, Kim Lehmann,
Zheng Lui, Christine Kiefer, Meggan Czapiga, Xinying Su,
Philip Brohawn, Yi Gu, Brandon Higgs, Yihong Yao.
2378
Harmonization of next generation sequencing
data within consortia for gene discovery in familial
breast cancer. Joseph Vijai, Steven Hart, Tinu Thomas,
Bradley Wubbenhorst, Lucia Guidugli, Kasmintan Schrader,
Kara Maxwell, Lauren Jacobs, Danylo Villano, Robert Klein,
Steven Lipkin, Susan Neuhausen, Jeffrey Weitzel, David
Altshuler, Fergus Couch, Kenneth Offit, Katherine Nathanson.
Poster
Section
20
20
377
POSTER SESSION
Poster
Section
21
21
378
Genomic Stability and DNA Repair 1
Poster Abstract
Board Number
1.
2379
96-Well CometChip validation for simultaneous
treatment and measurement of DNA damage in a single
platform. Sandra R. Woodgate, Clare Whittaker, Jay George,
Robert W. Sobol, Sandy Schamus-Haynes, Bevin P.
Engelward, Jing Ge.
2.
2380
Separate but important roles of ␣SpII and
FANCD2 in the FA pathway after DNA interstrand
crosslink damage. Muriel W. Lambert, Deepa Sridharan,
Pan Zhang.
3.
2381
DNA-dependent protein kinase modulates the
anticancer properties of silver nanoparticles in human
cancer cells through JNK and telomerase pathways.
Manoor Prakash Hande, Hui Kheng Lim, Resham Lal
Gurung.
4.
2382
Synthetic lethal killing of RAD54B-deficient
colorectal cancer cells by targeting SOD1. Babu V.
Sajesh, Kirk McManus.
5.
2383
Translesion DNA synthesis by DNA polymerase
kappa somatic variants found in prostate cancer.
Santosh Yadav, Sudurika Mukhopadhyay, Nick Makridakis.
6.
2384
Time-lapse imaging of response to DNA
damage occuring during mitosis. Shinji Miwa, Shuya
Yano, Mako Yamamoto, Yukihiko Hiroshima, Fuminari
Uehara, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro
Hayashi, Elena V. Efimova, Hiroyuki Tsuchiya, Robert M.
Hoffman.
7.
2385
Involvement of autophagy and senescence in
DNA repair in irradiated tumor cells. Moureq R. Alotaibi,
Daivd Gewirtz, Lawrence Povirk.
8.
2386
Molecular-cytogenetic analysis of the maternal
embryonic leucine-zipper kinase (MELK) oncogene in
cancer. Ashley Hardeman, Tatyana A. Grushko, Maria J.
Gomez, Mariann Coyle, Yusuke Nakamura, Olufunmilayo I.
Olopade.
9.
2387
Interplay between Aurora A kinase and BRCA1
promotes genetic stability. Christine M. Marion, Vanessa
Yu, Louis Dubeau.
10.
2388
Deciphering the role of APE1 protein variants in
disease etiology. Jennifer Illuzzi, Nicole A. Harris, Brittney
A. Manvilla, Daemyung Kim, Mengxia Li, Alexander C.
Drohat, David M. Wilson.
11.
2389
PTEN localizes to the nucleus and interacts
with Rad52 in response to DNA damage. Byeong Hyeok
Choi, Wei Dai.
12.
2390
Identification of BRCA2 genetic interactors in an
ES cell-based model. Xia Ding, Shyam K. Sharan.
13.
2391
USP7 deubiquitinates XPC in response to
ultraviolet light irradiation. Jinshan He, Qianzheng Zhu,
Nidhi Sharma, Gulzar Wani, Chunhua Han, Jiang Qian, Kyle
Pentz, Qi-en Wang, Altaf A Wani.
14.
2392
The role of ATM in lytic infection of EBV in
nasopharyngeal epithelial cells. George S. Tsao, Pok Man
Hau.
15.
2393
The BARD1 BRCT domains are essential for
maintenance of telomere integrity. Irmgard IrmingerFinger, Maxim Pilyugin, Magdalena Ratajska.
Poster Abstract
Board Number
16.
2394
The role of DNA repair in breast cancer risk
and recurrence. Jaime L. Matta, Erick Suarez, Wanda
Vargas, Carmen Ortiz, Manuel Bayona, Luisa Morales.
17.
2395
Progression of structural change in breast
cancer metastasis. Ryan J. Hartmaier, Adrian V. Lee.
18.
2396
Widespread occurrence of extrachromosomal
microDNAs in normal and cancerous vertebrate tissues
and cell lines. Laura Dillon, Pankaj Kumar, Yoshiyuki
Shibata, Anindya Dutta.
19.
2397
Nanoformulations of PARP inhibtors for cancer
therapy. Shifalika Tangutoori, Paige Baldwin, Houari
Korideck, Robert Cormack, Mike G. Makrigiorgos, Srinivas
Sridhar.
20.
2398
Activity of the PARP inhibitor olaparib in ATMdeficient gastric cancer: from preclinical models to the
clinic. Darren Hodgson, Helen Mason, Lenka Oplustilova,
Chris Harbron, Xiaolu Yin, Seock-Ah Im, Helen Jones, Lai
Zhongwu, Brian Dougherty, Matthew McLoughlin, James
Bradford, Andrew Dickinson, Anitra Fielding, Jane
Robertson, Woo-Ho Kim, Chris Womack, Yi Gu, Yung-Jue
Bang, Alan Lau, J. Carl Barrett, Mark J. O’Connor.
21.
2399
DNA-PK is activated by microtubule-targeting
agents; mechanistic studies using isogenic wild-type
and DNA-PK knockout cells. Emily V. Mould, David R.
Newell, Elaine Willmore.
22.
2400
Dinaciclib, an inhibitor of cyclin-dependent
kinases (CDKs), impairs homologous recombination,
abrogates G2 checkpoint arrest and sensitizes myeloma
cells to PARP inhibition. David A. Alagpulinsa, Shmuel
Yaccoby, Srinivas Ayyadevara, Robert J. Reis.
23.
2401
Identification of new target genes in
microsatellite unstable colorectal cancer by exome
sequencing. Johanna Kondelin, Esa Pitkänen, Alexandra E.
Gylfe, Kimmo Palin, Heikki Ristolainen, Riku Katainen, Eevi
Kaasinen, Minna Taipale, Jussi Taipale, Laura RenkonenSinisalo, Heikki Järvinen, Jan Böhm, Jukka-Pekka Mecklin,
Pia Vahteristo, Sari Tuupanen, Lauri A. Aaltonen.
24.
2402
Antitumor effect of a poly (ADP-ribose)
polymerase (PARP) inhibitor in endometrial carcinoma
cell lines. Aki Miyasaka, Katsutoshi Oda, Yuji Ikeda,
Tomoko Kashiyama, Takahiro Koso, Kanako Inaba, Tomohiko
Fukuda, Chinami Makii, Kayo Asada, Reiko Kurikawa,
Osamu W. Hiraike, Kenbun Sone, Yuriko Uehara, Yoko
Matsumoto, Takahide Arimoto, Hiroyuki Kuramoto, Tetsu
Yano, Kei Kawana, Yutaka Osuga, Tomoyuki Fujii.
25.
2403
Imaging of UVB and UVC-induced DNA damage
repair in cancer cells in Gelfoam histoculture and
minimal cancer in mice. Fuminari Uehara, Shinji Miwa,
Yasunori Tome, Hiroki Maehara, Fuminori Kanaya, Yukihiko
Hiroshima, Shuya Yano, Mako Yamamoto, Yasunori
Matsumoto, Elena V. Efimova, Robert M. Hoffman.
26.
2404
Cumulative dosage effect of TSGs and OGs
drives aneuploidy patterns in cancer. Teresa Davoli,
Andrew Wei Xu, Kristen E. Mengwasser, Laura M. Sack,
John C. Yoon, Peter J. Park, Stephen J. Elledge.
POSTER SESSION
Genomic Stability and DNA Repair 2
Poster
Section
Poster Abstract
Board Number
1.
2405
Rad18 regulates epistatic relationship between
FA-BRCA and homologous recombination pathways to
repair camptothecin induced DSB. Kaushlendra Tripathi,
Chinnadurai Mani, David Clark, Reagan Barnett, Komaraiah
Palle.
2.
2406
Epigenetics of chromosomal breakage sites and
translocations. Bharat Burman, Zhuzhu Zhang, Rebecca
Burgess, Vassilis Roukos, Jason Lieb, Tom Misteli.
3.
2407
Investigation of Novel Rad51c-ATXN7 fusion
gene in colorectal tumors. Arjun Kalvala, Li Gao, Brittany
Barnwell, Greg A Otterson, Miguel A Villalona-Calero, Wenrui
Duan.
4.
2408
Identification of R-Spondin fusions in various
types of human cancer. Gabriela Martinez Cardona,
Katherine Bell, Joseph Portale, Dana Gaffney, Christopher
Moy, Suso Platero, Matthew V. Lorenzi, Jayaprakash
Karkera.
5.
2409
BCL10 regulates RNF8/RNF168-mediated
ubiquitination in the DNA damage response. Hongchang
Zhao, Min Zhu, Xingzhi Xu.
6.
2410
Crucial role of the non-BRCT automodification
domain of PARP1 in either DNA binding and PARP
inhibitor-mediated cell toxicity. Jun Nakamura, Xu Tian.
7.
2411
Rapamycin sensitizes cancer cells to growth
inhibition by the PARP inhibitor olaparib. Atsushi
Osoegawa, Joell J. Gills, Shigeru Kawabata, Kenji Sugio,
Phillip A. Dennis.
8.
2412
The modulatory effects of H. pylori infection in
the DNA mismatch repair. Juliana C. Santos, Victor R. de
Almeida, Wolfgang Fischer, Rainer Haas, Marcelo L. Ribeiro.
9.
10.
Poster Abstract
Board Number
14.
2418
Investigating p53 and other potential
determinants of cell sensitivity to ATR inhibition by VE821. Fiona K. Middleton, Tao Chen, John R. Pollard, Nicola
J. Curtin.
15.
2419
Protective role of thioredoxin-1 in base excision
repair under redox modulation. Hye Lim Kim, Preeyaporn
Koedrith, Sang Min Lee, Yeo Jin Kim, Young R. Seo.
16.
2420
Ribonucleotide reductase promotes genomic
instability and tumor heterogeneity via increasing dUTP
misincorporation into DNA. Zee-Fen Chang.
17.
2421
Small molecule inhibitors of DNA glycosylases
as potential drugs in cancer therapy. Miral Dizdaroglu,
Pawel Jaruga.
18.
2422
Microsatellite stable colorectal cancers
stratified by the BRAF V600E mutation show distinct
patterns of chromosomal instability. Catherine E. Bond,
Derek J. Nancarrow, Leesa F. Wockner, Leanne Wallace,
Grant W. Montgomery, Barbara A. Leggett, Vicki L.
Whitehall.
19.
2423
Development of a validated high throughput
ELISA assay for gamma H2AX as a pharmacodynamic
marker. Jay George, Hai Xu.
20.
2424
DNA mismatch repair protein, PMS2, induces
apoptosis in human prostate cancer cells. Shinichiro
Fukuhara, Inik Chang, varahram shahryari, ankurpreet gill,
darryn K. wong, soichiro yamamura, shahana majid,
sharanjot saini, hiroshi hirata, koji ueno, gouren deng, laura
Z. tabatabai, norio nonomura, rajvir dahiya, yuichiro tanaka.
21.
2425
Exploiting DNA repair defects in breast cancer.
Kishan A. Naipal, Nicole S. Verkaik, Petra ter Brugge, Najim
Ameziane, Carolien H. van Deurzen, John W. Martens,
Johan P. de Winter, Jos Jonkers, Maaike P. Vreeswijk,
Agnes Jager, Jan Hoeijmakers, Roland Kanaar, Dik C. van
Gent.
22.
2426
Exacerbation of oxidative DNA damage as a
synthetic lethal approach in mismatch repair deficient
tumours. Yari Fontebasso, Madeleine Hewish, Chris J. Lord,
Alan Ashworth.
23.
2427
The 5’ endonuclease EEPD1 maintains genomic
stability by mediating DNA repair pathway choice.
Yuehan Wu, Suk-Hee Lee, Elizabeth A. Williamson, Brian L.
Reinert, Gayathri Srinivasan, Sudha Singh, Aruna-Shanker
Jaiswal, Silvia Tornaletti, Alexis C. Brantly, Robert A.
Hromas.
25.
2429
Temporally and spatially inducible mouse model
of aneuploidy. Daniel Eichberg, Kristin Knouse, Angelika
Amon.
2413
Unstable genomes and the average cancer cell.
Batoul Abdallah, Joshua B. Stevens, Steven Horne, Guo Liu,
Henry H. Heng.
2414
Overexpression of PAXIP1 potentiates WEE1
inhibitor action in lung cancer cells. Ankita Jhuraney,
Nicholas T. Woods, Fumi Kinose, Douglas W. Cress,
Jhanelle E. Gray, Eric B. Haura, Uwe Rix, Alvaro N.
Monteiro.
12.
2416
Protein expression analysis of premature
termination codon containing mutant proteins in colon
cancers with high microsatellite instability. SeongJu
Yoon, Won Kyu Kim, Jeon Han Park, Hoguen Kim.
13.
2417
Predictive and therapeutic impact of DNA
damage response activation in locally advanced cervical
cancer patients. Hylke W. Wieringa, Marieke Everts, G.Bea
A. Wisman, Ate G. van der Zee, Elisabeth G. de Vries,
Marcel A. van Vugt.
22
22
379
POSTER SESSION
Poster
Section
23
23
Metabolic Pathways 2
Poster Abstract
Board Number
1.
2430
Targeting estrogen-related receptor alpha using
pyrrole-imidazole polyamide. Yang Li, John Gallagher,
Bogdan Olenyuk, Bangyan Stiles, Ankeste Kassa.
2.
2431
Downregulation of PHLPP promotes glycolysis
in colon cancer cells. Yang-an Wen, Xiaopeng Xiong,
Tianyan Gao.
3.
4.
2433
Metabolic reprogramming by an epigenetic
mechanism in endocrine therapy resistance of breast
cancer. June X. Zou, Junjian Wang, Zhijian Duan, Hongwu
Chen, Hsing-Jien Kung, Xinbin Chen, Leigh C. Murphy,
Alexander Borowsky.
5.
2434
Therapeutic targeting of CD47 regulates cell
bioenergetics and autophagy to reduce breast tumor
growth and protect against anthracycline-mediated
cardiac toxicity. David R. Soto-Pantoja, John M. Sipes,
Arunima Ghosh, Maria J. Merino, David D. Roberts.
6.
2435
Novel regulators of renal cancer metabolism.
EunYoung Kho, Richard Kirkman, Eun-Hee Shim, Arindam
Goash, Sunil Sudarshan.
7.
2436
Regulation of breast cancer cell metabolism by
the AMPK/ERR/PGC pathway. Étienne Audet-Walsh, David
Papadopoli, Julie St-Pierre, Vincent Giguère.
8.
9.
2437
PKA/AMPK signaling is a mediator of the antiproliferative effect of adiponectin on multiple myeloma
cells. Edward A. Medina, Srikanth R. Polusani, Kelli
Oberheu, Babatunde Oyajobi.
2438
Defining the role of mutant isocitrate
dehydrogenase in malignant glioma. Gemma L. Robinson,
Matthew R. Guthrie, Marytheresa Ifediba, Matthew W.
VanBrocklin, Sheri L. Holmen.
10.
2439
HSulf-1 loss in ovarian cancer cells induces
lipid droplet biogenesis. Debarshi Roy, Xiaoping He,
Ashwani Khurana, Susmita Mondal, Deok-Beom Jung, Sung
Kim, Thomas Dierks, Clifford Folmes, Andre Terzic, Viji
Shridhar.
11.
2440
RNF5 mediates ER stress-induced degradation
of SLC1A5 in breast cancer. Young Joo Jeon, Sihem
Khelifa, Yongmei Feng, Eric Lau, Robert Cardiff, Hyungsoo
Kim, David L. Rimm, Yuval Kluger, Ze’ev Ronai.
12.
2441
mTOR complex 2 modulates glycosylation of
CD147 via the hexosamine biosynthetic pathway. ChangChih Wu, Thomas Lynch, Joseph Moloughney, Aixa Navia,
Olufunmilola Ibironke, Po-Chien Chou, Nicole M. Vega-Cotto,
Sisi Zhang, Joshua Rabinowitz, Guy Werlen, Estela Jacinto.
13.
380
2432
Phosphorylation of Raptor by pemetrexedactivated AMPK is sufficient to suppress mTORC1
activity promoted by loss of p53 and TSC2. Stuti
Agarwal, Catherine M. Bell, Richard G. Moran.
Poster Abstract
Board Number
14.
2443
Novel role of glucose-regulated protein 78
mediating lipid metabolism through controlling stearoylCoA desaturase 1. Katherine L. Cook, Pamela A. Clarke,
Margaret Axelrod, Anni Wärri, Robert Clarke.
15.
2444
Targeting Epstein-Barr virus oncoprotein LMP1mediated glycolysis sensitizes nasopharyngeal
carcinoma to radiation therapy. Lanbo Xiao, Zhe-yu Hu,
Ya Cao.
16.
2445
Estrogen promotes tumorigenesis by ADPribosyl-acceptor hydrolase 1 (ARH1)-deficient cells and
mice. Jiro Kato, Xiangning Bu, Joel Moss.
17.
2446
Signaling event of alcohol-induced deregulation
of Pol III genes in breast cancer cells. Shuping Zhong,
Qingsong Zhang, Ganggang Shi.
18.
2447
Lineage-specific metabolic reprogramming in
BCR-ABL1-driven leukemia. Lai N. Chan, Seyedmehdi
Shojaee, Christian Hurtz, Huimin Geng, Carina Ng, Behzad
Kharabi, Markus Müschen.
19.
2448
Meiosis activating sterols counteract KRasdriven epithelial carcinogenesis via an LXR-dependent
mechanism. Linara Gabitova, Andrey Gorin, Diana Restifo,
Dong-Hua Yang, David Cunningham, Gail E. Herman, Igor A.
Astsaturov.
20.
2449
Identifying therapy responsive and resistant
LKB1 mutant non-small cell lung tumor populations.
Evan Abt, Milica Momcilovic, Atsuko Seki, Robert McMickle,
David Stout, Michael C. Fishbein, David B. Shackelford.
21.
2450
CaMKK2-AMPK signaling facilitates androgenmediated prostate cancer cell metabolism. Daniel E.
Frigo, Yan Shi, Jenny J. Han, Efrosini Tsouko, Michael M.
Ittmann.
22.
2451
Insulin-like growth factor-1 receptor (IGF-1R)
inhibitors downregulate p53 expression and upregulate
the Warburg effect in paediatric glioblastoma cells.
Anne-Christine Wong Te Fong, Gabriela Andrejeva,
Aleksandra Bielen, Chris Jones, John Griffiths, Martin O.
Leach, Yuen-Li Chung.
23.
2452
Silibinin inhibits lipid metabolism by primarily
targeting the master regulator sterol response element
binding protein 1 (SREBP1) in prostate cancer cells.
Dhanya K. Nambiar, Gagan Deep, Rana P. Singh, Chapla
Agarwal, Rajesh Agarwal.
24.
2453
Transketolase (TKT) is a critical component of
the metabolic machinery of hepatocellular carcinoma
(HCC). Mingjing Xu, Carmen Chak-Lui Wong, Irene Oi-Lin
Ng.
2442
Community-based participatory research leads
to sustainable lifestyle intervention program for
reducing breast cancer risk among African American
and Latina women. Padma P. Tadi Uppala, Hildemaar Dos
Santos, Amanda Dupre, Persila Mohammadnia, Maheswari
Senthil.
POSTER SESSION
Tumor Suppressors 3
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2454
Ampk and hdac pathways and regulation
rassf1c gene expression. Yousef G. Amaar, Mark E.
Reeves, Matthew Firek.
2455
BRCA1 and BARD1 expression and localization
in breast cell lines. Cristobal Herrera, Elisa Pérez, Elías
Blanco, Patricia Gajardo, Pilar Carvallo.
2456
Overexpression of TOM40 (translocase in the
outer mitochondrial membrane 40) inhibits the cell
proliferation, invasion and migration abilities in ovarian
cancer cell lines. Sol Kim, Hanbyoul Cho, Wookyeom Yang,
Hyunja Kwon, Ha yeon Shin, Eunju Lee, Eun-Suk Kang,
Jae-hoon Kim.
2457
Functional Study of DCC Gene in multiple
myeloma mell lines. Dorival M. Rodrigues-Junior, Thais
Priscilla Biassi, Viviane Carlin, Joel Machado-Junior, André
Luiz Vettore.
2458
Automated analysis of four color PTEN deletion
in prostate cancer using FISHQuant on a whole slide
image. Annamaria Csizmadia, Ferenc Szipocs, Janet Park,
Mohammmed Harris, Peter Hartmayer, Thomas J. Moss.
2459
The oncogenic activity of MDMx is associated
with physical interaction and suppression of
retinoblastoma protein. Zhi-Xiong Xiao, Haibo Zhang, Yujun
Zhang.
2460
APC regulates COX-2 independent of Wnt
signaling in breast cancer. Monica K. VanKlompenberg,
Claire Bedalov, Jenifer R. Prosperi.
2461
SLC5A8: A strategic target for advanced
metastatic breast cancer. Sabarish Ramachandran,
Rajneesh Pathania, Ravi N. Padia, Selvakumar Elangovan,
Veena Coothankandaswamy, Puttur D. Prasad, Vadivel
Ganapathy, Muthusamy Thangaraju.
2462
Coiled-coil domain 68 (CCDC68) plays a tumor
suppressive role in pancreatic adenocarcinoma. Nikolina
Radulovich, Lisa Leung, Emin Ibrahimov, Roya Navab,
Shingo Sakashita, William Lockwood, Kelsie Thu, Yaroslav
Fedeshyn, Jason Moffat, Wan Lam, Ming Tsao.
2463
Suppression of hepatocyte nuclear factor 4␣ by
nuclear factor ␬B in hepatoma cells. Bei-Fang Ning, Xin
Zhang, Wei-Fen Xie.
2464
Angiomotin plays a tumor suppressor role by
sequestering oncogenic YAP/TAZ proteins and
decreasing amphiregulin secretion in lung cancer. PoLin Kuo, Jen-Yu Hung, Ya-Ling Hsu.
2465
p53-dependent and independent functions of
Mieap. Yasuyuki Nakamura, Hiroki Kamino, Yuri Saito,
Hitoya Sano, Hirofumi Arakawa.
2466
The tumor suppressor Merlin decreases TGF␤/
Smad signaling in metastatic breast cancer cells.
William P. Jackson, Kelly M. Kreitzburg, Shamik Das, Sarah
K. Bailey, Brandon J. Metge, Rajeev S. Samant, Lalita R.
Shevde-Samant.
2467
Connexin43 reduces melanoma growth within a
keratinocyte microenvironment and during
tumorigenesis in vivo. Qing C. Shao, Mark Jake Ableser,
Silvia Penuela, Dale W. Laird.
2468
A p53 and microRNA-mediated pathway
regulates mesenchymal stem cell differentiation. Yunlong
He, Shunlin Jiang, Wendy Dubois, Ling Ren, Chand Khanna,
Jing Huang.
Poster Abstract
Board Number
16.
17.
18.
19.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2469
A mutated ARID5B protein found in endometrial
cancer has a deleterious function with longer half-life.
Norihiko Kawamata, Keiichi Itakura.
2470
Cd177, a novel metastasis suppressor of breast
cancer. Qing Xie, Nicholas Borcherding, Ryan Kolb, Weizhou
Zhang.
2471
Direct down-regulation of eEF1A2 by Tumor
suppressor p16INK4a inhibits cancer cell growth. MeeHyun Lee, Bu Young Choi, Yong-Yeon Cho, Myoung Ok Kim,
Sung-Hyun Kim, Cheol-Jung Lee, Ji Hong Song, Ann M.
Bode, Zigang Dong, Yong-Joon Surh.
2472
Acute colitis and colitis-associated cancer are
exacerbated in mice deficient N-deacetylase/Nsulfotransferase-4. Tzu-Ming Jao, Ming-Hong Tsai, Chi-Yen
Huang, Sheng-Tai Tzeng, Jing-Xing Lee, Wei-Chen Lo, CheWei Chang, Ya-Chien Yang.
2474
Smad4 loss induces cetuximab resistance and
increased metastatic potential in head and neck
squamous cell carcinoma. Hiroyuki Ozawa, Haixia Cheng,
Elana J. Fertig, Jason D. Howard, Ana Markovic, Robert
Hughes, Jimena Perez, Harry Quon, Christine H. Chung.
2475
Zpo2 promotes aggressive breast cancer
development through downregulation of GATA3. Payam
Shahi, Euan M. Slorach, Jonathan Chou, Devon Lawson,
Ying Yu, Zena Werb.
2476
A novel NUT translocation partner binds to
BRD4 and is necessary for the blockade of
differentiation in NUT midline carcinoma. Erica Walsh,
Simone Kuhnle, Shaila Rahman, Madeleine Lemieux, Peter
Howley, Christopher French.
2477
Max inactivation in small cell lung cancer
disrupts the MYC-SWI/SNF programs and is synthetic
lethal with BRG1. Octavio A. Romero-Ferraro, Manuel
Torres-Diz, Eva Pros, Antonio Gomez Moruno, Sebastian
Moran Salama, Suvi Savola, Luis M. Montuenga, Ruben Pio,
Jun Yokota, Montse Sanchez-Cespedes.
2478
Glycosylation of tid1 regulates galectin-7
ubiquitination and localization to suppress head and
neck cancer metastasis. Yu-Syuan Chen.
2479
Nuclear promyelocytic leukemia bodies tether
to early endosomes during mitosis. Vuk Palibrk, Emma
Lång, Anna Lång, Alexander Rowe, Stig Ove Bøe.
2480
Ubiquitination of p53 by Trim39. Liguo Zhang,
Chen Chen, Naijia Huang, Wanli Tang, Sally Kornbluth.
2481
Complex deregulation of p73 transcripts in
breast tissues: overexpression in benign breast
fibroadenomas, and down-regulation in breast cancers.
Sophie Tourpin, Samar Alsafadi, Marie-Christine Mathieu,
Suzette Delaloge, Fabrice Andre, Jean C. Ahomadegbe.
2482
Key tumor suppressor genes inactivated by
promoter methylation and somatic mutations in head
and neck cancer. Rafael Guerrero-Preston, Christina
Michailidi, Luigi Marchionni, Curtis Pickering, Mitchell
Frederick, Jeffrey Myers, Srinivasan Yegnasubramanian, Tal
Hadar, Maartje Noordhuis, Elana Fertig, Nishant Agrawal,
William Westra, Wayne Koch, Joseph Califano, Victor
Velculescu, David Sidransky.
2482A
ARHI (DIRAS3) downregulates Ras-MAPK
signaling and inhibits transformation of NIH3T3 cells
through direct interaction with GTP-bound Ras. Margie
N. Sutton.
24
24
381
POSTER SESSION
Chemistry 3
Poster
Section
25
25
Proteomics and Biomarker Discovery
Poster Abstract
Board Number
1.
3.
4.
5.
6.
7.
8.
9.
10.
382
2483
An antibody-independent, complementary SRM
strategy for ultrasensitive and multiplexed quantification
of cancer biomarker candidates. Tujin Shi, Jintang He,
Chaochao Wu, Thomas L. Fillmore, Athena A. Schepmoes,
Mark Rubin, Javed Siddiqui, John Wei, Arul Chinnaiyan,
Alvin Liu, Richard D. Smith, Jacob Kagan, Sudhir Srivastava,
Karin D. Rodland, Wei-Jun Qian, Tao Liu, David G. Camp.
Poster Abstract
Board Number
13.
2495
Quantitative screening of protein biomarkers of
hepatocellular carcinoma by antibody array. Shuhong
Luo, Ruochun Huang, Zhongsheng Wang, Yun-Ru Chen,
Jinfei Lin, Ruo-Pan Huang.
14.
2485
Secretome signature associated with TITF1/
NKX2–1-negative non-small cell lung cancer. Ayumu
Taguchi, Muge Celiktas, Dhillon Dilsher, Qing Zhang, CheeHong Wong, Alice Chin, Adi Gazdar, Samir Hanash.
2496
Defining the cell surface landscape in cancer:
Comprehensive profiling of surface antigens for
biomarker discovery and immune monitoring. Erika A.
O’Donnell, Erica L. Alvendia, Benjamin E. Osetek, Tom S.
Wehrman, Peter O. Krutzik.
15.
2486
Global metabolic profiling identifies novel
serum markers for esophageal adenocarcinoma. Beatriz
Sanchez-Espiridion, Dong Liang, Jaffer A. Ajani, Su Liang,
Yuanqing Ye, Michelle A. Hildebrandt, Jian Gu, Xifeng Wu.
2497
Extracellular vesicle-mediated reversal of the
prostate cancer phenotype. Kiriaki Panagopoulos, Sam
Cross-Knorr, Joseph F. Renzulli, Peter J. Quesenberry,
Devasis Chatterjee.
16.
2498
Detection of S-nitrosylated heat shock protein
90 in renal cell cancer. Fumiya Hongo, Takashi Ueda, Saya
Ito-Ueda, Masakatsu Oishi, Terukazu Nakamura, Yoshio
Naya, Tsuneharu Miki.
17.
2499
Application of a multiplexed fluorescence
microscopy method (MultiOmyxTM) to dissect proteomic
biomarkers of (18)F-fluorodeoxy-glucose ((18)FDG)
uptake in breast cancer. Anup Sood, Alexandra M. Miller,
Fiona Ginty, Elizabeth McDonough, Yunxia Sui, Alexander
Bordwell, Qing Li, Sireesha Kaanumalle, Zhengyu Pang,
Franklin Torres, Edi Brogi, Steven Larson, Ingo Mellinghoff.
18.
2500
Predictive biomarker discovery in sunitinib
treated renal cancer patients: A non-hypothesis driven
proteomic approach. Rebecca L. Shreeve, Naveen
Vasudev, Alexandre Zougman, Peter Selby, Roz Banks.
19.
2501
Proteomics signature of lack of retinoic acid
signal surveillance at early breast cancer stages.
Stefano Rossetti, Wiam Bshara, Nicoletta Sacchi.
20.
2502
Immunoseroproteomic profiling of
autoantibodies to tumor associated autoantigens in
African American and Caucasian men with prostate
cancer. Tino W. Sanchez, Saied Mirshahidi, Nathan Wall,
Susanne Montgomery, Colwick Wilson, Carlos A. Casiano.
21.
2503
Differential expression of cytoskeletal proteins
in acute lymphoblastic leukemia in accordance with
initial response to chemotherapy. Kee R. Kang, Eun S.
Park.
22.
2504
In-depth proteome quantification of
hepatocellular carcinoma tissues reveals significant
liver dysfunction. Yexiong Tan, Fangjun Wang, Hanfa Zhou,
Hongyang Wang.
23.
2505
Exposure to a therapeutically relevant dose of
ionizing radiation reveals colorectal cancer biomarker
and associated receptor alterations. Shubhankar Suman,
Albert J. Fornace, Kamal Datta.
24.
2506
Differentiating pancreatic cystic neoplasms by
global protease specificity. Dana A. Dominguez, Anthony
J. O’Donoghue, Kimberly S. Kirkwood, Charles S. Craik.
25.
2507
Circulating proteolytic products of
carboxypeptidase N for early detection of breast cancer.
Ye Hu.
2487
Comprehensive quantitative proteomic profiling
of lung cancers reveals novel biomarkers and potential
drug targets. Hanibal Bohnenberger, Philipp Ströbel,
Hannah Henric-Petri, Christof Lenz, Alexander Emmert, Felix
Bremmer, Jasmin Strecker, Rainer Holland, Marc
Hinterthaner, Jasmin Corso, Sebastian Wagner, Stefan
Küffer, Martin Sebastian, Lothar Bergmann, Bernd Danner,
Friedrich A. Schöndube, Henning Urlaub, Hubert Serve,
Thomas Oellerich.
2488
Analysis of the salivary proteome of the
prolactin-inducible-protein knockout mouse. Anne
Blanchard, Peyman Ezzati, Xiuli Ma, John Wilkins, Yvonne
Myal.
2489
Glycoproteomic analysis of breast cancer cell
lines for biomarker discovery. Maria Arampatzidou,
Majlinda Kullolli, Sharon J. Pitteri.
2490
Integrative systems analysis of HPVⴙ and HPVoropharyngeal carcinomas. Lusia Sepiashvili, Angela Hui,
Wei Shi, Wei Xu, Daryl Waggot, Paul Boutros, Alex
Ignatchenko, Vladimir Ignatchenko, Shao Hui (Sophie)
Huang, John Waldron, Brian O’Sullivan, Jonathan C. Irish,
Fei-Fei Liu, Thomas Kislinger.
2491
Quantification of biomarker expression,
phosphorylation, and mutation in cancer using TMT
labeling prior to liquid chromatography-multiple
reaction monitoring mass spectrometry. Yi Chen, David J.
Britton, Kim Paraiso, Inna Fedorenko, Elizabeth R. Wood,
Anthony Magliocco, Vernon K. Sondak, Keiran Smalley, Ian
Pike, John M. Koomen.
2492
Discovery and validation of novel serum
glycoprotein biomarkers for Barrett’s esophagus and
esophageal adenocarcinoma. Alok K. Shah, David Chen,
Kim-Anh Le Cao, Eunju Choi, Derek Nancarrow, David
Whiteman, Nicholas A. Saunders, Andrew P. Barbour,
Michelle M. Hill.
11.
2493
Molecular biomarkers for cancer biospecimen
integrity. Lokesh Agrawal, Jim Vaught, Helen Moore.
12.
2494
A pilot proteomic analysis to identify biomarker
proteins in human pancreatic cancer using reverse
phase protein array. Yu-jing Huang, Nianxiang Zhang,
Marsha Frazier, Chongjuan Wei.
POSTER SESSION
Chemistry 4
Small Molecule Design, Identification, and Optimization 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2508
The development of anti-androgens with a
novel mechanism of action for treatment of castrationresistant prostate cancer. Ravi Shashi Nayana Munuganti,
Mohamed D. Hassona, Eric Leblanc, Fuqiang Ban, Emma T.
Guns, Paul S. Rennie, Artem Cherkasov.
2509
Hsp90-inhibitor drug conjugates (HDC): Novel
tumor-selective drug delivery platform with
unprecedented anticancer activity. Dinesh
Chimmanamada, David Proia, Takayo Inoue, Luisa Shin
Ogawa, Suqin He, Manuel Sequeira, Donald Smith, JohnPaul Jimenez, Chaohua Zhang, Jim Sang, Jaime Acquaviva,
Masazumi Nagai, Yuan Liu, Josephine Ye, Dan Zhou,
Andrew Sonderfan, Ritu Singh, Noriaki Tatsuta, Teresa
Przewloka, Jun Jiang, Junyi Zhang, Weiwen Ying.
2510
A porphodimethene chemical inhibitor of
uroporphyrinogen decarboxylase. Kenneth W. Yip, Zhan
Zhang, Noriko Sakemura-Nakatsugawa, Jui-Wen Huang,
Shijun Yue, Yulia Jitkova, Terence To, Emil Pai, Aaron
Schimmer, Jonathan Lovell, Jonathan Sessler, Fei-Fei Liu.
2511
New inhibitors the tyrosine kinase ACK1/TNK2
active in prostate, breast and pancreatic cancer.
Harshani R. Lawrence, Yunting Luo, Daniel Zhang, Nathan
Tindall, Sevil Ozcan, Miles Huseyin, Sakib Kazi, Sayantani
Bandyopadhyay, Kiran Mahajan, Nupam P. Mahajan,
Nicholas J. Lawrence.
2512
Design and antiproliferative evaluation of cellpenetrating TPM-Dox conjugates as prodrugs. Yousef
Beni, Andrew W. Pippas.
2513
NOSH-aspirin alone or in combination with 5fluorouracil induces tumor regression in a xenograft
model of estrogen receptor positive breast cancer. Sarin
A. Soyemi, Mitali Chattopadhyay, Khosrow Kashfi.
2514
Towards homogenous adcs: A new site-specific
antibody conjugation using bacterial transglutaminase
(btg-adc). Florence Lhospice, Delphine Bregeon, Christian
Belmant, Agnes Represa, Angelique Boedec, Yannis Morel,
Patrick Dennler, Roger Schibli, François Romagne.
2515
Synthesis of substituted chromone-2phenylcarboxamides as anti-breast cancer agents. Kinfe
K. Redda, Madhavi Gangapuram, Mohammad A. Ghaffari,
Suresh Eyunni.
2516
SL01, an oral gemcitabine prodrug as a potent
anticancer drug. Wenbao Li, Hua Yuan, Xianjun Qu.
2517
STAT3 inhibition by LLL12 in combination with
niclosamide and chemotherapy in ovarian cancer.
Rebecca C. Arend, Christen L. Walters Haygood, Chandrika
Kurpad, Abhishek Gangrade, Pui-Kai Li, Yonghi Li, Deepak
Bhasin, J. M. Straughn, Donald J. Buchsbaum.
2518
Development of a non-hydrolysable
phosphotyrosine mimetic peptide based on a high
affinity SHP2 substrate. Harshani R. Lawrence, Yiyu Ge,
Andreas Becker, Yuan Ren, Yunting Luo, Jie Wu and
Nicholas J. Lawrence.
2519
A small molecule that binds and inhibits the
ETV1 transcription factor oncoprotein. Marius Pop,
Nicolas Stransky, Colin Garvie, Jean-Philippe Theurillat,
Timothy Lewis, Cheng Zhong, Elizabeth Culyba, Fallon Lin,
Douglas Daniels, Raymond Pagliarini, Lucienne Ronco,
Angela Koehler, Levi Garraway.
2520
Novel inhibitors of ␤-catenin. Elmar
Nurmemmedov, Anton Cheltsov, Peter K. Vogt.
2521
Small molecule inhibitors targeting the
activation function-2 site of estrogen receptor-␣. Kriti
Singh, Ravi Shashi Nayana Munuganti, Eric Leblanc, Artem
Cherkasov, Paul S. Rennie.
2522
Development of GADD45␤ (growth arrest DNA
damage-inducible gene 45 beta) agonists for the
treatment of hepatocellular carcinoma (HCC). Chiun Hsu,
Da-Liang Ou, Kuen-Feng Chen, Zhong-Zhe Lin, Ann-Lii
Cheng, Chung-Wai Shiau.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
2523
Mechanism-based inhibitors of HGFA,
matriptase and hepsin for breast cancer treatment.
James Janetka, Zhenfu Han, Peter Harris, Scott Wildman.
2524
Promising early-stage novel androgen receptor
antagonists in head-head comparisons with
Enzalutamide and Bicalutamide. Arthur Y. Shaw, Vijay
Gokhale, Christopher Hulme, Steven P. Stratton.
2525
Identification and characterization of class I
HDAC-specific small-molecule inhibitors with a novel
pharmacophore. Yunfei Wang, Ryan Stowe, Christie E.
Pinello, Lisa Y. Zhao, Guimei Tian, Peter Hodder, William R.
Roush, Daiqing Liao.
2526
Polyploidy: A new breast cancer subtype and a
lead compound that targets it with high selectivity. Mark
E. Burkard, Alka Choudhary, Robert F. Lera, Ross Fedenia,
Craig Kanugh, Jennifer J. Laffin, Lauren M. Zasadil, Beth A.
Weaver, Kari B. Wisinski.
2527
Aspirin and aspirin analogs on esophageal
cancer. Rajagopal Sharada Kilari, Christopher J. Perry,
Andrew Devitt, Stephen T. Safrany, Iain D. Nicholl.
2528
Optimization of small molecules targeting BMI1
protein expression. Part 2. Improved potency, oral
bioavailability, and in vivo efficacy of amino-pyrazines
and amino-pyridines. Ramil Baiazitov, Nadiya Sydorenko,
Hongyu Ren, Wu Du, Steve Paget, Richard Wilde, Ronggang
Liu, Chang-Sun Lee, Liangxian Cao, Thomas W. Davis, Neil
G. Almstead, Young-Choon Moon.
2529
Optimization of small molecules targeting BMI1
protein expression. Part 1. Amino-thiazoles: the first-inclass highly potent inhibitors of BMI1 protein. Nadiya
Sydorenko, Ramil Baiazitov, Soongyu Choi, Chang-Sun Lee,
Liangxian Cao, Thomas W. Davis, Neil G. Almstead, YoungChoon Moon.
2530
Optimization of 5,6-fused pyrimidine-based
kinase inhibitors by computer-aided drug design for the
treatment of AML. Yung Chang Hsu, Hui-Yi Shiao, Yi-Yu
Ke, John T. A. Hsu, Wen-Hsing Lin, Chun-Hwa Chen, HsingPang Hsieh.
2531
Benzofuran derivatives as a novel class of
mTOR signaling inhibitors. Marie Serova, Christophe
Salomé, Vanessa Narbonne, Nigel Ribeiro, Frédéric Thuaud,
Eric Raymond, Armand de Gramont, Laurent Desaubry.
2532
Vemurafenib prodrugs suitable for oral and IV
administration. Ning Xi, Yingjun Zhang, Zhaohe Wang,
Taoxi Lin, Qian Wang.
2533
Design and preclinical profile of CH5183284/
Debio 1347, a novel orally available and selective FGFR
inhibitor acting on a gatekeeper mutant of FGFR2.
Hirosato Ebiike, Naoki Taka, Yoshito Nakanishi, Nukinori
Akiyama, Fumie Sawamura, Kenji Morikami, Masayuki
Matsushita, Masayuki Ohmori, Kyouko Takami, Ikumi
Hyohdoh, Masami Kohchi, Tadakatsu Hayase, Hiroki Nishii,
Nobuya Ishii, Hiroharu Matsuoka.
2534
High-affinity small molecule inhibitors of the
menin-MLL interaction reverse oncogenic transformation
mediated by MLL fusion proteins in leukemia. Jolanta E.
Grembecka, Shihan He, Timothy J. Senter, Dmitry Borkin,
Jonathan Pollock, Changho Han, Sunil Kumar Upadhyay,
Trupta Purohit, Hongzhi Miao, Rocco D. Gogliotti D. Gogliotti,
Craig W. Lindsley, Tomasz Cierpicki, Shaun R. Stauffer.
2535
Structure-activity relationships of novel Nbenzoyl arylpiperidine and arylazetidine FASN inhibitors.
Peter J. Connolly, Gilles Bignan, James Bischoff, Sabine De
Breucker, Norbert Esser, Erwin Fraiponts, Ron Gilissen,
Bruce Grasberger, Boudewijn Janssens, Tianbao Lu, Donald
Ludovici, Lieven Meerpoel, Christophe Meyer, Michael
Parker, Danielle Peeters, Carsten Schubert, Karine Smans,
Luc Van Nuffel, Peter Vermeulen.
Poster
Section
26
26
383
POSTER SESSION
Immunology 4
Poster
Section
27
27
Assessing Immune Responses to Interventional Therapies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
384
2536
Post-transplantation NK cell is a useful
predictor of graft-versus-host-disease in allogeneic
hematopoietic stem cell transplantation. Seo Yeon Kim,
Hyewon Lee, Hyoeun Shim, Hyeon-Seok Eom, Sun-Young
Kong.
2537
Antibody dependent cytotoxicity is enhanced by
Ari-4175 through NK cell activation. Alexander
MacFarlane, Tetyana Bagnyukva, Jiping Zhang, Kerry
Campbell, Barry Jones, William Bachovchin, Hossein
Borghaei.
2538
Immune responses to common melanomaassociated antigens following intratumoral injection of
alpha-gal glycolipids in patients with advanced
melanoma. Cindy L. Zuleger, Paul M. Sondel, Jacquelyn A.
Hank, Erik A. Ranheim, Thomas A. McFarland, Jennifer
Collins, Erin Clements, Giles Whalen, Uri Galili, Mark R.
Albertini.
2539
Clinical prospective study of PepTivator® WT1pulsed DC vaccines with assessment of immunological
responses in solid tumors. Shoko Saiwaki, Shigenori Goto,
Masashi Takahara, Haruka Matsushita, Takashige Kondo,
Hermann Bohnenkamp, Ryuji Maekawa, Takashi Kamigaki.
2540
Immune modulation by the TLR8 agonist VTX2337; a comparison of the pharmacodynamic response
in cancer patients and healthy volunteers. Greg Dietsch,
Donald Northfelt, Ramesh Ramanathan, Peter Cohen, Kristi
Manjarrez, Mona Newkirk, James Kyle Bryan, Robert
Hershberg.
2541
Differential trafficking of dendritic cells after
immunization determines establishment of systemic
anti-tumor responses. Noriko Sato, Kingsley Asiedu, Peter
L. Choyke.
2542
Sipuleucel-T-induced immune response against
secondary cancer antigens is associated with improved
overall survival. Debraj GuhaThakurta, Li-Qun Fan, Tuyen
Vu, Francis Stewart, Philip Kantoff, Eric Small, Celeste
Higano, Thomas Gardner, Nadeem Sheikh, James Trager.
2543
Circulating s100a9 myeloid-derived suppressor
cells are predictive for poor pfs in patients with egfr
mutation positive lung adenocarcinoma treated with
gefitinib. Po-Hao Feng, Chih-Teng Yu, Kang-Yun Lee.
2544
Identification of immune signatures predicting
for clinical outcome measured by flow-cytometry and
immunogenetic analysis of PBMCs from breast cancer
patients treated with docetaxel alone or docetaxel plus
vaccine. Italia Grenga, Maria Libera Ascierto, Renee N.
Donahue, James L. Gulley, Christopher R. Heery, Ravi A.
Madan, Jeffrey Schlom, Ena Wang, Benedetto Farsaci.
2545
Histamine dihydrochloride and interleukin-2 for
relapse prevention in AML: Initial results of the
Re:MISSION phase IV trial. Anna Martner, Anna Rydström,
Rebecca Riise, Johan Aurelius, Mats Brune, Kristoffer
Hellstrand, Fredrik Bergh Thorén.
2546
Analysis of immune cell subsets in a multidrug
therapeutic regimen for patients with metastatic
castration-resistant prostate cancer. Caroline Jochems,
Benjamin Boyerinas, Ravi A. Madan, Diane J. Poole, YangMin Ning, William D. Figg, David J. Liewehr, Seth M.
Steinberg, James L. Gulley, Kwong-Yok Tsang, Jeffrey
Schlom.
2547
Peripheral immune signatures and survival in
stage IV melanoma. Graham P. Pawelec, Alexander
Martens, Claus Garbe, Benjamin Weide, Evelyna
Derhovanessian, Dirk Schadendorf, Anna Maria Di Giacomo,
Michele Maio, Jolanda de Vries, Henning Zelba.
2548
Using whole slide digital image analysis to
quantify leukocyte populations in tumor sections. Joseph
S. Krueger, Brian Laffin, Holger Lange, Anthony Milici, Eric
Neeley, Mirza Peljto, Mahipal Suraneni, David Young.
2549
Defective STAT1 activation associated with
impaired IFN-␥ production in lymphocytes from
metastatic melanoma patients treated with HD IL-2.
Geok Choo Sim, Sheng Wu, Lei Jin, Patrick Hwu, Laszlo
Radvanyi.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
2550
Translational study on circulating markers in
advanced melanoma patients undergoing Dacarbazine
and Bevacizumab treatment. Pier Francesco Ferrucci,
Chiara Martinoli, Emilia Cocorocchio, Andrea Anichini, Sara
Gandini.
2551
B cells induced during CD4ⴙ T-cell mediated
destruction of primary tumors in neuN mice produce
mAbs that are capable of inhibiting spontaneous tumor
growth. Li-Xin Wang, Mona Patel, Michael Berk, Gregory
Plautz.
2552
T cell apoptosis signaling biomarker of PD-1
engagement in cancer patients. Wei Zhao, Haidong Dong.
2553
Pritumumab, a natural human IgG antibody
defines a tumor-associated biomarker useful in treating
brain cancer patients. Mark C. Glassy, Rishab Gupta.
2554
DDX3X-specific effector T cells in small cell
lung cancer patients reflect disease stage. Natsue
Igarashi, Hiroshi Kagamu, Koichiro Nozaki, Satoshi Shoji,
Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hirohisa
Yoshizawa, Ichiei Narita.
2555
A cell based bioluminescent reporter assay for
rapid measuring function of PD-1 or PD-L1 therapeutic
antibodies. Mei Cong, Natasha Karassina, Jey Cheng, Frank
Fan.
2556
The predictive role of tumor-associated
macrophages in stage IIIA pN2 non-small cell lung
cancer after neoadjuvant chemotherapy and surgery.
Po-Hao Feng, Chih-Teng Yu, Chin-Yang Wu, Tzung-Hai Yen,
Kang-Yun Lee.
2557
Immune modulating agent ibrutinib blocks Thelper 17 activation and release of IL-17A while
preserving T-regulatory cell function. Carrie S. Yang,
Jason A. Dubovsky, Danielle L. Chappell, Bonnie K.
Harrington, Samantha Jaglowski, Jennifer A. Woyach, Amy
J. Johnson, Natarajan Muthusamy, John C. Byrd.
2558
HLA-A2 and HER2 expression levels as clinical
prognostic factors in breast cancer patients:
implications for peptide cancer vaccine trials. Erika J.
Schneble, Alfred F. Trappey, Timothy J. Vreeland, John S.
Berry, Diane F. Hale, Alan K. Sears, Guy T. Clifton,
Sathibalan Ponniah, Elizabeth A. Mittendorf, George E.
Peoples.
2559
Molecular and immunological correlates of
latent versus productive reoviral infection in cancers.
James Mansfield, Andrew Stuff, Matt Coffey, Gerard Nuovo,
Flavia Picchiori, Craig C. Hofmeister.
2560
Strong cross-reactive responses to pancreatic
cancer cells induced by ␣-gal epitopes-expressing
tumor lysate and their implications for a universal
cancer vaccine. Masahiro Tanemura, Eiji Miyoshi, Hiroaki
Nagano, Masafumi Inoue, Toshimitsu Irei, Shinya Yamashita,
Kenta Furukawa, Katsuyoshi Matsunami, Wataru Kamiike,
Masaki Mori, Yuichiro Doki.
2561
Yeast vector-encoding multiple MUC1 agonist
epitopes (yeast-MUC1) can induce MUC1-specific T-cell
immune responses. Kwong Y. Tsang, Benjamin Boyerinas,
Caroline Jochems, Tim Rodell, Thomas King, Jeffey Schlom.
2562
Evaluate in vivo efficacy of anti-tumor immunotherapeutics using MixenoTM mouse models. Juan Zhang,
Junzhuan Qiu, Ziyong Sun, Xin Dong, Zha Jiping, Qian Shi.
2563
Development of clinical assay to mitigate
daratumumab, an IgG1␬ monoclonal antibody,
interference with serum immunofixation (IFE) and
clinical assessment of M-protein response in multiple
myeloma. Amy E. Axel, Christopher R. McCudden, Hong
Xie, Brett M. Hall, A. Kate Sasser.
2564
Histone deacetylase 6 is a novel target for
enhancing T-cell function during anti-tumor response
and tumor-peptide vaccination. Andressa S. Laino, David
M. Woods, Fengdong Cheng, HongWei Wang, Eduardo M.
Sotomayor.
POSTER SESSION
Immunology 5
Immune Modulatory Agents and Interventions
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
2565 Conformation overrides base sequence - insights from
a novel class TLR-9 agonists. Kerstin Kapp, Christiane Kleuss,
Matthias Schroff, Burghardt Wittig.
2566 Activation of tumor-initiated T cell priming and tumor
destruction with potent STING-activating cyclic dinucleotide
derivatives. Laura H. Glickman, David B. Kanne, Sarah M.
McWhirter, Meredith L. Leong, Edward E. Lemmens, Ken Metchette,
Russell E. Vance, Drew M. Pardoll, Thomas W. Dubensky.
2567 Enhancement of antitumor activity of DSP-6434, a
novel TLR7 agonist through reduction of TLR tolerance. Erina
Koga-Yamakawa, Masashi Murata, Simon J. Dovedi, Robert W.
Wilkinson, Hiroki Umehara, Eiji Sugaru, Yuko Hirose, Hideyuki
Harada, David T. Robinson, Philip J. Jewsbury, Setsuko Yamamoto,
Chiang J. Li.
2568 Application of novel phospholipid conjugated Toll like
receptor 7 ligands for cancer therapy by topical and systemic
administration. Dennis A. Carson, Tomoko Hayashi, Brian Crain,
Shiyin Yao, Jeffrey Cheng, Nadia Passini, Roberto Maj, Emanuela
Mura, Howard Cottam, Johanna Holldack, Alcide Barberis.
2569 Systemic delivery of STAT3 blocking/TLR9 activating
oligodeoxynucleotides induces regression of mouse and human
acute myeloid leukemia. Qifang Zhang, Ralf Buettner, Sergey
Nechaev, Dayson Moreira, Agnieszka Jozwiak, Piotr Swiderski,
Marcin Kortylewski.
2570 IMO-8400, a selective antagonist of TLRs 7, 8 and 9,
inhibits MYD88 L265P mutation-driven signaling and cell
survival: A potential novel approach for treatment of B-cell
lymphomas harboring MYD88 L265P mutation. Lakshmi Bhagat,
Daqing Wang, Weiwen Jiang, Sudhir Agrawal.
2571 Sustained induction of TRAIL and granzyme B as well
as intratumor infiltration of cytotoxic T lymphocytes (CTL) by a
novel TLR7 agonist, DSR-6434, after systemic administration.
Ryosaku Inagaki, Mikio Aoki, Toru Kimura, Yuko Hirose, Hiroki
Umehara, Erina Koga, Masashi Murata, Robert W. Wilkinson, David
T. Robinson, Philip J. Jewsbury, Chiang J. Li.
2572 CpG oligodeoxynucleotide enhances the efficacy of
anticancer monoclonal antibody in an in vivo xenograft model
using human endometrial cancer cell. Kosuke Hiramatsu, Satoshi
Serada, Kouji Kobiyama, Akiko Morimoto, Toshihiro Kimura, Kiyoshi
Yoshino, Minoru Fujimoto, Ken J. Ishii, Masami Fujita, Tetsuji Naka.
2573 The immunocytokine NHS-IL12 as a potential cancer
therapeutic. Jonathan K. Fallon, Robert Tighe, Amanda J. Lyon,
Helen Sabzevari, Jeffrey Schlom, John W. Greiner.
2574 Interleukin-7 (CYT107) treatment in lymphopenic 1st
line metastatic breast carcinoma patients treated with
chemotherapy regimen (Capecitabine) favors the restoration of
T-cell subsets number. Christine Menetrier-Caux, Isabelle RayCoquard, Claire Cropet, Estelle Verronese, Thomas Bachelot, Olivier
Tredan, Gwenaelle Garin, Pierre Heudel, Axelle N’Kodia, Ana Delgado,
Christine Bardin-Dit-Courageot, Chantal Rigal, Gilles Clapisson, Sylvie
Chabaud, David Perol, Paul Rebattu, Thérèse Croughs, Nicolas
Pasqual, Manuarii Manuel, Michel Morre, Jean-Yves Blay, Christophe
Caux.
2575 Results from the first-in-human phase I trials of
recombinant human Interleukin 15 (rhIL-15) administered as a
daily 30 minute intravenous infusion (IVB) for 12 consecutive
days or as continuous intravenous infusion (CIV) for 240 hours
in patients with refractory metastatic cancers. Kevin C. Conlon,
Enrico Lugli, Steven A. Rosenberg, John C. Morris, Thomas Fleisher,
Hugh Welles, Sigrid Dubois, Liyanage Perera, Carolyn Goldman,
Bonita Bryant, Jean Decker, Joanna Shih, Tat’Yana Worthy, William
Figg, Cody Peer, Michael Sneller, H. Clifford Lane, Jason Yovandich,
Stephen Creekmore, Mario Roederer, Thomas A. Waldmann.
2576 Polythymine oligonucleotides inhibit tumor growth
through the induction of IFN alpha. Nobuaki Kobayashi, Hidekazu
Shirota, Yoko Ichiki, Kiyoshi Sakasai, Yasushi Ichikawa, Takeshi
Kaneko, Yoshiaki Ishigatsubo.
2577 RLI, a sushi-IL-15R␣/IL-15 fusion protein, is a potent
immunomodulatory agent on NK and CD8ⴙ T cells and
synergizes with anti-PD1 treatment in preclinical mouse tumor
models. Mélanie Desbois, Coralie Beal, Clelia Coutzac, Magali
Terme, Geraldine Teppaz, Sebastien Morisseau, David Bechard,
Erwan Mortier, Nathalie Chaput.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2578 Synergistic activity of lenalidomide and interleukin-21
in chronic lymphocytic leukemia. Rebekah L. Browning, Jeffrey A.
Jones, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd.
2579 Combination with the novel tumor-targeted CEA-IL2v
immunocytokine enhances the activity of ADCC-competent and
glycoengineered antibodies in vitro and in vivo. Valeria Nicolini,
Inja Waldhauer, Anne Freimoser, Sara Colombetti, Federica Cavallo,
Marina Bacac, Christian Gerdes, Pablo Umana, Christian Klein.
2580 Construction of immunoglobulin light chain IL2
immunocytokines and mouse-specific surrogates for studying
the effects of IL2 receptor selectivity in mouse tumor models.
Stephen D. Gillies.
2581 Pancreatic cancer immunotherapy with chitosan/IL-12.
Haley K. Perlow, Lirong Yang, David Zaharoff.
2582 Cytotopic IL-15 as a novel therapeutic for prostate
cancer. Dorota A. Smolarek, Christina A. Sakellariou, Oussama
Elhage, Osamu Ukimura, Inderbir Gill, Angus G. Dalgleish, Prokar
Dasgupta, Richard A. Smith, Christine Galustian.
2583 Intratumoral treatment of one tumor lesion with LTX315 induces complete tumor regression and long-term specific
protective immune responses in a metastatic rodent tumor
model. Øystein Rekdal, Janne Nestvold, Meng Yu Wang, Ketil André
Camilio, Ali Areffard, Baldur Sveinbjørnsson, Gunnar Kvalheim.
2584 Complete regression and protective immune responses
obtained in B16 melanomas after treatment with LTX-315
(Oncopore®). Ketil André Camilio, Gerd Berge, Chandra Sekhar
Ravuri, Øystein Rekdal, Baldur Sveinbjørnsson.
2585 Bioactive compounds or metabolites from black
raspberries modulate T lymphocyte function, myeloid cell
differentiation and Jak/STATsignaling. Thomas A. Mace,
Samantha King, Zeenath Ameen, Omar Elnaggar, Gregory Young,
Kenneth Riedl, Steven Schwartz, Steven Clinton, Thomas Knobloch,
Christopher Weghorst, Gregory B. Lesinski.
2586 Bortezomib reduces preexisting antibodies to
recombinant immunotoxins in mice. Michael L. Manning, Emily
Mason-Osann, Masanori Onda, Ira Pastan.
2587 Dasatinib-induced reduction of tumor growth is
accompanied by the changes in the immune profile in
melanoma B16.OVA mouse model. Can Hekim, Mette Ilander,
Markus Vähä-Koskela, Paula Savola, Siri Tähtinen, Akseli Hemminki,
Kimmo Porkka, Satu Mustjoki.
2588 Antiangiogenic and immunomodulatory effects of
metronomic cyclophosphamide (CPM) treatment in prostate
cancer patients with PSA failure. Olivier Adotevi, Fabien Calcagno,
Tristan Maurina, Stefano Kim, Antoine Thiery-Vuillemin, Christophe
Borg, Yann Godet, Caroline Laheurte.
2589 In vitro activities of the cationic antitumoral peptide
LTX-315 against human melanoma cells. Liv-Marie Eike, Nannan
Yang, Øystein Rekdal, Baldur Sveinbjornsson.
2590 Oral combined therapy with probiotics and alloantigen
induces B cell dependent long lasting specific tolerance. Ana
Carolina T. Mercadante, Suelen Perobelli, Ana Paula G. Alves,
Triciana Gonçalves-Silva, Wallace Mello, Ana C Gomes-Santos,
Anderson Miyoshi, Ana Maria C. Faria, Adriana Bonomo.
2591 Ibrutinib can reverse established chronic graft-versushost disease, which is dependent upon IL-2 inducible T-cell
kinase (ITK) and Bruton’s tyrosine kinase (BTK)-driven
lymphocyte activation. Jason A. Dubovsky, Ryan Flynn, Jing Du,
Bonnie K. Harrington, Yiming Zhong, Carrie Yang, William Towns,
Amy Lehman, Amy Johnson, Steven Devine, Samantha Jaglowski,
Jonathan S. Serody, William J. Murphy, David H. Munn, Leo Luznik,
Geoffrey Hill, Kelli K. MacDonald, Ivan Maillard, John Koreth, Corey
Cutler, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Angela
Panoskaltsis-Mortari, John C. Byrd, Bruce R. Blazar.
2592 Tumor targeting and pharmacodynamics of the novel
targeted immunocytokine FAP-IL2v in a tumor-bearing Rhesus
monkey. Stefan Evers, Pradeep K. Garg, J. Mark Cline, Sudha Garg,
Greg Dugan, Anne Freimoser-Grundschober, Natalie D. Keirstead,
Christian Klein, Tapan Nayak.
2593 Multitargeted receptor tyrosine kinase inhibitors
synergize with folate-hapten mediated immunotherapy in folate
receptor positive cancers. Nimalka A. Bandara, Philip S. Low.
2594 Adjuvant cationic nanoliposomes induce anti-cancer
immunity in a murine model of breast cancer. Ismail M. Meraz,
David J. Savage, Jianhua Gu, Jessica Rhudy, Rita E. Serda.
28
28
385
POSTER SESSION
Poster
Section
29
29
Biologic Therapy 1
Poster Abstract
Board Number
1.
2595
Deubiquitinase USP9X inhibition induces
apoptosis in metastatic breast cancer cells. Anupama
Pal, Ming Luo, Max Wicha, Moshe Talpaz, Nicholas Donato.
14.
2608
Dissecting Myc inhibition as a cancer therapy.
Nicholas J. Salisbury, Catherine H. Wilson, Dan Lu, Trevor
D. Littlewood, Gerard I. Evan.
2.
2596
Suppression of lung cancer malignancy by
peptides targeting MARCKS phosphorylation site
domain: A comparative study. Ching-Hsien Chen, Sarah
Statt, Phillip Thai, Jasmine G. Lee, Kenneth B. Adler, PanChyr Yang, Reen Wu.
15.
2609
The role of focal adhesion kinase (FAK), PI3K/
AKT and p53/mouse double minute 2 homologue
(MDM2) complex in the pathobiology of Merlin-deficient
tumors. Clemens O. Hanemann, Sylwia Ammoun, Marei C.
Schmid, Lu Zhou.
3.
2597
Direct inhibition of oncogenic KRAS by
hydrocarbon-stapled SOS1 helices. Elizaveta Leshchiner,
Joseph Bellairs, Gregory H. Bird, Kwadwo Opoku-Nsiah,
Marina Godes, Lored D. Walensky.
16.
4.
2598
siRNA silencing of survivin enhances activity of
mitomycin C in human bladder RT4 xenografts. Minjain
Cui, M. Guillaume Wientjes, Jessie L. Au, Michael O’Donnell,
Kevin Loughlin, Ze Lu.
2610
AMG 232, a small molecular inhibitor of MDM2
augments radiation response in human tumors
harboring wild-type p53. Lauryn Werner, Shyhmin Huang,
Eric A. Armstrong, Dave Francis, Tao Osgood, Jude Canon,
Paul M. Harari.
17.
2599
KDM3A tyrosine phosphorylation by Ack1
promotes tamoxifen-resistance in breast cancer. Kiran
Mahajan, Sayantani Bandyopadhyay, Nupam Mahajan.
2611
Function blocking ERBB3 antibody inhibits
adaptive response to RAF inhibitor. Curtis H. Kugel,
Edward J. Hartsough, Michael A. Davies, Andrew E. Aplin.
18.
2612
ljm716, an anti her3 antibody that inhibits her3
dimerization, displays anti-tumor activity in esophageal
squamous cell cancer. Qing Sheng, Hui-Qin Wang, rita
das, yan chen, jinsheng liang, Fiona Xu, zongyao Wang, Z.
Alexander Cao, youzhen Wang, alan huang.
19.
2613
Wnt/␤-catenin signaling mediates the antitumor activity of three ginsenoside derivatives in lung
cancer. Xiuli Bi.
20.
2614
Bone sialoprotein is an essential target in
breast cancer skeletal metastasis. Marineta Kovacheva,
Michael Zepp, Stefan Berger, Martin R. Berger.
21.
2615
Novel combination therapy of adenoviral gene
transfer of HER2-extracellular domain and trastuzumabbased photoimmunotherapy for HER2 negative cancer
cells. Michihiro Ishida, Shunsuke Kagawa, Kyoko
Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke
Tanabe, Hiroshi Tazawa, Junji Matsuoka, Hisataka
Kobayashi, Toshiyoshi Fujiwara.
22.
2616
RFX1-dependent activation of SHP-1 inhibits
STAT3 signaling in hepatocellular carcinoma cells. JungChen Su.
23.
2617
Preclinical efficacy of GNE-317, a dual PI3K/
mTOR inhibitor, with or without bevacizumab in EGFR
and/or PTEN-mutated glioblastoma multiforme. Terence
T. Sio, Jenny L. Pokorny, Ann C. Mladek, Brett L. Carlson,
Mark A. Schroeder, Dennis O. Iyekegbe, Katrina Bakken,
Laurent Salphati, Heidi Phillips, Jann N. Sarkaria.
24.
2618
PTEN loss as a putative biomarker of
synergistic growth inhibitory activity of combined MEK/
ERK and PI3K/mTOR pathway blockade. Ludovica
Ciuffreda, Italia Falcone, Silvia Matteoni, Andrea Sacconi,
Federico Malusa, Teresa De Luca, Ursula Cesta Incani,
Anais Del Curatolo, Marina Konopleva, Michael Andreeff,
Adriana Eramo, Ruggero De Maria, Donatella Del Bufalo,
Francesco Cognetti, Michele Milella.
25.
2619
Meausuring PIP3 reveals the unexpected role of
p110〉 in luminal breast cancers. Carlotta Costa,
Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala,
Youngchul Song, Cyril H. Benes, Jeffrey A. Engelman.
5.
6.
2600
Preclinical evaluation of the novel fusion
molecule with high dual antiangiogenic and anticancer
potential. Jerzy S. Pieczykolan, Anna Pieczykolan, Piotr
Rozga, Sebastian Pawlak, Bartlomiej Zerek, Malgorzata
Teska - Kaminska, Szymanik Michal, Albert Jaworski, Karl
R. Erlemann, Jacek Capala.
7.
2601
EphB4/EphrinB2 targeting increases the efficacy
of cisplatin in triple negative breast cancer. Gloria W.
Yang-Kolodji, Ren Liu, Arjun Mehta, Parkash Gill, Debu
Tripathy.
8.
2602
KRAS G12D and G12V specific alkylating agent
(KR12) inhibits growth of colon cancer with those KRAS
mutations in vitro as well as in vivo. Hiroki Nagase,
Kiriko Hiraoka, Takahiro Inoue, Takayoshi Watanabe, KenIchi Shinohara, Nobuko Koshikawa, Ozaki Toshinori.
9.
2603
Specific growth suppression of wild-type p53
tumor cells by DNA-modified siRNA sequences targeting
MDM2. Mitsuaki Hirose, Kenji Yamato, Rie Saito, Takunori
Ueno, Sachiko Hirai, Hideo Suzuki, Shinji Endo, Ichinosuke
Hyodo.
10.
2604
Characterization of the activity and the
mechanism of action of the new retinoid derivative
ST5589 in pre-clinical models of lymphomas:
involvement of MYC and cell cycle genes. Elena
Bernasconi, Ivo Kwee, Andrea Rinaldi, Luciano Cascione,
Maurilio Ponzoni, Loredana Vesci, Giuseppe Giannini,
Anastasios Stathis, Emanuele Zucca, Eugenio Gaudio,
Francesco Bertoni.
11.
2605
Selective targeting of KRAS mutant cancer cells
by a novel small molecule compound. Kartini Iskandar,
Majidah Rezlan, Sanjiv K. Yadav, Shazib Pervaiz.
12.
2606
Cetuximab-mediated ADCC activity is correlated
with the cell surface expression level of EGF-R but not
the K-RAS/B-RAF mutational status in colorectal cancer.
Yoshiyuki Ishii, Yuki Seo, Shingo Akimoto, Kazumasa
Fukuda, Tetsu Hayashida, Koji Okabayashi, Masashi Tsuruta,
Hirotoshi Hasegawa, Yuko Kitagawa.
13.
386
Poster Abstract
Board Number
2607
G-rich DNA genomic sequences derived from
the promoter region of pro-oncogenes selectively inhibit
tumor growth and demonstrate strong synergies. Gilles
H. Tapolsky, Kara Sedoris, Shelia Thomas, Francine
Rezzoug, Donald M. Miller.
POSTER SESSION
Biologic Therapy 2
Poster
Section
Poster Abstract
Board Number
1.
2620
3D multicellular pancreatic cancer spheroids as
drug screening tool for pharmacological evaluation of
EHT 5372 and other Mirk/DYRK1B inhibitors. AnneSophie CASAGRANDE, Florence BACHELOT, Emeline THROO,
Florence MAHE, Bertrand LEBLOND, Thierry BESSON,
Matthew PANDO, Laurent DESIRE.
2.
2621
PAK4 mediated mechanisms contributing to
chemoresistance of ovarian cancer. Ya N. Du, Oscar G.
Wong, Ka K. Chan, Esther S. Wong, Annie N. Cheung.
3.
2622
New therapeutic strategies in neuroblastoma:
combined targeting of a novel tyrosine kinase inhibitor
and liposomal siRNAs against ALK. Daniela Di Paolo,
Laura Emionite, George Liu, Michele Cilli, Annarita Di Fiore,
Chiara Brignole, Chris Liang, Fabio Pastorino, Jay Gibbons,
Mirco Ponzoni, Patrizia Perri.
4.
5.
6.
7.
8.
2623
PI3K/mTOR dual inhibitor PF-5212384 inhibits
aberrant NF-kB activation and exhibits activity in
combination with MEK inhibitor PD-325901 and
docetaxel in human head and neck squamous cell
carcinoma. Suresh Mohan, Robert J. Vander Broek,
Anthony D. Saleh, Matthew L. Pierce, Jamie F. Coupar,
Danielle F. Eytan, Zhong Chen, Carter Van Waes.
2624
The novel Bruton’s tyrosine kinase inhibitor
ACP-196 shows in vivo efficacy against human chronic
lymphocytic leukemia cells xenografted to the NSG
mouse model. Carsten U. Niemann, Arnau Montraveta,
Sarah E. Herman, Tim Ingallinera, Tjeerd Barf, Dolors
Colomer, Adrian Wiestner.
2625
Increased sensitivity to Wnt/beta-catenin
inhibitors in hepatocellular carcinoma cells harboring
activating mutation of beta-catenin. Hsiao-Hui Lin, WenChi Feng, LI-Chun Lu, Ta-Wen Hsu, Ann-Lii Cheng, ChihHung Hsu.
2626
Novel naphtoquinone PIC21 targets PI3K in
triple negative breast cancer cell line. Renata D. Daltoe,
Klesia P. Madeira, Murilo F. Cerri, João F. Allochio Filho,
Maicon Delarmelina, Marcella L. Porto, Silvana S. Meirelles,
Silvana S. Meirelles, Ian V. Silva, Sandro J. Greco, Leticia B.
Rangel.
2627
Use of xenografts for preclinical drug testing.
Mark J. De Lange, Fariba Némati, Mieke Versluis, Martine J.
Jager, Gre P. Luyten, Didier Decaudin, Pieter A. van der
Velden.
Poster Abstract
Board Number
10.
2629
Nintedanib (BIBF-1120) inhibits hepatocellular
carcinoma growth independent of angiokinase activity.
Wei-Tien Tai, Chung-Wai Shiau, Yong-Shi Li, Chun-Wei
Chang, Jui-Wen Huang, Ting-Ting Hsueh, Kuen-Feng Chen.
11.
2630
Simvastatin induced apoptosis and suppressed
proliferation of breast cancer through deactivating PI3K/
Akt/mTOR pathway. Tingting Wang, Serena Seah, ChingWan Chan, Mikael Hartman, Nyein Nyein Thaw Dar, Philip
Iau, Boon-Cher Goh, Soo-Chin Lee.
12.
2631
Neuregulin-1 expression correlates with
sensitivity to the PI3K inhibitor, GDC-0032, outside of
PIK3CA mutations in head and neck cancer. Heidi M.
Savage, Carol O’Brien, Bob Yauch, Jeff Settleman, Mark R.
Lackner, Timothy R. Wilson.
13.
2632
Casein kinase II inhibitors regulate cell cycle
progression in leukemia. Chandrika Gowda, Chunhua
Song, Mansi Sachdev, Xiaokang Pan, Yali Ding, Kimberley
Payne, Sinisa Dovat.
14.
2633
TP53 loss creates therapeutic vulnerability in
cancer. Yunhua Liu, Xiongbin Lu.
15.
2634
Direct reprogramming of tumor cells: a basis
for novel therapeutic approaches. Lena Bluemel, Carolin
Huelsewig, Holm Zaehres, Hans Schoeler, Ludwig Kiesel,
Christof Bernemann.
16.
2635
Differential inhibition of autophagic pathways in
melanoma is oncogene-dependent. Kirsten A. White,
Salina M. Torres, Todd A. Thompson, Chien-An A. Hu,
Natalia J. Gurule, Marianne Berwick.
17.
2636
Connexin 43 suppresses tumor angiogenesis by
downregulation of vascular endothelial growth factor.
Man-Chin Chen, Che-Hsin Lee.
18.
2637
Role of d16HER2 splice variant in HER2-positive
breast cancer. Gaia C. Ghedini, Arianna Palladini, Valentina
Ciravolo, Lorenzo Castagnoli, Giulia Marzano, Roberta
Zappasodi, Guido Santilli, Augusto Amici, Alessia
Lamolinara, Manuela Iezzi, Patrizia Nanni, Elda Tagliabue,
Serenella M. Pupa.
19.
2638
Novel synergy of radiosensitizer prodrug IPdR
with Aurora kinase inhibitors in triple-negative breast
cancer. Murtuza M. Rampurwala, Alka Choudhary, Mark E.
Burkard.
20.
2639
Development of immunocytotoxic RNA
therapeutics for human melanoma. Jaewoo Lee, Youngju
Lee, Bruce A. Sullenger.
30
30
387
POSTER SESSION
Poster
Section
31
31
New Antibodies and Antibody Drug Conujugates
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
388
2640 RN927C, a potent site-specific Trop-2 antibody-drugconjugate (ADC) for treatment of solid tumors. Shu-Hui Liu, Pavel
Strop, Thomas-Toan Tran, Magdalena Dorywalska, Katherine Delaria,
Wei-Hsien Ho, Russell Dushin, Jaume Pons, Arvind Rajpal, Dave
Shelton.
2641 Tailored antibody drug conjugate (ADC) therapy
depending on a quantity of tumor stroma. Masahiro Yasunaga,
Shino Manabe, David Tarin, Yasuhiro Matsumura.
2642 Antibody-drug conjugate for human pancreatic cancer
cells using anti-tissue factor monoclonal antibody. Yoshikatsu
Koga, Ryuta Sato, Ryo Tsumura, Hikaru Machida, Yoshiyuki Yamamoto,
Yohei Hisada, Yuki Fujiwara, Masahiro Yasunaga, Shino Manabe,
Yasuhiro Matsumura.
2643 A highly cytotoxic EGFRvIII/CD3 TandAb recruits T cells
to specifically and potently kill several types of solid tumor
cancers. Eugene A. Zhukovsky, Kristina Ellwanger, Uwe Reusch,
Markus Eser, Fionnuala McAleese, Ivica Fucek, Carmen Burkhardt,
Stefan Knackmuss.
2644 Antibody-drug conjugates (ADCs) with a novel DNAalkylating agent, DGN462, are highly potent in vitro and in vivo
against human cancer models. Kathleen Whiteman, Charlene
Audette, Andre Dandeneau, Megan Ellis, Nathan Fishkin, Lauren
Harvey, Holly Johnson, Yelena Kovtun, Erin Maloney, Michael Miller,
Alan Wilhelm, Ravi Chari.
2645 Advantages of polyacetal polymer-based ADCs:
Application to low expression targets. Alex Yurkovetskiy, Natalya
Bodyak, Mao Yin, Joshua D. Thomas, Patrick Conlon, Cheri A.
Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena TerOvaneysan, Venu R. Gurijala, Dennis McGillicuddy, Roberta E. Glynn,
Michael DeVit, Laura L. Poling, Peter U. Park, Timothy B. Lowinger.
2646 Building a powerful ADCs discovery and development
platform with novel dolastatin/auristatin payloads. Shanghui Hu,
Lucy X. Zhao, Xu Liu, Chao Li, Wei Hu, Zunrong Wang, Xufang Tian.
2647 SGN-CD70A, a novel and highly potent anti-CD70 ADC,
induces double-strand DNA breaks and is active in models of
MDRⴙ renal cell carcinoma (RCC) and non-Hodgkin lymphoma
(NHL). Sharsti Sandall, Martha Anderson, Mechthild Jonas, Albina
Nesterova, Jamie Miyamoto, Ivan J. Stone, Weiping Zeng, Che-Leung
Law, Timothy S. Lewis.
2648 Enhanced antitumor effect of anti tissue factor (TF)
antibody-conjugated epirubicin-incorporating polymeric micelles in
human cancer xenografts with high TF expression. Yoshiyuki
Yamamoto, Ichinosuke Hyodo, Yoshikatsu Koga, Ryo Tsumura, Ryuta
Sato, Toshihumi Obonai, Hirobumi Fuchigami, Masahisa Kudo, Masahiro
Yasunaga, Mitsunori Harada, Tatsuyuki Hayashi, Yasuki Kato, Yasuhiro
Matsumura.
2649 Development of an antibody-drug conjugate targeting
TIM-1 for the treatment of ovarian and renal cell carcinoma.
Lawrence J. Thomas, Laura Vitale, Thomas O’Neill, Ree Dolnick, Paul
K. Wallace, Hans Minderman, Lauren E. Gergel, Eric M. Forsberg,
James M. Boyer, James R. Storey, Russell A. Hammond, Jennifer
Widger, Karuna Sundarapandiyan, Andrea Crocker, Henry C. Marsh,
Tibor Keler.
2650 Ags67e, an anti-cd37 monomethyl auristatin e antibody
(mmae) drug conjugate as a potential therapeutic for nonhodgkin’s lymphoma, chronic lymphocytic leukemia and acute
myeloid leukemia. Daniel S. Pereira, Claudia Guevara, Alla Verlinsky,
Cyrus Virata, J Hsu Ssucheng, Zili An, Chungying Zhang, Nick Dinh,
Hector Avina, Lisa Do, Sher Karki, Joseph Abad, Peng Yang, Jimmy Ou,
Karen Morrison, Sing-Ju Moon, Faisal Malik, Liqing Jin, Michael Choi,
Christina Wu, Banmeet Anand, Scott Cooper, Ingrid Joseph, Xiao-Chi
Jia, Kendall Morrison, Pia Challita-Eid, Fernando Donate, Thomas Kipps,
John Dick, David Stover.
2651 Impressive efficacy and safety profile of a novel
generation duocarmycin-based HER2-targeting ADC. Willem Dokter,
Ruud Ubink, Miranda van der Lee, Monique van der Vleuten, Tanja van
Achterberg, Daniëlle Jacobs, Diels van den Dobbelsteen, David Egging,
Ellen Mattaar, Patrick Groothuis, Patrick Beusker, Ruud Coumans,
Ronald Elgersma, Michel Eppink, Guy de Roo, Gijs Verheijden, Marco
Timmers.
2652 In vitro and in vivo antitumor activity of SYD985, a novel
HER2-targeting ADC: a comparison with T-DM1. Willem H. Dokter,
Miranda van der Lee, Patrick Groothuis, Tanja van Achterberg, Eline
Loosveld, Daniëlle Jacobs, Monique van der Vleuten, Patrick H.
Beusker, Leon Hooftman, Peter Goedings, Gijs Verheijden, Marco
Timmers.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2653 Anti-cancer antibody trastuzumab-melanotransferrin
conjugate (BT2111) for the treatment of metastatic HER2ⴙ breast
cancer tumors in the brain: An in vivo study. Mohamed Nounou,
Chris Adkins, Tori R. Terrell, Afroz Mohamed, Tim Vitalis, Reinhard
Gabathuler, Paul R. Lockman.
2654 Human antibodies specific for oxidized macrophage
migration inhibitory factor (oxMIF) synergize with
chemotherapeutic agents in animal models of cancer. Patrice
Douillard, Thorsten Hagemann, Michael Freissmuth, Michael Thiele,
Alexander Schinagl, Dirk Völkel, Friedrich Scheiflinger, Randolf
Kerschbaumer.
2655 A novel Trop-2/CD3 trivalent bispecific antibody
effectively redirects T cells to kill target human pancreatic and
gastric cancer cells. Diane L. Rossi, Thomas M. Cardillo, Edmund A.
Rossi, Maria Zalath, David M. Goldenberg, Chien-Hsing Chang.
2656 Rapid expansion of EGFR bispecific therapeutic pipeline
through a robust modular mAb2 antibody discovery platform
generates novel biologics with unique mechanism of actions. KinMei Leung, Robert Rowlands, Miguel Gaspar, Robert Pegram, Sandra
Uhlenbroich, Samine Isaac, Sarah Weller, Mateusz Wydro, Vicky
Drewett, Mihriban Tuna, John Haurum, Haijun Sun.
2657 Utilization of the Angiopep platform to enable brain
penetration of therapeutic mAbs or Antibody-Drug Conjugates for
treatment of brain tumors. Michel Demeule, Jean E. Lachowicz,
Sasmita Tripathy, Giogang Yang, Sanjoy Das, Christian Che, JeanChristophe Currie, Simon Lord-Dufour, Anthony Regina, Jean-Paul
Castaigne.
2658 GPEx® system to increase production of pritumumab in
a CHO cell line. Gregory T. Bleck, Rishab K. Gupta, Beatrix Kotlan,
Dona York, Mark C. Glassy.
2659 The MedImmune ADC platform: Building highly potent
and specific cancer drugs. Robert E. Hollingsworth, Adeela Kamal,
Philip W. Howard, John A. Hartley, David Tice, Changshou Gao,
Nazzareno Dimasi, Haihong Zhong, Jay Harper, Zhan Xiao, Dorin
Toader, Chris Martin, Herren Wu, Norman Greenberg, Bahija Jallal.
2660 Targeting an attenuated cytokine to tumor cells via
antibody fusion results in enhanced tumor killing with significantly
reduced off-target activity. Sarah L. Pogue, Tetsuya Taura, Mingying
Bi, Glen Mikesell, Yong Yun, Angela Sho, Collette Behrens, Maxwell
Stevens, Teresa Domagala, Maya Sokolovsky, Hussein Hallak, Moti
Rosenstock, Anthony Doyle, David S. Wilson.
2661 Patient-derived breast cancer targeting heavy chain
antibodies. Charan Kumar V. Devarakonda, Daniel Kita, Kathryn N.
Phoenix, Dewey M. Magee, Kevin P. Claffey.
2662 Site specific ADC generation using SMARTag technology
with programmable payload placement. David Rabuka.
2663 Hyperthermia improves Cetuximab accumulation in
pancreatic cancer mouse model. Ryoichi Miyamoto, Tatsuya Oda,
Shinji Hashimoto, Yoshimasa Akashi, Tomohiro Kurokawa, Yuki Inagaki,
Nobuhiro Ohkohchi.
2664 An anti-Jagged-1/-2 Probody demonstrates inhibition of
Jagged-dependent Notch signaling and is activated in multiple
types of tumors. Olga Vasiljeva, Elizabeth Menendez, Jason Sagert,
James W. West, Jennifer Richardson, Luc Desnoyers, Shouchun Liu,
Judi Ford, Krishna Plou, Henry Lowman.
2665 Transforming Notch ligands into tumor-antigen targets:
A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged
2. Jason Sagert, Jim West, Chihunt Wong, Luc Desnoyers, Olga
Vasiljeva, Jennifer Richardson, Krishna Polu, Henry Lowman.
2666 Monoclonal antibodies specific for the oncofetal antigen
- immature laminin receptor: Tumor selectivity, rapid
internalization and in vivo efficacy. Shannon D. McClintock, Michael
K. Dame, Muhammad N. Aslam, Saqib Ali, Randall N. Knibbs, Roscoe
L. Warner, James Varani.
2667 RG7287, a novel humanized anti-CDCP1 antibody with
superior preclinical in vivo efficacy in combination with Paclitaxel.
Gwendlyn Kollmorgen, Alexander Lifke, Adam Nopora, Frieder Bauss,
Gerhard Niederfellner, Birgit Bossenmaier.
2668 RG7116, a novel humanized anti-HER3 antibody with
superior preclinical in vitro and in vivo efficacy in combination
with, everolimus and other anti-cancer agents. Birgit Bossenmaier,
Thomas Friess, Martin Weisser, Stefanie Lechner, Esther Abraham,
Monika Hoch, Christian Mirschberger.
2669 Targeting the tumor vasculature with antibody drug
conjugates. Andrea T. Hooper, Chao-Pei Betty Chang, Kimberly
Marquette, Jonathon Golas, Justin Lucas, Timothy Nichols, Judy Lucas,
Gavriil Maria, Edward Rosfjord, Anton Xavier, Nathan Scott, Sadhana
Jain, Wei Cao, Mauricio Leal, Andreas Maderna, Magali Guffroy, Xiang
Zheng, Lioudmila Tchistiakova, Frank Loganzo, Hans-Peter Gerber,
Chad May.
POSTER SESSION
New Targets and Agents 2
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
2670 Exploring the in vitro and in vivo activity of lucitanib
in FGFR1-amplified lung cancer models. Ezia Bello, Rosaria Chilà,
Federica Guffanti, Monique Zangarini, Laura Ceriani, Massimo
Zucchetti, Saba Chaudi, Marie-Jeanne Pierrat, Anne JacquetBescond, Giovanna L. Damia.
2671 Targeting the KRAS signaling naocluster protein
CNKSR1 provides antitumor activity against mutant KRAS
xenografts. Gallen Triana-Balzer, Martin Indarte, Mike Scott, Garth
Powis, D. Lynn Kirkpatrick.
2672 Vinyl sulfone analogues of lysophosphatidylcholine
irreversibly inhibit autotaxin and prevent angiogenesis in
melanoma. Mandi M. Murph, Molly Altman, Wei Jia, Duy Nguyen,
Jada Fambrough, William J. Hardman, Guowei Jiang, Damian
Madan, Jianxing Zhang, Glenn D. Prestwich.
2673 A novel ligand-independent peptide inhibitor of TREM1 attenuates inflammation and suppresses tumor growth in
mice. Alexander B. Sigalov.
2674 Stroma biology identifies heparins as differentiating
agents in neuroblastoma. Erik H. Knelson, Angela L. Gaviglio,
Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G.
Marcus, Gerard C. Blobe.
2675 Optimization of antivascular tumor therapy with
retargeted tissue factor proteins to improve the activity/toxicity
profiles and therapeutic outcome. Christian Schwöppe, Caroline
Zerbst, Christoph Schliemann, Rolf M. Mesters, Wolfgang E. Berdel.
2676 Inhibition of bmp signaling suppresses metastasis in
mammary cancer. Philip Owens, Michael W. Pickup, Sergey V.
Novitskiy, Jennifer M. Giltnane, Agnes E. Gorska, Corey R. Hopkins,
Charles C. Hong, Harold L. Moses.
2677 Lysyl Oxidase a therapeutic target in pancreatic
cancer. Grazia Saturno, Filipa Lopes, Amaya Viros, Jennifer Morton,
Owen Sansom, Caroline Springer, Richard Marais.
2678 All-trans-retinoic acid as a new therapeutic approach
to target isocitrate dehydrogenase mutations in acute myeloid
leukemia. Helena Boutzen, Fabienne De Toni, Estelle Saland, Eric
Delabesse, Véronique De mas, Cécile Demur, Florence Castelli, Lara
Gales, Virginie Penard-lacronique, Stéphane De Botton, Jean-Charles
Portais, Christophe Junot, Stéphane Manenti, Christian Récher, Jeanemmanuel Sarry.
2679 Acetyl-CoA carboxylase inhibition by ND646 reduces
fatty acid synthesis and inhibits cell proliferation in human nonsmall cell lung cancer cells. Robert Svensson, Geraldine Harriman,
Jeremy Greenwood, Sathesh Bhat, H.James Harwood, Rosana
Kapeller, Reuben Shaw.
2680 Inhibition of activin-like kinases 4 and 5 attenuates
cancer cachexia associated muscle wasting. Stef Levolger, Ron
W. de Bruin, Jan N. IJzermans.
2681 4-methylumbelliferone: Dietary supplement turned
chemo-preventive and anti-metastatic agent for prostate cancer.
Travis Yates, David Alonzo, Soum Lokeshwar, Kelly Hoye, Luis E.
Lopez, Marie Hupe, Vinata Lokeshwar.
2682 ELTD1 as a target for anti-cancer therapy in rodent
gliomas. Rheal A. Towner, Richard Pody, Nataliya Smith, Debra
Saunders, Charity Njoku, Jonathan D. Wren.
2683 Inhibition of BCAT1 suppresses the expression of prometastatic proteins and reduces cancer metastasis. Adonia E.
Papathanassiu, Hong A. Vu.
2684 Inhibition of tumor growth and angiogenesis by SP-2,
an anti-LGALS3BP antibody. Enza Piccolo, Sara Trani, Nicola Tinari,
Cosmo Rossi, Rossana La Sorda, Rossano Lattanzio, Maurizia
D’Egidio, Annalisa Di Risio, Antonino Grassadonia, Francesca
Spinella, Anna Bagnato, Mauro Piantelli, Clara Natoli, Stefano
Iacobelli.
2685 Regulation of Ras stability via inhibition of Wnt/␤catenin pathway as a potential therapeutic strategy to treat
colorectal cancers. Pu-Hyeon Cha, Yong-Hee Cho, Woo-Jeong
Jeong, Hyun-Yi Kim, Kang-Yell Choi.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2686 The CDK inhibitor dinaciclib (SCH727965) inhibits the
unfolded protein response (UPR) through a CDK1- and CDK5dependent mechanism. Tri K. Nguyen, Steven Grant.
2687 CK2 inhibitor CX-4945 modulates AKT, NF-kB, TP53
and MEK inhibitor PD-325901 targets AP1 mediated CK2
inhibitor drug resistance in head and neck cancer. Yansong Bian,
Jiawei Han, Vishnu Kannabiran, Suresh Mohan, Jay Friedman, Kenna
Anderes, Zhong Chen, Carter Van Waes.
2688 Drugging MYCN through an allosteric transition in
Aurora A kinase. William C. Gustafson, Justin G. Meyerowitz, Erin
A. Nekritz, Elise A. Charron, Yvan Chanthery, Erin Simonds, Katherine
Matthay, Nicholas Hertz, Kevan Shokat, William A. Weiss.
2689 Breast cancer inhibition by a novel and potent
biguanide, N1-hexyl-N5-benzyl-biguanide. Zhijun Guo, Kathryn
J. Chavez, Juan Alvarez, Xia Zhang, Beverly Norris, Michael Maher,
Monique Morgan, Robert J. Schumacher, Rebecca Cuellar, Irina F.
Sevrioukova, Thomas L. Poulos, Ilia Denisov, Stephen G. Sligar,
Kalpna Gupta, Ian A. Blair, Jorge Capdevila, Ameeta Kelekar,
Elizabeth Amin, Gunda Georg, David A. Potter.
2690 Sorafenib/regorafenib and phosphatidyl inositol 3
kinase/thymoma viral proto-oncogene inhibition interact to kill
tumor cells. Larray A. Booth, Nichola A. Cruickshanks, G B. Sajithlal,
Hossein A. Hamed, Seyedmehrad Tavallai, J Syed, Steven Grant,
Andrew Poklepovic, Paul Dent.
2691 Smo-targeted sonic hedgehog signaling inhibitor
enhances therapeutic antibody deposition and efficacy in a
patient-derived pancreatic ductal adenocarcinoma model. Jun
Wang, Yang Qu, Rose Pitoniak, Sheryl A. Trueman-Fatallah, Bonnie
L. Hylander, Elizabeth A. Repasky, Wen Wee Ma, Robert M.
Straubinger.
2692 Nanoconjugates for inhibition of laminin-411-integrin
␤1-Dll4-Notch1 pathway to treat glioblastoma multiforme. Pallavi
R. Gangalum, Alexander V. Ljubimov, Alexandra Chesnokova, Bindu
Konda, Hui Ding, Jose Portilla-Arias, Adam Mamelak, Serguei
Bannykh, Surasak Phuphanich, Jeremy Rudnick, Jethro Hu, Keith L.
Black, Julia Y. Ljubimova.
2693 Harnessing MALT1 inhibition for rational combinatorial
therapy of ABC-DLBCL. Lorena Fontan, Chenghua Yang,
Venkataraman Kabaleeswaran, Laurent Volpon, Michael Osborne,
Elena Beltran, Monica Rosen, Rita Shaknovich, Shao N. Yang, Randy
D. Gascoyne, Leandro Cerchietti, Jose A. Martinez-Climent, J. Fraser
Glickman, Katherine Borden, Hao Wu, Ari Melnick.
2694 Novel sesquiterpene lactones derived from Vernonia
cinerea inhibit STAT3 activity and suppress human glioblastoma
phenotype. Gabriella Miklossy, Ui Joung Youn, Peibin Yue, Leng
Chee Chang, James Turkson.
2695 FTY720 as a novel therapeutic approach for colon
cancer carcinomatosis. Tomoyoshi Aoyagi, Dorit Avini, Masayuki
Nagahashi, Akimitsu Yamada, Krista P. Terracina, Wei-Ching Huang,
John Soong, Michael O. Idowu, Kazunori Aoki, Sheldon Milstien,
Sarah Spiegel, Kazuaki Takabe.
2696 PPAR beta/delta is a novel therapeutic target in acute
myeloid leukemia. Sophia Hu, David Wald, Reshmi Parameswaran.
2697 A novel therapeutic strategy to effectively kill CLL
cells in stromal microenvironment by targeting lipid metabolism.
Panpan Liu, Jinyun Liu, Marcia A. Ogasawara, Helene Pelicano,
Ruihua Xu, Michael J. Keating, Peng Huang.
2698 Degrasyn-like symmetrical compounds: Possible
therapeutic agents for multiple myeloma (MM-I). William G.
Bornmann, Zhenghong Peng, David Maxwell, Duoli Sun, Basvoju A.
Bhanu, Moshe Talpaz, Nicholas Donato, Alexander Levitzki.
2699 Identification and characterization of active
components of antrodia cinnamomea mycelia on targeting
cancer initiating cells. Meng-Chia Wu, Jeng-Fan Lo.
32
32
389
POSTER SESSION
Poster
Section
33
33
Novel Targets 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
390
2700 LSKL peptide inhibits thrombospondin-1-mediated
TGF-␤ signal activation and accelerates liver regeneration after
hepatectomy in mice. Hideyuki Kuroki, Hiromitsu Hayashi, Shigeki
Nakagawa, Keita Sakamoto, Takaaki Higashi, Hidetoshi Nitta,
Daisuke Hashimoto, Akira Chikamoto, Toru Beppu, Hideo Baba.
2701 Antitumor effects of peptide Rb4 derived from
proteolipid protein 2 (PLP2) in a syngeneic murine melanoma
model. Vera S. Maia, Rodrigo Berzaghi, Denise C. Arruda, Pollyana
M. Melo, Luiz R. Travassos.
2702 Suppression of c-Myc oncogenic signaling by MK591,
an inhibitor of arachidonate 5-lipoxygenase. Sivalokanathan
Sarveswaran, Debrup Chakraborty, Jagadananda Ghosh.
2703 Effect of route and dosing regimen on efficacy of
SH7139 in mouse Burkitt’s lymphoma xenografts. Rodney
Balhorn, Gary Mirick, Gerald L. DeNardo, Laurel Beckett, Judy Li,
Saphon Hok, Monique Balhorn.
2704 Simultaneous targeting of androgen receptor (AR) and
Eukaryotic Initiation Factor 4E (eIF4E) dependent translation
initiation by RAMBA Retinamides promotes apoptosis and
impedes cell growth, cell proliferation and matrix invasion in
androgen sensitive and castration-resistant prostate cancers.
Vidya priyadarsini Ramamurthy, Senthilmurugan Ramalingam, Lalji
Gediya, Vincent C. Njar.
2705 Study of Malformin C, a fungal cyclic pentapeptide, as
an anti-cancer drug. Jing Wang, Zaoli Jiang, Wing Lam, Elizabeth
Gullen, Caroline Zeiss, Amanda Beck, Ee-Chun Cheng, Yung-chi
Cheng, Yixuan Zhang.
2706 Tumor-targeting with novel pyridyl 6-substituted
pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate
receptor (FR) ␣ and the proton-coupled folate transporter
(PCFT) and inhibition of de novo purine nucleotide biosynthesis.
Christina Cherian, Lei Wang, Adrianne Wallace, Steven Orr, Zhanjun
Hou, Aleem Gangjee, Larry H. Matherly.
2707 In vitro and in vivo evaluation of SNG1153, a synthetic
modulator of ER-␣36. Bo Zhang, Kun Meng, Xiao Shang, Zhaoyi
Wang, Yanzhong Zhang, Fang Fang, Jing Wang, Zonghui Wang, Jun
Wang, Yuming Guo, Shiyang Liu, Feng Chen, Hongxia Ding, Jiancun
Zhang, Jun Bao.
2708 Development of allosteric regulators of the
dimerization domains of the plasminogen-related growth factor
family for the treatment of pancreatic cancer. Kevin J. Church,
Leen Kawas, Joseph Harding, Malte Lang, Michelle McMicheal.
2709 Identification of Aurintricarboxylic Acid (ATA) as an
inhibitor of TWEAK-Fn14 signaling in glioblastoma cells. Harshil
D. Dhruv, Ethan Holiday, Donald Chow, Holly Yin, Michael E. Berens,
Nhan L. Tran.
2710 Lead based development and evaluation of selective
estrogen mimics in tamoxifen resistant breast cancer. Hitisha
Patel, Rui Xiong, Jiong Zhao, Mary Ellen Molloy, Debra Tonetti,
Gregory R. Thatcher.
2711 CARP-1 functional mimetics are a novel class of small
molecule inhibitors of malignant pleural mesothelioma cells.
Shazia Jamal, Vino T. Cheriyan, Magesh Muthu, Sara Munie, Edi
Levi, Abdelkader E. Ashour, Harvey I. Pass, Anil Wali, Mandip Singh,
Arun K. Rishi.
2712 ISC-4, a novel inhibitor of hedgehog-Gli signaling,
inhibits growth of CSC and CTC of melanoma patients. Arun K.
Sharma, Jitesh Jani, Cristian Sharma, Patrick Cleary, Michael
Sharma, Shruthi Satish, Esteban Gomez, Michael Prez, Natalee
Amezcua, Mariam Navel, Deepkamal N. Karelia, Dhimant Desai,
Shantu Amin, Jay Sharma.
2713 Small-molecule FASN inhibitors promote growth
inhibition growth and apoptosis of breast cancer. Ruth Lupu,
Anatilde Gonzalez Guerrico, Ashwani Khurana, Timothy Heuer,
George Kemble, Chandra Mohan KVP.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
29.
30.
2714 A multi-targeted approach for pancreatic cancer
treatment by a novel cucurbitacin analogue. Mohammed
Sikander, Mohd S. Zaman, Neeraj Chauhan, Murali M. Yallapu,
Sheema Khan, Fathi T. Halaweish, Bhavin Chauhan, Meena Jaggi,
Subhash C. Chauhan.
2715 Discovery and characterization of a highly potent Wnt/
␤ -catenin pathway inhibitor targeting tankyrase. Ryoko Okada,
Yuichi Takahashi, Keiichi Motosawa, Yasuo Watanabe, Asae Igarashi,
Ran Okada, Masahiro Ikkaku, Hikaru Miyagi, Yusuke Miura, Kazuki
Asanome, Noriaki Uesaka, Jun-ichi Saito, Hiroshi Ishida, Ryuichiro
Nakai.
2716 Discovery of novel TAM family kinase inhibitors. Zaihui
Zhang, Rick Li, Erica Lee, Yuxiang Hu, Jun Yan, Jasbinder Sanghera.
2717 DMH1, a small molecule inhibitor of BMP type I
receptors, suppresses growth and invasion of lung cancer. Ying
Huang, Rachel Lee, Andy Chang, Jeffery Fan, Chantelle Labib, Cyrus
Parsa, Robert Orlando, Bradley Andresen, Jijun Hao.
2718 Targeting ribosome biogenesis with CX5461 as a
potential treatment for melanoma and ovarian cancer. Karen E.
Sheppard, Natalie Brajanovski, Katherine M. Hannan, Jessica Ahearn,
Jason Ellul, Denis Drygin, Sean O’Brien, Grant McArthur, Ross D.
Hannan, Richard B. Pearson.
2719 Use of abiraterone against a luminal androgen
receptor breast cancer cell line. Krishna A. Rao, Vishnu Modur,
Sumana Ghosh.
2720 In vitro evaluation of a novel chemotherapeutic agent,
NecroX-7, in human Burkitt lymphoma cells. Eun- J. Kim, Eun S.
Lee, Keon- I. Im, Soon H. Kim, Jung- Y. Lim, Nayoun Kim, Seok- G.
Cho.
2721 Novel biisoquinoimidazolium-derivatives for breast
cancer therapy. Satya Narayan, Aruna S. Jaiswal, Sukwon Hong.
2722 Suppression of breast cancer cell migration by novel
inhibitors that target transient receptor potential-melastatin-like
7 (Trpm7) kinase activity. Tamer S. Kaoud, Jihyun Park, Clint D.
Tavares, Shreya Mitra, Micael Cano, Chun-Chia Tseng, Kevin N.
Dalby.
2723 Breast cancer type 1 susceptibility protein mimetics
induce specific estrogen receptor confirmations and inhibit
MCF7 breast cancer cell proliferation. Bethany K. Asare, Christ
Ange Katche, Rajendram V. Rajnarayanan.
2724 Development of a sensitive assay for measuring
pharmacodynamic modulation of c-Met in biopsies. Friedhelm
Bladt, Frank Jaehrling, Manja Friese-Hamim, Gerald S. Falchook,
Hesham M. Amin, Manfred B. Klevesath, Andree Blaukat.
2725 Kinase activity profiling combined with genotyping as
a tool for predictive biomarker discovery for the treatment of
gastroesophageal adenocarcinoma (GEC). Daniel V. Catenacci,
Peng Xu, Les Henderson, Dirk Pijnenburg, Adrienne van den Berg,
Rob Ruijtenbeek.
2726 RET fusions identified in colorectal cancer PDX models
are sensitive to the potent RET inhibitor ponatinib. Joe M. Gozgit,
Tzu-Hsiu Chen, Tim Clackson, Victor M. Rivera.
2728 Thermal ablative therapy with novel gold nanorods in
an orthotopic model of urinary bladder cancer. Xiaoping Yang,
Lih-Jen Su, Francisco G. La Rosa, Elizabeth E. Smith, Suehyun K.
Cho, Brian Kavanagh, Won Park, Thomas W. Flaig.
2729 FGFR genetic alterations as a potential predictor of the
sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor
with a novel chemical scaffold. Yoshito Nakanishi, Nukinori
Akiyama, Toshiyuki Tsukaguchi, Yukako Tachibana-Kondo, Toshihiko
Fujii, Kiyoaki Sakata, Hitoshi Sase, Takehito Isobe, Yasuko Sato,
Kenji Morikami, Hidetoshi Shindoh, Toshiyuki Mio, Hirosato Ebiike,
Naoki Taka, Yuko Aoki, Nobuya Ishii.
POSTER SESSION
Targeting DNA Damage, Cell Division, and Apoptosis
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
2730 RNAi knockdown or chemical inhibition of anaphasepromoting complex components is synthetic lethal with HSP90
inhibition. Jennifer Howes, Bing-Feng Lu, Marissa Powers, Costas
Mitsopoulos, Bissan Al-Lazikani, Spiros Linardopoulos, Paul Clarke,
Paul Workman.
2731 PELP1 promotes DNA double-strand break repair via
alternative-NHEJ: Implications in therapy resistance. Samaya R.
Krishnan, Binoj C. Nair, Gangadhara R. Sareddy, Monica Mann,
Ratna K. Vadlamudi.
2732 Identification of a small molecule selectively kill
mismatch repair deficient tumors. Kyungjae Myung.
2733 Antitumor activity of the PARP inhibitor E7449 in
Ewing’s sarcoma. Sharon McGonigle, Zhihong Chen, Jingzang Tao
Miu, Kuan-Chun Huang, Donna Kolber-Simonds, Nanding Zhao,
Natalie C. Twine, Qiongfang Cao, Galina Kuznetsov, Shanqin Xu,
Kenichi Nomoto.
2734 Veliparib (ABT-888) potentiates the cytotoxic activity
of DNA alkylating agents by trapping PARP onto damaged
chromatin. Larry Solomon, Todd Hopkins, Yan Shi, Paul Ellis,
Cherrie Donawho, Eric F. Johnson, Guowei Fang, David Maag.
2735 Multi-point targeting of the synthetic lethal
interactions between Myc, ribosome biogenesis and ribosome
function cooperates to treat B-cell lymphoma. Richard B.
Pearson, Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein,
Megan J. Bywater, Gretchen Poortinga, Donald Cameron, Denis
Drygin, Sean O’Brien, Carleen Cullinane, Grant A. McArthur, Ross D.
Hannan.
2736 Thymidine catabolic and salvage pathways are
responsible for the heterogeneity of anticancer agent dT-QX in
liver cancer cells. Qibing Zhou, Qiong Wei, Dejun Zhang.
2737 Modulation of mitotic DNA damage as a paradigm for
glioblastoma therapy. Ying Shen, Masayuki Nitta, Jie Li, Diahnn
Futalan, Tyler Steed, Zack Taich, Jeffrey M. Treiber, Deanna
Stevens, Mark A. Schroeder, Jann N. Sarkaria, Hong-Zhuan Chen,
Tao Jiang, Bob S. Carter, Fumiko Esashi, Jill Wakosky, Frank
Furnari, Webster K. Cavenee, Arshad Desai, Clark C. Chen.
2738 Expression of p73 isoforms regulates proliferation and
chemotherapeutic response in diffuse large B-cell lymphoma.
Hesham M. Hassan, Michelle L. Varney, rakesh K. Singh, Bhavana J.
Dave.
2739 Specific interaction of human MGMT with ER-␣ in
breast cancer cells: Co-degradation of MGMT and ER- ␣
proteins by either fulvestrant or O6-benzylguanine and its
therapeutic significance. Kalkunte S. Srivenugopal, Ameya
Paranjpe.
2740 Identification of new binding partners of the DNA
repair protein MGMT using a proteomic discovery-based
approach in glioblastoma. Siham Sabri, Yaoxian Xu, Bassam
Abdulkarim.
2741 Sensitization of temozolomide-mediated glioblastoma
cell death by targeting MDM2: Assessment of PD biomarkers,
brain penetration, and efficacy in humanized orthotopic
xenograft models. Haiyan Wang, Shanbao Cai, Barbara J. Bailey,
Lawrence M. Gelbert, M. Reza Saadatzadeh, Aaron A. Cohen-Gadol,
Jann N. Sarkaria, Paul Territo, Taxiarchis M. Georgiadis, T. Zachary
Gunter, Samy Meroueh, Eric C. Long, David R. Jones, Lindsey D.
Mayo, Shannon Harlan, Karen E. Pollok.
2742 The PARP inhibitor niraparib demonstrates robust
activity in a subset of patient-derived triple-negative breast
cancer xenograft models. Yan Wang, Stefano Cairo, Delphine
Nicolle, Razvan Cristescu, Andrey Loboda, Michael Nebozhyn,
Theresa Zhang, Jean-Gabriel Judde, Keith Wilcoxen.
2743 Telomere transcripts improve synthetic inhibitors of
telomerase. Sandra Sampl, Doris Mejri, Christian Stern, Hui Wang,
Klaus Holzmann.
2744 The novel and contrasting roles of ATM and DNA-PK in
the response of cells to microtubule-targeting anticancer
agents. Emily V. Mould, Stephanie E. Burnell, Philip L. Berry, David
R. Newell, Elaine Willmore.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2745 Pharmacological characterisation of cell active
inhibitors of Poly(ADP-ribose) glycohydrolase (PARG). Dominic
James, Allan Jordan, Nicola Hamilton, Alison McGonagle, Kate Smith,
Alexandra Stowell, Ian Waddell, Bohdan Waszkowycz, Donald Ogilvie.
2746 An evaluation of poly (ADP-ribose) polymerase
inhibitor efficacy in head and neck cancer. Jana Heitmann, Paul
Geeleher, Michaela Keck, Zhixiang Zuo, Arun Khattri, Susanne
Tepper, Michael Beckett, Ralph R. Weichselbaum, Sebastian
Fetscher, Everett E. Vokes, Tanguy Seiwert.
2747 Pharmacological inhibition of the DNA damage
response kinases, ATR (Ataxia telangiectasia and Rad3 related)
and ATM (Ataxia telangiectasia mutated), broadly sensitizes
diverse subtypes of gynecological cancer cells to ionizing
radiation. Nicholas Bateman, Pang-ing Teng, Kelly Conrads, Chad
Hamilton, George Maxwell, Christopher Bakkenist, Thomas Conrads.
2748 Aurora A kinase inhibitor MLN8237 suppresses
neurosphere proliferation of pediatric glioblastoma and prolongs
animal survival in patient tumor-derived orthotopic xenograft
mouse model. Mari Kogiso, Linna Zhang, Lin Qi, Holly B. Lindsay,
Frank Y. Lin, Stacey Berg, Xiao-Nan Li, Jodi A. Muscal.
2749 SRPK1 inhibition and modulation of VEGF alternative
splicing as a potential therapeutic strategy in prostate cancer.
Athina Mavrou, Dave Bates, Sebastian Oltean.
2750 Conditional RNAi-mediated knockdown of TPX2
synergizes with vincristine and docetaxel cytotoxicity against
HeLa cell sub-clones in vitro and in vivo. Annette J. Allmendinger,
Kai Schönig, Oliver J. Gruss, Stefan Berger, Martin R. Berger.
2751 ASPM, a cell cycle regulated gene and silencing its
splicing variant as a molecular target in hepatocellular
carcinoma. Hung-Wei Pan, Su-Yeh Lin, Tony Wu, Hey-Chi Hsu.
2752 Effects of Debio 1143, a novel oral IAP inhibitor, in
monotherapy and in combination with platinum drugs in human
SCCHN tumor specimens. Marie Serova, Annemilai TijerasRaballand, Sebastien Albert, Sandrine Faivre, Eric Raymond, Anne
Vaslin, Claudio Zanna, Grégoire Vuagniaux, Armand de Gramont.
2753 Ormeloxifene inhibits cervical cancer cell growth
through intrinsic apoptotic pathway. Neeraj Chauhan, Mohd S.
Zaman, Murali M. Yallapu, Diane M. Maher, Mara C. Ebeling,
Subhash C. Chauhan, Meena Jaggi.
2754 Induction of Sp1 factor by CYP1B1 inhibits TRAILmediated apoptotic pathway. Yeo-Jung Kwon, Nahee Park,
Sangyun Shin, Dong-Jin Ye, Mihye Hong, Young-Jin Chun.
2755 Aggressive thyroid carcinomas are intrinsically
resistant to apoptosis but can be effectively targeted by a Bcl2
family inhibitor. Devora Champa, Ronald Ghossein, Antonio Di
Cristofano.
2756 Ceramide analog targets xIAP and cIAP1 to sensitize
metastatic colon carcinoma cells to apoptosis induction to
suppress tumor progression. Amy Paschall, Mary Zimmerman,
Christina Torres, Dafeng Yang, May Chen, Xia Li, Erhard Bieberich,
Aiping Bai, Jacek Bielawski, Alicja Bielawska, Kebin Liu.
2757 Pharmaco imaging study of the effects of Debio 1143,
a new orally available IAP inhibitor, in a triple negative breast
cancer model. Alexandra Oudot, Olivier Raguin, Lucile Bauché,
Francis Bichat, Anne Vaslin, Hélène Maby-El Hajjami, Claudio Zanna,
Grégoire Vuagniaux, Pierre Fumoleau, François Brunotte, Bertrand
Collin.
2758 Development of small molecule Bax agonists for lung
cancer treatment. Meiguo Xin, Rui Li, Dongkyoo Park, Taofeek K.
Owonikoko, Gabriel L. Sica, Patrick E. Corsino, Jia Zhou, Chunyong
Ding, Andrew T. Magis, Suresh S. Ramalingam, Walter J. Curran,
Fadlo R. Khuri, Xingming Deng.
2759 Colorectal cancer cell lines with high BCL-XL and low
MCL-1 expression are sensitive to a potent and selective BCLXL inhibitor. Lloyd T. Lam, Haichao Zhang, John Xue, Paul Hessler,
Stephen K. Tahir, Jun Chen, Sha Jin, Andrew J. Souers, Joel D.
Leverson.
Poster
Section
34
34
391
POSTER SESSION
Poster
Section
35
35
Targeting Signaling Pathways
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
392
2760 CSF3R ligand-independent mutations found in chronic
neutrophilic leukemia have altered O-linked glycosylation. Julia
Maxson, Samuel Luty, Jason MacManiman, Samantha Savage,
Melissa Abel, Swaleh Bahamadi, Brian Druker, Jeffrey Tyner.
2761 Characterizing the mechanism and the clinical
relevance of the synthetic lethal interaction between STAT3
inhibition and HER2 overexpression in breast cancers. Ruth
Rodriguez Barrueco, Jiyang Yu, Mariano Alvarez, Veronica Castro,
Netonia Marshall, Ruoxi Su, Laura Castro, Matthew Maurer, Andrea
Califano, Jose M Silva.
2762 Akt kinase-interacting protein1, a novel therapeutic
target for lung cancer with EGFR-activating and gatekeeper
mutations. Tadaaki Yamada, David P. Carbone, Shinji Takeuchi,
Naoya Fujita, Seiji Yano.
2763 EGFR endocytosis is a rational target in lung cancer
with wild-type EGFR. Ukhyun Jo, Kyong Hwa Park, Young Mi
Whang, Jae Sook Sung, Nam Hee Won, Jong Kuk Park, Yeul Hong
Kim.
2764 The depletion of LRP5, unlike that of LRP6, promotes
apoptosis in triple-negative breast cancer cells, making it an
interesting therapeutic target. Sylvie Maubant, Virginie Maire,
Bruno Tesson, Fariba Némati, David Gentien, Bérengère MartyProuvost, Stéphane Depil, Francisco Cruzalegui, Gordon Tucker,
Sergio Roman-Roman, Thierry Dubois.
2765 Metformin represses cancer cells via alternate
pathways in N-Cadherin wild-type and N-Cadherin-deficient
cells. Ge Rongbin, Zongwei Wang, Jijun Li, Aria Olumi.
2766 Inhibition of Chk1 and Wee1 as a new therapeutic
approach in Mantle Cell Lymphoma. Laura Carrassa, Rosaria Chilà,
Alessandra Basana, Francesca Ricci, Federica Guffanti, Monica Lupi,
Andrea Rinaldi, Luciano Cascione, Francesco Bertoni, Massimo
Broggini, Giovanna Damia.
2767 Identification of kinase fusion genes in bladder cancer
through kinome-centered RNA sequencing. Floris Groenendijk, Iris
de Rink, Laura Mertens, Annegien Broeks, Yann Neuzillet, Jeroen de
Jong, Bas van Rhijn, Rene Bernards, Michiel van der Heijden.
2768 ER stressors sensitize BCR-ABLⴙ Bp-ALL cells to
tyrosine kinase inhibitors via AMPK-dependent downregulation
of Mcl-1 expression. Guy J. Leclerc, Joanna DeSalvo, Yolanda
Cosme, Gilles M. Leclerc, Theodore J. Lampidis, Julio C. Barredo.
2769 PKC/MARCKS pathway is a novel therapeutic target
associated with breast cancer malignancy potential and
paclitaxel resistance. Ching-Hsien Chen, Muhammad Arif, Wen-Hsin
Chang, Yuan Yuan, Jing Zhai, David K. Ann, Reen Wu.
2770 MGAT5B expression in malignant peripheral nerve
sheath tumors and RAS-mutated tumors promote maturation of
tyrosine kinase receptors through a PI3K/AKT/MGAT5B
mechanism. Quansheng Zhu, Hui Shang, Yechun Song, Yi Zhang,
Raphael Pollock, Steven Hsesheng Lin.
2771 Novel SMAC-mimetic birinapant demonstrates
preclinical antitumor activity in human xenograft head and neck
cancer models exhibiting alterations in cell death pathway
components FADD, BIRC2, or CASP8. Danielle F. Eytan, Grace E.
Snow, Zhong Chen, Carter Van Waes.
2772 Ceramide analog sensitizes breast cancer cells to Fasmediated apoptosis to suppress spontaneous lung metastasis.
Xia Li, Amy V. Paschall, Aiping Bai, Jacek Bielawski, Alicja
Bielawska, Kebin Liu.
2773 AD-O56.9: A fusion of TRAIL/Apo2L with a membrane
disrupting peptide as a novel anticancer therapeutic. Bartlomiej
M. Zerek, Michal Szymanik, Piotr K. Rozga, Anna Pieczykolan,
Marlena Galazka, Katarzyna Bukato, Albert Jaworski, Katarzyna
Poleszak, Sebastian D. Pawlak, Malgorzata Teska-Kaminska,
Wojciech Strozek, Jerzy S. Pieczykolan.
2774 Coexpression of Delta16 isoform and full-length HER-2
in F1 hybrid transgenic mice: effects on tumor growth and
malignancy. Pier-Luigi Lollini, Valentina Grosso, Dario Ranieri,
Arianna Palladini, Marianna Ianzano, Massimiliano Dall’Ora, Lorena
Landuzzi, Giordano Nicoletti, Tania Balboni, Roberta Laranga, Carla
De Giovanni, Augusto Amici, Serenella M. Pupa, Manuela Iezzi,
Patrizia Nanni.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2775 Development and characterization of a MEK1 inhibitor
(AZD6244) sensitive childhood astrocytoma cell line. Adam W.
Studebaker, Hemant K. Bid, Doris A. Phelps, Peter J. Houghton.
2776 Overexpression of HGF is an effective indicator for
Met-targeting therapy in hepatocellular carcinoma. Qian Xie.
2777 Lycopene synergistically enhances quinacrine action to
inhibit Wnt-TCF signaling in breast cancer cells through APC.
Ranjan Preet, Rajasubramaniam Shanmugam, Purusottam Mohapatra,
Dipon Das, Shakti R. Satapathy, Michael D. Wyatt, Chanakya N.
Kundu.
2778 Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and
induces apoptosis in triple negative breast cancer cells. LingMin Tseng, Chun-Yu Liu, Chia-Jung Hsu, Duen-Shian Wang, JungChen Su, Chung-Wai Shiau, Kuen-Feng Chen.
2779 Rapid drug target ranking system developed from a
systematic analysis of cancer genomic data from the
Oncomine™ knowledgebase identifies an oncogenic role for the
NFE2L2 pathway in multiple cancer types. Sean Eddy, Mary Ellen
Urick, Mark Tomilo, Armand Bankhead, Dan Rhodes, Emma T.
Bowden.
2780 Tyro3 and Axl receptors tyrosine kinase as potential
therapeutic targets in leiomyosarcoma. Carmela Dantas-Barbosa,
François Le Loarer, Marta Mendiola, Isabelle Treilleux, Frederic
Chibon, Hyba El Sayadi, Jean M. Coindre, Laurent Alberti, Jean-Yves
Blay.
2781 Elimination of PanIn2/3 in a GEMM for pancreatic
cancer with disrupted p16 and activated Kras. Richard D. Dinnen,
Wanglong Qiu, Gloria H. Su, Daniel P. Petrylak, Robert L. Fine.
2782 The effect of ERRFI1 as a novel AKT regulator on cell
proliferation and response to therapy is cell context dependent.
Junmei Hou, Kaustubh N. Bhinge, Liewei Wang.
2783 Variability of HER2 expression between in vitro and in
vivo models within gastric cancer cell lines. Youme Gim, Hee Seo
Park, Hae Rim Jung, Hae Ryung Chang, Seungyoon Nam, Yong Doo
Choi, Ja-Lok Ku, Yon Hui Kim.
2784 Targeting TGF-␤ regulated E3 ligases: a novel
therapeutic approach for primary liver cancer. Jian Chen, JiunSheng Chen, YoungJin Gi, Lior H Katz, Ji-Hyun Shin, Liem Phan,
Wilma Jogunoori, Vivek Shukla, Bibhuti Mishra, Shulin Li, Milind
Javle, Mien-Chie Hung, Lopa Mishra.
2785 LYN is a new prognostic and therapeutic target in
non-small cell lung cancer. Yu Jin Kim, Minjung Sung, Min Jeong
Park, Young Kee Shin, Yoon-La Choi.
2786 Downregulated expression of hepatoma-derived
growth factor (HDGF) reduces glioma cancer cell tumor growth
and angiogenesis. Li-Feng Liu, Shu-Shong Hsu, Chih-Hao Chen.
2787 Modulation of autophagy and oncogenic phenotypes
through CYB5A-TRAF6 signaling influence prognosis of resected
and metastatic pancreatic cancer. Elisa Giovannetti, Qiuyan Wang,
Niccola Funel, Amir Avan, Tonny Lagerweij, Viola Caretti, Ugo Boggi,
Yisong Wang, Sara Caponi, Arjan van der Velde, Enrico Vasile, Henk
M. Verheul, Thomas Wurdinger, Giuseppe Giaccone.
2788 Antiproliferative schweinfurthins reveal a role of the
trans-Golgi-network in mTOR-AKT signaling and cancer cell
survival. Xingfeng Bao, Naoko Hata, Kishan Agarwala, Zichun Wang,
Winnie Lee, Lana Parent, Hongsheng Cheng, Dayong Qiu, Yongchun
Shen, Bingfan Du, Wanjun Zheng, Nanding Zhao, Maarten Postema,
Mary Woodall Jappe, Yasutaka Takase, Toshimitsu Uenaka, Kenichi
Nomoto.
2789 Iron chelation inhibits mTOR activity in cancer cells.
Chaowei Shang, Hongyu Zhou, Shile Huang.
POSTER SESSION
Clinical Research 6
Cell-based Therapies for Cancer
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
2790
The monocyte lineage is required for production
of clinically relevant interleukin-6 (IL-6) during chimeric
antigen receptor (CAR) T cell cytotoxicity. David M.
Barrett, Nathan Singh, Bruce Levine, Stephan A. Grupp.
2791
Advantages and clinical application of
fibronectin CH296-stimulated T cells in cancer
immunotherapy. Takeshi Ishikawa, Satoshi Kokura, Tetsuya
Okayama, Naoyuki Sakamoto, Mitsuko Ideno, Nobuko
Muraki, Akiko Kato, Tatsuji Enoki, Junichi Mineno, Yuji
Naito, Yoshito Itoh, Toshikazu Yoshikawa.
2792
Engineering T lymphocytes with protein
nanogels for cancer immunotherapy. Li Tang, Yiran
Zheng, Darrell J. Irvine.
2793
Phenotype and expansion profile of peripheral
␥␦ T cells in patients with gastrointestinal cancer.
Yasunobu Kobayashi, Mayuko Sakai, Izumi Fujita, Hiroshi
Komine, Masanori Matsushita, Koichi Shimizu, Atsushi
Aruga, Hirohito Kobayashi, Keishi Tanigawa.
2794
CD8ⴙ natural regulatory T cells as antitumor
immune effectors in carcinomas of breast and lung.
Anandi Sawant, Carnella Lee, Cara Schafer, Jessy Deshane,
Selvarangan Ponnazhagan.
2796
Engineering multiple chimeric antigen receptors
in T cells for the treatment of multiple myeloma. Lung-Ji
Chang, Yuchen Liu, Jan S. Moreb.
2797
Construction and validation of an activating and
inhibitory chimeric antigen receptor (CAR) system.
Leonardo Chicaybam, Martin H. Bonamino.
2798
Targeting IL13R alpha2 heterogeneity in
malignant glioma with engineered T cells. Sadhak
Sengupta, Irina Balyasnikova, Seema Naheed, Maciej S.
Lesniak, Richard P. Junghans, Prakash Sampath.
2799
Adoptive immunotherapy for pediatric solid
tumors with CAR-T cells (chimeric antigen receptor
bearing T cells) targeting ALK (anaplastic lymphoma
kinase, CD246). Alec Walker, Paola Lopomo, William
Babbitt, Marc Vigny, Crystal L. Mackall, Rimas J. Orentas.
2800
Immunotherapy of malignant pleural
mesothelioma using MET specific t – cells. Thivyan
Thayaparan, Sjoukje V. Stegen, Ana C. Parente Pereira,
Roseanna Petrovic, James Spicer, John Maher.
2801
The use of induced pluripotent stem (iPS) cells
for the safety testing of enhanced affinity TCRtransduced T cells. Katherine J. Adams, Andrew B. Gerry,
Joanna E. Brewer, Nicholas J. Pumphrey, Alan D. Bennett,
Bent K. Jakobsen.
2802
Fine-tuning T cell receptors for adoptive T cell
therapy. Bent Jakobsen.
2803
Preclinical models for the development of
HER2-specific T-cell therapy. Christiane Kreutzer, Heinke
Conrad, Peter Meyerhuber, Wolfgang Uckert, Philipp
Beckhove, Helga Bernhard.
2804
Expression of miR-17–92 enhances antitumor
activity of T cells transduced with the anti-EGFRvIII
chimeric antigen receptor in mice bearing human GBM
xenografts. Masasuke Ohno, Takayuki Ohkuri, Akemi
Kosaka, Carl H. June, Atsushi Natsume, Hideho Okada.
2805
Cancer-specific T cell receptor isolation for
cancer immunotherapy. Luise U. Weigand, Samantha
Paston, Linda Hibbert, Ruth K. Ryan, Debbie E. Baker, Ruth
A. Simmons, Jane V. Harper, Joseph D. Dukes, Giovanna
Bossi, Francis Grand, Emma Hickman, Alex Powlesland,
Annelise Vuidepot, Namir J. Hassan, Bent K. Jakobsen.
2806
A phase Ia/Ib trial of chemotherapy followed by
infusions of activated T cells armed with OKT3 x
trastuzumab bispecific antibody, IL-2 and GM-CSF for
stage II/ III, Her2ⴙ or Her2- high risk breast cancer
(> 10ⴙ nodes). Deepa B. Jagtap, Ritesh Rathore, Archana
Thakur, Gerald Colvin, Nicola Kouttab, Abby Maizel, Abhinav
Deol, Lawrence G. Lum.
Poster Abstract
Board Number
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2807
Activated NK cells efficiently kill Glioblastoma
through activating receptor-ligand interactions. Justyna
Kmiecik, Andrea Gras Navarro, Per Øyvind Enger, Lina Leiss,
Jacques Zimmer, Martha Chekenya.
2808
GD2-specific genetically engineered NK cell
therapy is effective in a drug-resistant neuroblastoma
xenograft mouse model. Diana Seidel, Anastasia Shibina,
C. P. Reynolds, Winfried S. Wels, Nicole Huebener, Holger
N. Lode.
2809
Removal of IL-10 augments the therapeutic
efficacy of antitumor B cells that directly kill tumor
cells involving both Fas/FasL and CXCL12/CXCR4
pathways. Huimin Tao, Lin Lu, Yang Xia, Steve Lundy, Qiao
Li, Alfred E. Chang.
2810
Dendritic cell-based immunotherapy in
combination with programmed cell death 1 blockade
reduced established tumors by activating Th-1 type
immune responses in a murine hepatocellular
carcinoma model. Eiichi Hayashi, Junichi Eguchi, Masashi
Sakaki, Hiroyoshi Doi, Risa Oomori, Atsushi Kajiwara, Hitoshi
Yoshida, Shigeaki Ishii, Kazumasa Hiroishi, Michio Imawari.
2811
Allogeneic cell cased vaccine development by
shared antigen screening. Vadim V. Deyev, Neal Schilling,
Taylor H. Schreiber.
2812
The clinical effects of dendritic cell and
cytokine-induced killer cell therapy for lung cancer
after surgery. Daiqing Gao, Changyou Li, Peng Zhao,
Xiaofang Wei, Xihe Xie, Weihong Sun, Qingming Guo, Danni
Zhu, Tianyi Gao, Aris T. Alexandrou, Jian Jian Li.
2813
Survival benefit of an add-on dendritic cell
vaccine for patients with inoperable pancreatic cancer
receiving chemotherapy: a multicenter study. Masanori
Kobayashi, Shimodaira Shigetaka, Kazuhiro Nagai, Masahiro
Ogasawara, Hidenori Takahashi, Hirofumi Abe, Mitsugu
Tanii, Masato Okamoto, Shun-ichi Tsujitani, Masaki Nagaya,
Yoshikazu Yonemitsu, The DC vaccine study group of Japan
Society of Innovative Cell Therapy (J-SICT).
2814
Therapeutic vaccination with GM-CSF genetransduced iPS cells induces potent T cells-mediated
antitumor immunity. Hiroyuki Inoue, Ayumi Watanabe,
Megumi Narusawa, Chika Sakamoto, Takafumi Hiramoto,
Shohei Miyamoto, Makoto Inoue, Koichi Takayama, Mamoru
Hasegawa, Yoichi Nakanishi, Tomoki Todo, Kenzaburo Tani.
2815
Induction of both OVA specific CD4ⴙ and
CD8ⴙ T cells by using PepTivator® OVA-pulsed DCs in
mouse model. Kenji Miki, Koji Nagaoka, Hermann
Bohnenkamp, Takayuki Yoshimoto, Takashi Kamigaki, Ryuji
Maekawa.
2816
Immune-tolerant elastin-like polypeptide (iTEP)
particles promote peptide vaccine presentation by
dendritic cells. Mingnan Chen, Shuyun Dong, Scott Cho.
2817
DCVex(TM): A novel DC-targeted vector platform
for cancer immunotherapy. Tina C. Albershardt, Semih U.
Tareen, Jared M. Odegard, David J. Campbell, Patrick Flynn,
Scott H. Robbins, Peter Berglund, Jan H. ter Meulen.
2818
Dendritic cell vaccination and regulatory T-cell
depletion augment antitumor immunity after cytotoxic
therapy. Tomohiro Tanaka, Satoshi Watanabe, Ko Sato, Yu
Saida, Junko Baba, Koichiro Nozaki, Daisuke Ishikawa,
Natsue Igarashi, Satoshi Shoji, Masaaki Okajima, Satoru
Miura, Junta Tanaka, Hiroshi Tanaka, Hiroshi Kagamu,
Hirohisa Yoshizawa, Ichiei Narita.
2819
Efficacy and safety of the Ad-GM•CAIX
dendritic cell-based vaccine in treating in vivo
metastatic renal cell carcinoma compared to sunitinib
monotherapy and simultaneous vaccine-sunitinib
combination therapy. Edward N. Rampersaud, Jonathan W.
Said, Adrian Bot, Frédéric D. Birkhäuser, Nils Kroeger, Gang
Zeng, Fairooz F. Kabbinavar, Antoni Ribas, Allan J. Pantuck,
Arie S. Belldegrun, Joseph Riss.
36
36
393
POSTER SESSION
Clinical Research 7
Poster
Section
37
37
Predictive Biomarkers 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
394
2820 Clinical significance of low frequency KRAS and BRAF
subclones for advanced colon cancer management. Valerie Taly, Pierre
Laurent-puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos,
Philippe Nizard, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Xinyu
Li, Qun Zhong, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno
Landi, Valérie Boige, Brian J. Hutchison.
2821 Dual-label microdosing approach to identify
chemoresistance to carboplatin and gemcitabine combination
chemotherapy. Maike Zimmermann, Tiffany M. Scharadin, Hongyong
Zhang, Tzu-yin Lin, Ralph W. deVere White, Chong-xian Pan, Paul T.
Henderson.
2822 A pan-cancer analysis of inferred homologous
recombination deficiency identifies potential platinum benefit in
novel subtypes. Andrea M. Marquard, Aron C. Eklund, Zhigang C. Wang,
Andrea L. Richardson, Zoltan Szallasi, Nicolai J. Birkbak.
2823 Low merlin level as a biomarker for sensitivity of ovarian
cancer cell lines to FAK inhibition. Nina R. Shah, Isabelle Tancioni,
Kristy K. Ward, Christine Lawson, Xiao Lei Chen, Nichol L. Miller, Florian
J. Sulzmaier, Sean Uryu, David D. Schlaepfer.
2824 Circulating tumor cells (CTCs) can predict survival and
response to treatment in non-metastatic colorectal cancer (CRC):
Correlation between flowcytometry, quantitative real-time pcr (qPCR)
and cytomorphology. Abeer Bahnassy, Abdel-Rahman N. Zekri, Salem E.
Salem, Marwa Mohamad, Marwa Mohanad.
2825 Germline genetic variants in ANGPT1 & 2 and FGF2 are
associated with pathologic complete response to bevacizumab in
breast cancer patients. Issam Makhoul, Robert Griffin, Stephen Erickson,
Ishwori Dhakal, Venay R. Raj, Dorothy A. Graves, Jeannette Y. Lee,
Mohammed S. Orloff, Eric R. Siegel, Susan A. Kadlubar.
2826 Multi-omic profiling to predict response to gemcitabine/
carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for
triple-negative (TN) and BRCA1/2 mutation-associated breast cancer
using a pathway-based approach. Shaveta Vinayak, Stephen C. Benz,
Charles J. Vaske, Melinda L. Telli, James M. Ford.
2827 Association between new onset hypothyroidism and
clinical response in patients treated with tyrosine kinase inhibitor
(TKI) therapy in phase I clinical trials. Mehmet A. Bilen, Amy Patel,
Kenneth R. Hess, Javier Munoz, Naifa Busaidy, Maen Abdelrahim, Jennifer
Wheler, Filip Janku, Gerald S. Falchook, David S. Hong, Funda MericBernstam, Mohammed A. Habra, Aung Naing.
2828 High expression of heat shock protein 27 in metastases is
correlated with response to bevacizumab monotherapy in patients
with metastatic melanoma. Cornelia Schuster, Lars A. Akslen, Oddbjørn
Straume.
2829 Identification of the role of SRBC methylation-associated
gene silencing as predictive factor of oxaliplatin secondary
resistance in metastasic colorectal cancer patients. Anna MartinezCardus, Catia Moutinho, Cristina Santos, Valentin Navarro-Perez, Eva
Martinez-Balibrea, Eva Musulen, Francisco Javier Carmona, Andrea
Sartore-Bianchi, Andrea Cassingena, Salvatore Siena, Elena Elez, Josep
Tabernero, Ramon Salazar, Albert Abad, Manel Esteller.
2830 Predictive biomarker identification for response to
vantictumab (OMP-18R5; anti-Frizzled) by mining gene expression
data of human breast cancer xenografts. Chun Zhang, Pete Yeung,
Lucia Beviglia, Belinda Cancilla, Tracy Tang, Wan-Ching Yen, Austin
Gurney, John Lewicki, Timothy Hoey, Ann M. Kapoun.
2831 A novel assay to predict cisplatin resistance in cancer
cells. Vengatesh Ganapathy, Ilangovan Ramachandran, Lurdes V.
Queimado.
2832 Single nucleotide polymorphisms of DPYD and MTHFR
predict adverse events associated with 5-fluorouracil in patients with
gastrointestinal cancer. Masahide Toshima, Shinobu Ohnuma, Michiiro
Tanaka, Koh Miura, Wataru Fujibuchi, Taiki Kajiwara, Toshihiro Komura,
Hiroaki Musha, Sho Haneda, Katsuyoshi Kudoh, Atsushi Kohyama, Takeshi
Naitoh, Michiaki Unno.
2833 Mutation analysis of cancer drivers and DNA repair genes
in chemosensitive versus resistant ovarian cancers. Einar Birkeland,
Rakel Blaalid, Merete Bjørnslett, Anne Dørum, Per Eystein Lønning, Stian
Knappskog.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2834 Identification of a critical level of anti-beta glucan IgG
antibody necessary for response to soluble beta-glucan therapy and
its application as a biomarker for analysis in clinical trials. Keith
Gorden.
2835 Telomere length: A novel biomarker for anti-EGFR therapy
in colorectal cancer. Titto A. Augustine, Mahadi A. Baig, John M.
Mariadason, Radhashree Maitra, Sanjay Goel.
2836 Development of a companion diagnostic IHC assay for the
biomarker-driven selection of C4.4a positive patients. Claudia
Schneider, Joseph Couto, Yifei Zhu, Zhiming Liao, Robert Pytela, Alton
Hiscox, Sabine Wittemer-Rump, Ulf Forssmann, Lars Linden, Joerg
Willuda, Daniel Forler, Matthew Nelson, Ricarda Finnern, Thomas Krahn,
Khusru Asadullah.
2837 Hitting the target: Dynamic BH3 profiling, a novel
functional assay to predict chemotherapy response. Joan Montero,
Kris A. Sarosiek, Joe D. DeAngelo, Huiying Piao, Neil Horowitz, Ross
Berkowitz, Ursula Matulonis, Ronny Drapkin, Anthony Letai.
2838 Differential effects of PIK3CA mutations and PTEN loss in
patients with advanced endometrial cancers on matched therapy.
Xiaochun Liu, Mingmou Hou, Jennifer Wheler, Aung Naing, David Hong,
Apostolia Tsimberidou, Sarina Piha-Paul, Gerald Falchook, Ralph Zinner,
Filip Janku, Ramondetta Lois, Kathleen Schmeler, Karen Lu, Razelle
Kurzrock, Siqing Fu.
2839 Antitumor activities of FGFR inhibitors in FGFR1overexpressing hepatocellular carcinoma patient-derived xenograft
tumor models. Douglas D. Fang, Bin Zhang, Weiguo Xu, Kang Yan,
Qingyang Gu, Qiang Xu, Yexiong Tan, Hongye Sun, Qin Luo, Weifeng Mao,
Chiho Li, Jiangpeng Liao, Guibai Liang, Shu-Hui Chen, Chi-Chung Chan.
2840 Evaluation of HER-2 RNA and protein levels in a large
cohort of breast cancer specimens to support development of a
diagnostic immunofluorescence assay quantified by AQUA®
Technology. Jennifer Bordeaux, Krupa Chandrasekaran, Sue Beruti, Mike
Nerenberg, Corinne Ramos, David Rimm, Jelveh Lameh, Naveen
Dakappagari.
2841 Characterization of ALK fusions in circulating tumor cells
(CTCs) of NSCLC. David Lu, Rachel Krupa, Natalee Bales, Jessica Louw,
Dena Marrinucci, Ryan Dittamore.
2842 Evaluation of immunohistochemistry assays against c-Met
and HGF to guide companion diagnostic decisions. Joseph S. Krueger,
Brian Laffin, Holger Lange, Eric Neeley, Mirza Peljto, Mohamed Salama,
Mahipal Suraneni, David Young.
2843 Development of a binary diagnostic immunofluorescence
assay by AQUA® technology for accurate detection of HER-2 levels
in breast cancer specimens. Lakshmi Krupa Chandrasekaran, Jennifer
Bordeaux, Sue Beruti, Naveen Dakappagari, Mike Nerenberg, Jelveh
Lameh, Armin Graber, David Rimm, Bruce Robbins, Nagesh Rao.
2844 MIF/CD74 guided therapeutic strategy for relapsed
glioblastoma patients. Kerrie L. Mcdonald, Hatice Sevim, Wendy Ha,
Liping Chung, Robert Baxter, Australian Genomics and Clinical Outcomes
of Glioma (AGOG) Network.
2845 Expression of FGFR2b in gastric cancer as measured by
immunohistochemistry with a highly specific monoclonal antibody.
Amit M. Deshpande, Servando Palencia, David I. Bellovin, Abigael T.
Gemo, Tina Giese, Bradley Stohr, Kristen L. Pierce, Gerrit Los.
2846 Molecular platforms for mutation analysis from whole
blood derived clinical samples by nextgen sequencing. William M.
Strauss, Erich Klem, Maria Cuellar, Jill Simmons, Jessamine Winer-Jones,
Paul W. Dempsey.
2847 Quantitative assessment of circulating BRAF DNA in stage
IV melanoma patients undergoing BRAF inhibitor treatment. David
Polsky, Jyothi Sakuntala Tadepalli, Gregory Chang, Nathaniel Fleming,
Yongzhao Shao, Anna C. Pavlick, Iman Osman, Cindy Spittle, Manohar
Furtado, Paula Stonemetz, Dawne Shelton, George Karlin-Neumann.
2848 Urinary prostaglandin E metabolite as a biomarker
predicting response to EGFR therapy in patients with head and neck
cancer. Vikram D. Kekatpure, Amritha Suresh, Bharath Rangarajan,
Gangotri Siddappa, Moni A. Kuriakose.
2849 Analysis of the cancer gene targeting of clinical kinase
inhibitor drugs by combining cellular and biochemical profiling. Guido
J. Zaman, Joost C. Uitdehaag, Rogier C. Buijsman, Jeroen A. de Roos,
Antoon M. van Doornmalen, Martine B. Prinsen, Jos de Man, Yusuke
Kawase, Yoshinori Tanizawa, Kohichiro Yoshino.
POSTER SESSION
Clinical Research 8
Prognostic Biomarkers 1
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
2850 Biomarkers for detection of exfoliated tumor cells in
the peritoneal cavity in rectal cancer. Annette T. Kristensen, Arne
Solbakken, Stein G. Larsen, Karl-Erik Giercksky, Eivind Hovig,
Ragnhild Lothe, Guro E. Lind, Marianne G. Guren, Kjersti Flatmark.
2851 Reduced Tip60 expression in human gastric cancer.
Guangdi Chen, Rongpan Bai, Zhongsheng Zhao, Jianwei Zhou, Yu
Weng.
2852 SNAI2 expression by cancer-associated fibroblasts is a
negative prognostic factor in non-small cell lung cancer.
Francesca Andriani, Giorgia Leone, Elena Landoni, Federica
Facchinetti, Tiziana Caputo, Erika Baldoli, Rosalba Miceli, Luigi
Mariani, Ugo Pastorino, Giuseppe Pelosi, Gabriella Sozzi, Luca Roz.
2853 Epidermal growth factor receptor (EGFR) and
prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic
biomarkers for metastatic colorectal cancer. Jeroen A. Goos,
Annemieke C. Hiemstra, Veerle M. Coupé, Begoña Diosdado, Wendy
Kooijman, Pien M. Delis-van Diemen, Cemile Karga, Jeroen A.
Beliën, C. Willemien Menke-van der Houven van Oordt, Albert A.
Geldof, Gerrit A. Meijer, Otto S. Hoekstra, Remond J. Fijneman.
2854 Clinical significance of inhibin beta A expression in
gastric cancer. Takashi Oshima, Toshio Imada, Naoto Yamamoto,
Tsutomu Sato, Norio Yukawa, Manabu Shiozawa, Takaki Yoshikawa,
Yasushi Rino, Chikara Kunisaki, Makoto Akaike, Munetaka Masuda.
2855 Association between plasma tissue factor and tumor
volume: A novel sensitive method for detecting plasma tissue
factor. Yuki Fujiwara, Yohei Hisada, Ryuta Sato, Ryou Tsumura,
Yoshikatsu Koga, Masahiro Yasunaga, Yasuhiro Matsumura.
2856 Fibroblast growth factor receptor 1 gene amplification
as an independent prognostic factor for recurrence in patients
with resected squamous cell esophageal cancer. Hyo Song Kim,
Seung Eun Lee, Yoon Sung Bae, Joo Hang Kim, Hye Ryun Kim, Dae
Joon Kim, Hyunki Kim, Yoon-La Choi, Byoung Chul Cho.
2857 S100A14 plays an important role in cell growth and
metastasis of epithelial ovarian cancer through PI3K-AKT
pathway. Ha-Yeon Shin, Maria Lee, Hanbyoul Cho, Eun-ju Lee,
wookyeom yang, Hyunja Kwon, Sol Kim, Jae-Hoon Kim.
2858 Angiopoietin-like protein 2 as a novel serum
biomarker for diagnosis and prognosis in patients with
colorectal cancer. Takahito Kitajima, Yuji Toiyama, Tadanobu
Shimura, Shozo Ide, Hiroki Imaoka, Satoru Kondo, Mikio Kawamura,
Yoshinaga Okugawa, Aya Kawamoto, Junichiro Hiro, Susumu
Saigusa, Masaki Ohi, Koji Tanaka, Yasuhiro Inoue, Yasuhiko Mohri,
Sekido Yoshitaka, Masato Kusunoki.
2859 The genetic polymorphisms of ATG5 and COL4A3 are
associated with the prognosis of patients with esophageal
squamous cell carcinoma. Jang-Ming Lee, Pei-Wen Yang, TzuHsuan Chiang, Ya-Chuan Huang, Ching-Yueh Hsieh.
2860 miR-21 overexpression assessed by in situ
hybridisation is an independent predictor of survival in patients
with resected pancreatic ductal adenocarcinoma. Asif Ali, Elisa
Giovannetti, Niccola Funel, Roderick Ferrier, Jennifer Morton, Karin A.
Oien.
2861 Independent validation of a prognostic gene-signature
based risk score in formalin-fixed paraffin-embedded
melanomas. Georg Brunner, Achim Heinecke, Ludwig Suter, Norbert
Blödorn-Schlicht, Hans-Joachim Schulze, Jens Atzpodien.
2862 Overexpression of nuclear karyopherin alpha2
correlates with poor prognosis in patients with colorectal
cancer. Moo Jun Baek, Dongjun Jeong, Tae Hyun Kim, Chang-Jin
Kim, Sang Han Lee, Han Jo Kim, Sang Byeong Bae, Tae Sung Ahn.
2863 TMPRSS2-ERG influences IGF-1R expression and
affects its prognostic value in prostate cancer. Caterina
Mancarella, Irene Casanova-Salas, Josè Antonio Lopez-Guerrero,
Katia Scotlandi.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
2864 RPS4X, a new prognostic and predictive biomarker of
ovarian and breast cancer. Serges P. Tsofack, Liliane Meunier,
Anne-Marie Mes-Masson, Michel Lebel.
2865 High serum transforming growth factor ␤1 levels
associated with poor survivals in patients with advanced
hepatocellular carcinoma. Tzu-Hsuan Lin, Yu-Yun Shao, Soa-Yu
Chan, Chung-Yi Huang, Ann-Lii Cheng, Chih-Hung Hsu.
2866 Proteins associated with pancreatic cancer survival in
patients with resectable pancreatic ductal adenocarcinoma. Ru
Chen, Sheng Pan, Anirban Maitra, Diane Simeone, David Dawson,
Teresa Brentnall.
2867 EGFR expression in T1/T2 oral tongue and floor of the
mouth carcinoma. Natalie Kelner, Clovis Antonio L. Pinto, Luiz Paulo
Kowalski, Claudia M. Coutinho-Camillo.
2868 Use of methionine metabolites in predicting recurrent
prostate cancer affordably. Diptiman Choudhury, Subhash Haldar,
Neil A. Bhowmick.
2869 A three-protein cytokine signature that correlates with
the prognosis of osteosarcoma. Ricardo J. Flores, Yiting Li, Aaron
Kelly, Ching Lau, Tsz-Kwon Man.
2870 ZGPAT gene expression in non-tumor hepatocellular
carcinoma tissue is a likely biomarker for survival risk. Mitsuhiro
Hishida, Shuji Nomoto, Yoshikuni Inokawa, Nao Takano, Mitsuro
Kanda, Naoki Iwata, Chie Tanaka, Daisuke Kobayashi, Yoko
Nishikawa, Suguru Yamada, Goro Nakayama, Tsutomu Fujii, Hiroyuki
Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera.
2871 Correlation between number and sites of metastases
and differential pretreated EBV DNA load profiles and their
effects on outcomes in patients with metastatic nasopharyngeal
carcinoma. Hung-Ming Wang, Kai-Ping Chang, Tung-Liang Lin,
Shiang-Fu Huang, Ngan-Ming Tsang, Sheng-Chieh Chan, ChengLung Hsu.
2872 Serum fucosylated haptoglobin is a novel prognostic
biomarker for prostate cancer: Detailed analyses of its
oligosaccharide structures. Kazutoshi Fujita, Motohide Uemura,
Wataru Nakata, Mototaka Sato, Akira Nagahara, Yasutomo Nakai,
Mayuka Shimomura, Miyako Nakano, Eiji Miyoshi, Norio Nonomura.
2873 A molecular signature predictive of indolent prostate
cancer. Shazia Irshad, Mukesh Bansal, Clementine Le Magnen,
Risham Dillon, Mireia Castillo-Martin, Tian Zheng, Alvaro Aytes, Sven
Wenske, Paolo Guarnieri, Pavel Sumazin, Mitchell Benson, Michael
M. Shen, Andrea Califano, Cory Abate-Shen.
2874 A prospective study of a repeat endoscopic biopsy to
identify HER2-positive tumors following an initial HER2-negative
endoscopic biopsy in unresectable or metastatic gastric cancer
patients: GASTHER1 study. Sook Ryun Park, Young Soo Park,
Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon
Lee, Gin Hyug Lee, Min-Hee Ryu, Yoon-Koo Kang.
2875 ATAD2 overexpression indentifies aggressive
endometrial carcinomas. Camilla Krakstad, Ingvild L. Tangen, Maria
B. Raeder, Erling Hoivik, Kanthida Kusonmano, June X. Zou, Anne M.
Øyan, Jone Trovik, Hongwu Chen, Karl H. Kalland, Helga B.
Salvesen.
2876 Genetic polymorphism in the mir-196a as a prognostic
biomarker for early breast cancer. Soo Jung Lee, Yee Soo Chae,
Byung Woog Kang, Jong Gwang Kim, Ji-Young Park, Jin Hyang
Jung, Ho Yong Park.
2877 Focal adhesion kinsase (FAK) protein overexpression
and gene copy number gain correlate with better outcome in
patients with surgically resected NSCLC tumors. Ximing Tang,
Yiran Cai, Carmen Behrens, Heather Lin, J. Jack Lee, Ignacio. I.
Wistuba.
2878 BCAM (breast cancer attractor metagenes): A new tool
for assessing breast cancer prognosis. Wei-Yi Cheng, Tai-Hsien
Ou Yang, Matthew Maurer, Dimitris Anastassiou.
38
38
395
POSTER SESSION
Clinical Research 9
Poster
Section
39
39
Prophylactic and Therapeutic Immune-based Therapies
Poster Abstract
Board Number
1.
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
396
2879 Anti-cancer effects of REIC/Dkk-3-encoding adenoviral
vector for the treatment of non-small cell lung cancer. Ken
Suzawa, Shinichi Toyooka, Kazuhiko Shien, Norimitsu Tanaka,
Masami Watanabe, Junichi Soh, Masakiyo Sakaguchi, Keitaro
Matsuo, Hiromasa Yamamoto, Masashi Furukawa, Hiroaki Asano,
Kazunori Tsukuda, Yasutomo Nasu, Nam-Ho Huh, Shinichiro Miyoshi,
Hiromi Kumon.
2880 Novel alphavirus-based vaccine targets dendritic cells
and efficiently breaks immunological tolerance to “self” tumorassociated antigen (PSA) in an HLA-DR mouse model of
prostate cancer. Vladimir Ryabov, Peter Pushko, Irina Tretyakova,
Rikka Saito, Richard B. Alexander, Elena N. Klyushnenkova.
2882 p53MVA therapy in patients with refractory
gastrointestinal malignancies primes robust CD8ⴙ T cell
responses. Nicola Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun
Qian, Jonathan Espenschied, Lucille Leong, Peiguo Chu, Joseph Kim,
Joseph Chao, Marwan Fakih, Joshua Ellenhorn, Don Diamond,
Vincent Chung.
2883 Improved generation of central memory CD8ⴙ T cells
with CD40L expressing recombinant vaccinia virus. Emanuele
Trella, Evangelos Panoupolos, Swantje Heidtmann, Nermin Raafat,
Giulio Cesare Spagnoli, Paul Zajac.
2884 Immune-based therapy with human tumor lysate,
expressing ␣-gal epitopes induce significant B cell response
and in vivo tumor destruction against pancreatic cancer. Kenta
Furukawa, Masahiro Tanemura, Eiji Miyoshi, Hiroaki Nagano,
Hidetoshi Eguchi, Toshimitsu Irei, Masashi Inoue, Shinya Yamashita,
Yoshito Tomimaru, Naoki Hama, Hiroshi Wada, Koichi Kawamoto,
Shogo Kobayashi, Katsuyoshi Matsunami, Kiyomi Taniyama, Wataru
Kamiike, Masaki Mori, Yuichiro Doki.
2885 Therapeutic microparticle-based tumor lysate
vaccination reduces spontaneous lung metastases in a murine
breast cancer model. Brett P. Gross, Amaraporn Wongrapanich,
Meghan Francis, Vijaya B. Joshi, Aliasger K. Salem, Lyse A. Norian.
2886 Primate study of TYG100 a novel rationally-designed
recombinant vaccine for pancreatic cancer: Immunogenicity and
tolerability in a species-homologous mode. Geert C. Mudde,
Robert L. Wardle, X Wang, Sonia Gaier, Johannes Pichler, Joyce
Chandler, Laxman Katwa, Shaun Reece, Peter Laing, Paul Broome,
Michael van Scott.
2887 Molecular farming and molecular engineering of
cancer vaccines. Sourabh Shukla, Nicole F. Steinmetz.
2888 Dendritic cell-targeted lentiviral vector vaccines
overcome tolerance to generate a protective T-cell immune
response to breast cancer antigens ERBB2 and ␣-lactalbumin.
Paul D. Bryson, Xiaolu Han, Norman Truong, Pin Wang.
2889 Human antibodies induced by vaccination with a
carbohydrate mimetic-peptide vaccine show functional antitumor activity on human lung-cancer cells. Konstantinos
Arnaoutakis, Fariba Jousheghany, Issam Makhoul, Laura Hutchins,
Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi.
2890 Mechanistic evaluation of the anti-tumor activities of
2-fluorofucose alone and in combination with anti-idiotype
vaccination. Nicole M. Okeley, Weiping Zeng, Matthew R.
Levengood, Julie A. McEarchern, Mechthild Jonas, Steven Duniho,
Peter D. Senter, Che L. Law.
2891 Bench-to-bedside development of a novel idiotype
vaccine against lymphoma. Hong Qin, Soungchul Cha, Sheetal S.
Rao, Kunhwa Kim, Dongho Gwak, Sung-doo Kim, Sapna R.
Parshottam, Sheeba K. Thomas, Larry W. Kwak.
2892 Vaccination with a therapeutic cancer vaccine
containing prostate specific antigen and the biological adjuvants
IL-2 and GM-CSF results in reduced serum PSA in prostate
cancer patients. Jonathan F. Head, Robert L. Elliott.
2893 Engineered release and presentation of antibodybound viral antigens: A highly specific and novel
immunotherapeutic approach to target cancer in vivo. David G.
Millar, Laura Morton, Manuela C. Gaspar, Punam Mistry, Hugo De La
Peña, Ricky Joseph, Sarah Penny, Oliver C. Goodyear, Margaret
Goodall, Guy E. Pratt, Mark Cobbold.
2894 Novel heteroclitic XBP1 peptides induce antigenspecific memory CD3ⴙCD8ⴙ T cells expressing critical T cell
markers and transcription regulators. Jooeun Bae, Rao Prabhala,
Ruben Carrasco, Ann-Hwee Lee, Alec Kimmelman, Kenneth C.
Anderson, Nikhil Munshi.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2895 Small cell lung cancer cells express the late stage
gBK tumor antigen: a possible immunotarget for the terminal
disease. Neil T. Hoa, Lisheng Ge, Rajeev B. Tajhya, Christine
Beeton, Andrew N. Cornforth, Amir Abolhoda, Nils Lambrecht, Maria
Dacosta-Iyer, Yi Ouyang, Michelle J. Hickey, Kate L. Erickson, Carol
A. Kruse, Martin R. Jadus.
2896 Identification of novel tumor associated antigens in
colorectal cancer. Slava Stamova, Christoph Schlude, Saskia Rösch,
Christel Herold-Mende, Taronish D. Dubash, Claudia R. Ball, Hanno
Glimm, Martin A. Schneider, Philipp Beckhove.
2897 ERBB2 amplicon passenger genes: A novel class of
breast cancer antigens. Gregory E. Plautz, Arun Modi, Li-Xin Wang.
2898 HCA519/TPX2: a potential T-cell tumor-associated
antigen for human hepatocellular carcinoma. Ahmed M. Aref, Neil
T. Hoa, Lisheng Ge, Anshu Agrawal, Maria Dacosta-Iyer, Nils
Lambrecht, Yi Ouyang, Andrew N. Cornforth, Martin R. Jadus.
2899 Immunologic effects of a HER2 peptide (GP2) vaccine
booster in previously vaccinated breast cancer patients. Erika
Schneble, John S. Berry, Alfred F. Trappey, Timothy J. Vreeland,
Diane F. Hale, Alan K. Sears, Guy T. Clifton, Sathibalan Ponniah,
Elizabeth A. Mittendorf, George Peoples.
2900 IMCgp100: A novel bi-specific biologic for the
treatment of malignant melanoma. Namir J. Hassan, Giovanna
Bossi, Debbie Baker, Katherine Adams, Jane Harper, Joseph Dukes,
Nathaniel Liddy, Samantha Paston, Yvonne McGrath, Tara Mahon,
Peter Molloy, Malkit Sami, Emma Baston, Brian Cameron, Andrew
Johnson, Annelise Vuidepot, Gerry Linette, Michael Kalos, Carl June,
Bent Jakobsen.
2901 Cell surface-associated anti-MUC1-derived signal
peptide antibodies: implications for cancer diagnostics and
therapy. Riva Kovjazin, Galit Horn, Nechama I. Smorodinsky, Michael
Y. Shapira, Lior Carmon.
2902 Obinutuzumab (GA101) significantly increases overall
survival against CD20ⴙ rituximab-sensitive and -resistant
Burkitt (BL) and acute lymphoblastic leukemia (B-ALL): potential
targeted therapy in patients with high risk BL and pre-B-ALL.
Aradhana A. Tiwari, Janet Ayello, Carmella van de Ven, Matthew J.
Barth, Mitchell S. Cairo.
2903 IMAB362, a novel first-in-class monoclonal antibody
for treatment of pancreatic cancer. Oezlem Tuereci, Stefan Woell,
Stefan Jacobs, Rita Mitnacht-Kraus, Ugur Sahin.
2904 SN-38 antibody-drug conjugates as a novel platform
for solid cancer therapy: preclinical science. David M.
Goldenberg, Thomas M. Cardillo, Robert M. Sharkey, William J.
McBride, Edmund A. Rossi, Chien-Hsing Chang, Serengulam V.
Govindan.
2905 The activity of a new class of biologics: trastuzumab
conjugates designed to treat brain metastases of HER2ⴙ breast
cancers. Timothy Vitalis, Wilfred Jefferies, Reinhard Gabathuler.
2906 An effective anti-EpCAM antibody EpAb2– 6 for the
treatment of colon cancer and its underlying mechanisms. MeiYing Liao.
2907 Everolimus enhances the cytotoxic action of the
immunotoxin, HA22, directed to CD22 on B-cell malignancies.
Antonella Antignani, Matteo Pasetto, Chris Choo, Evan Angelus,
Lesley Mathews, Rajarshi Guha, Paul Shinn, Marc Ferrer, Craig
J. Thomas, Ira Pastan, David J. Fitzgerald.
2908 A first-in-human phase I study of SAR650984, a
humanized anti-CD38 antibody in patients with CD38ⴙ
hematological malignancies: Preliminary PK and PD results of
escalation phase. Marie-Laure L. Ozoux, Hélène Guillemin, MarieHélène H. Pascual, Sylvaine Cartot-Cotton, Christine Veyrat-Follet,
Delphine Valente, Maxime Moulard, Christine Mauriac, Antoine
Deslandes, Dorothee Semiond.
LATE-BREAKING POSTER SESSIONS
Monday, 1:00 p.m.-5:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 40
Late-Breaking Research: Molecular and Cellular Biology 2
Poster Section 41
Late-Breaking Research: Tumor Biology 3
397
Monday, 2:30 p.m.-3:30 p.m.
Choosing the Right Postdoctoral Fellowship for a Successful
Research Career
Career Conversations, organized by the Associate Member Council (AMC), are informal
networking and discussion sessions designed to allow early-career scientists the opportunity to
interact with junior faculty and scientists. This session topic, offered by the AMC at every Annual
Meeting, will address how to choose the most appropriate postdoctoral fellowship for your
research interests and career goals. Open to all graduate students, medical students, residents,
and clinical and postdoctoral fellows, this session will take place in the Associate Member
Resource and Career Center located in AACRcentral; limited seating is available on a first-come,
first-served basis. #AACR14 #AACRCC
Speakers:
Sendurai A. Mani, The University of Texas MD Anderson Cancer Center, Houston, TX
Lacey R. McNally, University of Louisville Brown Cancer Center, Louisville, KY
398
MEET AND GREET
Monday, 2:30 p.m.-3:30 p.m.
Meet the AACR President,
Carlos L. Arteaga, MD
All Annual Meeting attendees are invited to meet AACR
President Carlos L. Arteaga, MD. Dr. Arteaga is a
professor of medicine and cancer biology at Vanderbilt
University School of Medicine where he holds the Donna
S. Hall chair in breast cancer research. He also serves as
associate director for clinical research and director of the
Breast Cancer Research Program at Vanderbilt-Ingram
Cancer Center in Nashville, Tenn. In his role, Dr. Arteaga
will work collaboratively with the AACR Board of
Directors and the 34,000-plus membership to further the
AACR’s mission to prevent and cure cancer through
research, education, communication, and collaboration.
He assumed the presidency on April 7, 2014 during the
Annual Business Meeting of Members at the AACR
Annual Meeting 2014. Dr. Arteaga was also an editorial
board member of Clinical Cancer Research from 2001 to
2004 and is currently deputy editor. He has served on
behalf of the AACR as co-chair of the annual CTRCAACR San Antonio Breast Cancer Symposium since
2009 and is a principal investigator on the Stand Up To
Cancer Dream Team, “Targeting the PI3K Pathways in
Women’s Cancers.” His research interests include
oncogene signaling and molecular therapeutics in breast
cancer with an emphasis on targeted therapies,
mechanisms of drug resistance, translational research,
and investigator-initiated clinical trials. Early in his career,
Dr. Arteaga was the first to report the role of IGF-I
receptors and TGF-beta on breast cancer progression
and their potential as therapeutic targets. More recent
work has focused on the role of presurgical and
neoadjuvant trials to discover molecular biomarkers that
inform patient selection in clinical trials and/or for the
discovery of mechanisms of drug resistance in breast
cancer. He showed the role of aberrant activation of the
PI3K pathway in promoting escape from antiestrogens
and the ability of inhibitors of HER2 and PI3K to reverse
resistance to antiestrogen therapy in human breast
cancer in studies focused on hormone receptor-positive
breast cancer. All of his work has significant implications
for novel clinical trials in patients with breast cancer,
some of which are completed or in progress. He has
received many honors and awards, including the AACRRichard and Hinda Rosenthal Award, the American
Cancer Society Clinical Research Professor Award, the
Gianni Bonadonna Award from the American Society of
Clinical Oncology, the Brinker Award for Scientific
Distinction from the Susan G. Komen for the Cure Breast
Cancer Foundation and, early in his career, the Clinical
Investigator Award from the U.S. Department of Veteran
Affairs. Additionally, he is an elected member of the
Association of American Physicians and the American
Society for Clinical Investigation and a member of Susan
G. Komen’s Scientific Advisory Board. Dr. Arteaga
received his medical degree in 1980 from the Facultad
de Ciencias Médicas at the Universidad de Guayaquil in
Ecuador. Following internal medicine residency at Emory
University in Atlanta, Ga., Dr. Arteaga completed a
fellowship in medical oncology at The University of Texas
Health Science Center at San Antonio. He joined the
faculty at Vanderbilt University in 1989.
399
.
NCI’s Center for Strategic Scientific Initiatives (CSSI):
Programs and Highlights
Chairperson: Emily J. Greenspan, National Ccancer Institute, Bethesda, MD
The mission of the Center for Strategic Scientific Initiatives (CSSI) is to create and uniquely
implement exploratory programs focused on the development and integration of advanced
technologies, transdisciplinary approaches, infrastructure, and standards to accelerate the
creation of publicly available, broadly accessible, multidimensional data, knowledge, and tools to
empower the entire cancer research continuum for patient benefits. In this session we will highlight
the programmatic objectives and research efforts supported by the CSSI’s Office of Cancer
Nanotechnology Research (OCNR), Office of Cancer Clinical Proteomics Research (OCCPR), and
the Center for Cancer Genomics Office of Cancer Genomics (OCG), provide an update on two
trans-NCI grant initiatives, the Innovative Molecular Analysis Technologies (IMAT) program and the
Provocative Questions (PQ) initiative, coordinated by CSSI’s Office of the Director (OD), and share
highlights from the Division of Cancer Biology’s (DCB) Physical Sciences-Oncology Centers (PSOC) program.
OCG seeks to advance and accelerate development of genomics science and technology toward
the goal of enhancing the understanding of the molecular mechanisms of cancer. Programs
include the Cancer Genome Characterization Initiative (CGCI), whose goal is to support the
molecular characterization of tumors through the development of cutting-edge genomic
approaches, the Therapeutically Applicable Research to Generate Effective Treatments (TARGET)
initiative, which is focused on childhood cancers, and the Cancer Target Discovery and
Development (CTD2) initiative, which extracts therapeutically relevant information from large-scale
genomics data sets.
The NCI’s DCB supports the PS-OC program, which brings together transdisciplinary teams from
the physical sciences and cancer research communities to investigate the emergence and behavior
of cancer from a physical sciences perspective. This portion of the session will provide an overview
of the PS-OC program, highlighting the new perspectives being brought to cancer research. They
will also discuss resources available to support work at the intersection of the physical sciences
and oncology including the PS-OC Data Coordinating Center and upcoming funding opportunities.
OCNR directs the NCI Alliance for Nanotechnology in Cancer (ANC), a program to pioneer the
development and deployment of nanotechnology-based interventions, which hold enormous
promise for advancing all aspects of cancer research and medicine. OCNR will give an overview of
the goals, organization, and recent successes of the ANC program, as well as describe
interactions with other NCI initiatives to leverage their capabilities towards collaborative efforts.
There will also be a discussion of resources available to the cancer nanotechnology community,
including the Nanotechnology Characterization Laboratory (NCL) and Translation of
Nanotechnology in Cancer (TONIC) consortium.
OCCPR’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is applying proteomic
technologies to systematically identify proteins from genomically characterized tumors, such as
those from TCGA program. Resources presented from OCCPR will include: the Data Coordinating
Center and Proteomic Data, the Antibody Characterization Program and Portal, and the Proteomic
Assay Portal. The audience will hear an overview of each resource and learn how to learn how to
access data and assays developed through CPTAC.
400
Monday, 2:30 p.m.-4:00 p.m.
Our session will close with an overview of the IMAT and PQ programs, including overarching goals
of the initiatives, examples of supported research, and future directions.
Introduction to NCI’s Center for Strategic Scientific Initiatives and review of the
Provocative Questions Initiative
Emily J. Greenspan, National Cancer Institute, Bethesda, MD
Overview of the Innovation Molecular Analysis Technologies (IMAT) Program
Anthony Dickherber, National Cancer Institute, Marietta, GA
What’s happening in the NCI Office of Cancer Genomics
Jaime M. Guidry Auvil, National Cancer Institute, Bethesda, MD
Funding opportunities and resources from the NCI’s Physical Sciences in
Oncology Initiative
Sean E. Hanlon, National Cancer Institute, Bethesda, MD
NCI’s Alliance for Nanotechnology in Cancer Program and resources for cancer
nanotechnology research
Stephanie Morris, National Cancer Institute, Rockville, MD
CPTAC: Proteomic resources for cancer research
Christopher Kinsinger, National Cancer Institute, Bethesda, MD
401
MEET AND GREET
Monday, 3:00 p.m.-4:00 p.m.
Meet the Jane Cooke Wright Lecturer
Levi A. Garraway, MD, PhD
Please join us for discussion with AACR-Minorities in Cancer Research Jane Cooke Wright
Lectureship Ninth Annual Recipient Levi A. Garraway, MD, PhD. Dr. Garraway's award lecture,
“The Cancer Genome in Biology, Therapy, and Drug Resistance,” was presented on Sunday,
April 6, from 3:15 p.m.-4:30 p.m. The lectureship is intended to give recognition to an outstanding
scientist who has made meritorious contributions to the field of cancer research and who has,
through leadership or by example, furthered the advancement of minority investigators in
cancer research.
402
MINISYMPOSIA
Monday, 3:00 p.m.-5:00 p.m.
Clinical Research 10
Epidemiology 8
Novel Biomarkers Predictive of
Response
Cancer Risk and Survival: New Insights
Chairpersons: John P. Pierce and Ann W. Hsing
Chairpersons: Scott Kopetz and Matthew A. Maurer
3:00
Introduction
3:05
2909
A gene signature composed of 13 p53 target genes
predicts for response to NVP-CGM097, a novel p53-Mdm2
inhibitor, in cell lines and in human primary tumor xenograft
models. Sebastien Jeay, Swann Gaulis, Stéphane Ferretti,
Geneviève Albrecht, Louise Barys, Daniel Guthy, Ensar Halilovic,
Moriko Ito, Masato Murakami, Astrid Pornon, Stephan Ruetz,
Kavitha Venkatesan, Jianjun Yu, Michael Jensen, Marion
Wiesmann, Jens Wuerthner, Diana Graus-Porta.
3:20
2910
Androgen receptor splice variant-7 predicts
resistance to enzalutamide in patients with castrationresistant prostate cancer. Emmanuel S. Antonarakis, Changxue
Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C. Roeser,
Yan Chen, Helen L. Fedor, Tamara L. Lotan, Angelo M. De Marzo,
John T. Isaacs, William B. Isaacs, Rosa Nadal, Channing J. Paller,
Samuel R. Denmeade, Michael A. Carducci, Mario A. Eisenberger,
Jun Luo.
3:35
2911
Immune related melanoma gene expression profile
predicts neoadjuvant ipilimumab clinical benefit . Ahmad A.
Tarhini, Yan Lin, Hui-Min Lin, Cindy Sander, William A. La
Framboise, John M. Kirkwood.
3:50
2912
The isoform 2 of FKBP51 is induced by PDL-1/PD1
interaction and marks peripheral blood mononuclear cells of
melanoma patients. Maria Fiammetta Romano, Anna D’Angelillo,
Simona Romano, Ester Simeone, Paolo Ascierto, Stefania Staibano,
Paolo D’Arrigo, Massimiliano Scalvenzi, Gennaro Ilardi, Rita
Bisogni.
4:05
2913
Glutamate-enriched breast cancer as new entity and
target for metabolic drugs. Jan Budczies, Berit M. Pfitzner,
Klaus-Jürgen Winzer, Cornelia Radke, Manfred Dietel, Oliver Fiehn,
Carsten Denkert.
4:20
2914
Phosphoproteomic and transcriptional biomarkers
predict response to SAR302503, a JAK2 inhibitor, in human
acute myeloid leukemia preclinical models. Weihsu C. Chen,
Julie S. Yuan, Nathan Mbong, Andreea C. Popescu, Yan Xing, Gitte
Gerhard, Wei Zhang, Yussanne Ma, Richard Moore, Marco Marra,
Mark D. Minden, Donna E. Hogge, Cynthia Guidos, John E. Dick,
Jean C. Wang.
4:35
2915
Circulating miRNAs as potential biomarkers for
esophageal adenocarcinoma risk and clinical outcomes. Xia
Pu, Jian Gu, Yuanqing Ye, Jaffer Ajani, Xifeng Wu.
4:50
Discussion
3:00
Introduction
3:05
2916
Childhood BMI is associated with risk of adult
pancreatic cancer. Leticia M. Nogueira, Rachael StolzenbergSolomon, Michael Gamborg, Thorkild Sørensen, Jennifer Baker.
3:20
2917
The association of smoking before first childbirth
with breast cancer risk is independent from alcohol use and
does not seem to differ across ethnic groups: the multiethnic
cohort study. Inger T. Gram, Song-Yi Park, Melissa A. Little,
Laurence N. Kolonel, Gertraud Maskarinec, Lynne R. Wilkens,
Brian E. Hendereson, Loic Le Marchand.
3:35
2918
Menopausal hormone therapy and B-cell non-Hodgkin
lymphoma (NHL) risk in the Los Angeles County NHL CaseControl Study. Sophia S. Wang, Jianning Luo, Jane SullivanHalley, Yani Lu, James V. Lacey, Jr., Wendy Cozen, Leslie
Bernstein.
3:50
2919
Plasma carotenoids and risk of breast cancer over 20
years of follow-up in the Nurses’ Health Study. A. Heather
Eliassen, Xiaomei Liao, Shelley S. Tworoger, Susan E. Hankinson.
4:05
2920
Circulating inflammation markers and subsequent
lung cancer risk: A discovery and replication study. Meredith
S. Shiels, Hormuzd A. Katki, Allan Hildesheim, Ruth M. Pfeiffer,
Eric A. Engels, Marcus C. Williams, Troy J. Kemp, Neil E.
Caporaso, Ligia A. Pinto, Anil K. Chaturvedi.
4:20
2921
Assessing colorectal cancer risk using known genetic
susceptibility variants and family history accounting for
endoscopy. Li Hsu, Jihyoun Jeon, Hermann Brenner, Sonja
Berndt, Andrew T. Chan, Jenny Chang-Claude, Stephen B. Gruber,
Tabitha Harrison, Michael Hoffmeister, Polly Newcomb, John
Potter, Fredrick Schumacher, Martha Slattery, Duncan Thomas,
Emily White, Yingye Zheng, Ulrike Peters, Colorectal
Transdisciplinary Study; Genetics and Epidemiology of Colorectal
Cancer Consortium.
4:35
2922
Prediagnostic smoking, alcohol intake, physical
activity and survival after colorectal cancer diagnosis in
Western European populations. Veronika Fedirko, Elio Riboli,
Teresa Norat, Anne Tjønneland, Mazda Jenab, on behalf of the
EPIC CRC Working Group.
4:50
Discussion
403
MINISYMPOSIA
Monday, 3:00 p.m.-5:00 p.m.
New Targets and New Combinations to
Overcome Resistance
Novel Therapeutic Strategies
Chairpersons: Zev A. Wainberg and Carolyn D. Britten
Chairpersons: Jeffrey A. Engelman and Frank P.
Stegmeier
3:00
Introduction
3:00
Introduction
3:05
2923
Identification and validation of dysregulated MAPK7
(ERK5) as a novel oncogenic target in squamous cell lung and
esophageal carcinoma. Paul R. Gavine, Mei Wang, Dehua Yu,
Eva Hu, Chunlei Huang, Jenny Xia, Xinying Su, Joan Fan, Tianwei
Zhang, Qingqing Ye, Li Zheng, Liang Xie, Luna Han, Guanshan
Zhu, Ziliang Qian, Qingquan Luo, Yingyong Hou, Qunsheng Ji.
3:05
3:20
2924
MAPK pathway inhibition enhances the efficacy of an
anti-endothelin B receptor drug conjugate by inducing target
expression in melanoma. Jyoti Asundi, Paul Polakis, Jennifer A.
Lacap, Michelle Nannini.
2930
Global chromatin profiling reveals NSD2 mutation in
pediatric ALL. Ho Man Chan, Jacob D. Jaffe, Yan Wang, Jinghui
Zhang, Robert Huether, Gregory V. Kryukov, Hyo-eun C. Bhang,
Jordan E. Taylor, Min Hu, Nathan P. Englund, Feng Yan, Zhaofu
Wang, E Robert McDonald III, Lei Wei, Jing Ma, John Easton,
Zhengtian Yu, Rosalie deBeaumount, Veronica Gibaja, Kavitha
Venkatesan, Robert Schlegel, William R. Sellers, Nicholas Keen,
Jun Liu, Giordano Caponigro, Jordi Barretina, Vesselina G. Cooke,
Charles Mullighan, Steven A. Carr, James R. Downing, Levi A.
Garraway, Frank Stegmeier.
3:35
2925
Mechanism-based combinatorial treatment of KRAS
mutant colorectal cancer with MEK and PI3K pathway
inhibitors. Paul A. Clarke, Toby Roe, Paul Workman.
3:20
3:50
2926
PNA as novel targeted cancer therapy for BRAFV600E
mutant melanoma. Jeffrey H. Rothman, Oliver Surriga,
Shyamprasad D. Vasudeva, Grazia Ambrosini, Ouathek Ouerfelli,
Gary K. Schwartz.
2931
Cancer cells deficient in DNA mismatch repair (MMR)
are selectively sensitive to inhibition of the DNA dependent
protein kinase (DNA-PK). Madeleine Hewish, Yari Fontebasso,
Sarah A. Martin, Richard Elliott, Kerry L. Perks, Asha Konde,
Ilirjana Bajrami, Antoinette Van Weverwijk, David Cunningham,
Christopher J. Lord, Alan Ashworth.
3:35
2932
SF3B1 mutations induce aberrant mRNA splicing in
cancer and confer sensitivity to spliceosome inhibition. Silvia
Buonamici, Kian Huat Lim, Jacob Feala, Eunice Park, Laura
Corson, Michelle Aicher, Daniel Aird, Betty Chan, Erik Corcoran,
Rachel Darman, Peter Fekkes, Gregg Keaney, Pavan Kumar, Kaiko
Kunii, Linda Lee, Xiaoling Puyang, Jose Rodrigues, Anand Selvaraj,
Michael Thomas, John Wang, Markus Warmuth, Lihua Yu, Ping
Zhu, Peter Smith, Yoshiharu Mizui.
4:05
2927
Rapamycin decreases expression of thymidylate
synthase and enhances the response to pemetrexed in
preclinical studies and a Phase I/II clinical study of subjects
with non-small cell lung cancer. Shigeru Kawabata, Chun-Te
Chiang, Regan M. Memmott, Takefumi Komiya, Joell J. Gills,
Phillip A. Dennis.
4:20
2928
AZD6244 inhibits cisplatin induced ERK1/2 activation
and potentiates its cytotoxic effects in NSCLC preclinical
models. Eun Young Kim, Arum Kim, Min Kwang Byun, Se Kyu
Kim, Hyung Jung Kim, Joon Chang, Chul Min Ahn, Yoon Soo
Chang.
3:50
2933
Assessment of ABT-263 activity across a
comprehensive cancer cell line collection leads to a novel,
potent combination therapy for small cell lung cancer.
Anthony C. Faber, Carlotta Costa, Anahita Dastur, Cyril Benes,
Jeffrey Engelman.
4:35
2929
The Mdm2 inhibitor NVP-CGM097 enhances the antitumor activity of NVP-LDK378 in ALK mutant neuroblastoma
models. Hui Qin Wang, Linda Battalagine, Jinsheng Liang, Ensar
Halilovic, Robert Schlegel, Alan Huang, Z. Alexander Cao, John
Monahan, Fang Li.
4:05
2934
Genomic alterations associated with resistance to
antiestrogens identified by multiplatform molecular analysis in
operable ERⴙ breast cancer. Jennifer M. Giltnane, Justin Balko,
Jasmine Mu, Jason Christiansen, Danielle Murphy, Ingrid Mayer,
Ingrid Meszoely.
4:50
Discussion
4:20
2935
RNAi screen identifies therapeutic targets in
hepatocellular carcinoma. Chun-Hao Huang, Amaia Lujambio,
Johannes Zuber, Thomas Kitzing, Darjus F. Tschaharganeh, Elisa
De Stanchina, Scott W. Lowe.
4:35
2936
JNJ-47117096, a selective small molecule inhibitor of
the MELK oncogene decreases DNA damage tolerance in
highly proliferating cancer cells. Lijs Beke, Joannes T. Linders,
Cenk Kig, An Boeckx, Erika van Heerde, Dirk Wuyts, Marc Parade,
Lieven Meerpoel, Chris Johnson, Monique Beullens, Mathieu
Bollen, Dirk Brehmer.
4:50
Discussion
404
MINISYMPOSIA
Monday, 3:00 p.m.-5:00 p.m.
Immunology 6
Immune-based Therapies: Responses,
Biomarkers, and Mechanisms
Gene Regulation and Transcription
Factors
Chairpersons: Pamela S. Ohashi and Nina Bhardwaj
Chairpersons: Martin Horstmann and Waldemar Priebe
3:00
Introduction
3:00
Introduction
3:05
2937
Localization of sipuleucel-T- expanded T cell clones
into tumors of treated prostate cancer patients. Lawrence
Fong, Todd DeVries, Jason Cham, Li Zhang, Mark Frohlich, James
Trager, Nadeem Sheikh.
3:05
2944
Decline in arylsulfatase B (N-acetylgalactosamine-4sulfatase) leads to increased expression of the
transmembrane glycoprotein GPNMB. Sumit Bhattacharyya, Leo
Feferman, Joanne K. Tobacman.
3:20
2938
Synergistic effects of properly timed HPV16 synthetic
long peptide vaccination during standard carboplatinpaclitaxel chemotherapy in animals and in patients with
metastatic cervical carcinoma. Sjoerd H. Van Der Burg, Tetje C.
van der Sluis, Helene van Meir, Judith R. Kroep, Gemma G.
Kenter, Mariette I. van Poelgeest, Koos Burggraaf, Cornelis J.
Melief, Marij J. Welters.
3:20
2945
Characterization of a novel protein-coding gene
named TIHL (Translocated in Hodgkin’s Lymphoma). Ujunwa C.
Okoye-Okafor, Laura Barreyro, Mario Pujato, Heng R. Wang, Boris
Bartholdy, Britta Will, Tihomira I. Todorova, Masahiro Kawahara,
Bruce Woolcock, Andras Fiser, Randy Gascoyne, Christian Steidl,
Ulrich Steidl.
3:35
3:35
2939
CAVATAK-mediated oncolytic immunotherapy in
advanced melanoma patients. Robert H. Andtbacka, Darren R.
Shafren, Mark Grose, Len Post, Jeffrey Weisberg.
3:50
2940
Comprehensive biomarker program demonstrates
proof of mechanism and modulation of the tumor
microenvironment due to RG7155, a novel therapeutic
antibody targeting tumor associated macrophages. Ann-Marie
Bröske, Irina Klaman, Jayantha Ratnayake, Georgina MenesesLorente, Kevin Smart, Phiippe Cassier, Carlos Gomez-Roca,
Christophe Le Tourneau, Antoine Italiano, Jean-Pierre Delord,
Jean-Yves Blay, Carola Ries, Dominik Ruettinger, Michael
Cannarile.
2946
Status of STAT3, STAT5, and NF-␬〉 in pancreatic
cancer cell lines, small molecule inhibitors, and potential
clinical implications. Arumugam Jayakumar, Venugopal
Radjendirane, Jason Fleming, Yaan Kang, Aleksandra Rusin, Rafal
Zielinski, Stanislaw Skora, Izabela Fokt, Waldemar Priebe.
3:50
2947
Regulation of PD-L1 expression in human melanoma
by NF-kB. Kavitha Gowrishankar, Dilini Gunatilake, Stuart
Gallagher, Jessamy Tiffen, Peter Hersey.
4:05
2948
HOXB13: Investigating mechanisms of G84E mutation
associated with prostate carcinogenesis. Dorhyun Johng,
Charles M. Ewing, Steven M. Mooney, Shuangling Chen, William
B. Isaacs.
4:20
2949
YK-4 –279 is a small molecule inhibitor of ETV1 and
inhibits metastasis in a mouse model. Said Rahim, Sarah
Justvig, Sung-Hyeok Hong, Perrer Tosso, Haydar Çelik, Yasemin
Sayedigar-Kont, Milton Brown, Colm Morrissey, Jeffrey Toretsky,
Aykut Üren.
4:35
2950
Regulation of the functional interface between
nucleotide excision repair and transcription by MITF
modulates melanoma growth. Marcos Seoane, Laia Pagerols
Raluy, Karoline Kaufmann, Julia Strauss, Kevin Dierck, Jüergen
Thomale, Johanna M. Brandner, Udo Schumacher, Peter Nollau,
Peter J. Wild, Martin Zimmermann, Jinyan Du, David E. Fisher,
Martin A. Horstmann.
4:50
Discussion
4:05
2941
Local tumor irradiation combined with ␣-PDL-1
immune checkpoint inhibition results in local and systemic
anti-tumor responses: Successful translation of a mouse
model to a human case series. Idit Sagiv-Barfi, Amanda
Rajapaksa, Debra Czerwinski, Serena Chang, Jonathan Hebb,
Cariad Chester, Erin Waller, Gregg Fine, Daniel Chen, Marcin
Kowanetz, Bryan Irving, Ronald Levy, Holbrook Kohrt.
4:20
2942
NRAS mutation as a predictor of response to
immune-based therapies in patients with metastatic
melanoma. Wade T. Iams, Douglas B. Johnson, Marisa Flavin,
Katherine Panageas, Gregory D. Ayers, Zhiguo Zhao, Anthony J.
Iafrate, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman,
Christine M. Lovly.
4:35
2943
14g2a-based GD2-specific chimeric antigen receptors
(CARs) constitutively signal, leading to rapidly induced T-cell
exhaustion and poor antitumor efficacy in vivo. Adrienne Long,
Rimas J. Orentas, Crystal L. Mackall.
4:50
Discussion
405
MINISYMPOSIA
Monday, 3:00 p.m.-5:00 p.m.
Metabolism and Programmed Cell Death
Tumor Suppressors 4
Chairpersons: Anthony G. Letai and Xiaolu Yang
Chairpersons: Laura D. Attardi and R. Daniel
Beauchamp
3:00
Introduction
3:05
2951
Vitamin C is selectively toxic to cancer cells
harboring KRAS or BRAF mutations by targeting GAPDH. Jihye
Yun, Adam Kavalier, Edouard Mullarky, Kaitlyn Bosch, Jatin Roper,
Carlo Rago, Jihye Paik, John Asara, Steven Gross, Bert Vogelstein,
Nickolas Papadopoulos, Lewis Cantley.
3:20
2952
Aberrant accumulation of 2-hydroxyglutarate in
human breast cancer with myc activation . Prachi Mishra.
3:35
2953
Rev-erb␣ modulates Myc-driven cancer cell growth
and altered metabolism. Brian J. Altman, Annie Hsieh, Arvin M.
Gouw, Zachary E. Stine, Anand Venkataraman, David I. Bellovin,
Sharon J. Diskin, Wenyun Lu, Sisi Zhang, Dean W. Felsher, John
M. Maris, Mitchell A. Lazar, Joshua D. Rabinowitz, John B.
Hogenesch, Chi V. Dang.
3:50
4:05
2954
A noncanonical mechanism for BCL-2 inhibition of
pro-apoptotic BAX. Lauren A. Barclay, Susan Lee, Michelle L.
Stewart, Craig R. Braun, Gregory H. Bird, Loren D. Walensky.
2955
Trail-R2: A death receptor turns malignant upon
nuclear localization. Holger Kalthoff, Verena Haselmann,
Alexandra Kurz, Uwe Bertsch, Sebastian Huebner, Hendrik
Fritsche, Charlotte Hauser, Christian Schem, Rob Tower, Thorsten
Heilmann, Sanjay Tiwari, Claus C. Glüer, Anna Trauzold.
4:20
2956
The role of apoptotic blebbing in tissue homeostasis
and cancer. Linda Julian, Michael F. Olson.
4:35
2957
Inhibition of glutaminase induces slows tumor growth
cell autonomously and promotes survival in a MYC driven
hepatocellular carcinoma mouse model. Zachary Stine, Yan
Xiang, Jinsong Xia, Ping Gao, Ramani Dinavahi, Chi V. Dang.
4:50
Discussion
406
3:00
Introduction
3:05
2958
Deconstructing p53 pathways in vivo. Colleen A.
Brady, Daniela Kenzelmann Broz, Dadi Jiang, Stephano Spano
Mello, Kathryn Bieging, Laura D. Attardi.
3:20
2959
The tumor suppressor CHD5 is an epigenetic
regulator of neuronal cell fate. Alea A. Mills, Dong-Woo Hwang.
3:35
2960
Identification of Runx3 as a gatekeeper of lung
adenocarcinoma. You-Soub Lee, Ju-Won Jang, Xin-Zi Chi,
Yoshiaki Ito, Suk-Chul Bae.
3:50
2961
The level of mitochondrial apoptotic priming
determines cell fate upon p53 restoration. Francisco J.
Sánchez-Rivera, Jeremy Ryan, Yadira M. Soto-Feliciano, David M.
Feldser, Michael T. Hemann, Anthony Letai, Tyler Jacks.
4:05
2962
Loss of the E3 ubiquitin ligase HACE1 results in
enhanced Rac1 signaling contributing to breast cancer
progression. Erik T. Goka, Marc E. Lippman.
4:20
2963
Loss of Smad4 within the intestinal tract results in
altered intestinal homeostasis and tumor development. Tanner
J. Freeman, Jillian Pope, Josh Smith, Daniel Sharbel, Kay
Washington, Xi Chen, Rupesh Chaturvedi, Keith Wilson, Noah
Shroyer, Punita Dhawan, Anna Means, Natasha G. Deane, R. D.
Beauchamp.
4:35
2964
The codon 47 Pro47Ser polymorphism influences p53
phosphorylation and apoptotic function. Matthew Jennis,
Monica Hollstein, Maureen E. Murphy.
4:50
Discussion
MINISYMPOSIA
Monday, 3:00 p.m.-5:00 p.m.
Tumor Biology 26
Cancer Prevention
Innovations in Modeling Cancer in Mice
Chairpersons: Steven M. Dubinett and Andrew J.
Dannenberg
Chairpersons: Cory Abate-Shen and Zhi-Min Yuan
3:00
Introduction
3:05
2965
Olaparib and veliparib as effective PARP inhibitors for
cancer prevention in a BRCA1-deficient mouse model. Ciric To,
Charlotte R. Williams, Darlene B. Royce, Ryan M. Collins, Michael
B. Sporn, Karen T. Liby.
3:20
2966
Targeting defective DNA repair as a novel
chemoprevention strategy for BRCA1-mutated breast cancer.
Elizabeth Alli, David Solow-Cordero, Stephanie C. Casey, James M.
Ford.
3:35
2967
Metformin selectively targets tumor initiating cells in
erbb-2 overexpressing breast cancer models . Pei Zhu, Meghan
Davis, Amanda Blackwelder, Nora Bachman, Bolin Liu, Susan
Edgerton, Leonard L. Williams, Ann D. Thor, Xiaohe Yang.
3:50
2968
FTY720 inhibits mutant Kras-induced lung cancer via
disrupting Stat3-S1PR1 vicious cycle and downregulating
tumor PD-L1 expression. Hsuan-Heng Yeh, Tsung-I Hsu, JanJong Hung, Wen-Pin Su, Wu-Chou Su.
4:05
2969
Combinational Targeting of EGFR and ODC pathways
by Gefitinib and DFMO lead to complete blockade of PanIN
progression to pancreatic ductal adenocarcinoma. Altaf
Mohammed, Naveena B. Janakiram, Rebekah L. Ritchie, Laura
Biddick, Misty Brewer, Stan Lightfoot, Vernon E. Steele,
Chinthalapally V. Rao.
4:20
2970
Differential effects of caloric and carbohydrate
restriction on prostate cancer in a mouse model. Everardo
Macias, Jean A. Thomas, Elizabeth M. Masko, Alexis R. Gaines,
Brian Whitley, Tanisha Coburn, Susan L. Poulton, Tameika E.
Phillips, Stephen J. Freedland.
4:35
2971
Hypothalamic beta-endorphin neuron transplants
modulate colonic proinflammatory cytokines and epithelialmesenchymal transition factors and suppress preneoplastic
and neoplastic lesions in 1,2-dimethylhydrazine-induced colon
cancer. Dipak K. Sarkar, Sengottuvelan Murugan, Yatee Dave,
Ankush Rakhit.
4:50
3:00
Introduction
3:05
2972
Conditionally reprogrammed cells (CRCs): A new
model for cancer research and personalized medicine. Xuefeng
Liu, Ewa Krawczyk, Nancy Palechor-Ceron, Weisheng Wang, Hang
Yuan, Aleksandra Dakic, Vera Simic, Bhaskar Kullakury, Priscilla
Furth, Richard Schlegel.
3:20
2973
Mouse models of lung cancer mediated by lentiviral
gene delivery. Yifeng Xia, Narayana Yeddula, Eugene Ke, Mathias
Leblanc, Inder Verma.
3:35
2974
RNAi mouse models: Revolutionizing drug discovery
in vivo. Prem K. Premsrirut, BoYoung Yoon, Marina Pesic, Lukas
E. Dow, Johannes Zuber, Scott W. Lowe, Gregory J. Hannon, Lars
Zender, Christof Fellmann.
3:50
2975
The pluripotency factor LIN28 promotes colorectal
tumorigenesis and tumor progression. Sarah Schwitalla, HoChou Tu, Srinivas Viswanathan, Hao Zhu, Zhirong Qian, Samar
Shah, Shuji Ogino, George Q. Daley.
4:05
2976
Intratumoral cellular heterogeneity of epithelial
ovarian carcinoma and its impact on tumor behavior. Suha
Naffar-Abu Amara, Laura Selfors, Marit Krohn, Tan Ince, Gordon
Mills, Joan Brugge.
4:20
2977
Myc and Miz1 in medulloblastoma. BaoHan T. Vo,
Elmar Wolf, Daisuke Kawauchi, Jerold Rehg, David Finkelstein,
Brian Murphy, Martin Eilers, Martine F. Roussel.
4:35
2978
Generation of drug response data from 57 new
patient-derived colon cancer xenografts and 3D cell cultures
for systematic correlation with tumor biology within the
OncoTrack* project. Maria Rivera, Marlen Keil, Karsten Boehnke,
Martin Lange, Dirk Schumacher, Reinhold Schäfer, Christian R.
Regenbrecht, David Henderson, Ulrich Keilholz, Alexander Kuehn,
Amin El-Heliebi, Tabea Hohensee, Johannes Haybäck, Christoph
Reinhard, Juan A. Velasco, Hans Lehrach, Pilar Garin-Chesa, Garry
Beran, Jens Hoffmann.
4:50
Discussion
Discussion
407
CLINICAL TRIALS MINISYMPOSIUM
Monday, 3:00 p.m.-5:00 p.m.
Early Phase Clinical Trials of Novel Targeted Agents
Chairperson: S. Percy Ivy, National Cancer Institute, Rockville, MD, and Lillian L. Siu,
Princess Margaret Cancer Center, Toronto, ON, Canada
3:00 p.m.
Introduction
3:05 p.m.
CT236 MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in
patients with advanced solid tumors: Results of the first-in-human
phase I trial
Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina
Anne Piha-Paul, Filip Janku, J. Gabrielle Granda, HongXia Zheng, Manfred B.
Klevesath, Karola Köhler, Friedhelm Bladt, Andreas Johne, Razelle Kurzrock
3:20 p.m.
CT237 Interim results of a first-in-human phase I study of the oral MET kinase
inhibitor, LY2801653, in patients with advanced cancer
Jimmy Hwang, Roger Cohen, Kimberly Perez, Howard Safran, Aiwu Ruth
He, Jennifer Giles, Tianle Hu, Brian Moser, Patricia Kellie Turner, Richard A.
Walgren, Elizabeth Plimack
3:35 p.m.
CT238 Phase III randomized, placebo-controlled trial of COX-2 inhibition in
addition to standard chemotherapy for advanced non-small cell lung
cancer (NSCLC): CALGB 30801 (Alliance)
Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria
Baggstrom, Thomas Sachdev, Ajeet Gajra, Erin Bertino, Karen Reckamp,
Julian Molina, Joan Schiller, Kisha Mitchell-Richards, Paula Friedman, Jon
Ritter, Everett Vokes, Alliance for Clinical Trials in Oncology
3:50 p.m.
CT239 ARN-509 in patients with metastatic castration-resistant prostate
cancer (mCRPC) previously treated with abiraterone acetate (AA)
Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald
Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J.
Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla de Boer, Mary Todd,
Margaret K. Yu, Howard I. Scher
4:05 p.m.
CT240 Molecular screening for cancer treatment optimization (MOSCATO 01):
A prospective molecular triage trial; interim analysis of 420 patients
Charles Ferté, Christophe Massard, Ecaterina Ileana, Antoine Hollebecque,
Ludovic Lacroix, Samy Ammari, Maud Ngo-Camus, Rastislav Bahleda, Anas
Gazzah, Andrea Varga, Sophie Postel-Vinay, Yohann Loriot, Nathalie Auger,
Valerie Koubi-Pick, Bastien Job, Thierry De Baere, Frederic Deschamps,
Philippe Vielh, Vladimir Lazar, Marie-Cécile Le Deley, Catherine Richon,
Vincent Ribrag, Eric Deutsch, Eric Angevin, Gilles Vassal, Alexander
Eggermont, Fabrice André, Jean-Charles Soria
4:20 p.m.
CT241 Gene expression profiling in the context of neoadjuvant chemotherapy
for urothelial cancer with DDMVAC+B (dose-dense methotrexate,
vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict
clinical outcomes and tumor biology
Arlene O. Siefker-Radtke, Woonyoung Choi, John Melquist, Yu Shen, Ashish
Kamat, Surena Matin, Randall Millikan, Colin P. Dinney, Bodgan A. Czernial,
David J. McConkey
4:35 p.m.
Discussion
408
REGULATORY SCIENCE
AND SCIENCE POLICY
Monday, 3:00 p.m.-5:00 p.m.
Breakthrough Therapies: Case Studies of Successful
Applications in Oncology
Chairperson: William N. Hait, Janssen Research and Development, LLC, Raritan, NJ
In 2012, the FDA was given Statutory Authority via passage of the Food and Drug Administration
Safety and Innovation Act (FDASIA) to designate medical products (drugs and biologics) as a
“Breakthrough Therapy” if the therapy met the following conditions:
• treated a serious or life threatening disease or condition;
• and preliminary clinical evidence indicated that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development.
FDA data indicate that there have been more than 140 Breakthrough Therapy Designation (BTD)
applications in 2013, of which 37 have been granted. The majority of BTDs granted have been for
oncology products. Thus far, three breakthrough-designated products have received approval, of
which two have been in oncology: Genentech/Roche’s Gazyva (obinutuzumab) and
Pharmacyclics/Janssen Imbruvica (ibrutinib). Since BTDs are a new and exciting pathway to gain
expedited approval of medical products, this session will include discussions of: 1) how developers
can take advantage of BTD, 2) how to recognize and apply for BTD designation in early
development, and 3) case studies of the two successful BTD product applications in oncology.
A panel discussion moderated by William Hait, Janssen Research and Development, and audience
Q & A will follow the presentations.
Patient advocate’s perspective on expedited approval pathways
Ellen V. Sigal, Friends of Cancer Research, Washington, DC
Regulator’s perspective on expedited approval pathways
Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, MD
Case study of a successful BTD product application in oncology:
Gazyva (obimutuzumab)
Nancy Valente, Genentech, Inc., South San Francisco, CA
Case study of a successful BTD product application in oncology:
Imbruvica (ibrutinib)
Peter F. Lebowitz, Janssen Research and Development, LLC, Wayne, PA
409
SPECIAL SYMPOSIUM
Monday, 3:00 p.m.-5:00 p.m.
Data Reproducibility in Cancer Research: Can You Believe
Everything You Read?
Chairperson: Lee M. Ellis, The University of Texas MD Anderson Cancer Center, Houston, TX
The ability to translate basic science discoveries into clinical benefit for our patients depends upon
reliable and robust preclinical data. However, the failure rate of new drugs in cancer clinical trials is
lower than in any other discipline. Recently, many investigators, both from academia and industry,
have raised the issue that data reproducibility is poor, and may explain our high failure rate in drug
development. Manuscript retractions are increasing rapidly, and most retractions are due to
misconduct. It has been noted that the impact factor of a journal correlates with the retraction
rate, but the reasons for this association remain to be elucidated. In this session, speakers will
address the issue of data reproducibility, potential causes of the inability to reproduce data, and
possible mechanisms to address these issues.
3:00 p.m.
Issues with the publication and replication of scientific studies in cancer
research
Lee M. Ellis, The University of Texas MD Anderson Cancer Center, Houston, TX
3:20 p.m.
Discussion
3:25 p.m.
Raising the standards for biomedical research
C. Glenn Begley, TetraLogic Pharmaceuticals, CA
3:45 p.m.
Discussion
3:50 p.m.
Challenges in the preclinical validation of cancer drug targets
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA
4:10 p.m.
Discussion
4:15 p.m.
Failure analysis: Learning from retracted scientific articles
Ferric C. Fang, University of Washington School of Medicine, Seattle, WA
4:35 p.m.
Discussion
4:40 p.m.
Panel Discussion
410
SPECIAL SESSION
Monday, 3:15 p.m.-5:15 p.m.
New SU2C Dream Teams: Patient Benefit Through Targeted
Therapeutics and Immunotherapy
Chairperson: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
In the past 2 years, Stand Up To Cancer (SU2C) has awarded seven new jointly funded Dream
Team and Translational Team grants in collaboration with the Melanoma Research Alliance, the
Prostate Cancer Foundation, the Dutch Cancer Society, the Cancer Research Institute, and the St.
Baldrick’s Foundation. During this session, which is available to all attendees, the Dream Team
Leaders, Co-leaders, and members will give a brief overview of their respective projects and
discuss the cancer science driving the current and future clinical trials. A brief Q & A will follow the
presentation of the Dream Team and Team reports.
Opening remarks from the SU2C Scientific Advisory Committee Chairperson
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
Precision therapy of advanced prostate cancer
Introduction: Arul M. Chinnaiyan, University of Michigan Center for Translational
Pathology, Ann Arbor, MI
Speaker: Nikolaus Schultz, Memorial Sloan-Kettering Cancer Center, New York, NY
Immunologic checkpoint blockade and adoptive cell transfer in cancer therapy
Introduction: Antoni Ribas, University of California, Los Angeles (UCLA),
Los Angeles, CA
Speaker: Cassian Yee, The University of Texas MD Anderson Cancer Center,
Houston, TX
Targeting adaptive pathways in metastatic treatment-resistant prostate cancer
Introduction: Eric J. Small, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
Speaker: Joshi J. Alumkal, Oregon Health and Science University, Portland, OR
Personalized medicine for patients with BRAF wild-type (BRAFwt) cancer
Introduction: Jeffrey M. Trent, Translational Genomics Research Institute,
Phoenix, AZ
Speaker: Alexsandar Sekulic, Mayo Clinic Arizona, Scottsdale, AZ
Prospective use of DNA-guided personalized cancer treatment
Speaker: Emile E. Voest, Netherlands Cancer Institute, Amsterdam, The Netherlands
Immunogenomics to create new therapies for high-risk childhood cancers
Introduction: John M. Maris, The Children’s Hospital of Philadelphia, Philadelphia, PA
Speaker: Nabil M. Ahmed, Baylor College of Medicine, Houston, TX
Tumor organoids: A new preclinical model for drug sensitivity analysis
Speaker: Hans Clevers, Hubrecht Institute, Amsterdam, The Netherlands
411
AACR PRINCESS TAKAMATSU LECTURE
Monday, 3:30 p.m.-4:30 p.m.
Eighth Annual AACR Princess Takamatsu Memorial Lectureship
Reengineering the Tumor Microenvironment to Enhance
Cancer Treatment: Bench to Bedside to Biomarkers
Rakesh K. Jain, PhD
A.W. Cook Professor of Tumor Biology
Director, E.L. Steele Laboratory
Department of Radiation Oncology
Harvard Medical School and Massachusetts General Hospital, Boston, MA
The AACR Princess Takamatsu Memorial Lectureship
was established and first presented in 2007 in honor of
the late Princess Takamatsu of Japan. During her
extraordinary life, Her Imperial Highness Princess
Takamatsu expended tremendous efforts toward the
public and humanitarian cause of the eradication of
cancer. She is an honored and respected figure in Japan,
the United States, and the cancer research community
worldwide.
The Lectureship will recognize an individual scientist
whose novel and significant work has had or may have a
far-reaching impact on the detection, diagnosis,
treatment, or prevention of cancer, and who embodies
the dedication of the Princess to multinational
collaborations.
Dr. Rakesh K. Jain, who is also the Andrew Werk Cook
professor of tumor biology (radiation oncology) at
Harvard Medical School, is being recognized for his
pioneering work in tumor biology and his leadership in
developing diverse international collaborations and
training the next generation of scientists.
Dr. Jain is renowned for his work characterizing the
abnormal state of blood vessels within tumors and for
proposing and then validating the groundbreaking
hypothesis that “normalizing” the network of blood
vessels in a tumor can improve treatment outcomes. In
testing his hypothesis he made discoveries that
fundamentally changed understanding about the ways in
which anticancer therapeutics called antiangiogenic
agents work. Developed to prevent tumor blood vessels
from forming, Dr. Jain’s research showed that
antiangiogenic agents can actually normalize tumor
blood vessels in both animal models and cancer
patients, and that this improves outcomes for patients.
412
Throughout his career, Dr. Jain has mentored graduate
and postgraduate students from around the world from
diverse backgrounds, including chemistry, molecular and
cellular biology, immunology, radiology, pathology,
surgical oncology, engineering, mathematics, and
physics, many of whom are now leaders.
Dr. Jain’s contributions to cancer research have been
recognized with numerous other accolades, including
election to the National Academy of Sciences, the
National Academy of Engineering, and the Institute of
Medicine; he is one of only 20 people ever to have been
elected to all three U.S. National Academies. He also
received the American Society for Clinical Oncology’s
Science of Oncology Award in 2012.
Dr. Jain received his bachelor’s degree from the Indian
Institute of Technology in Kanpur, India, and his master’s
and doctorate degrees from the University of Delaware in
Newark, Del., all in chemical engineering. Prior to joining
Massachusetts General Hospital and Harvard Medical
School in 1991, Dr. Jain was assistant professor of
chemical and biomedical engineering at Columbia
University in New York (1976-1978), and then rose
through the ranks to become professor of chemical and
biomedical engineering in 1983 at Carnegie Mellon
University in Pittsburgh, Pa.
Monday, 4:00 p.m.-5:00 p.m.
AACRcentral, Exhibit Hall A-E, San Diego
Convention Center
Career Conversations: Career Paths
in Pancreatic Cancer Research
The pancreatic cancer research community
continues to seek new investigators to join efforts in
the laboratory and clinic. This session, which
focuses on career paths in the field of pancreatic
cancer, will be co-led by Dr. M. Celeste Simon,
Professor of Cell and Developmental Biology,
Scientific Director of the Abramson Family Cancer
Research Institute, and Howard Hughes Medical Institute Investigator, and Dr. Andrew D. Rhim, Assistant Professor of
Internal Medicine and Assistant Director for Translational Research in the Division of Gastroenterology at the University
of Michigan Medical School and Comprehensive Cancer Center. Both Drs. Simon and Rhim received 2013 Pancreatic
Cancer Action Network-AACR grants.
This informal and interactive session will provide the opportunity to engage with both a renowned established
investigator and a highly successful junior faculty physician-scientist and will focus on basic, translational, and clinical
research paths in pancreatic cancer. Pick up new ideas and suggestions about career paths, priority research needs
for the field, postdoctoral opportunities, funding opportunities, how to start your own laboratory, the importance of
clinical trials, choosing a mentor, networking and collaborations, etc. The forum will be an open dialogue, and question
and answer format. Come meet others in the field and share your experiences. This session will take place in the
AACR Amphitheatre located in AACRcentral.
Speakers:
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, PA
Andrew D. Rhim, University of Michigan, Ann Arbor, MI
How to Distinguish Yourself from Your Mentor
Career Conversations, organized by the Associate Member Council, are informal networking and discussion sessions
designed to allow early-career scientists the opportunity to interact with junior faculty and scientists. This session will
address how to build a career strategy that will allow you benefit from your mentor’s instruction, while still developing
your own career independently. Open to all graduate students, medical students, residents, and clinical and
postdoctoral fellows, this session will take place in the Associate Member Resource and Career Center located in
AACRcentral; limited seating is available on a first-come, first-served basis. #AACR14 #AACRCC
Speakers:
Kimberly J. Johnson, Washington University in St. Louis, St. Louis, MO
Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
413
Monday, 4:00 p.m.-5:30 p.m.
NCI’s Provocative Questions Initiative: Highlights and Outcomes
Chairperson: Emily J. Greenspan, National Cancer Institute, Bethesda, MD
In 2011, the NCI’s Director, Dr. Harold Varmus, created the Provocative Questions (PQ) initiative to
encourage imaginative, bold approaches designed to tackle perplexing and previously neglected
or understudied areas of cancer research. Based upon workshops and discussions with the
extramural cancer research community, as well as NCI program directors, a set of 24 questions
and accompanying requests for applications (RFAs) were developed, focused on diverse topics in
cancer risk and prevention, tumor development, and cancer detection, diagnosis, and treatment.
In order to stimulate innovative hypotheses and approaches, the “power of the ideas” was heavily
weighted in the applications with a de-emphasis on preliminary data. In the first year of the
initiative, the NCI awarded 56 grants, totaling $21.5 million of research support via the R01 and
R21 mechanisms. Building upon the 2011 RFAs and adjusting to changes in the research
landscape, 24 revised questions were developed for the 2012 RFAs with a commitment of up to
$30 million in support. The NCI released the 2013 RFAs in September 2013 with a revised set of
20 questions, including a new thematic area related to clinical effectiveness.
In this session, a general programmatic summary of the PQ initiative will be given, including
history and development of the program and funding data to date. Several PQ-supported research
projects funded in the first year of the initiative will also be highlighted in order to demonstrate the
breadth of research topics and high level of innovation supported by the initiative. Projects will be
selected from the four main PQ thematic areas in order to provide an overview of the many diverse
approaches being used to answer a selected PQ. In addition, trends and evaluation criteria from
awarded grants will be presented to offer insight to potential applicants regarding the outcomes of
the program to date as well as put forward ideas as to how the initiative may influence future NCI
program development and funding areas.
Introduction to the NCI’s Provocative Questions Initiative
Douglas R. Lowy, National Cancer Institute, Bethesda, MD
NCI’s Provocative Questions Initiative: Program review and evaluation
Emily J. Greenspan, National Cancer Institute, Bethesda, MD
Advanced immune monitoring as a companion diagnostic for adoptive cell
transfer immunotherapies
James R. Heath, California Institute of Technology, Pasadena, CA
Mouse intestinal stem cell dynamics and how NSAIDs may prevent
colorectal cancer
Darryl K. Shibata, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Leveraging individual polyp signatures to define the malignant transformation
of colon polyps
Lisa A. Boardman, Mayo Clinic, Rochester, NY
414
AACR OACR AWARD LECTURE
Monday, 4:30 p.m.-5:30 p.m.
Thirty-Fourth Annual AACR Award for Outstanding Achievement in
Cancer Research
Androgen Metabolism Drivers in Prostate Cancer:
From Mechanism to Therapy
Nima Sharifi, MD
Kendrick Family Endowed Chair for Prostate Cancer Research
Cleveland Clinic, Cleveland, OH
Beginning in 1979, the AACR Award for Outstanding
Achievement in Cancer Research has been given to a
young investigator no more than 40 years of age, to
recognize his or her meritorious achievements within the
field of cancer research.
Dr. Nima Sharifi is recognized for having found that
dihydrotestosterone (DHT) synthesis in patients with
castration-resistant prostate cancer (CRPC) circumvents
the need for testosterone, using instead a previously
underappreciated intermediate steroid and for
discovering the first gain-of-function mutation in a
steroidogenic enzyme, which increases DHT synthesis
and drives CRPC.
As a medical oncology and postdoctoral fellow at the
National Cancer Institute, Dr. Sharifi focused on the
clinical importance of the androgen receptor (AR) as a
transcription factor in advanced prostate cancers that
are resistant to hormonal therapies; as a result, he has
made a significant impact in the field. His interest was
captured by the observation of others that prostate
cancers become resistant to androgen deprivation
therapy by means of a gain-of-function mechanism that
essentially reactivates the AR to drive CRPC. A major
mechanism required for AR gain-of-function comes into
play when tumors acquire the metabolic capability to
synthesize their own DHT from adrenal precursor
steroids, a capacity that has been clinically validated by
FDA-approved next-generation drugs that block the
synthesis or effects of DHT, such as abiraterone and
enzalutamide.
In 2008, at UT Southwestern, Dr. Sharifi’s prostate
cancer clinic enabled him to take fundamental
observations from his laboratory to clinical confirmation
in patients with this disease. The generally accepted
convention in the field had been that testosterone is an
obligate intermediate metabolite that undergoes
5α-reduction to DHT from adrenal precursor steroids in
CRPC. In 2011, Dr. Sharifi challenged this dogma and
demonstrated that androstenedione, an altogether
different steroid, undergoes 5α-reduction to 5αandrostanedione, a previously underappreciated
intermediate, en route to DHT. Dr. Sharifi confirmed these
findings in fresh metastatic CRPC tissues, obtained with
CT-guided biopsies from patients in his clinic using an
IRB-approved protocol, to take this story from
fundamental biochemistry to clinical confirmation.
Also noteworthy is that elevated DHT concentrations in
CRPC were first observed 35 years ago; however, no
mutation responsible for this observation had been
described. Dr. Sharifi’s recent research identifies the first
gain-of-function mutation in a steroidogenic enzyme that
increases metabolic flux from steroid precursors to DHT
and is responsible for the development of CRPC. This
mutation, in 3β-hydroxysteroid dehydrogenase-1
(3βHSD1), blocks the ubiquitination and degradation of
this enzyme, increasing its half-life, leading to higher
protein levels, and thus increasing metabolic flux in the
rate-limiting step from DHEA (the predominant adrenal
precursor steroid) to DHT, which in turn stimulates the AR
and confers resistance to androgen deprivation therapy.
The significance of these findings may be similar to the
discovery of EGFR mutations in non-small cell lung
cancer and BRAF mutations in melanoma. Patients with
tumors that harbor these gain-of-function enzyme
mutations are generally dependent on these genetic
lesions, and these tumors are generally responsive to
pharmacologic inhibition of these enzymes.
Dr. Sharifi is the recipient of a Howard Hughes Medical
Institute Physician-Scientist Early Career Award, an
American Cancer Society Research Scholar Award, a
Prostate Cancer Foundation Young Investigator Award,
and is also supported by the National Cancer Institute. In
2013, he was appointed the Kendrick Family Endowed
Chair for Prostate Cancer Research at the Cleveland Clinic.
415
FORUMS
Antioxidant to Pro-Oxidant
Therapy for Cancer
Moderator: Navdeep S. Chandel, Northwestern
University, Chicago, IL
Cancer cells produce high levels of reactive oxygen
species (ROS), primarily superoxide and hydrogen
peroxide. Oncogene activation, coupled with the loss of
tumor suppressors, promotes ROS production at
mitochondria, endoplasmic reticulum, and NADPH
oxidases. The tumor microenvironment, characterized by
low glucose, hypoxia, and inflammatory infiltration, further
increases ROS levels in cancer cells. Elevated ROS levels
can hyperactivate multiple pathways (PI3K, MAPKs,
NF‐KB, HIFs) that are known to be protumorigenic.
However, uncontrolled oxidant production is incompatible
with cellular viability. Thus, cancer cells have enhanced
antioxidant function which allows them to maintain a
balance between the growth-promoting and damageinducing properties of ROS. We will discuss the current
thinking regarding disabling cellular antioxidants to
increase ROS levels in cancer cells to levels that elicit
damage and thus reduce tumor burden.
Panel:
Shyam Biswal, Johns Hopkins University School of
Public Health, Baltimore, MD
Tak W. Mak, Campbell Family Institute for Breast Cancer
Research, Toronto, ON, Canada
Controversies and Challenges Posed
By Incidental Findings from Tumor
Genome Analysis
Moderator: Kenneth Offit, Memorial Sloan-Kettering
Recent advances in massively parallel sequencing have
made possible high-throughput analysis of tumor
samples in order to individualize and target treatment
strategies. In the process, incidental information can be
found indirectly (germline mutations identified in the
tumor sequence) or directly (when germline DNA is used
as a comparison with the tumor DNA). At present, there
is a debate regarding whether laboratories and clinicians
have an obligation to inform patients about incidental
416
findings, or if such an obligation would constitute a
violation of a patient’s autonomous right to decide what
genetic information he or she wishes to receive. This
session will focus on the scientific as well as ethical
underpinnings of this debate, and will seek to inform the
discussion with emerging data and experience from
investigators engaged in cancer genomic analysis and
counseling.
Panel:
Stephen J. Chanock, National Cancer Institute,
Bethesda, MD
Sharon E. Plon, Baylor College of Medicine, Houston, TX
Crowdsourcing Cancer Research: The
Role of Quantitative Challenges
Moderator: Gustavo A. Stolovitzky, IBM Computational
Biology Center, Yorktown Heights, NY
During the past decade, challenge-based competitions
have grown in number and prominence in a wide range
of disciplines, including cancer research. One example is
the NCI-sponsored DREAM challenge to predict the
sensitivity of breast cancer cells to chemotherapeutic
drugs, successfully conducted in 2012. Advantages of
challenge-based competitions include the unbiased
assessment of the performance of predictive models and
the nucleation of communities around a given topic.
There are, however, important unknowns about the
potential of collaborative competitions. Which problems
are not amenable to crowdsourcing? What is the best
set of incentives to balance the competitive and
collaborative aspects of challenge-based research? How
sustainable is a research program based on challenges
in terms of its economics and challenge fatigue in
participants? This discussion will address these
questions, trying to flesh out the benefits and limitations
of collaborative competitions and the extent to which
challenges can become a mainstream research modality.
Panel:
Stephen H. Friend, Sage Bionetworks, Seattle, WA
Daniel Gallahan, National Cancer Institute, Rockville, MD
Monday, 5:00 p.m.-6:30 p.m.
Genomics: How Deep Is a Deep
Enough Dive?
Chairperson: Todd R. Golub, Broad Institute of MIT and
Harvard, Cambridge, MA
It is becoming possible to generate increasingly large
biological datasets, ranging from cancer genome
sequencing studies, to large-scale perturbational
profiling studies, to functional genomic studies of cancer
vulnerabilities. With such large datasets comes the
potential for additional false positive results. The
question thus becomes: as we add more data, does the
biological picture crystalize or do we become overrun
with noise? This forum will address this question from
the perspective of the LINCS Consortium (Connectivity
Map), cancer genome sequence analysis, and cancer
vulnerabilities studies (Project Achilles).
Panel:
Peter J. Campbell, Wellcome Trust Sanger Institute,
Cambridge, United Kingdom
William C. Hahn, Dana-Farber Cancer Institute,
Boston, MA
Plasticity vs. Hierarchy in Tumors
Panel:
Inder M. Verma, The Salk Institute, La Jolla, CA
Luis F. Parada, UT Southwestern Medical Center,
Dallas, TX
Targeting Autophagy in Cancer:
Promise or Peril?
Chairperson: Douglas R. Green, St. Jude Children’s
Autophagy is a fundamental biological process that
functions to preserve cell survival under conditions of
metabolic stress and cellular damage. As such, it clearly
has potential as a target for cancer therapy. However,
some cancers show defects in autophagy, and indeed,
some autophagic proteins act as tumor suppressors in
some settings. In this forum we will look at the benefits
and dangers associated with inhibition of autophagy and
discuss those situations where it may help or hurt the
efforts to treat disease.
Panel:
Kevin Ryan, Beatson Institute for Cancer Research,
Glasgow, United Kingdom
Eileen P. White, UMDNJ-The Cancer Institute of New
Jersey, New Brunswick, NJ
Moderator: Bradley E. Bernstein, Massachusetts
The importance of cellular heterogeneity in tumor
pathology and therapeutic resistance is now well
appreciated. In certain tumors, heterogeneity appears to
be predicated in a strict hierarchy with multipotent
“cancer stem cells” at the apex giving rise to other more
restrictive cell types in a tumor. Yet clear counter
examples exist in other malignancies, with dynamic
interchange among represented cell states (“plasticity”).
The extent to which these alternate models can explain
cellular heterogeneity in tumors has important
implications for mechanisms of transformation,
diagnostics, and therapeutics. This forum will critically
evaluate current models of tumor hierarchies and cellular
plasticity, and consider their clinical implications.
417
FORUM
Monday, 5:00 p.m.-6:30 p.m.
Panel:
What Is (Are) the Mechanism(s) by
Which the p53 Protein Enforces
Tumor Suppression?
Andreas Strasser, Walter and Eliza Hall Institute of
Medical Research, Parkville, Australia
Moderator: Arnold J. Levine, Institute for Advanced
Study, Princeton, NJ
Wei Gu, Columbia University Medical Center,
New York, NY
The p53 protein responds to a wide variety of stress
signals, which include DNA damage, telomere
shortening, hypoxia, metabolic alterations, aneuploidy,
alterations in ribosome biogenesis, and oncogene
activation via mutations. The nature of the p53 protein
response is to increase the concentration of this protein
in the cell and to acquire several types of posttranslational modifications. This leads to an increase in
the transcriptional activity of the p53 protein resulting in
a transcriptional program composed of many genes. The
genes that have an increased initiation of transcription
by the p53 protein all have a p53 DNA binding sites and
just which genes are transcribed depends upon the
nature of the stress, the cell type, whether the cell is
normal or transformed and likely other variables that are
not yet clear. These transcriptional programs result in
one of a variety of outcomes thought to be responsible
for tumor suppression. These responses include
apoptosis, cellular senescence, cell cycle arrest,
metabolic alterations, DNA repair and enhanced
inactivation of reactive oxygen species, cytokine
synthesis modulating the immune response, extracellular
matrix alterations, and others yet to be elucidated.
Recently several publications have demonstrated
p53-mediated tumor suppression in the absence of
apoptosis, cell cycle arrest, and cellular senescence
providing evidence that additional mechanisms are
critical for p53-mediated tumor suppression. In addition,
a second transactivation domain in the p53 protein has
been described that may well regulate a new set of
genes involved in tumor suppression. There is even a
suggestion that the p53 protein could act directly (not as
a transcription factor) in some types of tumor
suppression. Because p53 mutations are the single most
common alterations identified in human cancers, the
mechanisms of tumor suppression by p53 forms a
central part of understanding cancer initiation, sustained
tumor expansion and responses to therapeutics. It may
well be that there are several independent and redundant
mechanisms of tumor suppression by p53.
418
MAJOR SYMPOSIUM
Monday, 5:00 p.m.-6:30 p.m.
AACR/ASCO Presidential Symposium: Precision Medicine:
Next-Generation Sequencing
Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY,
and Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY
Regulatory approval of molecularly targeted cancer drugs is often linked to co-approval of a
"companion diagnostic" test that identifies the patients most likely to benefit from treatment. This
paradigm, initially pioneered with trastuzamab and HER2 immunohistochemistry in breast cancer,
has resulted in dozens of novel drug/target approvals over the past decade and exemplifies
successful implementation of the precision medicine vision in clinical practice. However, the
remarkable advances achieved in next-generation DNA sequencing in the past 2-3 years, that
enable analysis of thousands of genes inexpensively from small biopsy samples, present
unanticipated challenges to the companion diagnostic paradigm. In this session we will review the
scope of these remarkable advances and their potential impact on medicine, we will consider
various regulatory approaches to ensure that clinical next-generation sequencing is reliable and
robust, and we will discuss emerging challenges in implementing next-generation sequencing data
into real-time oncology practice.
5:00 p.m.
Personalized genomic analyses of human cancer
Victor E. Velculescu, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
5:25 p.m.
Discussion
5:30 p.m.
Moving forward in the companion diagnostic paradigm: Regulatory
considerations
Elizabeth Mansfield, U.S. Food and Drug Administration, Rockville, MD
5:55 p.m.
Discussion
6:00 p.m.
Enabling a genetically informed approach to cancer medicine in the clinic
William Pao, Vanderbilt University, Nashville, TN
6:25 p.m.
Discussion
419
SPECIAL SESSION
Monday, 5:00 p.m.-6:30 p.m.
Grand Ballroom Salons DE, Omni San Diego Hotel
AACR Radiation Oncology Task Force Networking Reception
Radiation-related cancer researchers, clinicians, and all those interested in radiation oncology are
invited to attend this special networking session.
420
MICR TOWN MEETING
Monday, 5:00 p.m.-6:30 p.m.
Marina Ballroom G, South Tower, San Diego Marriott Marquis & Marina
MICR Town Meeting
Chairperson: Christopher I. Li, Fred Hutchinson Cancer Research Center, Seattle, WA
This session is a can’t-miss for MICR Members and Annual Meeting attendees. The MICR Town
Meeting provides an open forum for discussion with the MICR Council and AACR CEO Margaret
Foti, as well as an opportunity for the MICR Council to present its members, agenda, and
programs to AACR members and annual meeting participants, honor past MICR Council
Members, and share the progress we have made this year.
421
AACR-CLOWES LECTURE
Monday, 5:30 p.m.-6:30 p.m.
Fifty-Fourth Annual AACR G.H.A. Clowes Memorial Award
James P. Allison, PhD
Chairman, Immunology Program
The University of Texas MD Anderson Cancer Center
Houston, TX
This award was established in 1961 by AACR and Eli
Lilly and Company to honor Dr. G.H.A. Clowes, a
founding member of AACR and past research director at
Eli Lilly and Company. The award recognizes an
individual that has had outstanding recent
accomplishments in the field of basic cancer research.
Dr. James P. Allison has laid the foundation for our ability
to manipulate the T cell system for therapeutic
applications against cancers, and is therefore greatly
deserving of this honor.
Dr. Allison’s early research focused on understanding
how the immune system defends the body from
pathogens and cancer, with particular emphasis on the
role of T lymphocytes. In this process, he uncovered
previously unknown mechanisms of T cell function.
In 1982, Dr. Allison and his colleagues identified the T
cell antigen receptor (TCR), which recognizes foreign
antigens. He also discovered that this recognition is not
sufficient for the activation of naïve T cells.
Subsequently, he discovered two key molecules, the
CD28, which is constitutively expressed on the surface
of the T cell and is needed for its activation, and a
homolog of CD28 called CTLA-4, which is induced after
the activation of the T cell, and is a major downregulator
of T cells. Dr. Allison described how all these molecules
act in concert in the process of engaging the antigen
presenting cells that carry the foreign antigens, such as
cancer antigens.
Dr. Allison hypothesized that the immune system fails to
recognize tumor cells since CTLA-4 downregulates T cell
activation. Based on this theory, he created antibodies to
this molecule and demonstrated the rejection of
established tumors in several mouse model systems. He
then developed an antibody to human CTLA-4,
ipilimumab, which has been used in clinical trials in more
than 4,000 patients with a variety of cancers including
422
metastatic melanoma, prostate, renal, lung, and
ovarian cancers.
In recent years, Dr. Allison identified several other
checkpoint and costimulatory molecules and he has
been testing the combination of immunological therapies
and targeted therapies, such as tyrosine kinase
inhibitors, for more effective treatment against cancers.
He will play an instrumental role in MD Anderson’s Moon
Shots Program to dramatically accelerate the pace of
converting scientific discoveries into clinical advances
that reduce cancer deaths.
Dr. Allison has received numerous awards and honors,
including the Breakthrough Prize in Life Sciences, the
inaugural AACR-Cancer Research Institute Lloyd J. Old
Award in Cancer Immunology, the Lifetime Achievement
Award of the American Association of Immunologists,
the Centeon Award for Innovative Breakthroughs in
Immunology, the William B. Coley Award for
Distinguished Research in Basic and Tumor Biology from
the Cancer Research Institute, the Dana Foundation
Award in Human Immunology Research, the Richard V.
Smalley Award from the International Society for
Biological Therapy of Cancer, and the Roche Award for
Cancer Immunology and Immunotherapy. He is a
member of the American Association for Immunologists,
the Academy of Cancer Immunology, the National
Academy of Sciences, and the American Association for
the Advancement of Science, among others.
Dr. Allison obtained his doctoral degree in biological
sciences from The University of Texas in Austin and
did his postdoctoral fellowship in molecular immunology
at the Scripps Clinic and Research Foundation in La
Jolla, Calif. He served as the chair of the immunology
program at the Memorial Sloan-Kettering Institute from
2004 to 2012.
Monday, 6:00 p.m.-8:00 p.m.
San Diego Ballroom C, San Diego Marriott Marquis & Marina
Conducting Effective Peer Review of Manuscripts: A View from
the Editor’s Chair
Chairperson: Michael A. Caligiuri, The Ohio State University Comprehensive Cancer Center,
Columbus, OH
Join AACR journal editors who render decisions on thousands of original research articles each
year and gain insight on critical aspects of peer review of manuscripts. The editors will review
topics including the role and responsibility of the peer reviewer; imparting an editor with the most
informative review; and providing the authors with an honest, comprehensive, unbiased
assessment of the value of their research. Come with your questions and leave with some takeaway ideas for your next review! For AACR members, Professional Advancement Sessions are free
with your Annual Meeting registration and are an added benefit of your membership. For
nonmembers, there is an additional fee of $50 for attendance at each session to be paid onsite.
Participation for sessions is on a first-come, first-served basis and space is limited.
Speakers:
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Theodore S. Lawrence, University of Michigan, Ann Arbor, MI
Danny R. Welch, University of Kansas Cancer Center, Kansas City, KS
423
SPECIAL SESSION
Monday, 6:00 p.m.-8:00 p.m.
Marriott Hall Salon 4, San Diego Marriott Marquis & Marina
Joint Cancer Immunology (CIMM)/Tumor Microenvironment (TME)
Working Groups Evening Scientific Session
Tumor microenvironment and immunology are at an exciting crossroads. This session,
“Collaboration of TME and Immune Responses in Irradiated Tumors,” will discuss tumor response
to targeted radiotherapy mediated by the immune system. The Chairpersons of the Cancer
Immunology (CIMM) and Tumor Microenvironment (TME) Working Groups invite you to attend this
evening scientific session to hear leaders from both fields present the most current information on
this topic.
6:00 p.m.
Chairperson, CIMM: Opening remarks
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania,
Philadelphia, PA
6:15 p.m.
Radiation and immunotherapy: The role of the tumor microenvironment
Silvia Formenti, New York University, New York, NY
6:45 p.m.
Effects of radiation therapy on Treg infiltration of tumors
Charles G. Drake, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
7:15 p.m.
Insights into combining immune checkpoint blockade with radiation to treat
metastatic melanoma
Andy J. Minn, Abramson Family Cancer Research Institute, Philadelphia, PA
7:45 p.m.
Chairperson, TME: Closing remarks
Mary Helen Barcellos-Hoff, New York University, New York, NY
424
Monday, 6:30 p.m.-8:45 p.m.
Marina Ballroom D-E, San Diego Marriott Marquis & Marina
MICR Professional Advancement Roundtables:
Navigating the Road to a Successful Career in Cancer Research
Co-Chairpersons: A. William Blackstock, Wake Forest
University School of Medicine, Winston-Salem, NC, and
Chanita Hughes-Halbert, Medical University of SC
Hollings Cancer Center, Charleston, SC
This exciting Professional Advancement Session
organized by the Minorities in Cancer Research provides
a forum in which students, postdoctoral candidates, and
junior faculty discuss important career development
issues and survival skills with senior established
scientists. This event includes mentored roundtable
discussions facilitated by senior researchers from a
variety of sectors in the cancer community, including
academia, government, and industry.
For AACR members, all 2014 Professional Advancement
Sessions are free with your Annual Meeting registration
(except for the Grant Writing Workshop) and are an
added benefit of your membership. For nonmembers,
there is an additional fee of $50 ($95 for the Grant
Writing Workshop) for attendance at each session. If you
are not an AACR member, we strongly encourage you to
join and take advantage of the many benefits of
membership, which include attendance at these
sessions. Participation is on a first-come, first-served
basis, and space is limited. Nonmembers are required to
pay onsite.
6:30 p.m.
Registration and Reception
6:50 p.m.
Welcome
Chanita Hughes-Halbert, Medical
University of SC Hollings Cancer Center,
Charleston, SC
7:00 p.m.
First Roundtable Discussion
7:55 p.m.
Second Roundtable Discussion
8:40 p.m.
Closing Remarks
A. William Blackstock, Wake Forest
University School of Medicine,
Winston-Salem, NC
Career Objectives: Clinical Fellow
Victoria L. Seewaldt, Duke University Medical Center,
Durham, NC
Career Objectives: Junior Faculty
Lisa L. Baumbach-Reardon, TGEN, Phoenix, AZ
Career Objectives: Postdoctoral Fellows
Joanna L. Groden, Ohio State University College of
Medicine, Columbus, OH
Career Transitioning: From Fellow to Junior Faculty
Charles R. Thomas, OHSU Knight Cancer Institute,
Portland, OR
Career Transitioning: From Graduate School to
Fellow
Carla V. Finkielstein, Virginia Polytechnic Institute and
State University, Blacksburg, VA
Career Transitioning: From Junior Faculty to Tenure
Electra D. Paskett, Ohio State University College of
Medicine, Columbus, OH
Career Transitioning: From Medical School to
Careers in Research
Malcolm V. Brock, Johns Hopkins University School of
Medicine, Baltimore, MD
Career Transitioning: From Undergraduate to
Graduate
Khosrow Kashfi, City University of New York Medical
School, New York, NY
Career Transitioning: From Undergraduate to Medical
Jose G. Treviño, University of Florida, Gainesville, FL
Careers in Cancer: Academia
Wen-Jen Hwu, The University of Texas MD Anderson
Sean Kimbro, North Carolina Central University, Durham,
NC
Careers in Cancer: Government
Beverly Lyn-Cook, FDA-National Center for Toxicological
Research, Jefferson, AR
Luz Maria Rodriguez, NCI-DCP, Bethesda, MD
425
Monday, 6:30 p.m.-8:45 p.m.
Careers in Cancer: Industry
Arturo Molina, Janssen Research & Development, Menlo
Park, CA
Gregory R. Reyes, Celgene Corp., San Diego, CA
Research Funding for New Investigators and
Fellowship Opportunities: Postdoctoral Level
Pamela Marino, NIH-National Institute of General
Medical Sciences, Bethesda, MD
Careers in Cancer: Nontraditional
LeeAnn Bailey, Deloitte Consulting LLP, Arlington, VA
Research Funding/Grant Opportunities: Graduate
Student Level
John Ojeifo, Center to Reduce Cancer Health Disparities,
Bethesda, MD
Effective Leadership, Communication, and
Negotiation Skills
William G. Nelson, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
Survival Skills: Graduate Level
Cynthia A. Romerdahl, Taxolog, Inc., Framingham, MA
Effective Management, Communication, and
Negotiation Skills (for Junior Investigators)
Victoria M. Richon, Sanofi Oncology, Cambridge, MA
Survival Skills: Junior Faculty
Marcia R. Cruz-Correa, University of Puerto Rico
Comprehensive Cancer Center, San Juan, PR
Grantsmanship: Junior Faculty
Peter O. Ogunbiyi, NCI-CRCHD, Bethesda, MD
Survival Skills: Postdoctoral Level
Eileen J. Brantley, Loma Linda University School of
Medicine, Loma Linda, CA
How to Advance from Poster to Paper - Challenges
of Publishing in Peer-Reviewed Journals
Elena Martinez, UCSD Moores Cancer Center, La Jolla,
CA
Tenure Track-Research Track
James W. Lillard, Morehouse School of Medicine,
Atlanta, GA
How to Be a Good Mentor
Carlos A. Casiano, Loma Linda University School of
Medicine, Loma Linda, CA
The Physician/Scientist
Levi A. Garraway, Dana-Farber Cancer Institute,
Boston, MA
How to Get Your Papers Published in Journals with a
High Impact Factor
Timothy R. Rebbeck, University of Pennsylvania,
Philadelphia, PA
What to Look for in a Good Mentor
Yusri A. Elsayed, Janssen Pharmaceutical Companies of
Johnson & Johnson, Raritan, NJ
How to Set Up a Lab and Management of Resources
and Personnel
Wayne D. Bowen, Brown University, Providence, RI
Networking for Professional and Scientific
Development
Mary J.C. Hendrix, Northwestern University Lurie
Comprehensive Cancer Center, Chicago, IL
Chanita Hughes-Halbert, Medical University of South
Carolina Hollings Cancer Center,
Charleston, SC
Networking Professional Meetings Successfully
Lucile L. Adams-Campbell, Georgetown Lombardi
Comprehensive Cancer Center, Washington, DC
Ethan Dmitrovsky, The University of Texas MD Anderson
426
NOTES
427
NOTES
428

Detailed Schedule - Monday, April 7

Transcription

Similar documents

Trattamento delle metastasi ossee

ROAD MAP PILOT PROJECT PENGEMBANGAN INDUSTRI OBAT

I tumori professionali - Azienda USL di Modena

Preservazione fertilità carcinoma mammario

extreme gigantomastia

Untitled - Istituto Nazionale dei Tumori

Documento PDF - Padua@Research - Università degli Studi di

FOXP3 - SIES

kuliah limfatik darah BS2

Biologi kertas 2 Ting 5 TOV Terengganu 2012

Annual Meeting Program

Lesioni melanocitarie borderline: criteri di diagnostica

annual meeting program

Ambiente e rappresentazione della natura nei manifesti del Giappone

Terapia cellulare

Appendices - OSU Center for Continuing Medical Education

da pubblicare on line - AMS Tesi di Laurea

GRANDE offerta

Scarica la rivista - Quaderni del Ministero della Salute

+ NAC - Igienisti on line

this PDF file - PAGEPress Publications

1. Akershus Universitetssykehus HF